
<html lang="en"     class="pb-page"  data-request-id="34980326-b68b-45f7-9b32-bd5f2c4d49fa"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/jm501624r;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2015.58.issue-1;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease" /></meta><meta name="dc.Creator" content="Timothy D.  Cushing" /></meta><meta name="dc.Creator" content="Xiaolin  Hao" /></meta><meta name="dc.Creator" content="Youngsook  Shin" /></meta><meta name="dc.Creator" content="Kristin  Andrews" /></meta><meta name="dc.Creator" content="Matthew  Brown" /></meta><meta name="dc.Creator" content="Mario  Cardozo" /></meta><meta name="dc.Creator" content="Yi  Chen" /></meta><meta name="dc.Creator" content="Jason  Duquette" /></meta><meta name="dc.Creator" content="Ben  Fisher" /></meta><meta name="dc.Creator" content="Felix  Gonzalez-Lopez de Turiso" /></meta><meta name="dc.Creator" content="Xiao  He" /></meta><meta name="dc.Creator" content="Kirk R.  Henne" /></meta><meta name="dc.Creator" content="Yi-Ling  Hu" /></meta><meta name="dc.Creator" content="Randall  Hungate" /></meta><meta name="dc.Creator" content="Michael G.  Johnson" /></meta><meta name="dc.Creator" content="Ron C.  Kelly" /></meta><meta name="dc.Creator" content="Brian  Lucas" /></meta><meta name="dc.Creator" content="John D.  McCarter" /></meta><meta name="dc.Creator" content="Lawrence R.  McGee" /></meta><meta name="dc.Creator" content="Julio C.  Medina" /></meta><meta name="dc.Creator" content="Tisha  San Miguel" /></meta><meta name="dc.Creator" content="Deanna  Mohn" /></meta><meta name="dc.Creator" content="Vatee  Pattaropong" /></meta><meta name="dc.Creator" content="Liping H.  Pettus" /></meta><meta name="dc.Creator" content="Andreas  Reichelt" /></meta><meta name="dc.Creator" content="Robert M.  Rzasa" /></meta><meta name="dc.Creator" content="Jennifer  Seganish" /></meta><meta name="dc.Creator" content="Andrew S.  Tasker" /></meta><meta name="dc.Creator" content="Robert C.  Wahl" /></meta><meta name="dc.Creator" content="Sharon  Wannberg" /></meta><meta name="dc.Creator" content="Douglas A.  Whittington" /></meta><meta name="dc.Creator" content="John  Whoriskey" /></meta><meta name="dc.Creator" content="Gang  Yu" /></meta><meta name="dc.Creator" content="Leeanne  Zalameda" /></meta><meta name="dc.Creator" content="Dawei  Zhang" /></meta><meta name="dc.Creator" content="Daniela P.  Metz" /></meta><meta name="dc.Description" content="The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry e..." /></meta><meta name="Description" content="The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry e..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 3, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501624r" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501624r" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501624r" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501624r" /></link>
        
    
    

<title>Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501624r" /></meta><meta property="og:title" content="Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0017.jpeg" /></meta><meta property="og:description" content="The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry effort led to the identification of 1 (AMG319), a compound with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501624r"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501624r">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501624r&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501624r&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501624r&amp;href=/doi/10.1021/jm501624r" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 480-511</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501603h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm500305p" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and in Vivo Evaluation of (<i>S</i>)-<i>N</i>-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+D.++Cushing">Timothy D. Cushing</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaolin++Hao">Xiaolin Hao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youngsook++Shin">Youngsook Shin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristin++Andrews">Kristin Andrews</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Brown">Matthew Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mario++Cardozo">Mario Cardozo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Chen">Yi Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Duquette">Jason Duquette</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ben++Fisher">Ben Fisher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Felix++Gonzalez-Lopez+de+Turiso">Felix Gonzalez-Lopez de Turiso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao++He">Xiao He</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kirk+R.++Henne">Kirk R. Henne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Ling++Hu">Yi-Ling Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Randall++Hungate">Randall Hungate</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+G.++Johnson">Michael G. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ron+C.++Kelly">Ron C. Kelly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Lucas">Brian Lucas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++McCarter">John D. McCarter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+R.++McGee">Lawrence R. McGee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julio+C.++Medina">Julio C. Medina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tisha++San+Miguel">Tisha San Miguel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deanna++Mohn">Deanna Mohn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vatee++Pattaropong">Vatee Pattaropong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liping+H.++Pettus">Liping H. Pettus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Reichelt">Andreas Reichelt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+M.++Rzasa">Robert M. Rzasa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Seganish">Jennifer Seganish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+S.++Tasker">Andrew S. Tasker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+C.++Wahl">Robert C. Wahl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharon++Wannberg">Sharon Wannberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+A.++Whittington">Douglas A. Whittington</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Whoriskey">John Whoriskey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Yu">Gang Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leeanne++Zalameda">Leeanne Zalameda</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dawei++Zhang">Dawei Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniela+P.++Metz">Daniela P. Metz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Therapeutic Discovery, <sup>‡</sup>Department of Pharmacokinetics and Drug Metabolism, and <sup>§</sup>Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>∥</sup>Department of Inflammation Research, and <sup>⊥</sup>Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">#</span> <span class="aff-text">Department of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-243-8265. E-mail: <a href="/cdn-cgi/l/email-protection#e3978096908b8a8d84a3828e84868dcd808c8e"><span class="__cf_email__" data-cfemail="9de9fee8eef5f4f3faddfcf0faf8f3b3fef2f0">[email protected]</span></a>; E-mail: <a href="/cdn-cgi/l/email-protection#ee9a87838d9b9d86878089ae8d81838d8f9d9ac0808b9a"><span class="__cf_email__" data-cfemail="087c61656b7d7b6061666f486b67656b697b7c26666d7c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501624r&amp;href=/doi/10.1021%2Fjm501624r" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 480–511</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 3, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 October 2014</li><li><span class="item_label"><b>Published</b> online</span>3 December 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 January 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501624r" title="DOI URL">https://doi.org/10.1021/jm501624r</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D480%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTimothy%2BD.%2BCushing%252C%2BXiaolin%2BHao%252C%2BYoungsook%2BShin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D1%26contentID%3Djm501624r%26title%3DDiscovery%2Band%2Bin%2BVivo%2BEvaluation%2Bof%2B%2528S%2529-N-%25281-%25287-Fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2B%2528AMG319%2529%2Band%2BRelated%2BPI3K%25CE%25B4%2BInhibitors%2Bfor%2BInflammation%2Band%2BAutoimmune%2BDisease%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D511%26publicationDate%3DJanuary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501624r"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2971</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">54</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501624r" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;D. Cushing&quot;},{&quot;first_name&quot;:&quot;Xiaolin&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Youngsook&quot;,&quot;last_name&quot;:&quot;Shin&quot;},{&quot;first_name&quot;:&quot;Kristin&quot;,&quot;last_name&quot;:&quot;Andrews&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Brown&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Cardozo&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Duquette&quot;},{&quot;first_name&quot;:&quot;Ben&quot;,&quot;last_name&quot;:&quot;Fisher&quot;},{&quot;first_name&quot;:&quot;Felix&quot;,&quot;last_name&quot;:&quot;Gonzalez-Lopez de Turiso&quot;},{&quot;first_name&quot;:&quot;Xiao&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Kirk&quot;,&quot;last_name&quot;:&quot;R. Henne&quot;},{&quot;first_name&quot;:&quot;Yi-Ling&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Randall&quot;,&quot;last_name&quot;:&quot;Hungate&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;G. Johnson&quot;},{&quot;first_name&quot;:&quot;Ron&quot;,&quot;last_name&quot;:&quot;C. Kelly&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Lucas&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. McCarter&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;R. McGee&quot;},{&quot;first_name&quot;:&quot;Julio&quot;,&quot;last_name&quot;:&quot;C. Medina&quot;},{&quot;first_name&quot;:&quot;Tisha&quot;,&quot;last_name&quot;:&quot;San Miguel&quot;},{&quot;first_name&quot;:&quot;Deanna&quot;,&quot;last_name&quot;:&quot;Mohn&quot;},{&quot;first_name&quot;:&quot;Vatee&quot;,&quot;last_name&quot;:&quot;Pattaropong&quot;},{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;H. Pettus&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Reichelt&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;M. Rzasa&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Seganish&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;S. Tasker&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;C. Wahl&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;Wannberg&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;A. Whittington&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Whoriskey&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Leeanne&quot;,&quot;last_name&quot;:&quot;Zalameda&quot;},{&quot;first_name&quot;:&quot;Dawei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;P. Metz&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;480-511&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501624r&quot;},&quot;abstract&quot;:&quot;The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry effort led to the identification of 1 (AMG319), a compound with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501624r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501624r" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501624r&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501624r" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501624r&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501624r" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501624r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501624r&amp;href=/doi/10.1021/jm501624r" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501624r" /></input><a href="/doi/pdf/10.1021/jm501624r" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26pmid%3D25469863%26genre%3Darticle%26aulast%3DCushing%26date%3D2015%26atitle%3DDiscovery%2Band%2Bin%2BVivo%2BEvaluation%2Bof%2B%2528S%2529-N-%25281-%25287-Fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2B%2528AMG319%2529%2Band%2BRelated%2BPI3K%25CE%25B4%2BInhibitors%2Bfor%2BInflammation%2Band%2BAutoimmune%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D1%26spage%3D480%26epage%3D511%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jmcmar.2015.58.issue-1/20150108/jmcmar.2015.58.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry effort led to the identification of <b>1</b> (AMG319), a compound with an IC<sub>50</sub> of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/58/1"><issue-title>New Frontiers in Kinases</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositides (PIs) play key roles in multiple cell functions in their capacity as second messengers, including cell survival, signal transduction, and control of membrane trafficking and transport.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Dysfunctional regulation of the various phosphoinositides has been implicated in a variety of diseases including cancer, autoimmune disorders, and inflammation, to name a few. Phosphoinositides are lipids consisting of two bilayer fatty acids attached via a glycerol phosphate linkage to a cytosolic 1-inositol. Lipid kinases known as PI3Ks utilize ATP to phosphorylate the 3-OH of the inositol ring moiety, converting the PI phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> PIP3 functions as an anchoring site for protein kinases containing the highly conserved pleckstrin homology (PH) domain.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> These kinases in turn are further activated (phosphorylated or dephosphorylated), regulating a great number of important cellular functions. Arguably, the most important PIP3 binding protein kinase, the serine/threonine kinases AKT (or PKB), controls much of the growth, survival, and proliferation of the cell through further downstream proteins such as mTOR, GSK3β, Foxo3a, p70S6K, and NF-κB. Calcium mobilization and gene transcription are also governed by PH-domain containing tyrosine kinases of the Tec family; BTK, ETK, and ITK.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus, phosphoinositide metabolizing enzymes such as PI3Ks are attractive targets to modulate the functions of these second messengers.</div><div class="NLM_p">Of the several classes of PI3Ks, the most studied is class 1, which is further delineated into two subclasses (class 1A and class 1B). Class 1A (PI3Kα, -β, and -δ) are downstream of receptor tyrosine kinases (RTKs), while the class 1B (PI3Kγ) is downstream of G-protein-coupled receptors (GPCRs). These four homologous kinases exist as heterodimers of regulatory and catalytic subunits. The regulatory subunit contains domains that allow for anchoring to cell surface receptors and other regulatory proteins, and the catalytic subunit (p110α, -β, -γ, -δ) contains the ATP binding domain. It is this catalytic subunit and its ATP binding site that are the focus of small molecule inhibitor development. By the competitive inhibition of ATP binding, the phosphorylation of PIP2 is blocked and PIP3 is not formed. The important regulatory proteins such as AKT are prevented from anchoring to the cell membrane, thus inhibiting their function.</div><div class="NLM_p">While PI3Kα and PI3Kβ are ubiquitously expressed, PI3Kγ and PI3Kδ are found in leukocytes with PI3Kδ nearly confined to spleen, thymus, and peripheral blood leukocytes.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Although the dysregulation of PI3Kα and PI3Kβ is implicated in the etiology of solid tumors, the dysregulation of PI3Kγ and PI3Kδ has been implicated in diseases of the innate and adaptive immune system such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and hematological malignancies. Our interest in developing a small molecule inhibitor targeting PI3Kδ stems from its more restrictive expression pattern, the data accumulated from genetically modified mice and two successful biologics targeting B cells. These biologics, the monoclonal antibodies rituximab and belimumab, have proven efficacious against RA and SLE, respectively. Because PI3Kδ has a singular role in B cell maturation and function,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> its targeting should mimic the effects of the two biologic drugs. In addition to B cell modulation, PI3Kδ plays a partial role in T-cell activation<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and neutrophil trafficking<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and also contributes to activation of other leukocytes that have been implicated in autoimmune disease, such as macrophages, dendritic cells, and NK T-cells.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">New and surprising insights into the role of PI3Kδ in leukocyte function stem from two recent publications describing a dominant gain-of-function PI3Kδ mutation in several unrelated European families with an unusual combination of lymphoproliferation and immunodeficiency that predisposes them to lung and ear infections.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The immunodeficiency associated with this mutation is somewhat surprising, and the mechanism is currently not understood. It was speculated that the hyperactive p110δ-AKT-mTOR pathway promotes aerobic glycolysis, limiting the function and survival of lymphocytes and driving them to premature senescence, thus impairing proper immune responses to pathogens.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Chronic inflammation is not unique to autoimmune disease but is also associated with long-term exposure to stress or physical insult to the body and can lead to continuous signaling of the PI3Kδ pathway in responding leukocytes. For example, in chronic obstructive pulmonary disease (COPD), constant exposure to cigarette smoke is associated with high levels of PI3Kδ and phospho-AKT in the lung.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Like individuals with the gain-of-function PI3Kδ mutations, COPD patients are plagued by recurrent bacterial respiratory infections, including <i>H. influenza</i> and <i>S. peumoniae</i>, suggesting that a similar immunodeficiency may be associated with persistent PI3Kδ signaling in COPD as is seen with the genetic gain-of function mutation. The leukocyte defect in the patients with the gain-of-function mutation can be ameliorated by treatment with rapamycin, an inhibitor of the mTOR signaling pathway downstream of PI3Kδ. It is tempting to speculate that inhibition of PI3Kδ may be a viable treatment option not just for complex autoimmune disorders such as SLE and RA, where PI3Kδ likely drives B-cell and other leukocyte subset activities that culminate in pathology,<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> but also for chronic nonautoimmune conditions, such as COPD, where high levels of PI3Kδ and phospho-AKT are prominent but may drive immune deficiencies and hence persistent infections.</div><div class="NLM_p last">In this report we discuss the SAR development and in vivo properties of a series of compounds that selectively target the PI3Kδ isoform in the context of autoimmune and inflammatory disorders. This effort culminated in the discovery of purinylquinoline <b>1</b> (AMG319). Although this compound was deemed exceptional compared to the other analogs in this series, we determined that it would be more advantageous to develop this compound in an oncology setting. <b>1</b> is currently undergoing phase 1 clinical trials targeting hematological malignancies.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17-20)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Genesis of Compounds</h3><div class="NLM_p">Knight et al. published a landmark paper<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> describing an interesting class of compounds existing in a propeller-shaped configuration exemplified by <b>2</b> (PIK-39) that was profoundly more potent (>50-fold) toward the PI3Kδ isoform relative to the other class 1 PI3Ks. This selectivity between the highly homologous isoforms was attributed to the unusual overall shape of the molecules. Typical flat kinase inhibitors such as <b>3</b> (LY294002)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> bind in the ATP-binding pocket with no significant difference between the PI3K isoforms. In contrast the quinazolinone <b>2</b> forces a key methionine (Met804 PI3Kγ, conserved in all isoforms) to reorient, accommodating the large quinazolinone moiety. This ligand-induced methionine reorientation induces a shift of the peptide backbone that propagates through the upper loop (amino acids 803–811 in PI3Kγ), leading to a conformational change in the ATP-binding region enhancing isoform selectivity in favor of the PI3Kδ isoform. It was this theory of binding and selectivity that we set out to exploit.</div><div class="NLM_p">Molecular modeling indicated that an overlap between the known PI3K inhibitors <b>2</b>, <b>3</b>, and a cinnoline template (a key functional component of a p38 program)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> could provide a novel structural starting point (<b>A</b>) with a twist similar to the propeller shape found in <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). By combining these precursor structures and a gem-dimethylindoline found useful in a NIK (nuclear factor κB inducing kinase) program,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> we obtained <b>4</b>, a compound with modest activity in a PI3Kδ enzyme assay. However, after replacement of the cinnoline with a quinoline moiety, compounds were found that dramatically improved the potency, such as <b>5</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (0.30 μM) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><div class="NLM_p">Further SAR development of this indoline series as exemplified by <b>4</b> and <b>5</b> led to very potent, selective, and bioavailable analogs.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> On the basis of these results, it was envisioned that the quinoline moiety could provide a significant advantage as a replacement of the quinazolinone found in <b>2</b>. Compound <b>6</b> had similar enzyme potency to <b>2</b>, although with significantly weaker cell potency.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SAR development of the purinylquinoline series, which led to compound <b>1</b>. By utilization of known literature compounds and insights gained from two internal kinase programs, compounds <b>4</b> and <b>5</b> were generated, which in turn led to analog <b>6</b>. Shown are IC<sub>50</sub> values against PI3Kδ (enzyme, Alphascreen assay; for a description see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial SAR around the Linker between Purine and Quinoline Bicycle</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Alphascreen assay.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">In vitro anti-IgM/CD40L-induced B cell proliferation (as measured by thymidine incorporation) assay.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Rat liver microsomal (RLM)/human liver microsomal (HLM) % turnover (TO) (the percentage of compound that is metabolized in 30 min at 37 °C).</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Phosphate buffered saline, pH 7.4, Symyx benchtop system, equilibrated 42–78 h.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Rat clearance dosed iv, 0.5 mg/kg, 100% DMSO.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Rat % oral bioavailability dosed po 2.0 mg/kg, 1% Tween 80, 1% methyl cellulose, 98% water.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> SAR of Compounds</h3><div class="NLM_p">Although <b>6</b> was a reasonable starting point, the thioether moiety was a potential metabolic liability. The ether-linked analog <b>7</b> was significantly more potent in the PI3Kδ enzyme and cell assays (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). To determine the optimal linkage, several related analogs, <b>8</b>, <b>9</b>, and <b>10</b>, were synthesized. The methylene linked <b>10</b> had very weak PI3Kδ potency, but the ether-linked <b>8</b> and amino-linked <b>9</b> were similar in PI3Kδ potency to <b>7</b>. Additionally, <b>8</b> was 34-fold selective for PI3Kδ over the PI3Kγ isoform, while the N-linked <b>9</b> was only 7-fold selective. These analogs exhibited improved potency and selectivity but were poorly soluble and had high turnover in microsomes and consequently displayed poor pharmacokinetics in the rat. The observed high clearance was hypothesized to be due to action of aldehyde oxidase (AO) or xanthine oxidase (XO) on the purine ring.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The similarly potent and selective pyrrolopyrimidine <b>11</b> was an attempt to blunt this activity, but <b>11</b> still suffered high microsomal clearance, much like <b>8</b> and <b>9</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In spite of the low solubility and high metabolism of the ether-linked analogs <b>7</b>, <b>8</b>, and <b>11</b>, we were interested in these compounds because of their higher selectivity; however, it became apparent that the compounds are chemically unstable, as the fragment 9<i>H</i>-purin-6-ol (from <b>7</b>, <b>8</b>) was identified in solutions after several days at neutral pH. This fragmentation could occur via an S<sub>N</sub>2 hydrolysis or an S<sub>N</sub>1 ionization or both. Analog <b>12</b> was synthesized with a methyl group α to the ether moiety in an attempt to decrease the rate of putative S<sub>N</sub>2 hydrolysis. However, steric hindrance to minimize the S<sub>N</sub>2 mechanism might actually enhance an S<sub>N</sub>1 mechanism, leading to no net improvement, which was the outcome with <b>12</b>. Analog <b>12</b> exhibited no improvement in stability over the des-methyl analogs but the enzyme potency of <b>12</b> toward PI3Kδ increased 5-fold over the des-methyl analog <b>11</b>. This potency enhancement was not unexpected, as the methyl moiety was advantageous in similar propeller shaped molecules<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> because of a stereospecific ligand–protein interaction.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> This is demonstrated by a comparison of the PI3Kδ enzyme potency of the <i>S</i>-methyl isomer (<b>12</b>, IC<sub>50</sub> = 7.1 nM) and <i>R</i>-methyl isomer (<b>13</b>, IC<sub>50</sub> = 2.6 μM). This <i>S</i>-methyl isomer stereoselectivity is a property of the entire series (data not shown), perhaps due to a steric clash between the <i>R</i>-methyl group and the protein. Analog <b>12</b> also had significantly improved cellular potency including a 60-fold positive shift in the B cell proliferation assay (as measured by <sup>3</sup>H thymidine incorporation; for details see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) compared to <b>11</b>. Because the metabolic instability of the ether-linked compounds was still quite high, our focus shifted to the amino-linked analog <b>9</b>, which was less potent but chemically stable. The identification of metabolites of <b>9</b> treated with rat liver microsomes implied that the metabolic instability of <b>9</b> and <b>12</b> was partially due to oxidative metabolism of the aromatic methyl groups. This adverse metabolism led to the synthesis of dichloro <b>14</b>. Analog <b>14</b> was found to be more stable in the RLM assay than <b>9</b> and <b>12</b>. The major metabolites of <b>9</b> were found in the quinoline and toluyl moieties, but the major metabolites of <b>14</b> were confined to the purine moiety. The lower metabolism of <b>14</b> translated to a slightly improved rat clearance of 1.6 L h<sup>–1</sup> kg<sup>–1</sup>. Additionally, <b>14</b> had a rat oral bioavailability of 43% compared to 9% for <b>9</b>. This is interesting, as both <b>9</b> and <b>14</b> have low solubility but high permeability (LLC-PK1 parental cell line, <i>P</i><sub>app</sub> of 47 × 10<sup>–6</sup> and 41 × 10<sup>–6</sup> cm/s, respectively). Thus, the higher oral bioavailability of <b>14</b> compared to <b>9</b> implied that the oral bioavailability was a function of metabolic stability (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_p">Analog <b>14</b> was the first compound tested in the in vivo models in spite of the high intrinsic rat clearance and high CYP2D6 inhibition. Additionally, the main driver of the in vivo/in vitro correlation, the human whole blood (HWB) assay (anti-IgD induced CD-69 on B cells in 90% human whole blood), was still suboptimal (HWB<sub>int,u</sub> = 8.4 nM). The noticeable improvement in potency in the enzyme and B cell proliferation assay with <b>12</b> compared to <b>11</b> led to the synthesis of the (<i>S</i>)-methyl containing <b>15</b>, the direct analog of <b>14</b>. Analog <b>15</b> had the expected increase in potency in both enzyme and cellular assays over <b>14</b>, including the critical HWB assay where the increase in potency was >9-fold (HWB<sub>int,u</sub> of 0.85 vs 8.4 nM). The cellular potency improvement was noticed in other α-methyl analogs as well. For example, <b>16</b> compared very favorably to <b>17</b>, with the B cell proliferation cellular activity improved over 11-fold and the HWB intrinsic unbound potency increased by a factor of 5. The intrinsic rat iv clearance for these analogs <b>12</b>, <b>14</b>, <b>15</b>, <b>16</b>, and <b>17</b> remained high despite the α-methyl group’s contribution to improvements in other properties such as potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of (<i>S</i>)-Methyl Analogs to Des-Methyl Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0014.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Ability of compound to inhibit anti-IgM induced AKT phosphorylation (Ser473) in mouse B cells; phospho-AKT (pAKT) expression on B220+ gated B cells was determined by flow cytometry in mouse splenocytes.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Compound pretreated HWB was stimulated with anti-IgD to induce CD-69 expression on B cells (6 h) and was evaluated by flow cytometry.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">The intrinsic unbound human whole blood (HWB<sub>int,u</sub>) potency was derived by multiplying the PPB fraction unbound by the total HWB potency (<i>f</i><sub>u</sub> × HWB).</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">CYP: cytochrome p450 competitive assay, probe substrates (midazolam (3A4), 5 μM) (bufuralol (2D6), 8 μM) with compound (3.0 μM) reported as % inhibition (LC/MS).</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Passive permeability in LLC-PK1 cells, apparent permeability (<i>P</i><sub>app</sub>) measured by mass balance (LC/MS).</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">Tested at 1.0 μM concentration in rat and human plasma, protein binding measured by ultracentrifugation and LC/MS.</p></div><div class="footnote" id="t2fn7"><sup>Table g</sup><p class="last">Intrinsic unbound hepatic clearance equals the hepatic (total) clearance divided by the fraction unbound (CL<sub>int,u</sub> = CL<sub>H</sub>/<i>f</i><sub>u</sub>).</p></div><div class="footnote" id="t2fn8"><sup>Table h</sup><p class="last">This compound has a high extraction ratio such that the clearance depends exclusively on hepatic blood flow.</p></div><div class="footnote" id="t2fn9"><sup>Table i</sup><p class="last">These drugs have intermediate extraction ratios (0.3 < 0.7) so that the numbers in parentheses could be dependent on liver blood flow, unbound drug fraction, and the intrinsic metabolic clearance.</p></div><div class="footnote" id="t2fn10"><sup>Table j</sup><p class="last">Dose po 2.0 mg/kg, 1% Tween 80, 1% methylcellulose, 98% water.</p></div></div><div></div></div><div class="NLM_p">Much of the improvement in enzyme and cellular potency is likely because the methyl group limits the free rotation around the bond at the 3-position of the quinoline, rigidifying the structure in a low energy state closer to the binding conformation. Molecular modeling calculations indicate that this difference is about 1 kcal/mol, equivalent to a 10-fold shift in potency, which is generally consistent with what is observed. With the superiority of the <i>S</i>-methyl group established, we embarked on further SAR development to improve these analogs. An intensive effort to explore the substitution pattern around the 2-phenyl group and the quinoline core structure was undertaken (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Substituting the chlorine on <b>15</b> for fluorine gave <b>18</b> providing nearly a 2-fold improvement in the HWB intrinsic unbound potency and a 4-fold improvement in the rat iv intrinsic clearance. The quinoxaline <b>19</b>, an analog of <b>16</b>, provided a very similar overall profile with almost identical cellular and HWB potency. The biochemical selectivity profile and PK were very similar, but <b>19</b> had a lower level of solubility. Because of the improved HWB with fluorine substitution on the pendent phenyl ring, it was hypothesized that a similar improvement would be actualized by replacing the 8-chloroquinoline. The 8-fluoroquinoline <b>20</b>, a direct analog of <b>16</b>, had the same high bioavailability (<i>F</i> = 100%), similar (high) intrinsic rat iv clearance, but high intrinsic unbound HWB potency. The cellular potency (B cell proliferation and pAKT) was also similar. Additional fluorine containing analogs <b>21</b> and <b>22</b> displayed a similar intrinsic unbound HWB potency and high intrinsic rat clearance, in the case of <b>22</b>. The related 7-fluoroquinoline analog <b>23</b> displayed no advantage over <b>20.</b> The intrinsic clearance and HWB activity were very similar, and the oral bioavailability was worse (41% vs 100%). Replacing the 3-fluorophenyl of <b>23</b> with 2-methylsulfonylphenyl provided <b>24</b>, a compound with weaker (17-fold) intrinsic unbound HWB potency but with a large increase in PBS solubility (62 vs >200 μg/mL). The rPPB fraction unbound (<i>f</i><sub>u</sub>) was significantly higher, 0.30 (as was hPPB <i>f</i><sub>u</sub>), leading to the lower rat iv intrinsic clearance (3.7 L h<sup>–1</sup> kg<sup>–1</sup>) and potentially leading to the lower oral bioavailability.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">The solubility of the compounds remained problematic. In the early analogs <b>8</b>, <b>9</b>, and <b>11</b> there appeared to be a correspondence between low solubility and poor bioavailability. A slight improvement in solubility as in <b>14</b>, <b>16</b>, and <b>17</b> provided an improvement in oral bioavailability but could still be attributed to the high permeability found in these compounds. For example, <b>19</b> had poor solubility, high permeability, but high oral bioavailability. In general, the overall permeability of the series of compounds was quite high and most small structural changes had little effect. For example, the (<i>S</i>)-methyl analog <b>16</b> and des-methyl <b>17</b> had identical <i>P</i><sub>app</sub> values of 37 × 10<sup>–6</sup> cm/s. The increase in oral bioavailability of <b>16</b> compared to <b>17</b> could be attributed to the increased rigidity of <b>16</b> relative to <b>17</b>. Large increases in the PBS solubility led to decreased activity in a bile salt export pump (BSEP) assay, thought to be a key toxicological assay for the assessment of compounds. Analog <b>23</b> had BSEP activity of 19 μM, while the soluble analog <b>24</b> was tested at >133 μM. There was also a trend for increases in solubility providing positive effect on CYP inhibition. Therefore, our focus remained on further increasing the solubility in spite of the increased rPPB (and hPPB) unbound fraction, which was interesting<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> but initially at least to the detriment of the rat PK.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The goal was to provide a compound that would be highly tractable in a clinical setting.</div><div class="NLM_p">The high solubility of <b>24</b>, while an intriguing result, was not replicated with <b>25</b>, an analog of <b>16</b>. 3-Methylsulfonyl <b>25</b> had lower solubility than <b>24</b>, and the oral bioavailability (36%) was lower than <b>16</b>. Additionally, <b>25</b> was less potent in the B cell proliferation assay and was less potent in the HWB assay (HWB<sub>int,u</sub>) compared to <b>16</b> or even <b>24</b>, although <b>24</b> and <b>25</b> displayed an acceptable permeability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR: Potency and Selectivity Data for Analogs<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">For a description of the assays see Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">The intrinsic unbound human whole blood (HWB<sub>int,u</sub>) potency was derived by multiplying the PPB fraction unbound by the total HWB potency (<i>f</i><sub>u</sub> × HWB). <i>f</i><sub>u</sub> values are found in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR: Physicochemical Properties and PK of Analogs in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Permeability; for a description of this and other assays see Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Dose iv, 0.5 mg/kg, 100% DMSO.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Dose po, 2.0 mg/kg, 1% Tween 80, 1% methylcellulose, 98% water.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Intrinsic unbound hepatic clearance equals the hepatic (total) clearance divided by the fraction unbound (CL<sub>int,u</sub> = CL<sub>H</sub>/<i>f</i><sub>u</sub>). This value is an indication of how the unbound exposure increased with decreasing CL<sub>int,u</sub> (AUC<sub>u</sub> = dose/CL<sub>int,u.</sub>).</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">The equation CL<sub>int,u</sub> = CL<sub>H</sub>/<i>f</i><sub>u</sub> holds only for compounds with low extraction ratios (<0.3), where <i>f</i><sub>u</sub>(CL<sub>int, u</sub>) ≪ <i>Q</i> (liver blood flow). These drugs have intermediate extraction ratios (0.3 < 0.7) so that the numbers in parentheses could be dependent on liver blood flow, unbound drug fraction, and the intrinsic metabolic clearance.</p></div></div><div></div></div><div class="NLM_p">The 3-pyridyl-2-quinoline analog <b>26</b> had significantly higher solubility in PBS buffer compared to 7-fluorophenyl <b>20</b> but suffered high CYP3A4 inhibition (92%) and higher rat iv clearance. The CYP3A4 inhibition was reduced by placing a methyl group ortho to the 3-pyridyl nitrogen of <b>26</b>, but this analog, <b>27</b> still possessed high rat iv clearance (CL = 2.9 L h<sup>–1</sup> kg<sup>–1</sup>). <b>27</b> also had very high solubility, similar to <b>26</b>, and was potent in the HWB assay (HWB<sub>int,u</sub> = 5 nM). The high rat iv clearance was modulated by the addition of a fluoro group to the pyridine ring providing <b>28</b>, which lowered the rat iv clearance (CL = 0.78 L h<sup>–1</sup> kg<sup>–1</sup>) substantially. The CYP3A4 inhibition also decreased in the 2-pyridyl <b>29</b>, but this analog exhibited higher rat iv clearance. Similarly, 2-pyridyl <b>30</b>, an analog of <b>16</b>, did not have the CYP3A4 inhibition of the 3-pyridyl analogs, but it did have higher CYP2D6 inhibition. In spite of this, <b>30</b> had a reasonable overall profile, including HWB potency (HWB<sub>int,u</sub> = 2.8 nM), solubility, and permeability. The compound had good oral exposure (<i>F</i> = 87%) but still unacceptable high rat iv clearance (CL<sub>int,u</sub> = 37 L h<sup>–1</sup> kg<sup>–1</sup>). The pyridyl <b>31</b>, an analog of quinoxaline <b>19</b> and <b>30</b>, had lower rat iv clearance (CL<sub>int,u</sub> = 8.5 L h<sup>–1</sup> kg<sup>–1</sup>) than both of these and higher % <i>F</i> than <b>14</b>. 8-Chloroquinoxaline <b>32</b>, an analog of <b>31</b>, had similar properties but with significantly weaker HWB potency. Although the electron withdrawing 8-cyano substituted quinoline <b>33</b> had a lower rat iv clearance than the corresponding 8-fluoro <b>29</b>, the intrinsic unbound clearance was similar. A comparison between <b>33</b> and <b>30</b> is revealing. <b>33</b> had similar intrinsic unbound HWB potency, 2.5 nM vs 2.8 nM, respectively, but <b>33</b> had a significantly higher unbound fraction in rat plasma (0.14 vs 0.027). The in vivo rat iv clearance was similar, but the intrinsic clearance of <b>33</b> is considerably less with CL<sub>int,u</sub> values of 7.0 and 37 L h<sup>–1</sup> kg<sup>–1</sup> for <b>33</b> and <b>30</b>, respectively, indicating a level of protection toward metabolism provided by the cyano group, although <b>33</b> had a lower rat oral bioavailability than <b>30</b> (26% vs 87%). The SAR indicated that the 2-pyridyl substituted quinoline was nearly optimal, providing greater solubility, lower CYP inhibition, and generally lower intrinsic unbound clearance without sacrificing intrinsic unbound HWB potency. However, the question of where and of what type of electron withdrawing group in the quinoline ring was best remained open. Clearly, the necessity of an electron withdrawing group in the quinoline resulting in a decrease of the in vivo rat iv clearance was demonstrated with compounds like <b>33</b>. In general, the difference in SAR between a chlorine substituent and a fluorine substituent on the quinoline core is subtle. Consider the difference in solubility between <b>16</b>, <b>20</b>, and <b>23</b>. The fluoroquinolines are slightly less lipophilic and more soluble than the chloroquinoline. It is only when the 2-pyridyl moiety is combined with the fluoroquinoline core or the chloroquinoline core that the differences in PK start to manifest. For example, a larger difference in CL<sub>int,u</sub> values is displayed by the 2-pyridyl analogs <b>29</b> (8.1 L h<sup>–1</sup> kg<sup>–1</sup>) and <b>30</b> (37 L h<sup>–1</sup> kg<sup>–1</sup>) than the related pair 16 (43 L h<sup>–1</sup> kg<sup>–1</sup>) and <b>20</b> (54 L h<sup>–1</sup> kg<sup>–1</sup>). The other 7-fluoro substituted <b>34</b>, <b>35</b>, and <b>1</b> had very high solubility, permeability, and low CYP inhibition. All three compounds are potent in the two cellular and HWB assays, and the rat iv intrinsic unbound clearance was also very low in <b>1</b> and <b>35</b>, lower than found in <b>34</b>. The rat oral bioavailability was also higher for <b>1</b> than <b>35</b>. The 7-fluoroquinoline <b>1</b> had lower rat iv intrinsic unbound clearance than 8-fluoroquinoline <b>29</b> and 8-chloroquinoline <b>30</b> and without the CYP2D6 inhibition signal found in <b>30</b>. <b>1</b> had minimal CYP3A4/2D6 inhibition and did not inhibit CYPs (1A2, 2C8, 2C9, 2C19, 2E1, all >20 μM). There was no time dependent inhibition (TDI) against CYPs 3A4, 2D6, 1A2, and 2C9 nor CYP induction (3A4, 2D6, 1A2, 2B6) as measured in hepatocytes.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a><b>1</b> was clean in a hERG binding assay (>25 μM), and an Ames micronucleus test proved negative. <b>1</b> had minimal effects in a BSEP assay up to >200 μM. Additionally, <b>1</b> was clean in a large side effect profiling panel (CEREP) and had no activity in a large panel (Kinomescan) of 359 unique protein kinases tested at 10 μM drug concentration (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase dendogram of <b>1</b>. Red balls on the protein kinase family “tree” mark the level of binding. Binding assay results are shown as <i>K</i><sub>d</sub> values (nM) against 359 separate protein kinases, tested at 10 μM compound concentration. As can be seen from the figure, <b>1</b> was inactive under these criteria. All kinases tested at >35 POC and 80% were >70 POC. Kinase selectivity experiment and figure were supplied by DiscoveRx, formerly AMBIT Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vivo Pharmacology</h3><div class="NLM_p">An in vivo model (phosphorylation of AKT) was employed as a way to correlate the in vitro pAKT cellular data with in vivo pAKT levels. Similar to the in vitro studies, membrane-bound immunoglobulin (such as IgM or IgD) serves as a functional B cell receptor through which the cells can be activated via cross-linkage of the receptor with soluble antibody to the receptor, which leads to increased phosphorylation of AKT within the cells; in vitro this phosphorylation can be completely blocked with functional PI3Kδ-selective inhibitors. For this purpose, in these in vivo studies, mice were injected with anti-IgM to stimulate circulating B cells. A B-cell transgenic mouse, line 3751,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> was used as these mice are engineered to only express surface-bound IgM and are devoid of circulating IgM. The lack of circulating IgM is critical, as circulating IgM can form immune complexes with the injected antibody that could lead to immune-complex-mediated toxicities. Animals were dosed with compound 15 min prior to iv delivery of FITC-labeled anti-IgM to stimulate B cells. After 30 min the animals were sacrificed and the blood and spleen analyzed for B cells activation by measuring pAKT via flow cytometry (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a,b). When the pAKT vs unbound blood concentrations of the compound was plotted, an IC<sub>50</sub> value was generated (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>c). This was done for several compounds, and there was a striking correlation between the in vivo generated IC<sub>50</sub> values and the in vitro IC<sub>50</sub> values (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). This experiment was also used as a gauge for the multidose functional, 10-day protein–antigen (KLH-keyhole limpet hemocyanin) challenge model in rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). These studies were performed to determine the correlation between biochemical coverage (i.e., pAKT) with functional activity in vivo. This model allowed assessment of compound impact on T-cell-dependent primary B cell responses by measuring the ability of the compounds to reduce KLH-specific IgM and IgG production. Doses were chosen that would start to provide coverage at trough over the calculated in vivo pAKT IC<sub>50</sub> values. Some of these doses were envisioned to provide a complete knockdown of the KLH-specific Ig response.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The key compound <b>1</b> achieved this coverage at the 3 mg/kg level, which also covered the HWB (CD-69) IC<sub>90</sub> at trough for a full 24 h period, perhaps a more relevant marker of how the compound would behave clinically. The lower doses 0.1, 0.3, and 1 mg/kg covered trough concentrations between the HWB IC<sub>50</sub> and IC<sub>90</sub> and evinced partial efficacy. Similarly, the plasma concentration of <b>1</b> covered the IC<sub>90</sub> at the 1 mg/kg dose of the mouse anti-IgM pAKT in vitro assay (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><div class="NLM_p">Comparisons of inhibitory activity in HWB to establish potency are confounded by differences in PPB between compounds. PPB corrected HWB IC<sub>50</sub> values (HWB<sub>int,u</sub>) reflect intrinsic activity normalized for unbound compound in the assay matrix. Compound <b>1</b> was among the more active molecules in blood (HWB<sub>int,u</sub> = 2.6 nM), and it also exhibited meaningful in vivo efficacy when tested in the in vivo pAKT and KLH antigen-challenge pharmacology models. Not unique to <b>1</b> was the observation that molecules in the series possessed relatively low PPB in rat and human (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), which likely enabled good ex vivo HWB and in vivo activity. Though low PPB could be a factor leading to high hepatic clearance (CL<sub>H</sub>) in vivo, compounds with sufficiently low intrinsic clearance (CL<sub>int,u</sub>) are able to maintain efficacious exposures at lower overall doses. Analog <b>1</b> exhibits the lowest rat CL<sub>int,u</sub> (2.7 L h<sup>–1</sup> kg<sup>–1</sup>) in the series (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), which translated to the lowest ED<sub>50</sub> values for IgM and IgG reduction among compounds of similar potency tested in the KLH antigen-challenge model. These observations were key in the selection of <b>1</b> as a clinical candidate.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Vehicle, benchmark compound 2-(((2-amino-9<i>H</i>-purin-6-yl)amino)methyl)-5-methyl-3-(<i>o</i>-tolyl)quinazolin-4(3<i>H</i>)-one (D-073),<a onclick="showRef(event, 'ref28 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref35">(28, 35)</a> and <b>1</b> were dosed orally to the transgenic (IgM<sub>m</sub>) mice. Fifteen minutes later they were injected (iv) with anti-IgM/FITC. Blood (a) and spleen tissue (b) were collected after 30 min, stained, and analyzed for phospho-AKT (p-AKT) levels by flow cytometry. The cells were gated on B220+ (B cells) and FITC positive cells analyzed. Mann–Whitney <i>U</i> test was used to evaluate differences between groups. The asterisk (∗) denotes statistical significance (<i>p</i> < 0.05) when compared to the control group. (c) Unbound concentrations were plotted against % remaining pAKT activity (100 – % pAKT inhibition) measured in peripheral blood B cells for each corresponding dose. Total plasma concentrations of <b>1</b> from two separate experiments (a) were converted to estimated unbound concentrations using mouse plasma protein binding data (<i>f</i><sub>u</sub> = 0.0442). The estimated in vivo unbound drug concentration pAKT IC<sub>50</sub> was 1.9 nM and was in reasonable agreement with the pAKT murine splenocyte B-cell-based in vitro unbound drug concentration IC<sub>50</sub> of 1.1 nM [calculated from 1.5 nM total drug IC<sub>50</sub> × 0.711<i>f</i><sub>u,media</sub>. Quantitation of <b>1</b> in mouse plasma was performed using a sensitive and selective LC–MS/MS method. MS analysis was carried out using electrospray ionization (ESI) in the positive mode, with detection of analyte and internal standard <i>N</i>-((1<i>R</i>)-1-(3-(4-(ethyloxy)phenyl)-4-oxo-3,4-dihydropyrido[2,3-<i>d</i>]pyrimidin-2-yl)ethyl)-<i>N</i>-(3-pyridinylmethyl)-2-(4((trifluoromethyl)oxy)phenyl)acetamide by multiple reaction monitoring (MRM). The lower limit of quantitation (LLOQ) in the assay was 0.3 ng/mL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro–in Vivo pAKT IC<sub>50</sub> Correlations for Tested Analogs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">calculated, unbound drug concentration IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analog</th><th class="colsep0 rowsep0" align="center" char=".">in vitro pAKT</th><th class="colsep0 rowsep0" align="center" char=".">in vivo pAKT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">In vitro–in vivo pAKT IC<sub>50</sub> correlations for selected analogs. Analyses done in a similar way as in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>c. All values corrected for PPB (in vivo) and serum protein binding (in vitro). <i>R</i><sup>2</sup> correlation is 0.62</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Vehicle or <b>1</b> in 2% HPMC, 1% Pluronic F68, 10% Captisol, pH 2.0, was administered (0.1, 0.3, 1, 3 mg/kg) q.d. po for 10 days in female Lewis rats (<i>N</i> = 8/dose group). At 2 h after the first dosing, 200 μL of PBS containing 60 μg of KLH was administered to each rat intravenously. Ten days after the KLH priming, rats were euthanized and blood was taken by cardiac puncture for the measurement of KLH specific IgG (a) and IgM (b) by ELISA. The <i>y</i>-axis is represented as a mean serum dilution factor. Error bars represent the standard error of the mean (SEM) of eight rats. (c) After administration of <b>1</b>, plasma was harvested to assess exposures in each dose group. Unbound drug concentrations (mean ± SD) were measured by LC–MS/MS and plotted relative to HWB<sub>int,u</sub> CD-69 (IC<sub>50</sub> = 2.0 nM; IC<sub>90</sub> = 15 nM) and in vitro mouse anti IgM pAKT<sub>unbound</sub> (IC<sub>50</sub> = 1.1 nM; IC<sub>90</sub> = 9.2 nM) estimates, represented as dashed lines. The percent values are the attenuation of KLH-specific IgG responses from (a).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. % Inhibition of the KLH Induced Inflammatory Response with Selected Analogs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">% KLH inhibition<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> with dose q.d. of</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analog</th><th class="colsep0 rowsep0" align="center">day 10</th><th class="colsep0 rowsep0" align="center">30 mg/kg</th><th class="colsep0 rowsep0" align="center">25 mg/kg</th><th class="colsep0 rowsep0" align="center">10 mg/kg</th><th class="colsep0 rowsep0" align="center">3 mg/kg</th><th class="colsep0 rowsep0" align="center">2.5 mg/kg</th><th class="colsep0 rowsep0" align="center">1 mg/kg</th><th class="colsep0 rowsep0" align="center">0.3 mg/kg</th><th class="colsep0 rowsep0" align="center">0.1 mg/kg</th><th class="colsep0 rowsep0" align="center">ED<sub>50</sub> <a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">88 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">80 ± 13</td><td class="colsep0 rowsep0" align="left">67 ± 15</td><td class="colsep0 rowsep0" align="left">3 ± 23*</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">95 ± 1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">83 ± 7</td><td class="colsep0 rowsep0" align="left">48 ± 14</td><td class="colsep0 rowsep0" align="left">32 ± 11*</td><td class="colsep0 rowsep0" align="left">0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">99<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">90 ± 4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">99<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96 ± 2</td><td class="colsep0 rowsep0" align="left">54 ± 23*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96 ± 3</td><td class="colsep0 rowsep0" align="left">89 ± 4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">–0.9 ± 45*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">70 ± 12</td><td class="colsep0 rowsep0" align="left">64 ± 10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14 ± 10*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">99<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">92 ± 2</td><td class="colsep0 rowsep0" align="left">77 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">84 ± 7</td><td class="colsep0 rowsep0" align="left">27 ± 20*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96 ± 2</td><td class="colsep0 rowsep0" align="left">94 ± 2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">91 ± 3</td><td class="colsep0 rowsep0" align="left">58 ± 24*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">95 ± 2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">59 ± 18</td><td class="colsep0 rowsep0" align="left">42 ± 18*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left">99 ± 1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96 ± 2</td><td class="colsep0 rowsep0" align="left">80 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">46 ± 7*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left">100 ± 22</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100 ± 20</td><td class="colsep0 rowsep0" align="left">73 ± 20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">20 ± 11*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">89 ± 5</td><td class="colsep0 rowsep0" align="left">87 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">62 ± 10</td><td class="colsep0 rowsep0" align="left">65 ± 11</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">76 ± 10</td><td class="colsep0 rowsep0" align="left">71 ± 9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">19 ± 12*</td><td class="colsep0 rowsep0" align="left">26 ± 14*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">IgM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">83 ± 7</td><td class="colsep0 rowsep0" align="left">84 ± 4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">61 ± 9</td><td class="colsep0 rowsep0" align="left">29 ± 7*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IgG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96 ± 5</td><td class="colsep0 rowsep0" align="left">81 ± 9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">42 ± 18</td><td class="colsep0 rowsep0" align="left">32 ± 13*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Percent inhibition of the IgM and IgG response of several compounds and the corresponding doses in the KLH model; all data points have <i>p</i> < 0.05 compared to vehicle control except for those marked with an asterisk (∗).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">ED<sub>50</sub> (mg/kg) was calculated from these data.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Experiment with <b>1</b> repeated. All experiments performed as described in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Calculated % SEM is <1.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Structure and Selectivity</h3><div class="NLM_p">The hypothesis that substituting a quinoline would be a viable structural isostere of the quinazolinone in <b>2</b> proved to be correct and was supported by the data and cocrystal structures (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a shows the propeller-shaped <b>1</b> bound in the ATP binding pocket of PI3Kγ. The 7-fluoroquinoline lies in the inducible specificity pocket between Trp812 and Met804, and the pyridine projects out of the ATP-binding pocket toward a site referred to as hydrophobic region II.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b shows the inhibitor with selected residue differences between the class I PI3K isoforms, and several key intramolecular hydrogen bonds are indicated as dashed lines, including the energetically important hinge Val882-purine contact. Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>c shows the overlay of PI3Kγ + <b>1</b> with the published cocrystal structure of <b>2</b> (yellow) bound to PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF">2WXF</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This overlay illustrates the similar binding conformation of the two structural types and highlights the similarity of the two ATP binding pockets. Structural and computational analyses suggest that the main difference in the selectivity of the propeller-shaped kinase inhibitors among the various PI3K isoforms is due to differences in the flexibility of the P-loop.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> This loop (analogous to the P-loop found in protein kinases) comprises residues 752–758 in PI3Kδ and is more accommodating of the perpendicular quinoline and quinazolinone of <b>1</b> and <b>2</b>, respectively, than are similar loops in other isoforms.</div><div class="NLM_p">The significant conformational similarity between <b>1</b> and <b>2</b> is replicated with other analogs in this series. The selectivity differences observed between the analogs are subtle and have much to do with a slight shifting of the inhibitor in the binding site due to small structural changes. For example, the ether-linked <b>8</b> was 5-fold more selective for PI3Kδ selective over PI3Kγ than the amino-linked <b>9</b>, but structural studies and modeling show a very close overlap. Generally, although PI3Kδ potency improved, there was little difference in selectivity with a methyl substituent in the amino or ether linkage, as a comparison of the pairs <b>11</b> vs <b>12</b>, <b>14</b> vs <b>15</b>, and <b>17</b> vs <b>16</b> shows (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The largest selectivity gain involved PI3Kα/δ where 1-ethanamine <b>15</b> exhibited a 4-fold improvement in selectivity over methanamine <b>14</b>. However, for the ether-linked pair <b>11</b> and <b>12</b> the selectivity difference of PI3Kα/δ was reversed. The ethoxy-linked <b>12</b> was 4-fold less selective compared to the methoxy-linked <b>11</b>. The final pair was most similar to methylamine <b>17</b> having a 3-fold PI3Kγ/δ selectivity advantage compared to 1-ethylamine <b>16</b>. There was only a small selectivity trend when substituting the quinoline core for a quinoxaline. The PI3Kβ/δ selectivity of quinoxaline <b>31</b> was 6-fold greater than the PI3Kβ/δ selectivity of quinoline <b>30</b>, and there was a 50-fold difference in favor of <b>31</b> comparing PI3Kγ/δ selectivity. For the structurally similar pair <b>16</b> and <b>19</b> the selectivity differential was less pronounced. Quinoxaline <b>19</b> was 5-fold more PI3Kγ/δ selective than quinoline <b>16</b> and only 4-fold more PI3Kβ/δ selective. However, this trend was contradicted with quinoline <b>1</b> and quinoxaline <b>34</b>, which had nearly equivalent selectivity on average. With respect to the substituted phenyl (or pyridyl) group, e.g., the third arm of the propeller, there appeared to be a small preference for 2-substituted phenyl groups compared to 3-substitution, as the selectivity difference between <b>16</b> and <b>18</b> bears out. <b>18</b> is nearly 7-fold more selective for PI3Kδ versus PI3Kγ. The X-ray cocrystal structure of <b>16</b> indicates that the 3-fluoro substituent makes a positive (σ-hole) contact with the carbonyl of Ala885 in PI3Kγ while the 2-fluoro substituent is unable to make this contact in the same orientation (pointing toward Trp812).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The three other isoforms have a serine instead of alanine at this position. This analysis is complicated in that the barrier toward phenyl ring rotation remains small, even though the final low energy form adopts a 90° configuration relative to the quinoline moiety (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a). The 2-chlorophenyl <b>15</b> also proved much weaker in potency toward PI3Kα, which has almost 10-fold greater selectivity than 3-fluoro <b>16</b>. A fluorine substituted at either the 7- or 8-position of the quinoline exhibits a larger level of selectivity than the 8-chloroquinolines, as a comparison of 8-fluoro- <b>20</b> (PI3Kγ/δ = 24), 7-fluoro- <b>23</b> (PI3Kγ/δ = 18), and 8-chloro- <b>16</b> (PI3Kγ/δ = 3) or 7-fluoro- <b>1</b> (PI3Kγ/δ = 48), 8-fluoro- <b>29</b> (PI3Kγ/δ = 57), and 8-chloro- <b>30</b> (PI3Kγ/δ = 2) shows. This selectivity differential was similar for the other two isoforms. Structurally, it was hypothesized that while the purine ring is exactly superimposed, the 7- and 8-fluoroquinolines are slightly puckered out of the plane relative to their 8-chloroquinoline analogs. This rotational difference was attributed to a larger steric demand placed on the chloroquinoline, enhancing the isoform selectivity. Additional selectivity gains over PI3Kγ were found on going to the 2-pyridylquinoline analogs <b>1</b> and <b>29</b>, which were thought to sit lower in the binding pocket than the substituted phenyl or pyridine analogs, such as <b>23</b>, <b>20</b>, or <b>27</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b,c). The protein kinase selectivity found with <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) can generally be attributed to the structural differences between the PI3K lipid kinases and protein kinases. The PI3Ks have a large “mouth” perpendicular to the ATP binding region not typically found in protein kinases. Additionally the adenine binding pocket is larger in lipid kinases than found in most protein kinases.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Cocrystal structure of p110γ + <b>1</b> at 2.7 Å resolution. The orientation of the pyridine ring could not be determined from the electron density and was assigned arbitrarily. Dashed lines indicate hydrogen bonds; the red sphere is an ordered water molecule. (b) Amino acid differences cluster on the P-loop (top) and at the mouth of the active site. Not all differences are shown. (c) Overlay of <b>1</b> (green) bound to PI3Kγ (blue) and <b>2</b> (yellow) bound to PI3Kδ (beige). The P-loop in PI3Kγ is colored pink. Residue labels correspond to PI3Kγ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Cocrystal structure of p110γ + <b>16</b> at 2.30 Å resolution. The 3-fluoro substituent points toward the carbonyl of Ala885 enhancing potency. (b) Crystal structure of p110γ + <b>27</b> at 2.40 Å resolution. (c) Overlay of <b>1</b> (green) onto p110γ + <b>27</b> (magenta). <b>1</b> sits lower in the pocket compared to <b>27</b>, enhancing selectivity over PI3Kγ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p">2-Chloroquinoline-3-carbaldehydes <b>36a</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and <b>36b</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> were converted to various substituted 2-phenylquinolines <b>38a</b>–<b>d</b> via a Suzuki coupling and the aldehydes <b>38b</b>–<b>d</b> directly reduced to primary alcohols (<b>40b</b>–<b>d</b>). Alcohol <b>40a</b> was accessed most smoothly by the NaBH<sub>4</sub> reduction of <b>36a</b> followed by a Suzuki coupling of the resulting <b>37</b>. The carbon linked <b>10</b> was prepared from <b>38a</b> via a Corey–Fuchs procedure<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> providing <b>39a</b> followed by a Sonogashira cross-coupling and reduction of the resulting alkyne <b>39b</b>. Aldehydes <b>38a</b> and <b>38b</b> were treated with a Grignard reagent to supply the secondary alcohols <b>40e</b> and <b>40f</b>, respectively. Conversion of the alcohols <b>40b</b>–<b>d</b> to the primary halides <b>41a</b>–<b>c</b> was performed with SOCl<sub>2</sub> or carbon tetrabromide and triphenyphosphine. Chlorides <b>41a</b> and <b>41b</b> were displaced with azide to provide <b>42a</b> and <b>42b</b> followed by hydrogenation with Pd/C to provide the amines <b>43a</b> and <b>43b</b>, which were coupled with 6-chloropurine to provide the analogs <b>14</b> and <b>17</b>. Alternatively, the ether linked analogs <b>7</b>, <b>8</b>, and <b>11</b> were prepared directly from intermediates <b>40a</b> and <b>40d</b> by coupling with either the 6-chloropurine or 3-chloropyrrolopyrimidine and sodium hydride with DABCO in DMSO. In a similar way <b>12</b> and <b>13</b> were prepared from <b>40e</b> followed by SFC chiral purification. The thioether <b>6</b> was prepared via the thiolate of 6-mercaptopurine and <b>41c</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><div class="NLM_p">This overall sequence was also employed to provide enantiomerically pure <b>15</b>. The α-methyl <b>40f</b> was subjected sequentially in one pot to thionyl chloride, sodium azide, and hydrogenation to produce <b>43c</b>, which was treated with 6-chloropurine and after chiral HPLC provided <b>15</b>. Because of the inherent difficulties in purification of racemic compounds on a larger scale, we needed to find a more satisfactory method of chiral synthesis. This was explored in the synthesis of <b>9</b>. When a Mitsunobu reaction was employed with phthalimide, <b>40a</b> produced <b>44</b> followed by cleavage to amine <b>45</b>, which was then coupled with chloropurine to provide <b>9</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaBH<sub>4</sub> (1.5 equiv), THF (0.5–0.9 M), or MeOH (0.1 M), 0 °C, 0.5–4 h; (ii) boronic acid (1.1 or 1.3 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), CH<sub>3</sub>CN–H<sub>2</sub>O, 100 °C; (iii) <i>o</i>-tolylboronic acid (1.5 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (4.0 equiv), DME, EtOH, H<sub>2</sub>O, 150 °C, microwave, 60%; (iv) MeMgBr (2.0 equiv), THF (0.2 or 0.3 equiv), 0 °C; (v) NaH (4.0 equiv), DMSO (0.4 M), DABCO (4.0 equiv), chiral purification as needed; (vi) 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (2.0 equiv), DABCO (2.0 equiv), NaH (2 equiv), DMSO (2.4 mL), rt, 4 h, chiral HPLC; (vii) SOCl<sub>2</sub> (5.0 equiv), CHCl<sub>3</sub> (0.25 M); (viii) CBr<sub>4</sub> (1.5 equiv), PPh<sub>3</sub> (1.5 equiv), DCM (0.17 M), 0 °C, 0.5 h; (ix) NaN<sub>3</sub> (3.0 equiv), DMSO (0.25 M); (x) Pd–C, H<sub>2</sub>, MeOH, rt; (xi) (bromomethyl)triphenylphosphonium bromide (1.2 equiv), potassium <i>tert</i>-butoxide (6.8 equiv), −78 to 40 °C, 5 h, 41%; (xii) NaOH (0.7 mL, 4.0 equiv, 2 M), THF (0.7 mL), 6-mercaptopurine monohydrate (1.5 equiv), 4 h, reflux, 60%; (xiii) 6-chloropurine (1.2 equiv) or 6-brompurine (1.2 equiv), DIEA (2.0 equiv), EtOH (0.05 M) or <i>n</i>-BuOH, reflux; (xiv) 6-iodopurine (3.0 equiv), DMF (0.1 M), Et<sub>3</sub>N (2.90 mL), CuI (0.4 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.2 equiv), 50 °C, 3 h, 41%; (xv) EtOH/MeOH (1:1, 2 mL), 10% Pd/C (0.05 equiv), 34%.</p></p></figure><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SOCl<sub>2</sub> (5 equiv), CHCl<sub>3</sub> (0.2 M); (ii) NaN<sub>3</sub> (2 equiv), DMSO (0.28 M), 4 h; (iii) 10% Pd/C, H<sub>2</sub>, MeOH (0.09 M), 70%, three steps; (iv) 6-chloropurine, DIEA, <i>n</i>-BuOH, 115 °C; (v) chiral HPLC; (vi) phthalimide (2.0 equiv), PPh<sub>3</sub> (1.7 equiv), ADDP (1.7 equiv), THF (0.2 M), rt, 35 h, 43%; (vii) NH<sub>2</sub>NH<sub>2</sub>–H<sub>2</sub>O (5.0 equiv), EtOH (0.08 M), reflux, 2 h, 97%; (viii) 6-chloropurine (2.0 equiv), Et<sub>3</sub>N (2.0 equiv), DMF (0.3 M), rt to 90 °C, 19 h, 40%.</p></p></figure><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) POCl<sub>3</sub> (7.0 equiv), DMF (2.5 equiv); (ii) MeMgBr (2.0 equiv), THF; (iii) LDA, THF; CH<sub>3</sub>CHO, −78 °C; (iv) MnO<sub>2</sub> (10.0 equiv), Tol (0.17 M), reflux, 2 h; (v) (+) DIP-Cl (2.2 equiv), THF (0.45 M), −47 °C; (vi) phthalimide (1.2 equiv), DIAD (1.2 equiv), PPh<sub>3</sub> (1.2 equiv), 0 °C to rt; (vii) boronic acid (1.1–1.8 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05–0.15 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), MeCN, water, 80–90 °C; (viii) 2-tri-<i>n</i>-butylstannylpyridine, PPh<sub>3</sub>, 1,4-dioxane, 100 °C; (ix) 2-chloro-5-fluoropyridin-3-ylboronic acid (1.2 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.5 equiv), CsF (3.0 equiv), CuI (0.2 equiv), 1,2-ethanediol, dimethyl ether (1.0 equiv), microwave, 100 °C, 1 h, 40%; (x) K<sub>2</sub>CO<sub>3</sub> (0.4 equiv (for <b>53f</b>)), or Na<sub>2</sub>CO<sub>3</sub> (5.2 equiv, (for <b>53e</b>)), Pd(dppf)Cl<sub>2</sub> (0.1 equiv), dry DMF (0.15 M), phenylboronic acid (2.0 equiv), 100 °C, 2.5 h; (xi) Pd(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub>, Xphos, tributyltin cyanide, NMP, dicyclohexylamine, 160 °C, 3.25 h, 67.5%; (xii) AlMe<sub>3</sub> (5.0 equiv), dioxane (0.02 M), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.2 equiv), reflux, 4 h, 75%; (xiii) hydrazine or hydrazine hydrate (1.5–20 equiv), EtOH (0.1 M), 50–90 °C, 0.5–4 h; (xiv) conc HCl (10–20 equiv), EtOH (0.2–0.5 M), reflux, 4 h to 6 days and (<b>54b</b>) hydrazine monohydrate (10 equiv); (xv) conc HCl, sealed flask, 24 h, 76.5% of <b>56f</b>; (xvi) 6-chloropurine (1.0–1.1 equiv) or 6-bromopurine (1.2 equiv), DIEA (1.0–3.0 equiv), <i>n</i>-BuOH (0.1–1.0 M), 100–118 °C.</p></p></figure><div class="NLM_p">In the subsequent chiral synthesis the Misunobu reaction was utilized to install the amino group after a stereospecific reduction of a ketone. The commercial 2-chloro-7-fluoroquinoline-3-carbaldehydes <b>47a</b> and <b>47b</b> (prepared in one step from <i>N</i>-(3,5-difluorophenyl)acetamide) were treated with methylmagnesium bromide to provide secondary alcohols <b>49a</b> and <b>49b</b>. Alternatively, the secondary alcohols <b>49c</b> and <b>49d</b> could be prepared in one step from the commercially available 2,8-dichloroquinoline (<b>48a</b>) or 2-chloro-8-fluoroquinoline (<b>48b</b>) condensed with acetaldehyde and LDA. These secondary alcohols were then oxidized to ketones <b>50a</b>–<b>d</b> followed by the key chiral reduction involving (+) DIP-Cl in THF to supply <b>51a</b>–<b>d</b> in high enantiomeric excess. These chiral alcohols were inverted, protected, and transformed to the amino containing phthalimides <b>52a</b>–<b>d</b> via a Mitsunobu reaction. The 2-chloroquinoline intermediates <b>52a</b>–<b>d</b> were treated to Suzuki coupling conditions. Standard conditions involving boronic acid and tetrakistriphenylphosphine)palladium(0) with sodium carbonate in acetonitrile–water caused a ring opening of the phthalimide in conjunction with the coupling. These benzoic acid intermediates could be isolated, characterized (<b>53a</b>–<b>c</b>), and converted to the free amines <b>54a</b> and <b>54c</b> with refluxing concentrated HCl in ethanol and for <b>54b</b>, by the addition of hydrazine monohydrate. Alternatively, the ring opened intermediate (uncharacterized) of <b>53d</b> was converted in situ back to the phthalimide <b>53d</b> with hot ethanolic HCl. To prevent the hydrolysis, the Suzuki reaction was modified to avoid water by employing 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane complex and dry DMF. Under these conditions the fluorophenylphthalimides <b>53e</b> and <b>53f</b> were isolated. For the synthesis of the pyridyl compounds Stille couplings of <b>52a</b>–<b>d</b> were employed providing 2-pyridylquinolines <b>55a</b>, <b>55b</b>, <b>55d</b>, and <b>55e</b>. A Stille coupling was also used to convert the 8-chloroquinoline moiety of <b>55b</b> to the cyanoquinoline <b>55c</b>. Additionally, for the conversion of <b>52c</b> to <b>55f</b>, a copper(I) mediated Suzuki coupling was utilized, which in turn could be converted to <b>55g</b> via a palladium catalyzed cross-coupling involving trimethylaluminum. Subsequently the isolated phthalimides <b>53d</b>–<b>f</b>, <b>55a</b>–<b>e</b>, and <b>55g</b> were converted to the amines <b>54d</b>–<b>f</b> and <b>56a</b>–<b>f</b> with hydrazine. These amines in turn were converted to the target molecules <b>16</b>, <b>18</b>, <b>20</b>, <b>22</b>, <b>23</b>, <b>25</b>, <b>28</b><b>29</b>, <b>30</b>, <b>33</b>, <b>35</b>, and <b>1</b> with chloro- or bromopurines as described previously (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><div class="NLM_p">We modified this general procedure in several instances (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). For example, instead of relying on the phthalimide, the amine could be accessed by way of a reduction of an azide, which was easily prepared from <b>51d</b> by a Mitsunobu reaction with sodium azide to give <b>57</b>. This in turn was subjected to either a Stille or Suzuki coupling providing <b>58a</b> and <b>58b</b>. The azides at this stage were easily reduced in the usual way with triphenylphosphine providing <b>59a</b> and <b>59b</b> followed by the final S<sub>N</sub>Ar reaction to give analogs <b>26</b> and <b>21</b>. Experimentally, low yields resulted when a thioether phthalimide adduct was oxidized to the sulfone. This issue was surmounted by converting <b>52a</b> to a <i>tert</i>-butyloxycarbonyl protected amine <b>60</b>, which was subjected to the Suzuki coupling providing 2-(methylthio)phenylquinoline <b>61</b>. This analog could be easily oxidized to the sulfone <b>62</b> followed by the standard S<sub>N</sub>Ar reaction to yield analog <b>24</b>. Compound <b>65</b> was prepared in several steps from aldehyde <b>36b</b> as outlined previously in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Racemic <b>65</b> was then converted to <b>66</b> by displacement of the chloride in <b>65</b> with phthalimide potassium salt. After deprotection to the amine <b>67</b>, S<sub>N</sub>Ar displacement and chiral HPLC purification provided <b>27</b>. The alternative series analog <b>4</b> was prepared by treatment of 1-(2-amino-5-chlorophenyl)propan-1-one with sodium nitrite under acidic conditions to providing the cyclized cinnoline alcohol <b>68</b>. This was converted to chloride <b>69</b> with POCl<sub>3</sub> and subjected to a hot solution of 4-(3,3-dimethylindolin-6-yl)morpholine in 1-pentanol to provide the product (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span><sup><i>a</i></sup>Reagents and conditions: (i) PPh<sub>3</sub>, DIAD, DPPA, THF, 0 °C to rt; (ii) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, MeCN, water, 80–100 °C; (iii) PPh<sub>3</sub>, THF, water, 60 °C; (iv) DIEA, <i>n</i>-BuOH, 6-bromopurine or 6-chloropurine, 100–130 °C; (v) NH<sub>2</sub>NH<sub>2</sub> (10 equiv), EtOH, 90 °C, 0.5 h, then Boc<sub>2</sub>O (1.1 equiv), Et<sub>3</sub>N (1.0 equiv), reflux, 76%; (vi) OsO<sub>4</sub> (0.13 equiv), NMO (3.0 equiv), acetone (0.79 M), 100%; (vii) TFA, DCM, rt, 1 h; (viii) MeMgBr (2.0 equiv), THF, 0 °C, 98%; (ix) SOCl<sub>2</sub> (5.0 equiv), CHCl<sub>3</sub> (0. 3M), rt, 3 h; (x) potassium phthalimide (2.5 equiv), DMF (0.37 M), 1.5 h, 100 °C; (xi) NH<sub>2</sub>NH<sub>2</sub> (10 equiv), EtOH (0.1 M), reflux, 1.5 h, 60%, three steps; (xii) chiral HPLC; (xiii) NaNO<sub>2</sub> (1.1 equiv), HCl (5.0 N), 92%; (xiv) POCl<sub>3</sub>, (15.1 equiv), 90 °C, 3 h, 78%; (xv) 4-(3,3-dimethylindolin-6-yl)morpholine, 1-pentanol, 140 °C, 51%.</p></p></figure><div class="NLM_p">The three quinoxoline analogs <b>31</b>, <b>32</b>, and <b>34</b> were prepared in several steps (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Starting with the condensation of ethyl 2-oxobutanoate and 2-amino, 3-chloroaniline in PPA supplied 8-chloroethylquinoxalinone (<b>70a)</b> together with a minor amount of the 5-chloro regioisomer. 7-Fluoroquinoxalinone <b>70b</b> was prepared by DDQ oxidation of the commercially available 3-ethyl, 7-fluoro-3,4-dihydroquinoxalinone.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Bromo compounds <b>71a</b> and <b>71b</b> were subsequently prepared by treatment of <b>70a</b> and <b>70b</b> with 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, benzoyl peroxide in CCl<sub>4.</sub> These intermediates were then subjected to POCl<sub>3</sub> treatment to supply chloroquinolines <b>72a</b> and <b>72b</b>, which were then treated with potassium phthalimide to give <b>73a</b> and <b>73b</b>. The synthesis of the 3,8-dichloroquinoxaline <b>73c</b> was done in a slightly different manner. 3-Chlorobenzene-1,2-diamine was condensed and cyclized with methyl 3-(1,3-dioxoisoindolin-2-yl)-2-oxobutanoate<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> to produce the phthalimide <b>74</b>, which was converted to the chloroquinoxaline <b>73c</b> as before. A Stille coupling installed the 2-pyridyl group supplying <b>75a</b>–<b>c</b> followed by a deprotection of the phthalimide, leaving the amino intermediates <b>76a</b>–<b>c</b>. The amine <b>76d</b> was obtained by chiral HPLC purification of <b>76c</b>. These amines were then converted to the final products <b>31</b>, <b>32</b>, and <b>34</b> by treatment with DIEA and chloropurine followed by a final chiral purification using SFC.</div><div class="NLM_p">Finally, the synthesis of <b>19</b> was done in a very similar way to the other quinoxalines (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). 2-Aminobutanic acid was heated with 1-chloro-3-fluoro-2-nitrobenzene to provide <b>78</b>, which was reductively cyclized to deliver the dihydroquinoxaline <b>79</b>. The oxidation of <b>79</b> with DDQ supplied <b>70a</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which was converted to the 2-chloroquinoxaline <b>80</b>. At this point, the 3-fluorophenyl group was installed with a Suzuki coupling to give <b>81</b>, which was then brominated to provide <b>82</b>. The secondary bromide in <b>82</b> was displaced with azide to give <b>83</b>, which was reduced with trimethylphosphine to give the racemic amine <b>84</b>, which was treated to the standard S<sub>N</sub>Ar conditions, and following a chiral purification <b>19</b> was obtained. Although this was a lengthy sequence, it provided the desired product in high yield and allowed for reasonable scaling up, even with the final purification (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>).</div><figure id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ethyl 2-oxobutanoate (1.0 equiv), PPA (1.0 equiv), 100–160 °C, 2.7 h, 60%; (ii) 1,4-dioxane (0.2 M), DDQ (1.05 equiv), rt, 2.5 h, 95%; (iii) 1, 3-dibromo-5,5-dimethylimidazolidine-2,4-dione (0.7 equiv), benzoyl peroxide (0.1 equiv), CCl<sub>4</sub> (1.0 equiv), 20 h, 80 °C to reflux, 80–100%; (iv) POCl<sub>3</sub> (10–13 equiv), 1.5–2 h, 100–110 °C; (v) potassium phthalimide (1.0 equiv), DMF (0.3 M), 1–3 h, rt, 70–76%; (vi) 2-tri-<i>n</i>-butylstannylpyridine (1.3–2.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 equiv), 1,4-dioxane or toluene, 110 °C, 19–29 h; (vii) methyl, 3-(1,3-dioxoisoindolin-2-yl)-2-oxobutanoate (1.0 equiv), EtOAc (0.4 M), rt, 3 h, ∼3.5:1 mixture of regioisomers; (viii) hydrazine hydrate (5–10 equiv), EtOH, 95 °C, 1–1.5 h; (ix) chiral purification SFC or chiral HPLC; (x) DIEA (3.0 equiv), <i>n</i>-BuOH (0.1 or 0.28 M), 6-chloropurine (1.0 equiv) or 6-bromopurine (1.0 equiv), 100–110 °C, 5–24 h.</p></p></figure><figure id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 2-aminobutanic acid (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (1.0 equiv), DMSO, 80 °C, 18 h, 76%; (ii) SnCl<sub>2</sub>–2H<sub>2</sub>O (5.0 equiv), HCl, EtOH, 90 °C, 2.5 h, 94%; (iii) DDQ (1.0 equiv), 1,4-dioxane, rt, 2 h, 97%; (iv) POCl<sub>3</sub> (10 equiv), 100 °C, 2.0 h, 90%; (v) (3-fluorophenyl)boronic acid (1.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), CH<sub>3</sub>CN–H<sub>2</sub>O (3:1, 0.1 M), 8 h, 89%; (vi) 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (0.55 equiv), benzoyl peroxide (0.1 equiv), CCl<sub>4</sub> (0.2 M), reflux, 17 h, 92% ; (vii) NaN<sub>3</sub> (2 equiv), DMSO (0.3 M), rt, 2 h, 100%; (viii) PMe<sub>3</sub> (1.0 equiv, 1 M), THF–H<sub>2</sub>O (4:1, 0.17 M), rt, 1.7 h, 87.8%; (ix) 6-chloropurine (1.0 equiv), DIEA (3.0 equiv), 1-BuOH (1.0 M), 100 °C, 22 h, 48%; (x) chiral separation using SFC, 37%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26634" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26634" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this report we review the discovery and development of <b>1</b> focusing on inflammation and autoimmunity (<b>1</b> is currently undergoing clinical trials for oncology). <b>1</b> has a high degree of potency toward PI3Kδ and selectivity over the other PI3K isoforms. PI3Kδ is known to be a key player in the inflammatory response; therefore, small molecule inhibitors of PI3Kδ would be very useful in diseases of dysfunctional immunity such as RA and SLE. Although many analogs reported here such as <b>14</b> and <b>16</b> had reasonable profiles in both in vitro assays and in vivo rodent models of disease, these were not our only considerations. Mindful of potential pitfalls that could occur in the clinic and beyond, we focused on the physicochemical properties of these analogs as well as their potency and selectivity. PI3K isoform selectivity gains were found by pinpointing electron withdrawing groups on either the 2-aryl group or the quinoline core, with the 7-fluoroquinoline being the most advantageous. In large part, the high kinase selectivity of <b>1</b> was due to the unusual shape of the molecule, which limits its ability to bind to the ATP binding site of protein kinases. Because permeability was consistently high for this series, we focused on improving solubility. This focus yielded compounds that were substantially improved in their overall in vitro profiles, such as increased HWB potency and decreasing CYP inhibition. A consequence of this was lower plasma protein binding. Initially, this led to compounds with higher clearance, but structural changes in the inhibitors provided compounds with much lower intrinsic clearance. This had the effect of increasing the unbound drug concentration, which led to higher efficacy in the rat KLH model. Key developments along this path include the discovery of the 2-methylsulfonylphenyl moiety as found in <b>24</b>, a group which dramatically increased the solubility. Additionally, the 2-pyridine substituted quinoline moiety, as in <b>1</b>, was an improved soluble isostere of the methylsulfonylphenyl group, further enhancing the compound profile including lowering of the rat iv clearance. Although the pAKT mouse model was used only to benchmark compounds and many compounds performed similarly, it was the close correlation between the in vitro and in vivo assays that allowed a smooth selection of doses for the 10-day KLH IgG-IgM response rat model. It was the performance in this model that led to the selection of compounds such as <b>1</b> for further preclinical evaluation. Finally, we will be reporting on additional structurally related, potent, and selective PI3Kδ inhibitors for inflammation and more details pertaining to <b>1</b> including details related to its use in an oncology clinical setting in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Biology. Recombinant Expression of PI3Ks</h3><div class="NLM_p last">Full length p110 subunits of PI3kα, -β, and -δ, N-terminally labeled with polyHis tag were coexpressed with p85 with baculovirus expression vectors in Sf9 insect cells. P110/p85 heterodimers were purified by sequential Ni-NTA, Q-HP, and Superdex-100 chromatography. Purified α, β, and δ isoforms were stored at −20 °C in 20 mM Tris, pH 8, 0.2 M NaCl, 50% glycerol, 5 mM DTT, 2 mM Na cholate. Truncated PI3Kγ, residues 114–1102, N-terminally labeled with polyHis tag, was expressed using baculovirus in Hi5 insect cells. The γ isoform was purified by sequential Ni-NTA, Superdex-200, Q-HP chromatography, and stored frozen at −80 °C in NaH<sub>2</sub>PO<sub>4</sub>, pH 8, 0.2 M NaCl, 1% ethylene glycol, 2 mM β-mercaptoethanol.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vitro Assays</h3><div class="NLM_p"><i>PI3K Enzyme Assays.</i> A PI3K Alphascreen assay (PerkinElmer, Waltham, MA) was used to measure the activity of a panel of four phosphoinositide 3-kinases: PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ. Enzyme reaction buffer was prepared using sterile water (Baxter, Deerfield, IL) and 50 mM Tris-HCl, pH 7, 14 mM MgCl<sub>2</sub>, 2 mM sodium cholate, and 100 mM NaCl. 2 mM DTT was added fresh on the day of the experiment. The Alphascreen buffer was made using sterile water and 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.10% Tween 20, and 30 mM EDTA. Then 1 mM DTT was added fresh on the day of the experiment. Compound source plates used for this assay were 384-well Greiner clear polypropylene plates containing test compounds at 5 mM and diluted 1:2 over 22 concentrations. Columns 23 and 24 contained only DMSO, as these wells comprised the positive and negative controls, respectively. Source plates were replicated by transferring 0.5 μL per well into 384-well Optiplates (PerkinElmer, Waltham, MA). Each PI3K isoform was diluted in enzyme reaction buffer to 2× working stocks. PI3Kα was diluted to 1.6 nM, PI3Kβ was diluted to 0.8 nM, PI3Kγ was diluted to 15 nM, and PI3Kδ was diluted to 1.6 nM. PI(4,5)P2 (Echelon Biosciences, Salt Lake City, UT) was diluted to 10 μM, and ATP was diluted to 20 μM. This 2× stock was used in the assays for PI3Kα and PI3Kβ. For assay of PI3Kγ and PI3Kδ, PI(4,5)P2 was diluted to 10 μM and ATP was diluted to 8 μM to prepare a similar 2× working stock. Alphascreen reaction solutions were made using beads from the anti-GST Alphascreen kit (PerkinElmer, Waltham, MA). Two 4× working stocks of the Alphascreen reagents were made in Alphascreen reaction buffer. In one stock, biotinylated-IP<sub>4</sub> (Echelon Biosciences, Salt Lake City, UT) was diluted to 40 nM and streptavadin-donor beads were diluted to 80 μg/mL. In the second stock, PIP<sub>3</sub>-binding protein (Echelon Biosciences, Salt Lake City, UT) was diluted to 40 nM and anti-GST-acceptor beads were diluted to 80 μg/mL. As a negative control, a reference inhibitor at a concentration ≫<i>K</i><sub>i</sub> (40 μM) was included in column 24 as a negative (100% inhibition) control. Using a 384-well Multidrop (Titertek, Huntsville, AL), 10 μL/well of 2× enzyme stock was added to columns 1–24 of the assay plates for each isoform. An amount of 10 μL/well of the appropriate substrate 2× stock (containing 20 μM ATP for the PI3Kα and -β assays and containing 8 μM ATP for the PI3Kγ and -δ assays) was then added to columns 1–24 of all plates. Plates were then incubated at room temperature for 20 min. In the dark, 10 μL/well of the donor bead solution was added to columns 1–24 of the plates to quench the enzyme reaction. The plates were incubated at room temperature for 30 min. Still in the dark, 10 μL/well of the acceptor bead solution was added to columns 1–24 of the plates. The plates were then incubated in the dark for 1.5 h. The plates were read on an Envision multimode plate reader (PerkinElmer, Waltham, MA) using a 680 nm excitation filter and a 520–620 nm emission filter.</div><div class="NLM_p"><i>Human B Cell Proliferation Assay.</i> B cells were purified from human peripheral blood mononuclear cells (PBMCs) by negative selection. Approximately 3 × 10<sup>4</sup> purified B cells per well were seeded into a 96-well plate. Compounds were dissolved in DMSO at a concentration of 10 mM, and a 10-point, 3-fold serial dilution of the compound was carried out in DMSO. Then 0.5 μL of compound was added to each well in duplicates so that the final DMSO concentration was 0.25% and the highest compound concentration was 10 μM. After preincubating for 30 min, B cells were treated with 2 μg/mL of anti-human IgM antibody plus 300 ng/mL human CD40L or 5 ng/mL human IL-4 plus 200 ng/mL of CD40L as a counterscreen to evaluate the off-target effects (data not shown). The plates were incubated at 37 °C and 5% CO<sub>2</sub> for 72 h, then pulsed with 0.5 μCi per well <sup>3</sup>H thymidine for 18 h, and B cells were collected to count the incorporation of <sup>3</sup>H thymidine.</div><div class="NLM_p last"><i>Murine B Cell in Vitro Anti-IgM Induced pAKT Assay.</i> B cells were harvested from BALB/c mouse spleens as approved by the Amgen Institutional Animal Care and Use Committee. The 1 ×10<sup>6</sup> splenocytes were plated into 96-deep well plates in dilution medium (PBS + 0.5% BSA) and rested for 30 min. A 96-well compound dilution plate was prepared starting at 2.5 mM with a 10-point 1:3 serial dilution in 100% DMSO, with lanes 6 and 12 containing DMSO only to provide stimulation and no stimulation control values. A further 10× compound dilution plate was prepared starting at 25 μM by transferring 2 μL of diluted compounds into 198 μL of dilution media in a 96-well U bottom plate. Ten microliters of diluted compound was transferred to the resting splenocytes for a final starting concentration of 2.5 μM, mixed, and incubated 45 min at room temperature. To stimulate the cells, 10 μL of antimurine IgM (20 μg/mL final concentration in dilution medium) was added to columns 1–11. No anti-IgM was added to column 12 containing the no stimulation control wells. Cells were mixed and incubated 15 min at room temperature. The stimulation was ended by the addition of 37 °C prewarmed 1× lyse/fix solution (BD Biosciences). The plate was covered, shaken, and incubated at 37 °C for 10 min for RBC lysis and cell fixation. The cells were centrifuged, and the supernatant was removed. To permeabilize the cells, 600 μL of 90% ice cold methanol was added per well while vigorously shaking. The plate was sealed and stored at −20 °C until further FACS analysis. For flow cytometry analysis, the plates were centrifuged and washed twice to remove residual methanol and then stained with 50 μL of the following antibodies: CD45R/B220, Pacific Blue, 1:100 dilution; anti-phospho-AKT (Ser473) (193H12) rabbit mAb, 1:100 dilution; Zap70 (pY319)/Syk (pY352), PE, 10 μL/well; ERK1/2 (pT202/pY204), FITC, 10 μL/well. The samples were stained for 1 h at room temperature and then washed with 1.8 mL of wash buffer (2% FBS in PBS). To detect rabbit anti-mouse pAKT, 50 μL of anti-rabbit Alexa Fluor-647 secondary (1:500) in dilution medium was added per well. The plate was incubated 15 min at room temperature and then washed twice with wash buffer. An amount of 200 μL of cells was transferred to a 96-well U bottom tissue culture plate and analyzed on a Becton Dickenson LSRII flow cytometer. Then 5–10000 CD45R/B220+ B cells were analyzed for their mean fluorescent activity (MFI) of pAKT. pSyk and pERK1/2 MFI levels were also measured on the B cells as controls for on target activity of the compounds. To derive IC<sub>50</sub> values, percent of control (POC) values for pAKT, pSyk, and pERK1/2 were plotted against the compound concentration (log μM) in GraphPad Prism, version 5.0.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Studies</h3><div class="NLM_p"><i>pAKT Mouse in Vivo Studies.</i> IgM membrane only homozygous transgenic mice (6- to 12-week-old female) were orally dosed with compound or vehicle control (<i>n</i> = 5 per group). At 15 min after treatment, mice were tail iv injected with 50 μg of endotoxin-free FITC-labeled μ chain specific anti-IgM (Jackson Immunoresearch) or PBS only control. Blood and spleen tissue were collected after 30 min of stimulation for drug concentration and B cell pAKT analysis via flow cytometry. Briefly, blood and dispersed splenocytes were fixed with BD Phosflow lyse/fix buffer (Becton Dickinson), pelleted, and permeabilized with cold 90% MeOH. Cells were then stained with pAKT (Cell Signaling Technology) and Alexa-647 secondary (Invitrogen) and B220-Pacific Blue (Becton Dickinson) for FACS analysis. Stimulated B220+/anti-IgM FITC+ B cells were analyzed for pAKT levels with B220+/FITC– B cells from anti-IgM untreated mice serving as a control. Mice were maintained and experiments were performed at Amgen Inc., Thousand Oaks, CA, under a protocol approved by the Institutional Animal Care and Use Committee (IACUC).</div><div class="NLM_p last"><i>KLH Rat in Vivo Studies.</i> Female Lewis rats (<i>N</i> = 8/dose group) were dosed po with test compounds or vehicle (2% HPMC, 1% Pluronic F68, 10% Captisol, pH 2.0) once a day for 10 days at various doses. Two hours after the first dosing, 200 μL of PBS containing 60 μg of KLH was administered to each rat intravenously. Ten days after the KLH priming, rats were euthanized and blood was taken by cardiac puncture for the measurement of KLH specific IgG and IgM by ELISA.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Crystallography</h3><div class="NLM_p last">Human p110γ(144–1102) was expressed, purified, and crystallized, and inhibitor complexes were prepared according to published procedures.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> Diffraction data for p110γ + <b>1</b> were collected on an FR-E rotating anode X-ray source equipped with an RAXIS IV++ detector. Diffraction data for p110γ + <b>16</b> and p110γ + <b>27</b> were collected at the Advanced Photon Source, beamline 31-ID, using λ = 0.9793 Å and a MAR 165 mm CCD detector. Data were processed using the HKL software suite,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and the structures were refined using REFMAC starting from previously solved models of PI3Kγ.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Model building was performed with COOT.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Chemistry</h3><div class="NLM_p last">All solvents and chemicals used were reagent grade unless otherwise noted. Anhydrous solvents were purchased from Aldrich and used without further purification. Analytical thin layer chromatography (TLC) and column (flash) chromatography were performed on Merck silica gel 60 (230–400 mesh) utilizing Combi-Flash or Biotage instrumentation. Microwave reactions were performed with a CEM Discover benchtop apparatus. Concentration refers to solvent removal, which was conducted with a Buchi type rotary evaporator. Residual solvent was removed using a vacuum manifold (1 Torr). Reported yields are isolated yields. All final compounds were purified to ≥95% purity as determined by an Agilent 1100 series HPLC instrument with UV detection at 220 nm using the following method: Zorbax SB-C8 column (3.5 μm, 150 mm × 4.6 mm i.d.), eluting with binary solvent systems A and B using a 5–95% B (0–15 min) gradient elution [A, H<sub>2</sub>O with 0.1% TFA; B, CH<sub>3</sub>CN with 0.1% TFA]; flow rate 1.5 mL/min. Preparative reversed-phase high pressure liquid chromatography (RP-HPLC) was performed using an Agilent 1100 series HPLC and Phenomenex Gemini C18 column (5 μm, 100 mm × 30 mm i.d.), eluting with binary solvent systems A and B using a gradient elution [A, H<sub>2</sub>O with 0.1% TFA; B, CH<sub>3</sub>CN with 0.1% TFA] with UV detection at 220 nm. Low resolution electrospray ionization (ESI) mass spectrometry analysis was conducted on an Agilent 1100 series LC/MSD electrospray mass spectrometer with UV detection at 254 nm. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion in parentheses. Compounds were analyzed in the positive ESI mode with acetonitrile/water with 0.1% formic acid. NMR spectra were recorded on a Varian Gemini 400 MHz or Bruker Avance 500 or 600 MHz or NMR spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to residual undeuterated solvent or TMS as internal reference. Spin–spin coupling constants (<i>J</i>) are reported in hertz (Hz) and obtained from the splitting patterns, which are indicated as follows: s = singlet; d = doublet; t = triplet; q = quartet; qn = quintet; dd = doublet of doublet; dt = doublet of triplets; m = multiplet; br = broad peak. Enantiomeric excess determinations were done with chiral HPLC on Chiralpak AD-H or OD-H, OH-H, AS-H, and IA columns, eluting with isopropanol in hexane. Preparative chiral HPLC was done with Chiracel OD-H columns (0.46 mm × 250 mm, 5 mm) with isopropanol in hexane as eluent. Larger scale quantitative separations were done with supercritical fluid chromatography (SFC). An analytical vial of approximately 1 mg/mL (in methanol) was prepared from the sample material. Analytical SFC screening was performed on multiple chiral phases. The gradient method and columns used in the screen are below. Chiral columns: AD-H, AS-H, OD-H, OJ-H, IA, IB, IC, Lux2 (150 mm × 4.6 mm, 5 μm). Mobile phase: A, liquid CO<sub>2</sub>; B, methanol (0.2% DEA). CO<sub>2</sub> and methanol are mixed according to the gradient below, and mobile phase is held to an elevated (100 bar), constant outlet pressure at the outlet at all times during gradient. Oven/column temp: 40 °C. Flow rate: 5.0 mL/min total. Outlet pressure: 100 bar. Gradient, percent B, time (min): 5.00, 0.00; 60.00, 4.50; 60.00, 6.00; 5.00, 6.50; 5.00, 7.00. On the basis of the separation observed, an isocratic method was developed with the best column to project conditions on preparative (quantitative) scale and for QC analysis following prep. Typical conditions: OD-H + IC 250 mm × 30 mm columns in-series using 36 g/min IPA (0.2% DEA) + 54 g/min CO<sub>2</sub> on Thar 350 SFC. Outlet pressure = 125 bar. Temp = 18 °C. Wavelength = 327 nm. Used 2.0 mL injections of 5.0 g/750 mL (9:1 IPA/ACN) sample solution.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-(1-(6-Chloro-3-methylcinnolin-4-yl)-3,3-dimethylindolin-6-yl)morpholine (<b>4</b>)</h3><div class="NLM_p last">A solution of 4-(3,3-dimethylindolin-6-yl)morpholine (232 mg, 1.00 mmol, 0.75 equiv) and <b>69</b> (320 mg, 1.5 mmol, 1.0 equiv) in 1-pentanol (10 mL, 0.15 M) was heated to 140 °C overnight. The reaction mixture was cooled to rt and poured into water and extracted with DCM (2 × 50 mL). The organic layer was washed with saturated NaHCO<sub>3</sub>, brine and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure and the crude residue purified by chromatography, eluting with 0–100% EtOAc/hexane. Yield 51% (208 mg, 0.51 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.44 (1 H, d, <i>J =</i> 9.0 Hz), 7.84 (1 H, dd, <i>J =</i> 9.0, 2.2 Hz), 7.50 (1 H, d, <i>J =</i> 2.0 Hz), 6.89 (1 H, s), 6.41 (1 H, s), 5.88 (1 H, s), 2.71 (3 H, s), 1.24 (6 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 409.1 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>25</sub>ClN<sub>4</sub>O + H<sup>+</sup> [M + H]: 409.1795. Found: 409.1795.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 3-((9<i>H</i>-Purin-6-ylthio)methyl)-2-(2-methoxyphenyl)-8-methylquinoline (<b>6</b>)</h3><div class="NLM_p last">To a stirred biphasic mixture of NaOH (2 M, 0.7 mL, 1.40 mmol) and <b>41c</b> (122 mg, 0.356 mmol) in THF (0.7 mL) was added 6-mercaptopurine monohydrate (91 mg, 0.54 mmol). After 4 h, refluxing for the last 3 h, the mixture was cooled to rt, diluted with H<sub>2</sub>O (10 mL), brought to pH 6 by the addition of 2 N HCl, saturated with NaCl, and extracted with THF. The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The resulting light yellow solid was recrystallized from THF/MeOH to provide <b>6</b>. White powder; yield 60% (89 mg, 0.214 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>8</sub>]THF) δ ppm 2.70 (3 H, s), 3.79–3.84 (3 H, m), 4.71 (2 H, s), 7.02–7.11 (2 H, m), 7.32–7.50 (5 H, m), 7.62 (1 H, d, <i>J =</i> 8.02 Hz), 8.09 (1 H, s), 8.37 (1 H, s) 8.55 (1 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 414.0 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>OS + H<sup>+</sup> [M + H]: 414.1389. Found: 414.1385.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Synthesis of <b>7</b> and <b>8</b></h3><div class="NLM_p last">A mixture of 6-chloropurine (2.0 equiv) or 4-chloropyrrolo[2.3-<i>d</i>]pyrimidine (75 mg, 0.49 mmol) and DABCO (4.0 equiv) in DMSO (1 mL) was stirred at rt for 4 h and was then added via cannula to a mixture of <b>40a</b> (94 mg, 0.36 mmol) or <b>40d</b> (70 mg, 0.25 mmol) and sodium hydride, 60% dispersion in mineral oil (4.0 equiv) in DMSO (0.4 M) that had been stirred at rt for 15 min prior to the addition. The final mixture was stirred at rt for 3.5 h, neutralized by the addition of glacial acetic acid, diluted with brine, and extracted with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3-((9<i>H</i>-Purin-6-yloxy)methyl)-2-(2-methoxyphenyl)-8-methylquinoline (<b>7</b>)</h3><div class="NLM_p last">The residue was purified by column chromatography, eluting with 0–2% DCM/MeOH to provide <b>7</b>. White solid; yield 84% (0.083 g, 0.21 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 13.41 (1 H, s), 8.51 (1H, s), 8.39 (1 H, s), 7.87 (1 H, d, <i>J =</i> 7.8 Hz), 7.65 (1 H, d, <i>J =</i> 7.0 Hz), 7.49–7.56 (1 H, m), 7.34–7.46 (2 H, m), 7.12 (1 H, d, <i>J =</i> 8.2 Hz), 7.03 (1 H, t, <i>J =</i> 7.2 Hz), 5.58 (2 H, s), 3.72 (3 H, s), 2.69 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 398.2 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]: 398.1617. Found: 398.1609.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-(((9<i>H</i>-Purin-6-yl)oxy)methyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>8</b>)</h3><div class="NLM_p last">The resulting yellow oil was dissolved in DCM, evaporated onto silica gel (deactivated with 2 M NH<sub>3</sub> in MeOH), and purified by flash chromatography, eluting with 5% MeOH/DCM. White solid; yield 64% (136 mg, 0.228 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.63 (1 H, s), 8.40 (1 H, s), 8.34 (1 H, s), 7.84 (1 H, d, <i>J =</i> 8.02 Hz), 7.65 (1 H, d, <i>J =</i> 6.85 Hz), 7.53 (1 H, dd, <i>J =</i> 8.02 Hz), 7.36 (1 H, d, <i>J =</i> 7.24 Hz), 7.29 (1 H, d, <i>J =</i> 7.88 Hz), 7.17–7.26 (1 H, m), 5.60 (2 H, s), 4.89 (4 H, s), 3.32–3.38 (8 H, m), 2.77 (3 H, s), 2.17 (3 H, s), 1.31 (1 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 282 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]: 382.1668. Found: 382.1672.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-((8-Methyl-2-<i>o</i>-tolylquinolin-3-yl)methyl)-9<i>H</i>-purin-6-amine (<b>9</b>)</h3><div class="NLM_p last">A mixture of <b>45</b> (50 mg, 0.19 mmol), 6-chloropurine (59 mg, 0.38 mmol), and triethylamine (0.053 mL, 0.38 mmol) in DMF (0.6 mL) was stirred at rt for 1 h, then 60 °C for 12 h and 90 °C for 6 h. The crude mixture was evaporated onto silica gel and purified by flash chromatography (Biotage Si 25+M, 5–10% MeOH/DCM) to provide 64 mg of a colorless glass. The compound was further purified by reversed-phase HPLC (Gilson, H<sub>2</sub>O/MeCN/THF) to provide <b>9</b>. White solid; yield 40% (29 mg, 0.076 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>4</sub>]methanol) δ ppm 8.29 (1 H, br s), 8.12 (1 H, br s), 8.07 (1 H, br s), 7.70 (1 H, d, <i>J =</i> 7.63 Hz), 7.56 (1 H, d, <i>J =</i> 6.06 Hz), 7.38–7.49 (1 H, m), 7.33 (2 H, d, <i>J =</i> 6.85 Hz), 7.18–7.30 (4 H, m), 4.73 (2 H, br s), 2.72 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 381.2 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>20</sub>N<sub>6</sub> + H<sup>+</sup> [M + H]: 381.1828. Found: 381.182.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3-(2-(7<i>H</i>-Purin-6-yl)ethyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>10</b>)</h3><div class="NLM_p last">To a solution of <b>39b</b> (0.069g, 0.14 mmol) in EtOH/MeOH (1:1, 2 mL) was added Pd/C (0.05 equiv). The resulting mixture was evacuated/backfilled with N<sub>2</sub> (3×) and with hydrogen (3×). The mixture was stirred under a hydrogen balloon overnight. At this time it was filtered through a Celite pad. Solvent was removed under reduced pressure and the crude residue was purified by flash chromatography, eluting with 0–10% MeOH/DCM to afford (<b>10</b>). Yield 34% (0.018g, 0.047 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 13.38 (1 H, s), 8.70 (1 H, br s), 8.46 (1 H, br s), 8.29 (1 H, br s), 7.73 (1 H, br s), 7.40–7.60 (2 H, m), 7.15–7.38 (4 H, m), 3.12 (2 H, br s), 2.61 (3 H, s), 2.00 (3 H, s), 1.24 (1 H, br s), 0.85 (1 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 380 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>24</sub>H<sub>21</sub>N<sub>5</sub> + H<sup>+</sup> [M + H]: 380.1875. Found: 380.1879.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-(((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)methyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>11</b>)</h3><div class="NLM_p last">A mixture of 4-chloropyrrolo[2.3-<i>d</i>]pyrimidine (75 mg, 0.49 mmol) and DABCO (109 mg, 0.973 mmol) in dry DMSO (1 mL) was stirred at rt for 4 h and was then added via cannula to a mixture of <b>40a</b> (70 mg, 0.27 mmol) and sodium hydride, 60% dispersion in mineral oil (39 mg, 0.98 mmol, 3.7 equiv) in DMSO (0.5 M) that had been stirred at rt for 15 min prior to the addition. The final mixture was stirred at rt for 3.5 h, neutralized by the addition of glacial acetic acid, diluted with brine, and extracted with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography, eluting with 0–2% DCM/MeOH to provide (<b>11</b>). White solid; yield 69% (70 mg, 0.18 mmol). <sup>1</sup>H NMR ([D<sub>6</sub>]DMSO) δ 12.0 (1 H, s), 8.60 (1 H, s), 8.26 (1 H, s), 7.90 (1 H, d, <i>J =</i> 7.9 Hz), 7.66 (1 H, d, <i>J =</i> 7.0 Hz), 7.54 (1 H, t, <i>J =</i> 7.4 Hz), 7.22–7.37 (5 H, m), 6.50 (1 H, d, <i>J =</i> 2.1 Hz), 5.45 (2 H, s), 2.68 (3 H, s), 2.11 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 381 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O + H<sup>+</sup> [M + H]: 381.1715. Found: 381.1713.</div></div><div id="sec4_2_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-3-(1-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)ethyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>12</b>) and (<i>R</i>)-3-(1-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)ethyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>13</b>)</h3><div class="NLM_p last">4-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.31 g, 2.0 mmol) and DABCO (0.45 g, 4.0 mmol) were stirred in DMSO (1.4 mL) at rt for 4 h. <b>40a</b> (0.28 g, 1.0 mmol) was stirred in 1.0 mL of DMSO, and sodium hydride, 60% dispersion in mineral oil (2 equiv) was added. After 10 min, the pyrrolopyrimidine–DABCO solution was added to the quinolinyl alcohol, and the mixture was stirred overnight. Chromatography, eluting with 0–100% EtOAc in hexane followed by chiral separation using IA column (5% isopropanol in hexane), gave the pure isomers</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-3-(1-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)ethyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>12</b>)</h3><div class="NLM_p last">Yield 10% (34 mg, 0.10 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 11.99 (1 H, br s), 8.59 (1 H, br s), 8.25 (1 H, br s), 8.08 (1 H, br s), 7.88 (1 H, d, <i>J =</i> 7.04 Hz, 2 H), 7.61 (1 H, d, <i>J =</i> 6.7 Hz), 7.49 (1 H, t, <i>J =</i> 7.04 Hz), 7.31–7.36 (3 H, m), 6.55 (2 H, br s), 2.65 (3 H, s.), 2.11 (3 H, s), 1.69 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 395.2 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O + H<sup>+</sup> [M + H]: 395.1872. Found: 395.1881.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-3-(1-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)ethyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>13</b>)</h3><div class="NLM_p last">Yield 11% (40 mg, 0.11 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 11.98 (1 H, br s), 8.59 (1 H, br s), 8.25 (1 H, br s), 8.08 (1 H, br s), 7.86 (2 H, d, <i>J =</i> 7.04 Hz), 7.61 (1 H, d, <i>J =</i> 6.7 Hz), 7.49 (1 H, t, <i>J =</i> 7.04 Hz), 7.31–7.36 (3 H, m) 6.55 (2 H, br s), 2.64 (3 H, s), 2.11 (3 H, s), 1.68 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 395.2 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O + H<sup>+</sup> [M + H]: 395.1872. Found: 395.1873.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Synthesis of <b>38a</b>–<b>d</b> and <b>63</b></h3><div class="NLM_p last">To a stirred mixture of 2-chloro-8-methylquinoline-3-carbaldehyde (<b>36a</b>) (1.00 equiv) or 2,8-dichloroquinoline 3-carbaldehyde (<b>36b</b>) (1.00 equiv) and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), and Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv, 2 M aqueous) in CH<sub>3</sub>CN–water (3:1, 0.1 M) was added <i>o</i>-tolyboronic acid (1.5 g, 11.0 mmol, 1.1 equiv) or 2-chlorophenylboronic acid (4.20 g, 30.9 mmol, 1.1 equiv) or 3-fluorophenylboronic acid (1.6 g, 12 mmol, 1.3 equiv) or 2-methoxyphenylboronic acid (0.167 g, 1.10 mmol, 1.1 equiv) or 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.01 g, 4.87 mmol, 1.1 equiv), and the mixture was heated at 100 °C under N<sub>2</sub> for several hours. The mixture was partitioned between EtOAc and H<sub>2</sub>O, the organic layer was separated, and the aqueous layer was extracted with EtOAc. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Column chromatography (silica gel) with 0–25% gradient of EtOAc in hexane provided 2-arylquinoline-3-carbaldehydes.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 8-Methyl-2-(2-methylphenyl)quinoline-3-carbaldehyde (<b>38a</b>)</h3><div class="NLM_p last">Starting amount of <b>6</b> (2.1 g, 10 mmol); white solid; yield 90% (2.35g, 8.99 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.96 (1 H, s), 8.83 (1 H, s), 7.88 (1 H, d, <i>J =</i> 7.8 Hz), 7.74 (1 H, d, <i>J =</i> 6.3 Hz), 7.55 (1 H, t, <i>J =</i> 7.8 Hz), 7.36–7.46 (4 H, m), 2.84 (3 H, s), δ 2.30 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 262 (M + 1).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 8-Chloro-2-(2-chlorophenyl)quinoline-3-carbaldehyde (<b>38b</b>)</h3><div class="NLM_p last">Starting amount of <b>36b</b> (6.35 g, 28.1 mmol); yellow solid; yield 74%, (6.3 g, 21 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 10.25 (1 H, s), 8.93 (1 H, s), 8.14 (1 H, d, <i>J =</i> 8.6 Hz), 8.03 (1 H, d, <i>J =</i> 9.0 Hz), 7.55–7.64 (1 H, t, <i>J =</i> 8.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 302.0 and 304.0 (M + 1).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 8-Chloro-2-(3-fluorophenyl)quinoline-3-carbaldehyde (<b>38c</b>)</h3><div class="NLM_p last">Starting amount of <b>36b</b> (2.0 g, 8.8 mmol); yield 71% (1.8 g, 6.3 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 286 (M + 1).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(2-Methoxyphenyl)-8-methylquinoline-3-carbaldehyde (<b>38d</b>)</h3><div class="NLM_p last">Starting amount of <b>36a</b> (0.206 g, 1.00 mmol); white solid; yield 90% (0.250g, 0.900 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.86 (1 H, s), 8.88 (1 H, s), 8.13 (1 H, d, <i>J =</i> 8.1 Hz), 7.85 (1 H, d, <i>J =</i> 7.1 Hz), 7.56–7.74 (3 H, m), 7.22–7.30 (2 H, m), 3.78 (3 H, s), 2.80 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 278 (M + 1).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 8-Chloro-2-(2-methylpyridin-3-yl)quinoline-3-carbaldehyde (<b>63</b>)</h3><div class="NLM_p last">Starting amount of <b>36b (</b>1.00 g, 4.24 mmol); off-white solid; yield 86% (1.25g, 3.82 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.96 (1 H, s), 9.16 (1 H, s), 8.62 (1 H, dd, <i>J =</i> 4.9, 1.8 Hz), 8.31 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 8.18 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.80 (1 H, dd, <i>J =</i> 7.6, 1.8 Hz), 7.76 (1 H, dd, <i>J =</i> 8.2, 7.4 Hz), 7.40 (1 H, dd, <i>J =</i> 7.4, 4.7 Hz), 2.35 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 283 (M + H).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3-Ethynyl-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>39a</b>)</h3><div class="NLM_p last">To (bromomethyl)triphenylphosphonium bromide (1.00 g, 2.30 mmol) in THF (12 mL) at −78 °C was added portionwise potassium <i>tert</i>-butoxide (4.8 equiv). The reaction mixture was stirred at −78 °C, and <b>38a</b> (0.500 g, 1.92 mmol) was added. The resulting mixture was stirred at −78 °C for 4 h. At this time, more potassium <i>tert</i>-butoxide (2 equiv) was added. The reaction mixture was allowed to warm to rt and heated to 40 °C for 1 h. Water was added and the mixture diluted with DCM and washed with water, brine and dried over MgSO<sub>4</sub>. Solvent was removed and the crude was purified by flash chromatography, eluting with 0–50% EtOAc/hexane to give <b>39a</b>. Yield 41% (207 mg, 0.787 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 258 (M + 1).</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-((7<i>H</i>-Purin-6-yl)ethynyl)-8-methyl-2-(<i>o</i>-tolyl)quinoline (<b>39b</b>)</h3><div class="NLM_p last">To a solution of 6-iodo-7<i>H</i>-purine (586 mg, 2.34 mmol) and <b>39a</b> (204 mg, 0.790 mmol) in DMF (0.1 M) was added TEA (2.9 mL). The resulting mixture was degassed followed by the addition of CuI (0.4 equiv) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.2 equiv). The reaction mixture was heated to 50 °C for 3 h. The reaction mixture was cooled to rt. Solvent was removed under reduced pressure and the crude residue was purified by flash chromatography, eluting with 0–10% MeOH/DCM to afford <b>39b</b>. Yield 41% (123 mg, 0.324 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 376 (M + 1).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (8-Methyl-2-<i>o</i>-tolylquinolin-3-yl)methanol (<b>40a</b>)</h3><div class="NLM_p last">A mixture of <b>37</b> (310 mg, 1.49 mmol), <i>o</i>-tolylboronic acid (304 mg, 2.24 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (52.4 mg, 0.0746 mmol), and Na<sub>2</sub>CO<sub>3</sub> (0.329 mg, 5.97 mmol) in (7:3:2 DME/H<sub>2</sub>O/EtOH) (7.2 mL) was heated at 150 °C in a microwave reactor. After 15 min the mixture was partitioned between EtOAc (25 mL) and H<sub>2</sub>O (25 mL), the layers were separated, and the aqueous layer was extracted with EtOAc (2 × 25 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The resulting black oil was dissolved in DCM, evaporated onto silica gel, and purified by flash chromatography (Biotage Si 25+M, 10–20% EtOAc/hexane) to provide (<b>40a</b>) White solid; yield 60% (237 mg, 0.898 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.28 (1 H, s), 7.71 (1 H, d, <i>J =</i> 8.0 Hz), 7.55 (1 H, d, <i>J =</i> 8.0 Hz), 7.44 (1 H, dd, <i>J =</i> 8.0 Hz), 7.37–7.26 (5 H, m), 4.92 (2 H, d, <i>J =</i> 4.0 Hz), 2.77 (3 H, s), 2.13 (3 H, s), 1.80 (1 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 264.4 (M + 1).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> General Procedure for the Synthesis of <b>37</b> and <b>40b</b>–<b>d</b></h3><div class="NLM_p last">To a solution of <b>36a</b> (1.05 g, 5.11 mmol) or <b>38a</b> (1.28 g, 4.90 mmol) or <b>38b</b> (1.18 g, 3.91 mmol) or <b>38c</b> (2.0 g, 7.0 mmol) or <b>38d</b> (0.800 g, 2.88 mmol) in THF (0.5 M) or MeOH (0.1 M, <b>37</b> synthesis) at 0 °C was added NaBH<sub>4</sub> (1.5 equiv) and stirred for 2 h (or 0.5 h, <b>37</b> synthesis). Water was added and the aqueous layer extracted with EtOAc. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography on silica gel using 50% of EtOAc in hexane to provide crude product (unless otherwise noted).</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (2-Chloro-8-methylquinolin-3-yl)methanol (<b>37</b>)</h3><div class="NLM_p last">The MeOH was removed under reduced pressure, and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated to provide <b>37</b>. White solid; yield 99% (1.05 g, 5.06 mmol). The crude product was sufficiently pure to be used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.23 (1 H, s), 7.68 (1 H, d, <i>J =</i> 8.0 Hz), 7.56 (1 H, d, <i>J =</i> 8.0 Hz), 7.47–7.43 (1 H, dd, <i>J =</i> 8.0, 8.0 Hz), 4.92 (2 H, d, <i>J =</i> 4.0 Hz), 2.77 (3 H, s), 2.13 (1 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 208.0 (M + 1).</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-(2-Chlorophenyl)-8-chloroquinolin-3-yl)methanol (<b>40b</b>)</h3><div class="NLM_p last">Yellow solid; yield 57%, (0.675 g, 2.22 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.56 (1 H, s), 8.10 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.94 (1 H, dd, <i>J =</i> 7.6, 1.4 Hz), 7.63 (2 H, t, <i>J =</i> 7.8 Hz), 7.44–7.59 (3 H, m), 5.54 (1 H, t, <i>J =</i> 5.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 304.0 and 306.1 (M + 1).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)methanol (<b>40c</b>)</h3><div class="NLM_p last">Yield 70% (1.4 g, 4.9 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 288.1 (M + 1).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (2-(2-Methoxyphenyl)-8-methylquinolin-3-yl)methanol (<b>40d</b>)</h3><div class="NLM_p last">White solid; yield 99% (0.80 g, 2.8 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.41 (1 H, s), 7.92 (1 H, d, <i>J =</i> 7.8 Hz), 7.64 (1 H, d, <i>J =</i> 7.0 Hz), 7.50–7.59 (2 H, m), 7.33 (1 H, dd, <i>J =</i> 7.4, 1.6 Hz), 7.22 (1 H, d, <i>J =</i> 7.8 Hz), 7.16 (1 H, t, <i>J =</i> 7.2 Hz), 5.37 (1 H, t, <i>J =</i> 5.5 Hz), 3.79 (3 H, s), 2.72 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 280.1 (M + 1).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure for the Synthesis of <b>40e</b>, <b>40f</b>, <b>49a</b>, <b>49b</b>, <b>64</b></h3><div class="NLM_p last">To a mixture of <b>38a</b> (0.36 g, 1.4 mmol) or <b>38b</b> (500 mg, 1.7 mmol) or <b>63</b> (1.07 g, 3.80 mmol) or <b>47a</b> (334 g, 1.60 mol) or <b>47b</b> (2.3 g, 10 mmol) in THF (0.2–0.3 M) at 0 °C was added dropwise a solution of a methylmagnesium iodide or bromide (2 equiv, 3 M), and the mixture was stirred overnight before adding saturated NH<sub>4</sub>Cl solution. The mixture was extracted with EtOAc, and the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was purified by column chromatography on silica gel (eluent, 1:1 EtOAc/hexane) to provide 1-(2-phenylquinolin-3-yl) alcohols.</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 1-(8-Methyl-2-(<i>o</i>-tolyl)quinolin-3-yl)ethanol (<b>40e</b>)</h3><div class="NLM_p last">Yield 97% (0.37 g, 1.4 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (1 H, s), 7.66 (1 H, d, <i>J =</i> 8.2 Hz), 7.48 (1 H, d, <i>J =</i> 6.7 Hz), 7.39 (1 H, t, <i>J =</i> 7.8 Hz), 7.19–7.27 (4 H, m), 2.69 (3 H, s), 2.08 (3 H, s), 1.30 (3 H, m). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 278 (M + 1).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 1-(8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)ethanol (<b>40f</b>)</h3><div class="NLM_p last">White solid; yield 87% (460 mg, 1.45 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 318.0 (M + 1).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 1-(2-Chloro-7-fluoroquinolin-3-yl)ethanol (<b>49a</b>)</h3><div class="NLM_p last">Yield 68% (244 g, 1.08 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 226 (M + 1).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 1-(2-Chloro-5,7-difluoroquinolin-3-yl)ethanol (<b>49b</b>)</h3><div class="NLM_p last">Pale yellow solid; yield 71% (1.75 g, 7.17 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.63 (1 H, s), 7.50 (1 H, d, <i>J =</i> 9.49 Hz), 7.06–7.13 (1 H, m), 5.38 (1 H, qd, <i>J =</i> 6.13, 3.91 Hz), 2.19 (1 H, d, <i>J =</i> 3.91 Hz), 1.58 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 244 (M + 1).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanol (<b>64</b>)</h3><div class="NLM_p last">Orange oil; yield 98% (1.12 g, 3.72 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.68 (1 H, s), 8.59 1 H, dd, <i>J =</i> 4.9, 1.8 Hz), 8.10 (l H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.94 (l H, dd, <i>J =</i> 7.6, 1.4 Hz), 7.74 (l H, dd, <i>J =</i> 7.8, 1.6 Hz), 7.58–7.65 (l H, m), 7.39 (l H, dd, <i>J =</i> 7.6, 4.9 Hz), 5.47 (l H, d, <i>J =</i> 4.3 Hz), 4.64 (l H, br s), 2.25 (3 H, s), 1.20 (3 H, d, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 299 (M + 1).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> General Procedure for the Synthesis of <b>41a</b> and <b>41b</b></h3><div class="NLM_p last">To a stirred solution of <b>40b</b> (0.675 g, 2.22 mmol) or <b>40c</b> (150 mg, 0.52 mmol) in CHCl<sub>3</sub> (0.25 M) was added SOCl<sub>2</sub> (5 equiv) at rt for 2 h. The mixture was concentrated, and the residue was partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub> solution. The organic layer was separated, washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by column chromatography on a Redi-Sep column using 0–100% gradient of EtOAc in hexane to provide 3-(chloromethyl)-2-arylquinolines.</div></div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 8-Chloro-3-(chloromethyl)-2-(2-chlorophenyl)quinoline (<b>41a</b>)</h3><div class="NLM_p last">Yellow foam; yield 96% (685 mg, 2.13 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.53 (1 H, s), 7.88 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.81 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.48 (1 H, d, <i>J =</i> 7.4 Hz), 7.42–7.46 (1 H, m), 7.27–7.41 (3 H, m), 4.63 (1 H, d, <i>J =</i> 9.8 Hz), 4.33–4.45 (1 H, m). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 322.0 and 324.0 (M + 1)</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 8-Chloro-3-(chloromethyl)-2-(3-fluorophenyl)quinoline (<b>41b</b>)</h3><div class="NLM_p last">Yield 91% (160 mg, 0.477 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 306 (M + 1).</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-(Bromomethyl)-2-(2-methoxyphenyl)-8-methylquinoline (<b>41c</b>)</h3><div class="NLM_p last">Solid CBr<sub>4</sub> (1.5 equiv) was added to a mixture of <b>40d</b> (313 mg, 1.12 mmol) and triphenylphosphine (1.5 equiv) in DCM (0.17 M) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. The crude mixture was concentrated under reduced pressure, evaporated onto silica gel, and purified by flash chromatography, eluting with 0–10% EtOAc/hexane to provide <b>41c</b>. White solid; yield 91% (347 mg, 1.02 mmol) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.26 (1 H, s), 7.68 (1 H, d, <i>J =</i> 8.0 Hz), 7.55 (1 H, d, <i>J =</i> 8.0 Hz), 7.49–7.41 (3 H, m), 7.14 (1 H, td, <i>J =</i> 1.0, 8.0 Hz), 7.01 (1 H, d, <i>J =</i> 8.0 Hz), 4.56 (2 H, br s), 3.77 (1 H, s), 2.78 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 342 (M + 1).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> General Procedure for the Synthesis of <b>42a</b> and <b>42b</b></h3><div class="NLM_p last">To a solution of <b>41a</b> (220 mg, 0.68 mmol) or <b>41b</b> (187 mg, 0.611 mmol) in DMSO (0.25 M) was added NaN<sub>3</sub> (3 equiv) at rt, and the mixture was stirred for 4 h. The mixture was diluted with water, extracted with EtOAc, and the organic layer was washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure.</div></div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-(Azidomethyl)-8-chloro-2-(2-chlorophenyl)quinoline (<b>42a</b>)</h3><div class="NLM_p last">Yield 80% (224 mg, 0.547 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 329 (M + 1).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-(Azidomethyl)-8-chloro-2-(3-fluorophenyl)quinoline (<b>42b</b>)</h3><div class="NLM_p last">Yield 100% (191 mg, 0.611 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 313 (M + 1).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> General Synthesis of <b>43a</b> and <b>43b</b></h3><div class="NLM_p last">To a N<sub>2</sub> purged solution of <b>42a</b> (180 mg, 0.547 mmol) or <b>42b</b> (191 mg, 0.611 mmol) in MeOH (2 mL) was added Pd/C (cat.), placed under a H<sub>2</sub> balloon overnight. After concentration, the crude mixture was applied to a Redi-Sep column using 0–100% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) to provide the product.</div></div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine (<b>43a</b>)</h3><div class="NLM_p last">Light yellow solid; yield 81% (134 mg, 0.442 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.62 (1 H, s), 8.05 (1 H, dd, <i>J =</i> 8.6, 1.2 Hz), 8.00 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.63–7.73 (2 H, m), 7.47–7.62 (3 H, m), 3.90 (1 H, s), 3.75 (1 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 303.1 and 305.0 (M + 1).</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)methanamine (<b>43b</b>)</h3><div class="NLM_p last">Yield 51% (90 mg, 0.31 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 287.0 (M + 1).</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-(8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)ethanamine (<b>43c</b>)</h3><div class="NLM_p last">A stirred solution of <b>40f</b> (460 mg, 1.44 mmol) in CHCl<sub>3</sub> (7 mL) was treated with SOCl<sub>2</sub> (0.5 mL, 5 equiv) dropwise. After 2 h the mixture was concentrated to dryness. The residue was dissolved in DMSO (5 mL) and treated with NaN<sub>3</sub> (0.19 g, 2.92 mmol, 2.0 equiv) at rt. After 4 h the reaction mixture was partitioned between EtOAc (20 mL) and water (15 mL), and the water layer was extracted with EtOAc (5 mL), washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give a foam. The foam was dissolved in MeOH (15 mL) and treated with Pd–C (10%, 40 mg) and the reaction stirred under a H<sub>2</sub> balloon for 2 h. The mixture was filtered and concentrated. Chromatography on silica gel (DCM/MeOH, 20/1) gave <b>43c</b>. Off white foam; yield 70% (320 mg, 1.01 mmol). It was slighty impure with starting material and was taken on without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.59 (1 H, s), 8.47 (1 H, s), 7.75–7.84 (3 H, m), 7.40–7.55 (5 H, m), 4.09–4.29 (1 H, m), 1.20 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 317.0 (M + 1).</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-((8-Methyl-2-<i>o</i>-tolylquinolin-3-yl)methyl)isoindoline-1,3-dione (<b>44</b>)</h3><div class="NLM_p last">To a stirred mixture of <b>40a</b> (258 mg, 0.980 mmol), phthalimide (216 mg, 1.47 mmol), PPh<sub>3</sub> (321 mg, 1.22 mmol) in THF (5 mL) at rt was added solid ADDP (309 mg, 1.22 mmol). After 24 h another 0.5 equiv of phthalimide, ADDP, and PPh<sub>3</sub> was added and the mixture was stirred at rt. After 5 h, the mixture was concentrated, evaporated onto silica gel, and purified by flash chromatography (Biotage Si 40+M, 15–25% EtOAc/hexanes) to provide <b>44</b>. White oil; yield 43% (165 mg, 0.420 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.96 (1 H, s), 7.85 (2 H, dd, <i>J =</i> 4.0, 8.0 Hz), 7.74 (2 H, dd, <i>J =</i> 4.0, 8.0 Hz), 7.59 (1 H, d, <i>J =</i> 8.0 Hz), 7.54 (1 H, d, <i>J =</i> 8.0 Hz), 7.40 (1 H, t, <i>J =</i> 8.0 Hz), 7.37–7.29 (4 H, m), 4.79 (1 H, d, <i>J =</i> 16.0 Hz), 2.78 (3 H, s), 2.22 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 393.2 (M + 1).</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (8-Methyl-2-<i>o</i>-tolylquinolin-3-yl)methanamine (<b>45</b>)</h3><div class="NLM_p last">A mixture of <b>44</b> (155 mg, 0.395 mmol) and hydrazine monohydrate (0.120 mL, 1.98 mmol) in EtOH (5 mL) was heated under reflux for 2 h. The mixture was cooled to rt, concentrated, and partitioned between saturated aqueous NaHCO<sub>3</sub> (25 mL) and EtOAc (25 mL). The aqueous layer was extracted with EtOAc (2 × 25 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The resulting yellow oil was dissolved in DCM, evaporated onto silica gel, and purified by flash chromatography (Biotage Si 25+M, 10–20% EtOAc/hexane) to provide <b>45</b>. Cloudy oil; yield 97% (101 mg, 383 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.21 (1 H, s), 7.70 (1 H, d, <i>J =</i> 8.0 Hz), 7.54 (1 H, d, <i>J =</i> 8.0 Hz), 7.43 (1 H, dd, <i>J =</i> 8.0, Hz), 7.36–7.27 (5 H, m), 3.8 (2 H, s), 2.77 (3 H, s), 2.13 (1 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 263.2 (M + 1).</div></div><div id="sec4_8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2-Chloro-5,7-difluoroquinoline-3-carbaldehyde (<b>47b</b>)</h3><div class="NLM_p last">To a stirred solution of POCl<sub>3</sub> (9.2 mL, 7.0 equiv) was added dropwise DMF (2.8 mL, 2.5 equiv) at 0 °C to rt for 30 min. To the resulting semisolid was added <i>N</i>-(2,3-difluorophenyl)acetamide (2.45 g, 140 mmol) in one portion, and the resulting mixture heated at 75 °C overnight. After cooling to rt, the reaction mixture was poured carefully into ice–water (300g). The white solid was filtered, washed with water, NaHCO<sub>3</sub>, water and dried in the air to give <b>47b</b>. White solid; yield 67% (2.78 g, 9.38 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 10.57 (1 H, s), 9.00 (1 H, d, <i>J =</i> 0.73 Hz), 7.58 (1 H, d, <i>J =</i> 9.16 Hz), 7.18 (1 H, t, <i>J =</i> 8.81 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 228 (M + 1). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 210 (M + 1).</div></div><div id="sec4_8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-(2,8-Dichloroquinolin-3-yl)ethanol (<b>49c</b>)</h3><div class="NLM_p last">A freshly prepared solution of LDA (1.1 equiv) in THF (100 mL) was kept in 0 °C for 30 min and cooled to −78 °C before the addition of a solution of <b>48a</b> (8.4 g, 42.4 mmol) in THF (44 mL) dropwise. After 45 min, acetaldehyde (3.6 mL, 1.5 equiv) was added dropwise. After 30 min, saturated NH<sub>4</sub>Cl was added and partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. After flash chromatography (silica gel) (DCM/hexane, 3/2) of the residue hexane (80 mL) was added to the colorless oil and the solution was left overnight. Filtration gave <b>49c</b>. White solid; yield 56% (5.8 g, 24 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.43 (1 H, s), 7.84 (1 H, d, <i>J =</i> 8.0 Hz), 7.79 (1 H, d, <i>J =</i> 8.0 Hz), 7.50 (1 H, t, <i>J =</i> 8.0 Hz), 5.40 (1 H, q, <i>J =</i> 8.0 Hz), 1.63 (3 H, d, <i>J =</i> 8.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 242 (M + 1).</div></div><div id="sec4_8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2 1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol (<b>49d</b>)</h3><div class="NLM_p last">A solution of <b>48b</b> (24.3 g, 108 mmol) in THF (200 mL) was placed into a jacketed dropping funnel on top of a flask cooled to −78 °C, containing freshly prepared LDA (1.9 equiv) in THF (80 mL). The solution was added dropwise maintaining temperature below −70 °C. After the addition, the mixture was allowed to stir for 5 min and then the entire reaction mixture was added dropwise (via cannula) to a three-necked flask with cold acetaldehyde (22.6 mL, 400 mmol) in 600 mL of THF at −78 °C. The temperature was maintained below −70 °C. The mixture was allowed to stir for an additional 25 min. At this time, NH<sub>4</sub>Cl (200 mL, 50% saturated) and EtOAc (500 mL) were added. The layers were separated, and the aqueous layer was extracted with EtOAc (100 mL). The organic layers were washed with saturated NaCl solution (200 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting oil was deposited on 100 g of silica gel and passed through 200 g silica plug using hexane/EtOAc 8:2 (6 L). (Note: Only the middle 2 L was collected first, and last 2 L was set aside.) Crystallization was from 9:1 hexanes/EtOAc. The mixture was cooled to rt and stirred overnight. It was filtered and washed with 9:1 hexanes/EtOAc, air-dried, then vacuum-dried to give <b>49d</b>. White powder; yield 54% (10.9 g, 48.3 mmol). <sup>1</sup>H NMR (400 MHz, (CDCl<sub>3</sub>) δ ppm 8.43 (1 H, br s), 7.64 (1 H, td, <i>J =</i> 7.8,5.1 Hz), 7.41 (1 H, ddd, <i>J =</i> 10.2, 7.4, 1.2 Hz), 5.39 (1 H, qdd, <i>J =</i> 6.3, 3.9, 0.8 Hz), 2.22 (1 H, d, <i>J =</i> 3.9 Hz), 1.62 (3 H, d, <i>J =</i> 6.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 226.0 (M + 1).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> General Procedure for <b>50a</b>–<b>d</b></h3><div class="NLM_p last">A mixture of <b>49a</b> (7.7 g, 34 mmol) or <b>49b</b> (1.75 g, 7.18 mmol) or <b>49c</b> (5.00 g, 207 mmol) or <b>49d</b> (6.20 g, 27.5 mmol) and MnO<sub>2</sub> (10 equiv) in toluene (0.17 M) was heated to reflux for 2 h. Filtration followed with removal of solvent gave the product.</div></div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>R</i>)-1-(2-Chloro-7-fluoroquinolin-3-yl)ethanol (<b>50a</b>)</h3><div class="NLM_p last">Off-white solid; yield 81% (6.2 g, 28 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 224 (M + 1).</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 1-(2-Chloro-5,7-difluoroquinolin-3-yl)ethanone (<b>50b</b>)</h3><div class="NLM_p last">Pale yellow solid; yield 85% (1.47 g, 6.12 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 242 (M + 1).</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-(2,8-Dichloroquinolin-3-yl)ethanone (<b>50c</b>)</h3><div class="NLM_p last">White solid; yield 91% (4.50 g, 18.8 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 239.9 (M + 1).</div></div><div id="sec4_9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 1-(2-Chloro-8-fluoroquinolin-3-yl)ethanone (<b>50d</b>)</h3><div class="NLM_p last">White solid; yield 72% (4.43 g, 19.8 mmol). <sup>1</sup>H NMR (400 MHz, (CDCl<sub>3</sub>) δ ppm 8.40 (1 H, d, <i>J =</i> 7.6 Hz), 7.71 (1 H, br d, <i>J =</i> 8.2 Hz), 7.56 (1 H, td, J =7.8, 5.1 Hz), 7.54 (1 H, ddd, <i>J =</i> 8, 7.8, 1:6 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 224 (M + 1).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> General Procedure for <b>51a</b>–<b>d</b></h3><div class="NLM_p last">To a stirred solution of (+) DIP-Cl  (2.2 equiv) in anhydrous THF (0.3 M) cooled to −47 °C (dry ice, acetonitrile bath) (or −78 °C for <b>51c</b> synthesis<b>)</b> was added <b>50a</b> (62.0 g, 277 mmol) or <b>50b</b> (34.7 g, 144 mmol) or <b>50c</b> (26.2 g, 109 mmol) or <b>50d</b> (63.4 g, 283 mmol) as a solution in THF (0.45 M) dropwise. The mixture was allowed to warm to 10 °C for 5 h or rt overnight. At this time, acetone (1.1 M) and 10% Na<sub>2</sub>CO<sub>3</sub> (1.1 M) were added at 0 °C and allowed to stir for 1 h at rt. EtOAc (0.22 M) was added, and the layers were separated. The organic phase was washed with a 50% saturated NaHCO<sub>3</sub> solution, brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to provide product.</div></div><div id="sec4_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>R</i>)-1-(2-Chloro-7-fluoroquinolin-3-yl)ethanol (<b>51a</b>)</h3><div class="NLM_p last">The resulting yellow residue was treated with hexane (100 mL) and water (165 mL), and the mixture was stirred at rt overnight. The resulting white solid was filtered, dissolved in ethyl acetate (400 mL), washed with brine and water, and then dried over MgSO<sub>4</sub> and evaporated in vacuo to give <b>51a</b>. White solid; yield 72% (45.0 g, 199 mmol). Chiral HPLC on AD column (isopropanol in hexane, 10%) showed >99% ee. Mass spectrum (ESI) <i>m</i>/<i>e</i> = 226 (M + 1).</div></div><div id="sec4_10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>R</i>)-1-(2-Chloro-5,7-difluoroquinolin-3-yl)ethanol (<b>51b</b>)</h3><div class="NLM_p last">The dried solids were treated with hexane (300 mL) and water (200 mL), stirred for 20 min, filtered, and washed with water and hexane to afford <b>51b</b>. White solid; yield 91% (31.7 g, 130 mmol). Chiral HPLC on AD column (isopropanol in hexane, 10%) showed >99% ee . Mass spectrum (ESI) <i>m</i>/<i>e</i> = 244 (M + 1).</div></div><div id="sec4_10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>R</i>)-1-(2,8-Dichloroquinolin-3-yl)ethanol (<b>51c</b>)</h3><div class="NLM_p last">The dried solids were treated with hexane (300 mL) and water (200 mL) and stirred for 20 min, filtered, and washed with water and hexane. Chiral HPLC on IA column (isopropanol in hexane, 10%) showed a ratio of 20:1 for two enantiomers. Recrystallization from a mixture of EtOAc (70 mL) and hexane (250 mL) provided <b>51c</b>. White needles; yield 90% (23.7 g, 97.9 mmol). Chiral HPLC AD-H column (isopropanol in hexane, 10%) showed >99 ee. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.43 (1 H, s), 7.84 (1 H, d, <i>J =</i> 8.0 Hz), 7.79 (1 H, d, <i>J =</i> 8.0 Hz), 7.50 (1 H, t, <i>J =</i> 8.0 Hz), 5.40 (1 H, q, <i>J =</i> 8.0 Hz), 1.63 (3 H, d, <i>J =</i> 8.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 242 (M + 1).</div></div><div id="sec4_10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (<i>R</i>)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol (<b>51d</b>)</h3><div class="NLM_p last">The dried solids were treated with hexanes (1.5 L) and H<sub>2</sub>O (1 L) and stirred at rt for 3 h before a white solid was filtered and washed with water and hexane to give <b>51d</b>. White solid; yield 83% (53.3 g, 236 mmol). Chiral HPLC AD-H column (isopropanol in hexane, 10%) showed >99 ee. <sup>1</sup>H NMR (400 MHz, (CDCl<sub>3</sub>) δ ppm 8.43 (1 H, br s), 7.64 (1 H, br d, <i>J =</i> 8.2 Hz), 7.50 (1 H, td, <i>J =</i> 7.8, 4.7 Hz), 7.41 (1 H, ddd, <i>J =</i> 10.2, 7.8, 1.2 Hz), 5.40 (1 H, qd, <i>J =</i> 5.9, 0.8 Hz), 2.22 (1 H, br s), 1.62 (3 H, d, <i>J =</i> 6.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 226 (M + 1).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> General Procedure for <b>52a</b>–<b>d</b></h3><div class="NLM_p last">To a solution of <b>51a</b> (3.03 g, 13.4 mmol) or <b>51b</b> (1.17 g, 4.80 mmol) or <b>51c</b> (22.2 g, 91.7 mmol) or <b>51d</b> (8.15g, 36.1 mmol) in THF (0.2 M) were added PPh<sub>3</sub> (1.2 equiv), phthalimide (1.2 equiv), and DIAD (1.2 equiv) dropwise at 0 °C to rt. The reaction mixture was stirred 4 h to overnight. The mixture was partioned between EtOAc or Et<sub>2</sub>O and water. The organic layer was separated, washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by column chromatography on silica gel, eluting with 0–25% EtOAc/hexane to give the product.</div></div><div id="sec4_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>S</i>)-2-(1-(2-Chloro-7-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>52a</b>)</h3><div class="NLM_p last">White foam; yield 80% (3.80 g, 10.7 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 355 (M + 1).</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>S</i>)-2-(1-(2-Chloro-5,7-difluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>52b</b>)</h3><div class="NLM_p last">Yield 80% (1.08 g, 3.84 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.76 (1 H, s), 7.80–7.84 (2 H, m), 7.73 (2 H, dd, <i>J =</i> 5.5, 3.1 Hz), 7.45–7.49 (1 H, m), 7.11 (1 H, td, <i>J =</i> 9.3, 2.2 Hz), 5.94 (1 H, q, <i>J =</i> 7.3 Hz), 1.98 (3 H, d, <i>J =</i> 7.1 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 373 (M + 1).</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (<i>S</i>)-2-(1-(2,8-Dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>52c</b>)</h3><div class="NLM_p last">Chromatography on silica gel, eluting with 1:1 DCM/hexane. White foam; yield 88% (29.8 g, 80.3 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.49 (l H, s), 7.77–7.73 (4 H, m), 7.66–7.63 (2 H, m), 7.43 (1 H, t, <i>J =</i> 8.0 Hz), 5.89 (1 H, q, <i>J =</i> 8.0 Hz), 1.91 (3 H, d, <i>J =</i> 8.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 372 (M + l).</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (<i>S</i>)-2-(1-(2-Chloro-8-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>52d</b>)</h3><div class="NLM_p last">Chromatography using 100% dichloromethane; yield 82% (10.5 g, 29.6 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.59 (1 H, s), 7.82 (2 H, dd, <i>J =</i> 5.5, 3.1 Hz), 7.69–7.75 (3 H, m), 7.53 (1 H, td, <i>J =</i> 8.1, 4.9 Hz), 7.43 (1 H, ddd, <i>J =</i> 10.1, 7.8, 1.1 Hz), 5.97 (1 H, q, <i>J =</i> 7.1 Hz), 1.99 (3 H, d, <i>J =</i> 7.1 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 355.2 (M + 1).</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>S</i>)-2-(1-(2,8-Dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>53d</b>)</h3><div class="NLM_p last">A stirred suspension of <b>52c</b> (250 mg, 0.673 mmol), 3-(methylsulfonyl)phenylboronic acid (162 mg, 0.810 mmol, 1.2 equiv), Na<sub>2</sub>CO<sub>3</sub> (214 mg, 2.01 mmol, 3.0 equiv), Pd(Ph<sub>3</sub>)<sub>4</sub> (35 mg, 0.034 mmol, 0.05 equiv) in MeCN (0.1 M) and H<sub>2</sub>O (0.3 M) was heated to 90 °C overnight. The reaction mixture was cooled to rt and partitioned between EtOAc and water. The organic layer was isolated and extracted with NaOH (1.0 N) The combined water layers were washed with DCM or EtOAc/hexane and neutralized to pH 3 with HCl (3.0 N). The resulting milky mixture was extracted with DCM. Combined extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The product was dissolved in EtOH (0.1 M) and 4 N HCl/dioxane to give a 25:1 EtOH/4 N HCl dioxane solution. The reaction mixture was heated to 90 °C overnight. After cooling to rt, the reaction mixture was concentrated to dryness to provide <b>53d</b>, used without characterization. White solid; yield, 62% (205 mg, 0.418 mmol).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> General Procedure for <b>53e</b> and <b>53f</b></h3><div class="NLM_p last">To a stirred mixture of <b>52d</b> (9.30 g, 26.2 mmol (for <b>53f</b>)) or <b>52d</b> (3.02 g, 8.51 mmol, <b>53e</b> synthesis), K<sub>2</sub>CO<sub>3</sub> (14.49 g, 10.49 mmol, 0.4 equiv (for <b>53f</b>)), or Na<sub>2</sub>CO<sub>3</sub> (4.71 g, 44.4 mmol, <b>53e</b> synthesis), Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (0.1 equiv), in dry DMF (0.15 M), purged with N<sub>2</sub> was added phenylboronic acid (2.0 equiv), and the mixture was heated to 100 °C. After 2.5 h the mixture was diluted with EtOAc, washed with water, brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give a crude product.</div></div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 2-((<i>S</i>)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>53e</b>)</h3><div class="NLM_p last">Recrystallization was from EtOAc/hexanes. Yield 70% (2.45 g, 5.91 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.63 (1 H, s), 7.66–7.75 (5 H, m), 7.53 (1 H, td, <i>J =</i> 7.9, 4.9 Hz), 7.42 (1 H, ddd, <i>J =</i> 10.4, 7.8, 1.4 Hz), 7.35 (1 H, td, <i>J =</i> 7.9, 5.7 Hz), 7.21 (1 H, dt, <i>J =</i> 7.7, 1.2 Hz), 7.04–7.14 (2 H, m), 5.80 (1 H, q, <i>J =</i> 7.0 Hz), 1.90 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 415.0 (M + l).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 2-((<i>S</i>)-1-(8-Fluoro-2-(3, 5-difluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>53f</b>)</h3><div class="NLM_p last">Purification: silica gel plug (400g), 30% EtOAc in hexanes, then DCM. Concentration and recrystallization with EtOAc (100 mL) and hexanes (400 mL) gave a voluminous white precipiate, which was filtered and washed with 200 mL of 9:1 hexanes/EtOAc(200 mL), isolating 7 g of white solid. It was dissolved in chloroform. Silica gel plug (15 g) and chloroform (150 mL) were used. Concentration and recrystallization were from EtOAc/hexanes. White solid; yield 66% (4.80 g, 11.1 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.66 (1 H, s), 7.68–7.76 (5 H, m), 7.55 (1 H, td, <i>J =</i> 8.0, 4.7 Hz), 7.44 (1 H, ddd, <i>J =</i> 10.3, 7.7, 1.2 Hz), 6.94 (2 H, dt, <i>J =</i> 5.8, 2.0 Hz), 6.83 (1 H, tt, <i>J =</i> 9.0, 2.3 Hz), 5.78 (1 H, q, <i>J =</i> 7.0 Hz), 1.92 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 432.9 (M + l).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> General Procedure for <b>53a</b>–<b>c</b></h3><div class="NLM_p last">A stirred mixture of <b>52c</b> (20.4 g, 55.1 mmol, <b>53a</b> synthesis) or <b>52c</b> (19.0 g, 51.2 mmol, <b>53b</b> synthesis) or <b>52a</b> (19.0 g, 53.6 mmol, <b>53c</b> synthesis), the appropriate boronic acid (1.1–1.6 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05–0.1 equiv), and Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv) in acetonitrile–water (3:1) (0.1 M) was heated to 100 °C. After 1–4 days, the mixture was cooled to rt, concentrated, and partitioned between DCM and water. The water layer (pH 10–11) was washed with DCM to remove byproducts. The organic and acidic aqueous layers were separated. The aqueous layer was treated with 2 N HCl (0.2 M in substrate) and extracted with DCM. The organic layer was washed with water brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated</div></div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 2-(((<i>S</i>)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)carbamoyl)benzoic Acid (<b>53a</b>)</h3><div class="NLM_p last">yield, ∼quant (25.9 g, 55.1 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.87 (1 H, s), 8.99 (1 H, d, <i>J =</i> 7.0 Hz), 8.61 (1 H, s), 7.92–8.03 (2 H, m), 7.78 (1 H, dd, <i>J =</i> 7.8, 1.2 Hz), 7.47–7.67 (6 H, m), 7.35–7.45 (2 H, m), 5.26–5.38 (1 H, m), 1.34 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 448.9 (M + 1).</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 2-((1<i>S</i>)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethylcarbamoyl)benzoic Acid (<b>53b</b>)</h3><div class="NLM_p last">Brown solid; yield 91% (20.9 g, 46.5 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.86 (1 H, br. s), 8.92 (1 H, br s), 8.62 (1 H, s), 8.02 (1 H, dd, <i>J =</i> 8.4, 1.2 Hz), 7.96 (1 H, dd, <i>J =</i> 7.5, 1.3 Hz), 7.75(1 H, dd, <i>J =</i> 7.5, 1.1 Hz), 7.53–7.67 (4 H, m), 2.03 (2 H, s), 7.46–7.52 (1 H, m), 7.36–7.45 (3 H, m), 5.09 (1 H, quin, <i>J =</i> 6.9 Hz), 1.36 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 449.0 (M + 1).</div></div><div id="sec4_13_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 2-((1<i>S</i>)-1-(7-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethylcarbamoyl)benzoic Acid (<b>53c</b>)</h3><div class="NLM_p last">Pale yellow solid; yield, ∼quant (23.4 g, 54 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 432.9 (M + l).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> General Procedure for <b>54a</b>–<b>c</b></h3><div class="NLM_p last">To a stirred suspension of <b>53a</b> (24.7 g, 55.1 mmol) or <b>53b</b> (20.9 g, 46.5 mmol) or <b>53c</b> (23.4 g, 54.1 mmol) in EtOH (0.2–0.5 M) was added conc HCl (10–20 equiv) and heated to reflux. After 4 h to 6 days, the mixture was cooled to rt and the ethanol removed under vacuum.</div></div><div id="sec4_14_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (1<i>S</i>)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine (<b>54a</b>)</h3><div class="NLM_p last">The mixture was refluxed for 6 days. To the residual acidic aqueous mixture was added ice–water (200 mL) at 0 °C with stirring. The mixture was treated with 10 N NaOH (∼50 mL) to pH ≈ 10 and extracted with DCM. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a brown syrup which was purified. Column chromatography: 330 g of Redi-Sep column using 0–20% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 50 min and then 20% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) for 50 min as eluent to give <b>54a</b>. Light yellow syrup; yield 84% (13.8 g, 46.1 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.74 (1 H, s), 8.01 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.92 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.54–7.63 (2 H, m), 7.43–7.52 (2 H, m), 7.32–7.39 (1 H, m), 4.25 (1 H, q, <i>J =</i> 6.7 Hz), 2.03 (2 H, s), 1.21 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 300.9 (M + 1).</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (1<i>S</i>)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethanamine (<b>54b</b>)</h3><div class="NLM_p last">The mixture was refluxed for 4 days. The mixture was poured into ice–water. The aqueous acidic mixture (pH ≈ 1.5) was extracted with DCM and concentrated to give a brown syrup. The remaining aqueous mixture was then treated with saturated aqueous NaHCO<sub>3</sub> solution (200 mL) and 10 N NaOH (10 mL) to give pH ≈ 11 and extracted with DCM. The organic layer was washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>54b</b>. Yellow syrup; yield 5.3% (0.74 g, 2.5 mmol). The brown syrup was dissolved in DCM (200 mL) and washed with saturated aqueous NaHCO<sub>3</sub> solution and extracted with DCM. The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a mixture of (major) desired product and the (minor) ethyl ester as a dark red syrupy solid, which was suspended in EtOH (230 mL) and treated with hydrazine monohydrate (22.5 mL, 465 mmol). This mixture was refluxed for 1.5 h, cooled to rt, and the resulting precipitate was filtered and washed with EtOAc. The filtrate was concentrated under reduced pressure, redissolved in EtOAc (200 mL), and washed with water (200 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give an orange syrup, which was purified by column chromatography on a 330 g Redi-Sep column using 0–50% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 25 min and then 50% isocratic of DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) for 25 min as eluent to give <b>54b</b> yellow syrup. Combined yield 86% (12.0 g, 39.8 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.74 (1 H, s), 8.03 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.93 (1 H, dd, <i>J =</i> 7.5, 1.3 Hz), 7.50–7.66 (3 H, m), 7.34–7.43 (2 H, m), 4.03 (1 H, q, <i>J =</i> 6.4 Hz), 1.98 (2 H, br s), 1.16 (3 H, d, <i>J =</i> 5.5 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 301.0 (M + l).</div></div><div id="sec4_14_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (1<i>S</i>)-1-(7-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine (<b>54c</b>)</h3><div class="NLM_p last">The mixture was refluxed for 4 h. The residue was treated with hydrazine hydrate (27.0 mL, 536 mmol) in EtOH (200 mL) at 70 °C for 3 h. The resultant mixture was concentrated, filtered, and rinsed with DCM–MeOH (9:1). The combined filtrates were concentrated. Purification of the residue by flash chromatography over silica gel, with gradient elution, 0–10% MeOH in DCM with 0.1% aqueous NH<sub>4</sub>OH, gave <b>54c</b>. Yield 78% (11.95 g, 42.03 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.70 (1 H, s), 8.12 (1 H, dd, <i>J =</i> 9.0, 6.5 Hz), 7.73 (1 H, dd, <i>J =</i> 10.6, 2.7 Hz), 7.51–7.67 (3 H, m), 7.39–7.48 (2 H, m), 7.29–7.37 (1 H, m), 4.21 (1 H, q, <i>J =</i> 6.5 Hz), 1.20 (3 H, d, <i>J =</i> 6.5 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 285.1 (M + 1).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> General Procedure for <b>55a</b>, <b>55b</b>, <b>55d</b>, and <b>55e</b></h3><div class="NLM_p last">A mixture of <b>52a</b> (85.6 g, 241 mmol) or <b>52b</b> (100 mg, 0.268 mmol) or <b>52c</b> (13.6 g, 36.6 mmol) or <b>52d</b> (0.803 g, 2.26 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv) or (0.1 equiv, for <b>55a</b> synthesis) and 2-(tributylstannyl)pyridine (1.2 equiv) or (1.0 equiv, for <b>55b</b> synthesis) in dioxane (0.12 M) or toluene (0.13 M, for <b>55b</b> synthesis) was heated to 100–120 °C under N<sub>2</sub> for 1 day, 4 days (<b>55b</b> synthesis), or 3 days (<b>55e</b> synthesis) and then allowed to cool to rt. Removal of solvent followed by colunm chromatography on silica gel (gradient elution EtOAc/hexane) provided the product.</div></div><div id="sec4_15_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (<i>S</i>)-2-(1-(8-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55a</b>)</h3><div class="NLM_p last">Chromatography, 40 g CombiFlash, 10% EtOAc/hexane to 100% EtOAC, gave <b>55a</b>. Yellow foam; yield 83% (0.750 g, 1.89 mmol,). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.78 (1 H, s), 8.51 (1 H, d, <i>J =</i> 3.9 Hz), 7.95–8.01 (1 H, m), 7.73–7.81 (3 H, m), 7.59–7.71 (5 H, m), 7.37 (1 H, dd, <i>J =</i> 7.0, 5.5 Hz), 6.22 (1 H, q, <i>J =</i> 6.9 Hz), 1.82 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 398.0 (M + l).</div></div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 2-((<i>S</i>)-1-(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55b</b>)</h3><div class="NLM_p last">The sample was dissolved in EtOAc, washed with saturated NaCl solution, dried with sodium sulfate, filtered, and concentrated. Chromatography, 330 g silica gel column with 0–70% EtOAc/hexane, gave <b>55b</b>. Yellow orange oil; yield 73% (11 g, 27 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.68 (1 H, s), 8.65–8.67 (1 H, m), 7.93 (1 H, dt, <i>J =</i> 7.8, 1.0 Hz), 7.85 (2 H, ddd, <i>J =</i> 10.5, 7.9, 1.2 Hz), 7.74 (1 H, td, <i>J =</i> 7.7, 1.8 Hz), 7.62–7.70 (4 H, m), 7.46–7.52 (1 H, m), 7.30 (1 H, ddd, <i>J =</i> 7.6, 4.9, 1.2 Hz), 6.58 (1 H, q, <i>J =</i> 7.0 Hz), 2.01 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 414.0 (M + 1).</div></div><div id="sec4_15_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 3-((<i>S</i>)-1-(1,3-Dioxoisoindolin-2-yl)ethyl)-2-(pyridin-2-yl)quinoline-8-carbonitrile (<b>55c</b>)</h3><div class="NLM_p last">To a flask were charged <b>55b</b> (3.00 g, 7.25 mmol), Pd(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub> (121 mg, 0.362 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (Xphos) (346 mg, 0.725 mmol), and tributyltin cyanide (2.29 g, 7.25 mmol). NMP (4 mL) and dicyclohexylamine (10 mL) were added, and the reaction was heated to 160 °C (in a hot oil bath) under N<sub>2</sub>. After 45 min additional amounts of Pd(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub> (0.05 equiv), Xphos (0.1 equiv), and dicyclohexylamine (5 mL) were added. Additional amounts of Pd(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub> (0.05 equiv), Xphos (0.1 equiv), and dicyclohexylamine (5 mL) were added every 30 min for 1.5 h (3×). After an additional 1 h, the mixture was cooled to rt and partitioned between EtOAc and saturated NaHCO<sub>3</sub>. The organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered, and evaporated in vacuo. Column chromatography (hexanes/EtOAc, 1:0 to 1:2) gave <b>55c</b>. Yield 68% (1.98 g, 4.90 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.74 (1 H, s), 8.68 (1 H, dq, <i>J =</i> 4.9, 0.8 Hz), 8.17 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 8.13 (1 H, dd, <i>J =</i> 7.2, 1.4 Hz), 8.01–8.04 (1 H, m), 7.78 (1 H, td, <i>J =</i> 7.7, 1.8 Hz), 7.61–7.70 (5 H, m), 7.34 (1 H, ddd, <i>J =</i> 7.5, 4.8, 1.4 Hz), 6.63–6.70 (1 H, m), 2.02 (3 H, d, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 405.1 (M + 1).</div></div><div id="sec4_15_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (<i>S</i>)-2-(1-(5,7-Difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55d</b>)</h3><div class="NLM_p last">Off white solid; yield 76% (85.0 mg, 0.205 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.88 (1 H, s), 8.59–8.70 (1 H, m), 7.61–7.75 (5 H, m), 7.58 (1 H, d, <i>J =</i> 9.78 Hz), 7.31 (2 H, ddd, <i>J =</i> 7.43, 4.70, 1.17 Hz), 7.11 (1 H, td, <i>J =</i> 9.39, 2.35 Hz), 6.33 (1 H, q, <i>J =</i> 7.04 Hz), 1.98 (3 H, d, <i>J =</i> 7.04 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 416 (M + 1).</div></div><div id="sec4_15_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (<i>S</i>)-2-(1-(7-Difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55e</b>)</h3><div class="NLM_p last">The reaction mixture was cooled to rt and decanted. The final 200 mL solution was filtered to remove Pd residue. The combined solvents were concentrated to 300 mL, filtered, washed (300 mL, 1:1 EtOAc/hexane), and dried to give a tan solid (82.1 g). The original mother liquor was concentrated to 100 mL and treated with (200 mL, 1:1 EtOAc/hexane) to precipitate an additional 2.2 g. The solids were combined yield 88% (84.3 g 212 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.69 (1 H, s), 8.65–8.67 (1 H, m), 7.94 (1 H, dd, <i>J =</i> 8.9, 6.0 Hz), 7.71–7.76 (2 H, m), 7.63–7.69 (5 H, m), 7.36–7.41 (1 H, m), 7.32 (1 H, ddd, <i>J =</i> 7.6, 4.9, 1.2 Hz), 6.31 (1 H, q, <i>J =</i> 7.1 Hz), 1.98 (3 H, d, <i>J =</i> 7.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 398.2 (M + 1).</div></div><div id="sec4_15_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 2-((<i>S</i>)-1-(8-Chloro-2-(2-chloro-5-fluoropyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55f</b>)</h3><div class="NLM_p last">A mixture of <b>52c</b> (280 mg, 0.754 mmol), 2-chloro-5-fluoropyridin-3-ylboronic acid (159 mg, 0.907 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (436 mg, 0.38 mmol), cesium fluoride (344 mg, 2.26 mmol), and copper(I) iodide (29 mg, 0.15 mmol) in 1,2-ethanediol, dimethyl ether (3.0 mL, 0.75 mmol) was subjected to microwave at 100 °C for 1 h and cooled to rt. The mixture was filtered and rinsed with EtOAc. The filtrates were collected and concentrated. Purification of the residue by flash chromatography over silica gel, eluting with 0–100% EtOAc in hexane, gave <b>55f</b>. Yield 40% (140 mg, 0.300 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.02 (1 H, s), 8.96 (1 H, s), 8.59 (1 H, d, <i>J =</i> 2.9 Hz), 8.51 (1 H, d, <i>J =</i> 2.9 Hz), 8.31 (1 H, dd, <i>J =</i> 8.4, 3.1 Hz), 8.24 (1 H, ddd, <i>J =</i> 8.3, 2.9, 1.2 Hz), 8.00–8.06 (2 H, m), 7.79 (6 H, ddd, <i>J =</i> 5.4, 3.1, 2.0 Hz), 7.65–7.75 (7 H, m), 5.49–5.56 (1 H, m), 5.40 (1 H, q, <i>J =</i> 7.3 Hz), 1.91 (3 H, d, <i>J =</i> 7.1 Hz), 1.85 (3 H, d, <i>J =</i> 6.8 Hz) (note that there is a mixture of two rotational isomers, ratio 1:1.4). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 466.0 (M + 1).</div></div><div id="sec4_15_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 2-((<i>S</i>)-1-(8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione (<b>55g</b>)</h3><div class="NLM_p last">A mixture of <b>55f</b> (140 mg, 0.300 mmol), dioxane (15 mL, 0.02 M), trimethylaluminum (0.5 mL, 1.50 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (69 mg, 0.060 mmol) was refluxed for 4 h under N<sub>2</sub> and then cooled to rt. The reaction mixture was acidified with 2 N HCl and the solvent evaporated. The residue was diluted with water, treated with NaOH and the mixture extracted with EtOAc. The combined extracts were washed with water, brine, dried, and concentrated. Purification of the residue by flash chromatography over silica gel, eluting with 0–100% EtOAc in hexane, gave <b>55g</b>. Yield 75% (100 mg, 0.225 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.70 (1 H, d, <i>J =</i> 7.1 Hz), 8.44 (1 H, d, <i>J =</i> 17.1 Hz), 7.85–7.94 (2 H, m), 7.66–7.77 (4 H, m), 7.55 (1 H, t, <i>J =</i> 7.9 Hz), 7.38 (1/2 H, d, <i>J =</i> 7.1 Hz), 7.14 (1/2 H, d, <i>J =</i> 6.1 Hz), 5.41–5.63 (1 H, m), 1.85–1.96 (3 H, m), 1.56 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 445.9 (M + 1).</div></div><div id="sec4_15_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (1<i>S</i>)-1-(8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)quinolin-3-yl)ethanamine (<b>56f</b>)</h3><div class="NLM_p last">A mixture of <b>55g</b> (100 mg, 0.224 mmol) and conc HCl in a sealed flask was heated to reflux for 24 h. The solvent was removed and the residue purified by flash chromatography over silica gel, gradient elution, 0–10% MeOH in DCM with 0.1% aqueous NH<sub>4</sub>OH, gave <b>56f</b>. Yield 76% (54.2 mg, 0.172 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>4</sub>]MeOH) δ ppm 8.68 (1 H, s), 8.51 (1 H, d, <i>J =</i> 2.7 Hz), 7.98 (1 H, dd, <i>J =</i> 8.4, 1.1 Hz), 7.91 (1 H, dd, <i>J =</i> 7.5, 1.3 Hz), 7.64–7.82 (1 H, m), 7.56–7.63 (1 H, m), 5.50 (2 H, s), 3.88–4.15 (1 H, m), 2.32 (3 H, s), 1.33 (3 H, d, <i>J =</i> 6.6 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 317 (M + 1).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> General Procedure for <b>54d</b>–<b>f</b> and <b>56a</b>–<b>e</b></h3><div class="NLM_p last">A stirred solution of <b>53d</b> (205 mg, 0.418 mmol) or <b>53e</b> (2.45 g, 5.91 mmol) or <b>53f</b> (8.50 g, 19.7 mmol) or <b>55a</b> (270 mg, 0.679 mmol) or <b>55b</b> (16.8 g, 40.6 mmol) or <b>55c</b> (7.50 g, 18.5 mmol) or <b>55d</b> (83 mg, 0.20 mmol) or <b>55e</b> (43.8 g, 110 mmol) in EtOH (0.1 M) was treated with NH<sub>2</sub>NH<sub>2</sub> (10 equiv) or hydrazine, monohydrate (20 equiv, <b>56a</b> synthesis) (25 equiv, <b>54e</b> synthesis) (1.5 equiv, <b>56c</b> synthesis) (10 equiv, <b>56e</b> synthesis) dropwise at rt. The mixture was then heated to 50–90 °C for 0.5–4 h and cooled to rt [unless noted below]. The reaction mixture was filtered and the filter cake washed with EtOAc. The organic layer was concentrated, partially dissolved in EtOAc, washed with water and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the product.</div></div><div id="sec4_16_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> (1<i>S</i>)-1-(8-Chloro-2-(3-(methylsulfonyl)phenyl)quinolin-3-yl)ethanamine (<b>54d</b>)</h3><div class="NLM_p last">Yellow oil. Mass spectrum (ESI) <i>m</i>/<i>e</i> = 361.2 (M + 1). The crude material was used immediately for <b>25</b>.</div></div><div id="sec4_16_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> (1<i>S</i>)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine (<b>54e</b>)</h3><div class="NLM_p last">Yield 80% (1.34 g, 4.71 mmol). <sup>1</sup>H NMR (400 MHz, (CDCl<sub>3</sub>) δ ppm 8.51 (1 H, d, <i>J =</i> 1.6 Hz), 7.65 (1 H, br d, <i>J =</i> 8.21 Hz), 7.52–7.42 (2 H, series of m), 7.39 (1 H, ddd, <i>J =</i> 10.5, 7.4, 1.2 Hz), 7.34 (1 H, dt, <i>J =</i> 7.5, 1.2 Hz), 7.30 (1 H, ddd, <i>J =</i> 9.4, 2.7, 1.6 Hz), 7.16 (1 H, tdd, <i>J =</i> 8.6, 2.4, 0.8 Hz), 4.48 (1 H, q, <i>J =</i> 6.2 Hz), 1.37 (d, <i>J =</i> 6.7 Hz, 3 H). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 285 (M + 1).</div></div><div id="sec4_16_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> (<i>S</i>)-1-(2-(3,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethanamine (<b>54f</b>)</h3><div class="NLM_p last">Yellow oil; yield 100% (5.9 g, 19.5 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.37 (3 H, d, <i>J =</i> 6.65 Hz), 1.55 (2 H, br s), 4.47 (1 H, q, <i>J =</i> 6.26 Hz), 6.92 (1 H, tt, <i>J =</i> 8.80, 2.35 Hz), 7.10–7.17 (2 H, m), 7.38–7.44 (1 H, m), 7.51 (1 H, td, <i>J =</i> 7.92, 4.89 Hz), 7.68 (1 H, d, <i>J =</i> 8.22 Hz), 8.53 (1 H, d, <i>J =</i> 1.56 Hz).</div></div><div id="sec4_16_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> (1<i>S</i>)-1-(8-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine (<b>56a</b>)</h3><div class="NLM_p last">The crude oil was used without purification. Yield 70% (0.127 g, 0.475 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 430.1 (M + 1).</div></div><div id="sec4_16_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> (1<i>S</i>)-1-(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine (<b>56b</b>)</h3><div class="NLM_p last">Tan oil; yield 100% (11.6 g, 40.9 mmol). The crude material was heated to 90 °C/2 mmHg to remove a colorless liquid byproduct. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.69 (1 H, dt, <i>J =</i> 4.9, 0.9 Hz), 8.46 (1 H, s), 8.18 (1 H, d, <i>J =</i> 7.8 Hz), 7.92 (1 H, td, <i>J =</i> 7.7, 1.7 Hz), 7.78–7.83 (2 H, m), 7.47 (1 H, t, <i>J =</i> 7.8 Hz), 7.38 (1 H, ddd, <i>J =</i> 7.6, 4.9, 1.0 Hz), 4.84 (1 H, q, <i>J =</i> 6.8 Hz), 1.45 (3 H, d, <i>J =</i> 6.6 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 284.0 (M + 1).</div></div><div id="sec4_16_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 3-((<i>S</i>)-1-Aminoethyl)-2-(pyridin-2-yl)quinoline-8-carbonitrile (<b>56c</b>)</h3><div class="NLM_p last">After heating to 85 °C for 4 h, the mixture was cooled to rt and treated with DCM (200 mL) and NaHCO<sub>3</sub> (saturated aqueous solution). The separated aqueous layer was extracted with DCM, and the combined organic layers were dried, filtered, and evaporated in vacuo. The resulting residue was taken up in EtOAc (100 mL) and water (100 mL) and acified to pH 2 with 1.0 M HCl. The aqueous layer was separated and the pH adjusted (pH 14) with 4.0 M NaOH. The aqueous layer was then extracted with DCM, dried, filtered, and evaporated in vacuo. Yield 97% (4.93 g, 17.9 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.41 (3 H, d, <i>J =</i> 6.65 Hz), 2.06 (2 H, br s), 4.89 (1 H, q, <i>J =</i> 6.65 Hz), 7.35 (1 H, ddd, <i>J =</i> 7.43, 4.69, 1.17 Hz), 7.55 (1 H, dd, <i>J =</i> 8.22, 7.43 Hz), 7.86 (1 H, td, <i>J =</i> 7.73, 1.76 Hz), 8.02–8.07 (2 H, m), 8.19–8.23 (1 H, m), 8.49 (1 H, s), 8.63–8.66 (1 H, m). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 275.2 (M + 1).</div></div><div id="sec4_16_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> (<i>S</i>)-1-(5,7-Difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine (<b>56d</b>)</h3><div class="NLM_p last">White solid; yield 100% (57 mg, 0.20 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 286 (M + 1).</div></div><div id="sec4_16_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> (1<i>S</i>)-1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine (<b>56e</b>)</h3><div class="NLM_p last">The filtrate was concentrated in vacuo, and then it was redissolved in EtOAc (1.5 L) and washed with water (500 mL). The aqueous layer was extracted with EtOAc (1 × 300 mL). The combined organic layers were reduced to a volume of 800 mL and then treated with water (800 mL) and acidified to pH 2 with aqueous HCl (4.0 M). The aqueous layer was washed with DCM (300 mL) and the pH adjusted (pH 14) with NaOH (4.0 M) and extracted with EtOAc (2 × 500 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and evaporated in vacuo. Yield 93% (27.5 g, 103 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.69–8.73 (1 H, m), 8.44 (1 H, s), 7.85–7.95 (3 H, m), 7.76 (1 H, dd, <i>J =</i> 10.2, 2.3 Hz), 7.33–7.42 (2 H, m), 4.63 (1 H, q, <i>J =</i> 6.7 Hz), 1.43 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 268.2 (M + 1).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> General Procedure for <b>1</b>, <b>15</b>, <b>16</b>, <b>17</b>, <b>18</b>, <b>19</b>, <b>22</b>, <b>23</b>, <b>25</b>, <b>29</b>, <b>30</b>, <b>31</b>, <b>33</b>, <b>34</b>, <b>35</b></h3><div class="NLM_p last">A mixture of <b>54d</b> (1.51 g, 4.18 mmol) or <b>56b</b> (11.0 g, 38.8 mmol) or <b>54f</b> (5.9 g, 19.5 mmol) or <b>54a</b> (530 mg, 1.76 mmol) or <b>54b</b> (12.0 g, 39.8 mmol) or <b>56a</b> (123 mg, 0.460 mmol) or <b>54c</b> (12.0 g, 42 mmol) or <b>56c</b> (4.93 g, 18.0 mmol) or <b>56d</b> (57 mg, 0.20 mmol) or <b>56e</b> (35.1 g, 131 mmol) or <b>84</b> (41.1 g, 136 mmol) or <b>43c</b> (165 mg, 0.520 mmol) or <b>76b</b> (206 mg, 0.724 mmol) or <b>76d</b> (11.8 g, 44.1 mmol) or <b>43b</b> (30.0 mg, 0.105 mmol) and 6-chloropurine (1.0–1.2 equiv) and DIEA (1.0–3.0 equiv) in <i>n</i>-BuOH (0.1–1.0 M) or EtOH (0.05 M (<b>17</b>) was heated to 100–118 °C. After heating overnight, the mixture was concentrated to provide a residue. The residue was partitioned between EtOAc and water. The water layer was extracted with EtOAc or DCM. The combined organic layers were washed with water, brine, dried with MgSO<sub>4</sub> and concentrated to give a crude product. Chromatography was with silica gel, 0–100% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) [unless otherwise noted].</div></div><div id="sec4_17_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> (<i>S</i>)-<i>N</i>-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>1</b>)</h3><div class="NLM_p last">DIEA (1.2 equiv) and 6-chloropurine (1 equiv) were heated to 110 °C, 24 h. The crude yield, 57 g, was divided into approximately 8 g portions and each portion purified on a 330 g Redi-Sep column by using a 20–60% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 30 min, isocratic at 60% for 30 min. Combined purified fractions provided a white solid, which was crushed into powder in a mortar and pestle and dried at 120 °C under high vacuum (300 mTorr) in a Kugelrohr apparatus. White powder; yield 69% (35 g, 62 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.76 (1 H, br s), 8.69 (1 H, br s), 8.63 (1 H, s), 8.21 (1 H, br s), 7.96–8.12 (4 H, m), 7.93 (1 H, s), 7.76 (1 H, dd, <i>J =</i> 10.4, 2.5 Hz), 7.45–7.57 (2 H, m), 6.00 (1 H, d, <i>J =</i> 1.2 Hz), 1.61 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 386.0 (M + 1).</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> (<i>S</i>)-<i>N</i>-(1-(8-Chlorophenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>15</b>)</h3><div class="NLM_p last">6-Chloropurine (1.1 equiv), DIEA (1.5 equiv), <i>n</i>-BuOH (0.17 M), and 115 °C were used. Purification with reverse-phase HPLC provided the racemic product (105 mg). Chiral HPLC was used (Chiralcel OD-H column, 0.46 mm × 250 mm, 5 mm) (isopropanol in hexane, 50%). The sample was then dissolved in DCM (1 mL) and put into two vials on chiral separation (15 min method) (retention time of 4.9 min) to give <b>15</b>. White solid; yield 9% (20 mg, 0.046 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.47 (1 H, br s), 8.36 (1 H, br s), 8.22 (1 H, br s), 7.94 (1 H, br s), 7.68–7.87 (3 H, m), 7.41–7.54 (2 H, m), 7.16–7.30 (2 H, m.), 5.42–5.73 (1 H, m), 3.98–4.10 (1 H, m), 1.22 (3 H, d, <i>J =</i> 5.9 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 435.1 (M + 1) (retention time of 6.7 min). (<i>R</i>)-<i>N</i>-(1-(8-Chlorophenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine white solid; yield 10% (22 mg, 0.051 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.45 (1 H, s), 8.36 (1 H, s), 8.21 (1 H, s), 7.92 (1 H, s), 7.69–7.83 (3 H, m), 7.39–7.50 (1 H, m), 7.34–7.16 (2 H, m), 5.43–5.71 (1 H, m), 4.04 (1 H, dt, <i>J =</i> 12.3, 6.0 Hz), 1.22 (3 H, d, <i>J =</i> 6.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 435.1 (M + 1).</div></div><div id="sec4_17_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>16</b>)</h3><div class="NLM_p last">DIEA (3 equiv), 6-chloropurine (1.5 equiv), and 100 °C were used. White solid; yield 65% (480 mg, 1.15 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.43 (1 H, s), 8.05 (1 H, s), 7.98 (1 H, s), 7.73–7.80 (2 H, m), 7.48–7.53 (1 H, m), 7.44–7.49 (1 H, m), 7.35–7.44 (2 H, m), 7.04–7.11 (1 H, m), 1.44–1.47 (d, 3 H). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 419 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>16</sub>ClFN<sub>6</sub> + H<sup>+</sup> [M + H]: 419.1187. Found: 419.1179.</div></div><div id="sec4_17_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> <i>N</i>-((8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)methyl)-9<i>H</i>-purin-6-amine (<b>17</b>)</h3><div class="NLM_p last">6-Chloropurine (1.2 equiv) was used. Chromatography, EtOAc/hexane (0–50%), gave a yield of 47% (20.0 mg, 0.0494 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.41 (1 H, s), 8.31 (1 H, s), 8.13 (2 H, s), 7.95 (2 H, dd, <i>J =</i> 19.07, 7.83 Hz), 7.61–7.55 (6 H, m), 7.38 (1 H, m), 4.88 (2 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 405.1 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>14</sub>ClFN<sub>6</sub> + H<sup>+</sup> [M + H]: 405.1031. Found: 405.1023.</div></div><div id="sec4_17_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>18</b>)</h3><div class="NLM_p last">DIEA (3 equiv), 6-chloropurine (1.0 equiv), <i>n</i>-BuOH (1.0 equiv), and 100 °C were used. The residue was purified by column chromatography with Redi-Sep column using 0–35% gradient of 89:9:1 DCM/MeOH/NH<sub>4</sub>OH in DCM over 14 min and then 35% isocratic 89:9:1 DCM/MeOH/NH<sub>4</sub>OH in DCM for 25 min as eluent to give a light yellow solid, which was suspended in DCM and filtered to give a white solid. Yield 44% (7.42g, 17.7 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.86 (1 H, s), 8.67 (1 H, s), 8.20 (1 H, s), 8.09 (1 H, s), 7.95–8.03 (2 H, m), 7.93 (1 H, dd, <i>J =</i> 7.6, 1.0 Hz), 7.69 1 H, s), 7.58 (1 H, t, <i>J =</i> 7.8 Hz), 7.46–7.55 (1 H, m), 7.25–7.39 (2 H, m), 5.38 (1 H, s), 1.55 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 419.0 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>16</sub>ClFN<sub>6</sub> + H<sup>+</sup> [M + H]: 419.1187. Found: 419.1190.</div></div><div id="sec4_17_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> <i>N</i>-((<i>S</i>)-1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>19</b>)</h3><div class="NLM_p last">The reaction involved 6-chloropurine (1.00 equiv), <i>n</i>-BuOH (1.0 M), DIEA (3.0 equiv), 100 °C, 22 h. For purification, the residue (brown syrupy solid) was suspended in water (500 mL), resulting in a precipitate, which was collected by filtration and washed with water (500 mL) to give a yellow solid. This was suspended in EtOAc–hexane (1:1, 400 mL), filtered, washed with EtOAc–hexane (1:1, 500 mL), and dried to give the crude product (43.0 g). The organic filtrate still contained product. The yellow solid (43.0 g) was purified by flash column chromatography using 20–100% gradient of 89:9:1 DCM/MeOH/NH<sub>4</sub>OH in DCM as eluent to give a light yellow solid, which was suspended in DCM (150 mL), filtered, washed with DCM (150 mL), dried under vacuum to give the pure racemic product. Off-white solid; yield 48% (27.2 g, 64.8 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.90 (1 H, br s), 7.89–8.20 (5 H, m), 7.82 (1 H, t, <i>J =</i> 8.0 Hz), 7.61–7.74 (2 H, m), 7.48–7.60 (1 H, m), 7.26–7.38 (1 H, m), 5.72 (1 H, br s), 1.55 (3 H, d, <i>J =</i> 5.5 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 419.8 (M + 1). All chiral HPLC (Chiralcel OD-H column, 0.46 mm × 250 mm, 5 mm) using 5% isocratic of isopropanol in hexane as eluent: two peaks at 9.503 and 12.045 min at 254 nm; using 3% isocratic of isopropanol in hexane as eluent, two peaks at 15.141 and 19.733 min at 254 nm. Chiral separation: OD-H + IC 250 mm × 30 mm columns in series using 36 g/min IPA (0.2% DEA) + 54 g/min CO<sub>2</sub> on Thar 350 SFC. Outlet pressure = 125 bar; temp = 18C; wavelength = 327 nm. Used 2.0 mL injections of 5.0 g/750 mL (9:1 IPA/ACN) sample solution, i.e., 6.7 mg/mL (13.3 mg/injection). Cycle time = 3.2 min; run time = 8.0 min. First peak on OD-H column: 99% pure. Chromatography (to remove <1% dipurine byproduct) with 330 g Redi-Sep column using 0–20% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 50 min, then 20% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) for 50 min, then 20–30% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 100 min as eluent to give the desired product <b>19</b>. Yield 37% (9.93 g, 23.6 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.90 (1 H, br s), 7.87–8.29 (5 H, m), 7.82 (1 H, t, <i>J =</i> 8.0 Hz), 7.61–7.74 (2 H, m), 7.48–7.61 (1 H, m), 7.24–7.39 (1 H, m), 5.72 (1 H, br s), 1.55 (3 H, d, <i>J =</i> 5.9 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 420.1 (M + 1). Enantiomeric excess analysis: >99% ee. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>15</sub>ClFN<sub>7</sub> + H<sup>+</sup> [M + H]: 420.1140. Found: 420.1132.</div></div><div id="sec4_17_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> (<i>S</i>)-<i>N</i>-(1-(2-(3,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>22</b>)</h3><div class="NLM_p last">White solid; yield 72% (5.9 g, 14 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.34–8.37 (2 H, m), 8.01 (1 H, s), 7.56 (1 H, d, <i>J =</i> 7.8 Hz), 7.42–7.52 (3 H, m), 7.34–7.41 (1 H, m), 6.90 (1 H, tt, <i>J =</i> 9.0, 2.3 Hz), 6.60 (1 H, br s), 5.79 (1 H, br s), 1.55 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 421.1(M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>15</sub>F<sub>3</sub>N<sub>6</sub> + H<sup>+</sup> [M + H]: 421.1389. Found: 421.1378.</div></div><div id="sec4_17_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> <i>N</i>-((<i>S</i>)-1-(7-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>23</b>)</h3><div class="NLM_p last">After chromatography, the product was washed in DCM–hexane (1:1). White solid; yield 52% (8.8 g, 22 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>4</sub>]MeOH) δ ppm 8.57 (1 H, s), 8.14 (1 H, s), 8.08 (1 H, br s), 8.01 (1 H, dd, <i>J =</i> 9.0, 6.1 Hz), 7.66 (1 H, dd, <i>J =</i> 10.3, 2.4 Hz), 7.47–7.56 (3 H, m), 7.44 (1 H, td, <i>J =</i> 8.7, 2.6 Hz), 7.18 (1 H, td, <i>J =</i> 8.5, 2.1 Hz), 5.60–5.77 (1 H, br., s), 1.57 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 402.9 (M + l). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>16</sub>F<sub>2</sub>N<sub>6</sub> + H<sup>+</sup> [M + H]: 403.1483. Found: 403.1482.</div></div><div id="sec4_17_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> <i>N</i>-((<i>S</i>)-1-(7-Fluoro-2-(2-(methylsulfonyl)phenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>24</b>)</h3><div class="NLM_p last">To a solution of <b>62</b> (15 g, 34 mmol) in DCM (50 mL, 0.67 M) was added TFA (50 mL, 653 mmol, 19 equiv) at rt. After 1 h, the reaction mixture was concentrated and neutralized with saturated NaHCO<sub>3</sub> (pH 7). The resulting mixture was extracted with EtOAc (3 × 100 mL). The organic layer was washed with NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give a white foam. This material was dissolved in <i>n</i>-BuOH (100 mL) and treated with 6-chloropurine (5.48 g, 1.05 equiv) and DIEA (7.05 mL, 1.2 equiv) at 130 °C overnight. The mixture was concentrated to dryness dissolved in EtOAc, washed with water, brine, and dried over MgSO<sub>4</sub>. Chromatography, silica gel (20:1:0.01 DCM/MeOH/NH<sub>4</sub>OH), gave a white solid; yield 51% (8.0 g, 17 mmol). <sup>1</sup>H NMR (400 Hz, [D<sub>4</sub>]MeOH) δ ppm 9.35 (l H, s), 8.53–8.47 (m, 2 H), 8.25 (l H, s), 7.98–7.76 (6 H, m), 5.85 (s, br, 0.4 H), 5.58–5.56 (m, 0.6 H), 3.19 (3 H, s), 1.88–1.81 (3 H, m). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.94 (1 H, s), 8.23 (1 H, dd, <i>J =</i> 7.9, 1.1 Hz), 8.02 (1 H, dd, <i>J =</i> 9.0, 5.9 Hz), 7.79–7.83 (1 H, m), 7.74–7.78 (1 H, m), 7.65 (1 H, dd, <i>J =</i> 9.7, 2.6 Hz), 7.45 (1 H, td, <i>J =</i> 8.7, 2.7 Hz), 7.37 (1 H, dd, <i>J =</i> 7.3, 1.2 Hz), 4.08–4.17 (1 H, m), 1.65 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 463.0 (M + l). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>2</sub>S + H<sup>+</sup> [M + H]: 463.1352. Found: 463.1343.</div></div><div id="sec4_17_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> (<i>S</i>)-<i>N</i>-(1-(8-chloro-2-(3-(methylsulfonyl)phenyl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>25</b>)</h3><div class="NLM_p last">The reaction mixture was purified by reverse phase HPLC (MeCN/H<sub>2</sub>O/0.1%TFA, 0–50%). White powder; yield 22%, (440 mg, 0.919 mmol) <sup>1</sup>H NMR (500 MHz, [D<sub>4</sub>]MeOH) δ ppm 8.66 (1 H, s), 8.35–8.40 (2 H, m), 8.31 (1 H, br s), 7.90–8.06 (4 H, m), 7.76 (1 H, br s), 7.60 (1 H, t, <i>J =</i> 7.9 Hz), 5.72 (1 H, br s), 3.14 (3 H, s), 1.71 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 479.0 (M + l). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>19</sub>ClN<sub>6</sub>O<sub>2</sub>S + H<sup>+</sup> [M + H]: 479.1057. Found: 479.1052.</div></div><div id="sec4_17_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> <i>N</i>-((<i>S</i>)-1-(8-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>29</b>)</h3><div class="NLM_p last">Yield 38% (68.0 mg, 0.176 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>4</sub>]MeOH) δ ppm 8.66 (1 H, d, <i>J =</i> 4.4 Hz), 8.62 (1 H, d, <i>J =</i> 1.0 Hz), 8.04–8.08 (2 H, m), 7.89–7.97 (2 H, m), 7.77 (1 H, d, <i>J =</i> 8.3 Hz), 7.57 (1 H, td, <i>J =</i> 8.1, 4.9 Hz), 7.42–7.50 (2 H, m), 5.98 (1 H, br s), 1.69 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 386.2 (M + l).</div></div><div id="sec4_17_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl) ethyl)-9<i>H</i>-purin-6-amine (<b>30</b>)</h3><div class="NLM_p last">After chromatography, the resulting white foam was treated with hot hexane and filtered to give a white powder; yield 96% (15.7 g, 37.2 mmol) <sup>1</sup>H NMR (400 Hz, [D<sub>6</sub>]DMSO) δ ppm 12.66 (l H, br s.), 8.54 (l H, s), 8.50 (l H, s), 8.12 (l H, s), 7.92–7.84 (2 H, m), 7.77–7.74 (3 H, m), 7.39 (1 H, t, <i>J =</i> 8.0 Hz), 7.34 (1 H, t, <i>J =</i> 8.0 Hz), 5.91 (l H, s), 1.48 (3 H, d, <i>J =</i> 4.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 402 (M + l). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>16</sub>ClN<sub>7</sub> + H<sup>+</sup> [M + H]: 402.1234. Found: 402.1229.</div></div><div id="sec4_17_13_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> <i>N</i>-((<i>S</i>)-1-(5-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>31</b>) and <i>N</i>-(1-(5-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>77b</b>)</h3><div class="NLM_p">The reaction involved 6-chloropurine (1.0 equiv), DIEA (3.0 equiv), <i>n</i>-BuOH (0.1 M), 100 °C, 24 h. For purification, the residue was dissolved in DCM–MeOH (9:1, 50 mL), washed with water (30 mL), brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Chromatography, 40 g of Redi-Sep column using 0–100% gradient of 89:9:1 DCM/MeOH/NH<sub>4</sub>OH and DCM over 14 min and then 100% isocratic 89:9:1 DCM/MeOH/NH<sub>4</sub>OH for 14 min, gave a light yellow solid, which was suspended in MeOH and filtered to give <b>77b</b>. Off-white solid; yield 63% (0.183 g, 0.455 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.87 (1 H, br s), 8.75 (1 H, br s), 8.00–8.18 (5 H, m), 7.96 (1 H, s), 7.90 (1 H, br s), 7.84 (1 H, dd, <i>J =</i> 8.4, 7.6 Hz), 7.55 (1 H, br s), 6.24 (1 H, br s), 1.71 (3 H, d, <i>J =</i> 5.1 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 402.9 (M + 1). Analytical chiral HPLC parameters. Chiralpak AD-H column: 0.46 mm × 250 mm, 5 mm (isopropanol in hexane, 10%), first peak at 13.431 min and second peak at 22.605 min at 254 nm. Chiralcel OD-H column: 0.46 mm × 250 mm, 5 mm, using 10% isocratic of isopropanol in hexane as eluent, first peak at 7.275 min and second peak at 9.237 min at 254 nm. For chiral separation, the racemic mixture (152.26 mg) was separated using SFC dissolved in 43.3 mL of ethanol, and 0.75 mL injections of this solution onto the SFC system at conditions below resulted in isolation of two major peaks. Column: 150 mm × 30 mm OD-H (5 μm). Mobile phase: A, liquid CO<sub>2</sub>, 52.5 g/min,; B, methanol (0.2% DEA), 22.5 mL/min. Mobile phase temp: ambient. Outlet pressure: 100 bar. Wavelength: 220 nm. Peak 1 (first peak at 4.82 min): <b>31</b>. Tan solid; 37% (562 mg, 0.267 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.36–13.26 (1 H, m), 8.76 (1 H, br s), 8.00–8.17 (5 H, m), 7.96 (1 H, s), 7.90 (1 H, br s), 7.80–7.87 (1 H, m), 7.55 (1 H, br s), 6.24 (1 H, br s), 1.71 (3 H, d, <i>J =</i> 5.9 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 402.9 (M + 1). Enantiomeric excess analysis: >99% ee, first-eluting enantiomer on OH-H column. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>1</sub>5ClN<sub>8</sub> + H<sup>+</sup> [M + H]: 403.1186. Found: 403.1179. Peak 2 (second peak at 5.18 min on OD-H column): <i>N</i>-((<i>R</i>)-1-(5-chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine, tan solid; yield 33% (50.9 mg, 0.241 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.46 (1 H, br s), 8.75 (1 H, br s), 8.00–8.17 (5 H, m), 7.96 (1 H, s), 7.90 (1 H, d, <i>J =</i> 7.4 Hz), 7.80–7.87 (1 H, m), 7.50–7.60 (1 H, m), 6.24 (1 H, br s), 1.71 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 402.9 (M + 1). Enantiomeric excess analysis: >99% ee, second-eluting enantiomer on OH-H column.</div><div class="NLM_p last">Note that the stereochemistry of the two isomers was arbitrarily assigned based on the comparison of retention time on chiral HPLC of similar analogs (first peak as <i>S</i>-isomer and second peak as <i>R</i>-isomer), confirmed by crystal structures of PI3Kγ protein and <b>27</b>.</div></div><div id="sec4_17_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> (<i>S</i>)-3-(1-((9<i>H</i>-Purin-6-yl)amino)ethyl)-2-(pyridin-2-yl)quinoline-8-carbonitrile (<b>33</b>)</h3><div class="NLM_p last">Yield 68% (4.80 g, 12.2 mmol). (S) Chiral separation by SFC: dissolved in 423 mL of methanol, and 5.0 mL injections of this solution onto the SFC system at conditions below resulted in isolation of two peaks, one major and one minor. Column: 250 mm × 30 mm AS-H (5 μm). Mobile phase: A, liquid CO<sub>2</sub>, 99 g/min; B, methanol (0.2% DEA), 37 mL/min. Mobile phase temp: 24 °C. Outlet pressure: 140 bar. Wavelength: 265 nm. Enantiomeric excess determination: 98.2% ee. <sup>1</sup>H NMR (400 MHz, [D<sub>4</sub>]MeOH) δ ppm 1.75 (3 H, d, <i>J =</i> 7.04 Hz), 6.22 (1 H, br s), 7.46–7.53 (1 H, m), 7.69–7.76 (1 H, m), 7.95–8.03 (1 H, m), 8.07 (2 H, s), 8.16 (1 H, d, <i>J =</i> 7.83 Hz), 8.26 (2 H, ddd, <i>J =</i> 12.52, 7.83, 1.17 Hz), 8.69 (1 H, s), 8.72 (1 H, d, <i>J =</i> 5.09 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 393.0 (M + l). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>16</sub>N<sub>8</sub> + H<sup>+</sup> [M + H]: 393.1576. Found: 393.1565.</div></div><div id="sec4_17_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> (<i>S</i>)-<i>N</i>-(1-(6-Fluoro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>34</b>)</h3><div class="NLM_p last">The reaction involved 6-chloropurine (1.0 equiv), DIEA (3.0 equiv), <i>n</i>-BuOH (0.1 M), 110 °C, 22 h. For purification, the residue was dissolved in DCM (1 L). The solution was washed with water (2 × 500 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a brown solid. The brown solid was suspended in DCM (100 mL), sonicated, filtered, and washed with DCM (100 mL) to give an off-white solid. Chromatography: 330 g Redi-Sep column using 0%–50% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 25 min and then 50% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) for 25 min as eluent to give <b>34</b> and <b>71</b>. White solid; yield 33% (5.68 g, 14.7 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.79 (1 H, br s), 8.74 (1 H, br s), 8.19 (1 H, dd, <i>J =</i> 9.3, 5.9 Hz), 7.99–8.14 (3 H, m), 7.96 (1 H, s), 7.93 (1 H, dd, <i>J =</i> 9.5, 2.7 Hz), 7.83–7.89 (1 H, m), 7.80 (1 H, td, <i>J =</i> 8.9, 2.8 Hz), 7.54 (1 H, br s), 6.16 (1 H, br s), 1.68 (3 H, d, <i>J =</i> 6.6 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 387 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>15</sub>FN<sub>8</sub> + H<sup>+</sup> [M + H]: 387.1482. Found: 387.148.</div></div><div id="sec4_17_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> (<i>S</i>)-<i>N</i>-(1-(5,7-Difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>35</b>)</h3><div class="NLM_p last">The reaction involved 6-chlorpurine (1.0 equiv), DIEA (1.2 equiv), <i>n</i>-BuOH (0.1 M), 110 °C. Purification was by reverse HPLC on C18 (MeCN/H<sub>2</sub>O/TFA, 0–50%). The major peak was collected and treated with HCl (3 N) and concentrated to give a white powder; yield 74% (60 mg, 0.15 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>4</sub>]MeOH) δ ppm 1.87 (3 H, d, <i>J =</i> 6.26 Hz), 5.77 (1 H, br s), 7.38–7.52 (1 H, m), 7.70 (1 H, d, <i>J =</i> 9.39 Hz), 8.18 (1 H, t, <i>J =</i> 6.46 Hz), 8.49 (2 H, br s) 8.60 (1 H, d, <i>J =</i> 7.04 Hz), 8.74 (1 H, t, <i>J =</i> 7.43 Hz), 8.99 (1 H, s), 9.11 (d, <i>J =</i> 5.09 Hz, 1 H). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 404.0 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>15</sub>F<sub>2</sub>N<sub>7</sub> + H<sup>+</sup> [M + H]: 404.1435. Found: 404.1431.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> General Procedure for the Synthesis of <b>14</b>, <b>20</b>, <b>21</b>, <b>26</b>, <b>27</b>, <b>28</b>, and <b>32</b></h3><div class="NLM_p last">To a round bottomed flask was charged <b>43a</b> (7.20 g, 23.8 mmol) or <b>54e</b> (22 mg, 0.077 mmol) or <b>56f</b> (54 mg, 0.17 mmol) or <b>76a</b> (314 mg, 1.10 mmol) or <b>59a</b> (60 mg, 0.22 mmol) or (<b>59b</b> (66 mg, 0.22 mmol) or <b>67</b> (0.68 g, 2.3 mmol), DIEA (2.0–3.0 equiv), 6-bromopurine (1.2 equiv), and <i>n</i>-BuOH (0.1–1.0 M). The mixture was heated to 100–118 °C for 14–24 h, cooled to rt, and the solvent was removed in vacuo to provide a crude product. Purification of the residue was by flash chromatography over silica gel, gradient elution, 0–10% MeOH/DCM with 0.1% aqueous NH<sub>4</sub>OH [unless otherwise noted].</div></div><div id="sec4_18_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> <i>N</i>-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9<i>H</i>-purin-6-amine (<b>14</b>)</h3><div class="NLM_p last">Crude product: orange syrup. Column chromatography: (silica gel) 50% of 89:9:1 DCM/MeOH/NH<sub>4</sub>OH in DCM. Yield: light yellow solid suspended in EtOH (150 mL). The mixture was refluxed for 30 min, cooled to rt. A precipitate formed and was collected by filtration, washed with cold EtOH (100 mL). Off-white solid; yield 80% (7.78 g, 19.0 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.94 (1 H, s), 8.36 (1 H, s), 8.05–8.29 (3 H, m), 7.99 (1 H, dd, <i>J =</i> 8.4, 1.0 Hz), 7.93 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.44–7.68 (5 H, m), 4.50–4.82 (2 H, m). Mass Specrum (ESI) major peak of <i>m</i>/<i>z</i> 421.1 [M + H]<sup>+</sup>. Elemental analysis calculated (%) for C<sub>21</sub>H<sub>16</sub>C<sub>l4</sub>N<sub>6</sub> (di-HCl salt): C 51.04, H 3.26, N 17.01. Found: C 51.74, H 3.77, N 16.79. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>6</sub> + H<sup>+</sup> [M + H]: 421.0735. Found: 421.0725.</div></div><div id="sec4_18_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> <i>N</i>-((<i>S</i>)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-7<i>H</i>-purin-6-amine (<b>20</b>)</h3><div class="NLM_p last"><i>n</i>-BuOH (0.1 M) yield 58% (18 mg, 0.045 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.33 (2 H, s), 7.97 (1 H, s), 7.65–7.61 (2 H, m), 7.52 (1 H, d, <i>J =</i> 8.2 Hz), 7.47–7.39 (2 H, m), 7.35 (1 H, ddd, <i>J =</i> 10.6,7.8, 1.6 Hz), 6.76 (1 H, br s), 5.80 (1 H, br s), 1.51 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 403 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>16</sub>F<sub>2</sub>N<sub>6</sub> + H<sup>+</sup> [M + H]: 403.1483. Found: 403.1487.</div></div><div id="sec4_18_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> <i>N</i>-((<i>S</i>)-1-(2-(2,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-7<i>H</i>-purin-6-amine (<b>21</b>)</h3><div class="NLM_p last">Purified by reverse phase chromatography (5–30% gradient). Yield 59% (54 mg, 0.13 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.37 (1 H, s), 8.24 (1 H, s), 7.94 (1 H, s), 7.60 (1 H, d, <i>J =</i> 8.2 Hz), 7.48 (2 H, td, <i>J =</i> 8.0, 5.1 Hz), 7.35–7.43 (2 H, m), 7.09 (2 H, d, <i>J =</i> 3.9 Hz), 6.40 (1 H, br s), 5.54 (1 H, d, <i>J =</i> 9.8 Hz), 1.68 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 420.9 (M + 1).</div></div><div id="sec4_18_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> <i>N</i>-((<i>S</i>)-1-(8-Fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethyl)-7<i>H</i>-purin-6-amine (<b>26</b>)</h3><div class="NLM_p last">DIEA (3.0 equiv) was used. Purified by reverse phase chromatography (5–30% gradient). Yield 23% (20 mg, 0.053 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.15 (1 H, s), 8.71 (1 H, dd, <i>J =</i> 4.7, 1.6 Hz), 8.34–8.38 (1 H, m), 8.26–8.30 (1 H, m), 8.22 (1 H, d, <i>J =</i> 7.8 Hz), 7.97 (1 H, s), 7.54 (1 H, d, <i>J =</i> 7.4 Hz), 7.32–7.48 (4 H, m), 6.67 (1 H, br s), 5.75 (1 H, br s), 1.53 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 385.9 (M + 1).</div></div><div id="sec4_18_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>27</b>)</h3><div class="NLM_p last">The reaction involved 6-bromopurine (1.1 equiv), DIEA (2.7 equiv), <i>n</i>-BuOH (2.5 M), reflux, 18 h. Chromatography, Redi-Sep column using 0–50% gradient of 89:9:1 DCM/MeOH/NH<sub>4</sub>OH in DCM, gave a yellow solid. The yellow solid was suspended in MeOH and filtered to give <i>N</i>-(1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine as an off-white solid, which was dissolved in MeOH–CH<sub>2</sub>Cl<sub>2</sub> (1:4, 5 mL), filtered, and separated on a Chiralpak IA column using 20% isocratic of isopropanol in hexane for 40 min as eluent to give the pure isomer as a white solid; yield 55% (0.867g, 1.15 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.90 1 H, s), 8.59 (2 H, d, <i>J =</i> 61.6 Hz), 7.70–8.37 (6 H,m), 7.58 (1 H, t, <i>J =</i> 7.8 Hz), 7.32 (1 H, s), 5.34 (1 H, br s), 2.32 (3 H, s), 1.53 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 416 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>18</sub>ClN<sub>7</sub> + H<sup>+</sup> [M + H]: 416.1390. Found: 416.1389.</div></div><div id="sec4_18_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>28</b>)</h3><div class="NLM_p last"><i>n</i>-BuOH (1.0 M); yield 37% (27 mg, 0.063 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.85 (1 H, br s), 8.70 (1 H, br s), 8.49 (1 H, br s), 8.11 (2 H, br s), 8.02 (1 H, d, <i>J =</i> 8.1 Hz), 7.96 (1 H, dd, <i>J =</i> 7.6, 1.2 Hz), 7.85–7.93 (1 H, m), 7.62 (1 H, t, <i>J =</i> 7.9 Hz), 5.77 (3 H, s), 5.37 (1 H, br s), 4.10 (1 H, q, <i>J =</i> 5.4 Hz), 2.27 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 433.9 (M + 1)</div></div><div id="sec4_18_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> <i>N</i>-((<i>S</i>)-1-(8-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>32</b>) and <i>N</i>-(1-(8-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9<i>H</i>-purin-6-amine (<b>77a</b>)</h3><div class="NLM_p last">The reaction involved <i>n</i>-BuOH (0.28 M), DIEA (3.0 equiv), and 6-bromopurine (1 equiv), 110 °C, 5 h. Chromatography provided <b>77a</b>. Tan solid; yield 77% (343 mg, 0.851 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.87 (1 H, br s), 8.74 (1 H, br s), 7.96–8.20 (6 H, m), 7.85 (2 H, t, <i>J =</i> 8.0 Hz), 7.53 (1 H, br s), 6.33 (1 H, br s), 1.67 (3 H, d, <i>J =</i> 6.3 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 403.1 (M + 1). The racemic tan solid (343 mg) was purified by Lotus separation with Chiralcel OJ-H (2 cm × 25 cm) 08-9805, 25% methanol/CO<sub>2</sub>, 100 bar, 80 mL/min, to give <b>32</b>. Yield 37% (143 mg, 0.315 mmol). 99% ee (Chiracel OJ-H (25 cm × 0.46 cm), 25% methanol (0.1% DEA)/CO<sub>2</sub>, 100 bar, 3 mL/min, <i>t</i><sub>R</sub> = 2.59 min). <sup>1</sup>H NMR (400 MHz, dichloromethane-<i>d</i><sub>2</sub>) δ ppm 8.85 (d, <i>J =</i> 4.30 Hz, 1 H), 8.28 (1 H, s), 8.20 (1 H, d, <i>J =</i> 7.83 Hz), 8.07 (1 H, dd, <i>J =</i> 8.41, 1.37 Hz), 7.98 (1 H, td, <i>J =</i> 7.63, 1.56 Hz), 7.93 (1 H, br s), 7.91 (1 H, dd, <i>J =</i> 7.83, 1.17 Hz), 7.71 (1 H, dd, <i>J =</i> 8.41, 7.63 Hz), 7.53 (1 H, br s), 7.50 (1 H, dd, <i>J =</i> 7.83, 4.69 Hz), 6.68 (1 H, br s), 1.70 (3 H, d, <i>J =</i> 6.26 Hz), 1.54 (1 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 403.1 (M + 1). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>15</sub>ClN<sub>8</sub> + H<sup>+</sup> [M + H]: 403.1186. Found: 403.1180.</div></div><div id="sec4_18_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> (<i>S</i>)-3-(1-Azidoethyl)-2-chloro-8-fluoroquinoline (<b>57</b>)</h3><div class="NLM_p last">Triphenylphosphine (1.81 g, 6.9 mmol, 1.2 equiv) was dissolved in anhydrous THF (30 mL) and cooled to 0 °C. To this solution was added DIAD (1.36 mL, 6.9 mmol). The mixture was stirred for 30 min at 0 °C, and (<i>R</i>)-1-(2-chloro-8-fluoroquinolin-3-yl)ethanol <b>51d</b> (1.31 g, 5.81 mmol) in THF (30 mL) was added, followed by diphenylphosphoryl azide (1.37 mL, 6.3 mmol). The mixture was allowed to warm to rt and stirred overnight. The crude material was purified by flash chromatography 0–3% EtOAc/hexane to give <b>57</b>. Yield 76% (1.10 g, 4.43 mmol). <sup>1</sup>H NMR (400 MHz, (CDCl<sub>3</sub>) δ ppm 8.30 (1 H, d, <i>J</i> = 1.2 Hz), 7.67 (1 H, d, <i>J =</i> 8.2 Hz), 7.54 (1 H, td, <i>J =</i> 7.8, 4.7 Hz), 7.45 (1 H, ddd, <i>J =</i> 10.2, 7.8, 1.2 Hz) 5.22 (1 H, q, <i>J =</i> 6.7 Hz), 1.68 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 250.9 (M + 1).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> General Procedure for the Synthesis of <b>58a</b> and <b>58b</b></h3><div class="NLM_p last">To a round bottomed flask, purged with N<sub>2</sub> were added <b>57</b> (100 mg, 0.399 mmol, 1.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (2.0 equiv), pyridin-3-ylboronic acid (1.5 equiv), or 2,5-difluorophenylboronic acid (1.5 equiv) in 3:1 MeCN/H<sub>2</sub>O, 0.1 M. This was heated to 80 °C for 1–1.5 h. The mixture was cooled to rt and the solvent removed. The residue was treated with EtOAc (20 mL) and washed with a saturated solution of NaHCO<sub>3</sub> (5 mL) and NaCl (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. Chromatography involved 50:50 hexanes/EtOAc and 12 g Redi-Sep column.</div></div><div id="sec4_19_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> 3-((<i>S</i>)-1-Azidoethyl)-8-fluoro-2-(pyridin-3-yl)quinoline (<b>58a</b>)</h3><div class="NLM_p last">Yield 64% (75 mg, 0.26 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.86 (1 H, d, <i>J =</i> 2.3 Hz), 8.76 (1 H, dd, <i>J =</i> 5.1, 1.6 Hz), 8.41 (1 H, d, <i>J =</i> 1.6 Hz), 7.97 (1 H, dt, <i>J =</i> 7.8, 2.0 Hz), 7.73 (1 H, d, <i>J =</i> 8.2 Hz), 7.57 (1 H, td, <i>J =</i> 7.9, 4.9 Hz), 7.46–7.51 (2 H, m), 4.89 (1 H, q, <i>J =</i> 6.7 Hz), 1.58–1.60 (1 H, m), 1.59 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 294.0 (M + 1).</div></div><div id="sec4_19_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> 3-((<i>S</i>)-1-Azidoethyl)-2-(2,5-difluorophenyl)-8-fluoroquinoline (<b>58b</b>)</h3><div class="NLM_p last">Chromatography (5% EtOAc in hexanes, 23 g silica, then 5% ether in hexanes, 10 g silica) gave <b>58b</b>. Yield 64% (84 mg, 0.26 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.40 (1 H, d, <i>J =</i> 1.2 Hz), 7.73 (1 H, d, <i>J =</i> 8.2 Hz), 7.58 (1 H, td, <i>J =</i> 7.9, 4.9 Hz), 7.47 (1 H, ddd, <i>J =</i> 10.3, 7.7, 1.2 Hz), 7.23–7.26 (1 H, m), 7.16–7.21 (2 H, m), 4.81 (1 H, q, <i>J =</i> 6.3 Hz), 1.56 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 328.9 (M + 1).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> General Procedure for the Synthesis of <b>59a</b> and <b>59b</b></h3><div class="NLM_p last">The reaction involved dissolving <b>58a</b> (72 mg, 0.24 mmol) or <b>58b</b> (80 mg, 0.24 mmol), PPh<sub>3</sub> (1.2 equiv), H<sub>2</sub>O (20 equiv) in THF (0.1 M). The mixture was heated to 60 °C overnight. Solvent was removed. Dilution was with ether (6 mL), and extraction was with HCl (1 N). The aqueous layer was adjusted to pH 12 with NaOH and extracted with ether (20 mL). The organic layer was dried ove MgSO<sub>4</sub>, filtered, and concentrated.</div></div><div id="sec4_20_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> (1<i>S</i>)-1-(8-Fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethanamine (<b>59a</b>)</h3><div class="NLM_p last">Yield 100% (66 mg, 0.24 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.85 (1 H, dd, <i>J =</i> 2.3, 0.8 Hz), 8.71 (1 H, dd, <i>J =</i> 4.7, 1.6 Hz), 8.56 (1 H, d, <i>J =</i> 1.6 Hz), 7.96 (1 H, dt, <i>J =</i> 7.8, 2.0 Hz), 7.68 (1 H, d, <i>J =</i> 7.4 Hz), 7.37–7.58 (5 H, m), 4.44–4.51 (1 H, m), 1.37 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 268.0 (M + 1).</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> (1<i>S</i>)-1-(2-(2,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethanamine (<b>59b</b>)</h3><div class="NLM_p last">Yield 90% (66 mg, 0.22 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.52 (1 H, s), 7.63–7.71 (2 H, m), 7.43–7.57 (2 H, m), 7.39 (1 H, ddd, <i>J =</i> 10.5, 7.7, 1.0 Hz), 7.19–7.26 (1 H, m), 7.13 (2 H, td, <i>J =</i> 6.2, 1.8 Hz), 4.29 (1 H, q, <i>J =</i> 6.3 Hz), 1.32 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 303.0 (M + 1).</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> <i>S</i>-<i>tert</i>-Butyl (1-(2-Chloro-7-fluoroquinolin-3-yl)ethyl)carbamate (<b>60</b>)</h3><div class="NLM_p last">To a rt solution of <b>52a</b> (1.0 g, 2.8 mmol) in EtOH (10 mL) was added dropwise NH<sub>2</sub>NH<sub>2</sub> (10 equiv, 0.88 mL), and the solution heated to 90 °C for 0.5 h. After cooling to rt, the reaction mixture was concentrated and partitioned between EtOAc (20 mL) and H<sub>2</sub>O (5 mL). The organic layer was separated, washed with water, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give a colorless oil, which was dissolved in THF (10 mL) and treated with Boc<sub>2</sub>O (1.1 equiv, 0.68 g) and Et<sub>3</sub>N (1.0 equiv, 0.39 mL) and refluxed. After cooling to rt, the reaction mixture was concentrated and purified by column chromatography on silica gel (EtOAc/hexane, 1:9). White solid; yield 76% (0.70 g, 2.2 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.12 (1 H, s), 7.82 (1 H, dd, <i>J =</i> 9.0, 5.9 Hz), 7.66 (1 H, dd, <i>J =</i> 9.8, 2.7 Hz), 7.36 (1 H, td, <i>J =</i> 8.6, 2.3 Hz), 5.13–5.24 (1 H, m), 5.07 (1 H, br s), 1.56 (9 H, s), 1.43 (3 H, br s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 325.1 (M + 1).</div></div><div id="sec4_20_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> (<i>S</i>)-<i>tert</i>-Butyl (1-(7-Fluoro-2-(2-(methylthio)phenyl)quinolin-3-yl)ethyl)carbamate (<b>61</b>)</h3><div class="NLM_p last">A mixture of <b>60</b> (382 mg, 1.2 mmol), 2-(methylthio)phenylboronic acid (257 mg, 1.3 equiv), Na<sub>2</sub>CO<sub>3</sub> (623 mg, 5.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (93 mg, 0.081 mmol), MeCN (9 mL), and water (3 mL) was heated to 85 °C under N<sub>2</sub> overnight. After cooling to rt, the reaction was partitioned between EtOAc (10 mL) and water (5 mL). The organic layer was separated, washed, dried (MgSO<sub>4</sub>, and concentrated. The residue was purified by column chromatography on silica gel to give a white solid; yield 95% (460 mg, 1.12 mmol). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 413.2 (M + 1).</div></div><div id="sec4_20_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> (<i>S</i>)-<i>tert</i>-Butyl (1-(7-Fluoro-2-(2-(methylsulfonyl)phenyl)quinolin-3-yl)ethyl)carbamate (<b>62</b>)</h3><div class="NLM_p last">Under an N<sub>2</sub> atmosphere, <b>61</b> (19.5 g, 47.3 mmol) was dissolved in acetone (600 mL) and water (150 mL). NMO (17.0 g, 142 mmol, 3.0 equiv) was added followed by OsO<sub>4</sub> (601 mg, 2.36 mmol 0.05 equiv). The mixture was allowed to stir at rt for 4 h. The mixture was treated with an additional amount of OsO<sub>4</sub> (1.0 g, 3.93 mmol, 0.083 equiv) and stirred overnight. The reaction mixture was treated with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (15 mL) and the acetone partially removed by concentration. The remaining solution was diluted with EtOAc and washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and saturated NaCl. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography, eluting with 0–50% EtOAc in hexanes to provide a white foam. Yield 100% (21 g, 47 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.22–8.27 (2 H, m), 7.91 (1 H, ddd, <i>J =</i> 18.8, 8.9, 6.0 Hz), 7.74–7.83 (1 H, m), 7.59–7.72 (2 H, m), 7.35–7.49 (2 H, m), 5.46 (1 H, br s), 4.94 (1 H, br s), 4.76–4.87 (1 H, m), 3.27–3.36 (3 H, m), 1.63 (1.5 H, d, <i>J =</i> 6.6 Hz), 1.42 (4.5 H, br s), 1.34 (1.5 H, d, <i>J =</i> 6.6 Hz), 1.26 (4.5 H, s) (mixture of two atropoisomers ratio 1.1:1). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 445.1 (M + 1).</div></div><div id="sec4_20_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> 8-Chloro-2-(2-methylpyridin-3-yl)quinoline-3-carbaldehyde (<b>63</b>)</h3><div class="NLM_p last">A mixture of <b>36b</b> (1.00 g, 4.42 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.26 g, 0.22 mmol), and Na<sub>2</sub>CO<sub>3</sub> (2.34 g, 22.1 mmol) in CH<sub>3</sub>CN–H<sub>2</sub>O (90 mL, 3:1) was stirred at 100 °C. After 3 h, the mixture was cooled to rt and partitioned between EtOAc (150 mL) and water (150 mL). The organic layer was washed with brine (2 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a yellow solid. Column chromatography, eluting with 0–100% gradient of EtOAc/hexane, gave an off-white solid; yield 86% (1.08g, 3.82 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.96 (1 H, s), 9.16 (1 H, s), 8.62 (1 H, dd, <i>J =</i> 4.9, 1.8 Hz), 8.31 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 8.18 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.80 (1 H, dd, <i>J =</i> 7.6, 1.8 Hz), 7.76 (1 H, dd, <i>J =</i> 8.2, 7.4 Hz), 7.40 (1 H, dd, <i>J =</i> 7.4, 4.7 Hz), 2.35 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 283 (M + H).</div></div><div id="sec4_20_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> 1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanol (<b>64</b>)</h3><div class="NLM_p last">To a stirred heterogeneous mixture of <b>63</b> (1.07 g, 3.80 mmol) in THF (14.6 mL, 3.80 mmol) was added MeMgBr (1.90 mL, 5.70 mmol, 3 M in diethyl ether) dropwise at 0 °C, and the mixture was allowed to warm to rt. After 2 h saturated NH<sub>4</sub>Cl (50 mL) was added and the mixture extracted with EtOAc (2 × 50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give an orange syrup (1.44 g). Colunm chromatography, eluting with 0–100% gradient of EtOAc in hexane, gave an orange solid; yield 98% (1.12g, 3.73 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.68 (1 H, s), 8.59 (1 H, dd, <i>J =</i> 4.9, 1.8 Hz), 8.10 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.94 (1 H, dd, <i>J =</i> 7.6, 1.4 Hz), 7.74 (1 H, dd, <i>J =</i> 7.8, 1.6 Hz), 7.58–7.65 (1 H, m), 7.39 (1 H, dd, <i>J =</i> 7.6, 4.9 Hz), 5.47 (1 H, d, <i>J =</i> 4.3 Hz), 4.64 (1 H, br s), 2.25 (3 H, s), 1.20 (3 H, d, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 299 (M + 1).</div></div><div id="sec4_20_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> 8-Chloro-3-(1-chloroethyl)-2-(2-methylpyridin-3-yl)quinoline Hydrochloride (<b>65</b>)</h3><div class="NLM_p last">To a rt stirred solution of <b>64</b> (1.11 g, 3.71 mmol) in chloroform (12.37 mL, 0.3 M) was treated with thionyl chloride (1.35 mL, 18.6 mmol) dropwise. After 3 h, the mixture was concentrated under reduced pressure and coevaporated three times with DCM to give an off-white syrupy solid (1.31 g, 3.71 mmol). The crude product was carried on to the next step without purification. <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.04 (1 H, s), 8.94 (1 H, dd, <i>J =</i> 5.7, 1.4 Hz), 8.56 (1 H, d, <i>J =</i> 7.4 Hz), 8.19 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 8.07 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 8.02 (1 H, dd, <i>J =</i> 7.6, 5.7 Hz), 7.71–7.77 1 H, m), 5.25 (1 H, d, <i>J =</i> 6.3 Hz), 2.52 (3 H, s), 1.92 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 317 (M + 1).</div></div><div id="sec4_20_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> 2-(1-(<i>S</i>-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-l,3-dione (<b>66</b>)</h3><div class="NLM_p last">To a stirred solution of <b>65</b> (1.31 g, 3.71 mmol) in DMF (10 mL, 0.37 M) at 100 °C was added potassium phthalimide (1.72 g, 9.28 mmol). After 1.5 h, the mixture was concentrated and triturated with water (50 mL). The resulting solid was filtered, washed with NaOH (2 N, 50 mL), water (500 mL), and air-dried to give a tan solid; yield 100% (1.58 g, 3.70 mmol). The product was carried on without purification for the next step. Mass spectrum (ESI) <i>m</i>/<i>e</i> = 428 (M + 1).</div></div><div id="sec4_20_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> 1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanamine (<b>67</b>)</h3><div class="NLM_p last">To a stirred suspension of <b>66</b> (1.58 g, 3.70 mmol) in EtOH (37 mL, 0.1 M) was added hydrazine, anhydrous (1.16 mL, 37 mmol, 10 equiv), and the resulting mixture was refluxed. After 1.5 h, the mixture was cooled to rt. The byproduct was filtered off, washed with MeOH (100 mL) and the filtrate concentrated under reduced pressure to give a yellow solid. Chromatography, RediSep colunm using 0–100% (89:9:1 MeOH/NH<sub>4</sub>OH)/DCM, gave a yellow syrup; yield 60% from <b>64</b> (1.1 g, 2.2 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.75 (1 H, s), 8.58 (l H, dd, <i>J =</i> 4.9, 1.8 Hz), 8.04 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 7.92 (1 H, dd, <i>J =</i> 7.4, 1.2 Hz), 7.77 (1 H, s), 7.60 (1 H, dd, <i>J =</i> 8.2, 7.4 Hz), 7.34–7.44 (1 H, m), 4.09 (1 H, d, <i>J =</i> 4.7 Hz), 2.25 (3 H, s), 2.05 (2 H, br s), 1.13 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 298 (M + 1).</div></div><div id="sec4_20_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> 6-Chloro-3-methylcinnolin-4-ol (<b>68</b>)</h3><div class="NLM_p last">A cooled (0 °C) suspension of 1-(2-amino-5-chlorophenyl)propan-1-one (4.88 g, 26.6 mmol) in HCl (35 mL, 5 N) was added to a solution of sodium nitrite (2.02 g, 29.2 mmol) in 10 mL of water dropwise. After the addition, the mixture was stirred at rt for 15 min. The clear yellow solution was then heated at 85 °C for 2 h, and a large amount of solid precipitated. The reaction was cooled to rt, filtered, and the solid was washed with water, Et<sub>2</sub>O and dried on the vacuum pump. Off white amorphous solid; yield 92% (4.73 g, 24.3 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 7.97 (1 H, d, <i>J =</i> 2.3 Hz), 7.77 (1 H, dd, <i>J =</i> 9.1, 2.4 Hz), 7.60 (1 H, d, <i>J =</i> 9.0 Hz), 2.27 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 195 (M + 1).</div></div><div id="sec4_20_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> 4,6-Dichloro-3-methylcinnoline (<b>69</b>)</h3><div class="NLM_p last">A stirred mixture of <b>68</b> (1.38 g, 7.09 mmol) and phosphorus oxychloride (10.0 mL, 107 mmol, 15.1 equiv) was heated at 90 °C for 3 h. The reaction was cooled to rt, and the excess POCl<sub>3</sub> was removed in vacuo. The residue was dissolved in DCM and washed with saturated NaHCO<sub>3</sub>. The organic layer was dried, filtered, and concentrated to dryness to give a black amorphous solid. The material was dissolved in DCM, washed with H<sub>2</sub>O, and dried in vacuo to provide a light-yellow amorphous solid; yield 78% (1.18g, 5.54 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.49 (1 H, d, <i>J =</i> 9.0 Hz), 8.17 (1 H, d, <i>J =</i> 2.2 Hz), 7.77 (1 H, dd, <i>J =</i> 9.0, 2.2 Hz), 3.06 (3 H, s). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 215.0 (M + 1).</div></div><div id="sec4_20_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155"> 8-Chloro-3-ethylquinoxalin-2(1<i>H</i>)-one (<b>70a</b>)</h3><div class="NLM_p last">A 3 L round-bottom flask fitted with an overhead stirrer was charged with 3-chlorobenzene-1,2-diamine (54.8 g, 384 mmol) and polyphosphoric acid (500.0 mL, 384.2 mmol). The resulting black viscous solution was heated to 80 °C. To the viscous mixture at 80 °C was added ethyl 2-oxobutanoate (50.0 g, 384 mmol), and the mixture was stirred at 100–160 °C. After 2 h 40 min, the mixture was cooled to 0 °C, thoroughly mixed with water (1.0 L), and cautiously neutralized with NaOH (1.35 L, 10 N) to pH ≈ 7.0. The resulting precipitate was collected by filtration, washed with water (1.50 L), and dried to give a mixture of two regiosiomers as a wet red solid. This (72.43 g) was suspended in EtOH (750 mL) and refluxed. After 1 h, the mixture was allowed to cool to rt over 15 h. The solid was collected by filtration and washed with EtOH (500 mL) to give the desired product in 94% purity (6% 5-chloro-3-ethylquinoxalin-2(1<i>H</i>)-one). Violet solid, yield 60% (48.4 g, 232 mmol) 94% purity as judged by HPLC (6% 5-chloro-3-ethylquinoxalin-2(1<i>H</i>)-one). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 11.85 (1 H, s), 7.71 (1 H, dd, <i>J =</i> 7.8, 1.2 Hz), 7.61 (1 H, dd, <i>J =</i> 7.8, 1.2 Hz), 7.28 (1 H, t, <i>J =</i> 8.0 Hz), 2.83 (2 H, q, <i>J =</i> 7.2 Hz), 1.22 (3 H, t, <i>J =</i> 7.2 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 208.9 (M + 1).</div></div><div id="sec4_20_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i156" class="anchor-spacer"></div><h3 class="article-section__title" id="_i156"> 3-Ethyl-7-fluoroquinoxalin-2(1<i>H</i>)-one (<b>70b</b>)</h3><div class="NLM_p last">To a round-bottom flask fitted with an overhead stirrer charged with 3-ethyl-7-fluoro-3,4-dihydroquinoxalin-2(1<i>H</i>)-one (60.61 g, 312.1 mmol) and 1,4-dioxane (1.35 L) was added DDQ (75.9 g, 327.7 mmol), and the mixture was stirred at rt. After 2.5 h, the mixture was concentrated under reduced pressure to give a brown residue. This was suspended in saturated NaHCO<sub>3</sub> (2 L), stirred for 30 min, filtered and the solid washed with saturated NaHCO<sub>3</sub> (1 L) to give a light green solid. This was resuspended in saturated NaHCO<sub>3</sub> (500 mL), well mixed, filtered, and washed with saturated NaHCO<sub>3</sub> (500 mL) to give an off-white solid. The off-white solid was suspended in water (500 mL), well mixed, filtered, washed with water (1 L), air-dried overnight, and dried under high vacuum at 22 °C for 2 h to give the product. Off-white solid yield 95% (56.87 g, 295.9 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.36 (1 H, br s), 7.76 (1 H, dd, <i>J =</i> 9.0, 5.9 Hz), 7.11 (1 H, td, <i>J =</i> 8.8, 2.7 Hz), 7.00 (1 H, dd, <i>J =</i> 9.6, 2.7 Hz), 2.78 (2 H, q, <i>J =</i> 7.4 Hz), 1.20 (3 H, t, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 193 (M + 1).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i157" class="anchor-spacer"></div><h3 class="article-section__title" id="_i157"> General Procedure for the Synthesis of <b>71a</b> and <b>71b</b></h3><div class="NLM_p last">To a stirred suspension of <b>70a</b> (1.32 g, 6.33 mmol) or <b>70b</b> (20.6 g, 107 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (0.7 equiv) in carbon tetrachloride (1 equiv) was added benzoyl peroxide (0.1 equiv), and the mixture was heated at reflux. After 20 h, the mixture was cooled to rt, and saturated NaHCO<sub>3</sub> (0.1 M) was added. A precipitate was collected by filtration and washed with water to give a solid. The two layers from the filtrate were separated. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, combined with the solid, and concentrated under reduced pressure to give the product.</div></div><div id="sec4_21_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i158" class="anchor-spacer"></div><h3 class="article-section__title" id="_i158"> 3-(1-Bromoethyl)-8-chloroquinoxalin-2(1<i>H</i>)-one (<b>71a</b>)</h3><div class="NLM_p last">Yellow solid; yield 100% (1.96 g, 6.33 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.22 (1 H, br s), 7.79 (1 H, d, <i>J =</i> 7.8 Hz), 7.72 (1 H, d, <i>J =</i> 8.2 Hz), 7.34 (1 H, t, <i>J =</i> 7.8 Hz), 5.66 (1 H, q, <i>J =</i> 6.9 Hz), 2.00 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 286.7 [M + H (<sup>79</sup>Br)]<sup>+</sup> and 288.7 [M + H (<sup>81</sup>Br)]<sup>+</sup></div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159"> 3-(1-Bromoethyl)-7-fluoroquinoxalin-2(1<i>H</i>)-one (<b>71b</b>)</h3><div class="NLM_p last">Tan solid; yield 80% (23.19 g, 85.54 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.68 (1 H, br s), 7.85 (1 H, dd, <i>J =</i> 9.0, 5.9 Hz), 7.19 (1 H, td, <i>J =</i> 8.8, 2.7 Hz), 7.05 (1 H, dd, <i>J =</i> 9.8, 2.7 Hz), 5.62 (1 H, q, <i>J =</i> 6.7 Hz), 1.99 (3 H, d, <i>J =</i> 6.7 Hz. Mass spectrum (ESI) <i>m</i>/<i>e</i> = 271 (M + 1).</div></div><div id="sec4_21_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160"> 2-(1-(8-Chloro-3-hydroxyquinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>74</b>)</h3><div class="NLM_p last">To a stirred solution of methyl 3-(1,3-dioxoisoindolin-2-yl)-2-oxobutanoate (1.13 g, 4.33 mmol) in EtOAc (9.85 mL, 4.33 mmol) was added 3-chlorobenzene-1,2-diamine (0.618 g, 4.33 mmol) at rt. After 3 h the resulting precipitate was filtered to give a ∼3.5:1 mixture of regioisomers, with the desired regiomer 2-(1-(5-chloro-3-hydroxyquinoxalin-2-yl)ethyl)isoindoline-1,3-dione <b>74</b> being dominant. Yield 69%, (1.53g, 3.00 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 12.57 (0.62 H, br s), 11.96 (0.16 H, br s), 7.84–7.91 (4 H, m), 7.66–7.78 (0.47 H, m), 7.48–7.54 (0.75 H, m), 7.42–7.46 (0.7 H, m), 7.32 (0.25 H, t, <i>J =</i> 8.0 Hz), 7.27 (0.68 H, dd, <i>J =</i> 8.0, 1.4 Hz), 5.54–5.63 (1.0 H, m), 1.80 (2.18 H, d, <i>J =</i> 7.0 Hz), 1.75 (0.62 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 353.8 (M + 1). (Stuctural assignment of <b>74</b> was verified with pure <b>73c</b> by <sup>1</sup>H–<sup>15</sup>N HMBC NMR.)</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> General Procedure for the Synthesis of <b>72a</b> and <b>72b</b></h3><div class="NLM_p last">A heterogeneous mixture of <b>71b</b> (58.86 g, 217.1 mmol) or <b>71a</b> (1.84 g, 6.41 mmol) and POCl<sub>3</sub> (10 equiv) was stirred at 100–110 °C. After 2 h, the mixture was cooled to rt and poured into ice with stirring and carefully neutralized with NH<sub>4</sub>OH and water. The resulting precipitate was collected by filtration, rinsed with water, and dried under high vacuum.</div></div><div id="sec4_22_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162"> 2-(1-Bromoethyl)-3,5-dichloroquinoxaline (<b>72a</b>)</h3><div class="NLM_p last">Brown solid; yield 88% (1.68 g, 5.51 mmol) including 3,5-dichloro-2-(1-chloroethyl)quinoxaline. <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.10–8.17 (2 H, m), 7.88–7.95 (1 H, m), 5.85 (1 H, q, <i>J =</i> 6.7 Hz), 2.16 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 306.7 (M + 1).</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i163" class="anchor-spacer"></div><h3 class="article-section__title" id="_i163"> 2-(1-Bromoethyl)-3-chloro-6-fluoroquinoxaline (<b>72b</b>)</h3><div class="NLM_p last">Brown solid; yield 93% (58.31 g, 201.5 mmol) including trace of 3-chloro-2-(1-chloroethyl)-6-fluoroquinoxaline. Mass spectrum (ESI) <i>m</i>/<i>e</i> = 288 (M + H (<sup>79</sup>Br)). The brown solid was carried on crude without purification for the next step.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> General Procedure for <b>73a</b> and <b>73b</b></h3><div class="NLM_p last">To a stirred rt solution of <b>72b</b> (57.17 g, 197.5 mmol) or <b>72a</b> (22.4 g, 73.2 mmol) in DMF (0.3 M) was added potassium phthalimide (1.0 equiv). After 1–3 h, water was added.</div></div><div id="sec4_23_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i165" class="anchor-spacer"></div><h3 class="article-section__title" id="_i165"> 2-(1-(3,5-Dichloroquinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>73a</b>)</h3><div class="NLM_p last">Precipitate was filtered, washed with water, and dried. Orange solid; yield 71% (19.2 g, 51.6 mmol). <sup>1</sup>H NMR (500 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.16 (1 H, dd, <i>J =</i> 8.3, 1.2 Hz), 8.12 (1 H, dd, <i>J =</i> 7.7, 1.3 Hz), 7.92 (1 H, dd, <i>J =</i> 8.4, 7.7 Hz), 7.87 (4 H, s), 5.86–5.92 (1 H, m), 1.87 (3 H, d, <i>J =</i> 6.8 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 371.8 (M + 1).</div></div><div id="sec4_23_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i166" class="anchor-spacer"></div><h3 class="article-section__title" id="_i166"> 2-(1-(3-Chloro-6-fluoroquinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>73b</b>)</h3><div class="NLM_p last">The mixture was extracted with DCM (3 × 500 mL). The organic layer was washed with brine (1 L), dried over MgSO<sub>4</sub>, filtered, and concentrated to give a red liquid. This was filtered though a plug of silica (5.5 in. diameter × 5 in. height) and eluted with 20–100% EtOAc/hexane to give the desired product. Pink solid; yield 76% (53.4 g, 150 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.25 (1 H, dd, <i>J =</i> 9.4, 5.9 Hz), 7.81–7.95 (6 H, m), 5.86 (1 H, q, <i>J =</i> 6.8 Hz), 1.86 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 356 (M + 1).</div></div><div id="sec4_23_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i167" class="anchor-spacer"></div><h3 class="article-section__title" id="_i167"> 2-(1-(3,8-Dichloroquinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>73c</b>)</h3><div class="NLM_p last">A 3.5:1 mixture of <b>74</b> and 2-(1-(8-chloro-3-hydroxyquinoxalin-2-yl)ethyl)isoindoline-1,3-dione (4.50 g, 12.7 mmol) was stirred in POCl<sub>3</sub> (16.0 mL, 172 mmol) at 110 °C for 1.5 h. The mixture was cooled to rt and poured into ice with stirring. NH<sub>4</sub>OH was added with additional ice until the mixture was slightly basic. The resulting mixture was extracted with DCM, and the combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated. Column chromatography (2×), 330 g Redi-Sep column, 8% EtOAc for 10 min, then gradient to 25% EtOAc in hexane, gave a yield of 49%, (2.30 g, 6.19 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.09–8.12 (1 H, m), 8.05 (1 H, dd, <i>J =</i> 8.6, 1.2 Hz), 7.90–7.93 (1 H, m), 7.87–7.89 (4 H, m), 5.89 (1 H, q, <i>J =</i> 7.0 Hz), 1.92 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 371.8 (M + 1). (Stuctural assignment was verified by <sup>1</sup>H–<sup>15</sup>N HMBC NMR.) <b>73a</b> yield, 9% (0.405g, 1.09 mmol) regioisomer impurity from starting material.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i168" class="anchor-spacer"></div><h3 class="article-section__title" id="_i168"> General Procedure for the Synthesis of <b>75a</b>–<b>c</b></h3><div class="NLM_p last">A stirred solution of <b>73a</b> (0.526 g, 1.41 mmol), or <b>73b</b> (50.14 g, 140.9 mmol), or <b>73c</b> (500 mg, 1.34 mmol), 2-tri-<i>n</i>-butylstannylpyridine (1.3–2.0 equiv), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 equiv) in 1,4-dioxane (0.12 M) was heated to 110 °C. After 19–29 h, the mixture was cooled to rt and concentrated to give a residue.</div></div><div id="sec4_24_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i169" class="anchor-spacer"></div><h3 class="article-section__title" id="_i169"> 2-(1-(8-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>75a</b>)</h3><div class="NLM_p last">Solvent: toluene (0.27 M). Chromatography: 40 g silica gel column with 0–40% EtOAc/hexane. White solid, yield 82% (457 mg, 1.10 mmol). <sup>1</sup>H NMR (400 MHz, dichloromethane-<i>d</i><sub>2</sub>) δ ppm 1.85 (3 H, d, <i>J =</i> 7.04 Hz) 6.77 (1 H, q, <i>J =</i> 7.04 Hz) 7.26–7.33 (1 H, m) 7.65–7.77 (6 H, m) 7.85 (1 H, d, <i>J =</i> 6.26 Hz) 7.94 (1 H, d, <i>J =</i> 7.83 Hz) 8.04 (1 H, dd, <i>J =</i> 8.41, 1.37 Hz) 8.61–8.70 (1 H, m). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 415.0 (M + 1).</div></div><div id="sec4_24_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i170" class="anchor-spacer"></div><h3 class="article-section__title" id="_i170"> 2-(1-(5-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>75b</b>)</h3><div class="NLM_p last">Chromatography: 40 g Redi-Sep column, 0–100% gradient EtOAc/hexane, 14 min, 100% isocratic EtOAc. Brown solid; yield 70%, (0.411 g, 0.991 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.51 (1 H, dt, <i>J =</i> 4.8, 1.3 Hz), 8.10 (2 H, ddd, <i>J =</i> 7.9, 6.6, 1.2 Hz), 7.87–7.92 (1 H, m), 7.75–7.80 (4 H, m), 7.68 (2 H, dd, <i>J =</i> 5.5, 2.7 Hz), 7.36 (1 H, ddd, <i>J =</i> 6.0, 4.8, 2.9 Hz), 6.45–6.52 (1 H, m), 1.78 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 414.9 (M + 1).</div></div><div id="sec4_24_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i171" class="anchor-spacer"></div><h3 class="article-section__title" id="_i171"> 2-(1-(6-Fluoro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione (<b>75c</b>)</h3><div class="NLM_p last">To the residue was added DCM (200 mL). The mixture was heated under reflux for 20 min and then cooled to 0 °C with stirring. The solid was collected by filtration and washed with EtOAc–hexane (1:5, 500 mL) to give the desired product as a dark brown solid. This was dissolved in DCM/MeOH (9:1, 400 mL), filtered through a plug of silica gel, and rinsed with DCM/MeOH (9:1, 600 mL). The filtrate was concentrated under reduced pressure to give a brown solid, which was suspended in EtOAc–hexane (1:9, 400 mL) and heated under reflux for 40 min. The mixture was cooled to rt, filtered, washed with EtOAc–hexane (1:9, 600 mL), and dried to give <b>75c</b>. Tan solid; yield 85% (47.76 g, 119.9 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.47–8.53 (1 H, m), 8.20 (1 H, dd, <i>J =</i> 9.4, 5.9 Hz), 7.94 (1 H, dd, <i>J =</i> 9.4, 2.7 Hz), 7.85 (1 H, td, <i>J =</i> 8.9, 2.9 Hz), 7.64–7.80 (6 H, m), 7.30–7.37 (1 H, m), 6.42 (1 H, q, <i>J =</i> 6.9 Hz), 1.76 (3 H, d, <i>J =</i> 7.0 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 399 (M + 1).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i172" class="anchor-spacer"></div><h3 class="article-section__title" id="_i172"> General Procedure for the Synthesis of <b>76a</b>–<b>c</b></h3><div class="NLM_p last">To a stirred slurry of <b>75a</b> (457 mg, 1.10 mmol) or <b>75b</b> (0.405 g, 0.977 mmol) or <b>75c</b> (47.26 g, 118.6 mmol) in EtOH (0.1–0.5-M) was added hydrazine monohydrate (5–10 equiv). The mixture was heated to reflux for 1–1.5 h.</div></div><div id="sec4_25_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i173" class="anchor-spacer"></div><h3 class="article-section__title" id="_i173"> 1-(8-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethanamine (<b>76a</b>)</h3><div class="NLM_p last">The reaction mixture was filtered while hot, and the filter cake was rinsed with methanol. Filtrate was concentrated to dryness and partitioned between EtOAc and saturated NaHCO<sub>3</sub>. The aqueous layer was extracted again with EtOAc. The organic layers were combined and dried with Na<sub>2</sub>SO<sub>4</sub> and filtered to give <b>76a</b>. Yellow oil; yield, quant (322 mg, 1.13 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm** 1.39 (3 H, d, <i>J =</i> 6.65 Hz), 2.21 (2 H, br s), 4.74 (1 H, q, <i>J =</i> 6.65 Hz), 7.60 (1 H, ddd, <i>J =</i> 6.75, 4.79, 2.15 Hz), 7.84 (1 H, t, <i>J =</i> 7.82 Hz), 8.04–8.15 (4 H, m), 8.77 (1 H, d, <i>J =</i> 4.69 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 285.1 (M + 1).</div></div><div id="sec4_25_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i174" class="anchor-spacer"></div><h3 class="article-section__title" id="_i174"> 1-(5-Chloro-3-(pyridin-2-yl)quinoxalin-2-yl)ethanamine (<b>76b</b>)</h3><div class="NLM_p last">The mixture was concentrated under reduced pressure. Column chromatography, 40 g Redi-Sep column using 0–100% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH) over 14 min and then 100% isocratic 89:9:1 DCM/MeOH/NH<sub>4</sub>OH for 3 min, gave a yellow solid; yield 78% (0.216 g, 0.760 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.77 (1 H, ddd, <i>J =</i> 4.9, 1.4, 1.2 Hz), 8.07–8.14 (3 H, m), 8.03 (1 H, dd, <i>J =</i> 7.8, 1.2 Hz), 7.83–7.90 (1 H, m), 7.57–7.64 (1 H, m), 4.76 (1 H, q, <i>J =</i> 6.4 Hz), 2.49 (2 H, br s), 1.37 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 285.0 (M + 1).</div></div><div id="sec4_25_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i175" class="anchor-spacer"></div><h3 class="article-section__title" id="_i175"> 1-(6-Fluoro-3-(pyridin-2-yl)quinoxalin-2-yl)ethanamine (<b>76c</b>) and (<i>S</i>)-1-(6-Fluoro-3-(pyridin-2-yl)quinoxalin-2-yl)ethanamine (<b>76d</b>)</h3><div class="NLM_p last">The precipitate was broken up with a spatula, filtered, washed with EtOAc (3 × 250 mL portions). The filtrate was concentrated under reduced pressure. The residue was redissolved in EtOAc (600 mL) and water (300 mL). The organic layer was separated, and the aqueous layer was back-extracted with EtOAc (3 × 100 mL). The EtOAc layer was dried over MgSO<sub>4</sub>, filtered, and concentrated to give <b>76c</b>. Brown solid; yield 97% (31.0 g, 115.3 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.75 (1 H, dq, <i>J</i> = 4.7, 0.9 Hz), 8.20 (1 H, dd, <i>J</i> = 9.0, 5.9 Hz), 7.98–8.11 (2 H, m), 7.91 (1 H, dd, <i>J</i> = 9.4, 2.7 Hz), 7.78–7.86 (1 H, m), 7.56–7.61 (1 H, m), 4.66 (1 H, q, <i>J</i> = 6.7 Hz), 2.08 (2 H, br s), 1.35 (3 H, d, <i>J</i> = 6.7 Hz). LC–MS (ESI) <i>m</i>/<i>e</i> = 269 (M + 1). HPLC: a peak at 4.991 min, 97.59% pure at 254 nm, 104104-8-1-HPLC. Analytical chiral HPLC: Chiralpak AD-H column, 0.46 mm × 250 mm, 5 mm) (isopropanol in hexane, 10%), two peaks at 9.350 min and at 10.678 min at 254 nm. Quantitative chiral purification (SFC): dissolved in 800 mL of methanol (plus few drops TFA for solubility). The 1.3 mL injections of this solution onto the SFC system at conditions below resulted in isolation of two major peaks. Column: 250 mm × 30 mm AS-H (5 μm). Mobile phase: A, liquid CO<sub>2</sub>, 54 g/min; B, methanol (0.2% DEA), 36 mL/min. Mobile phase, temp: 22 °C. Outlet pressure: 117 bar. Wavelength: 327 nm. After chiral separation, each fraction was coevaporated two times with toluene and ethanol to remove diethylamine which was contained in methanol as eluent on purification. <b>76d</b>: brown syrupy solid; yield 41% (12.67 g, 47.2 mmol). Chiral HPLC (Chiralpak AD-H column, 0.46 mm × 250 mm, 5 mm) (isopropanol in hexane, 10%): a peak at 9.135 min (first-eluting enantiomer) at 254 nm. Enantiomeric excess analysis: 98.86% ee, second-eluting enantiomer on AS-H column. <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.73–8.78 (1 H, dq, <i>J =</i> 4.8, 1.2, 0.9 Hz), 8.20 (1 H, dd, <i>J =</i> 9.4, 5.9 Hz), 7.99–8.10 (2 H, m), 7.91 (1 H, dd, <i>J =</i> 9.4, 2.7 Hz), 7.82 (1 H, td, <i>J =</i> 8.9, 2.9 Hz), 7.58 (1 H, ddd, <i>J =</i> 7.4, 4.9, 1.4 Hz), 4.66 (1 H, q, <i>J =</i> 6.4 Hz), 2.07 (2 H, br s), 1.35 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 269 (M + 1).</div></div><div id="sec4_25_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i176" class="anchor-spacer"></div><h3 class="article-section__title" id="_i176"> 2-((3-Chloro-2-nitrophenyl)amino)butanoic Acid (<b>78</b>)</h3><div class="NLM_p last">A stirred mixture of 1-chloro-3-fluoro-2-nitrobenzene (37.7 g, 215 mmol), 2-aminobutanoic acid (22.0 g, 215 mmol), and K<sub>2</sub>CO<sub>3</sub> (30.0 g, 215 mmol) in DMSO (80.0 mL) was heated to 80 °C. After 18 h the mixture was poured into water (300 mL) and extracted with Et<sub>2</sub>O. The aqueous layer was acidified to generate a solid, which was recovered by filtration. The solid was recrystallized from toluene (110 mL) to afford fine yellow needles. Yield 76% (56 g, 162 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 13.02 (1 H, br s), 7.35 (1 H, t, <i>J =</i> 8.2 Hz), 6.82–6.90 (2 H, m), 6.25 (1 H, d, <i>J =</i> 7.8 Hz), 4.14 (1 H, td, <i>J =</i> 7.2, 5.5 Hz), 1.74–1.92 (2 H, m), 0.88 (3 H, t, <i>J =</i> 7.2 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 259.0 (M + 1).</div></div><div id="sec4_25_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> 8-Chloro-3-ethyl-3,4-dihydroquinoxalin-2(1<i>H</i>)-one (<b>79</b>)</h3><div class="NLM_p last">To a stirred solution of <b>72</b> (10.0 g, 38.7 mmol) in EtOH (99.1 mL, 38.7 mmol) and HCl (64.4 mL, 193 mmol, 3 N) was added SnCl<sub>2</sub>·2H<sub>2</sub>O (44.0 g, 193 mmol). The mixture was heated under reflux. After 2.5 h, the mixture was cooled to rt, concentrated to remove excess EtOH, which precipitated a yellow solid. The mixture was then cautiously treated with an excess of KOH (300 mL, 10 M), water (300 mL) and extracted with DCM (4 × 200 mL). The organic layer was washed with water (3 × 300 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated to give <b>79</b>. Light yellow syrup; yield 94% (7.65 g, 36.3 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 9.70 (1 H, s), 6.75–6.81 (1 H, m), 6.66–6.73 (2 H, m), 6.36 (1 H, d, <i>J =</i> 1.2 Hz), 3.69 (1 H, ddd, <i>J =</i> 6.7, 5.2, 1.8 Hz), 1.53–1.71 (2 H, m), 0.93 (3 H, t, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 211.0 (M + 1).</div></div><div id="sec4_25_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> 8-Chloro-3-ethylquinoxalin-2(1<i>H</i>)-one (<b>70a</b>)</h3><div class="NLM_p last">To a rt stirred solution of <b>79</b> (1.10 g, 5.23 mmol) in 1,4-dioxane (52.3 mL) was added DDQ (1.19 g, 5.23 mmol). After 2 h, the mixture was concentrated and the residue was dissolved in DCM (200 mL). The solution was washed with saturated NaHCO<sub>3</sub> (2 × 100 mL), water (2 × 100 mL), brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>74</b>. Light yellow solid; yield 97% (1.06 g, 5.08 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 11.87 (1 H, br s), 7.71 (1 H, dd, <i>J =</i> 8.2, 0.8 Hz), 7.62 (1 H, d, <i>J =</i> 7.8 Hz), 7.28 (1 H, t, <i>J =</i> 8.0 Hz), 2.83 (2 H, q, <i>J =</i> 7.2 Hz), 1.23 (3 H, t, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 208.9 (M + 1).</div></div><div id="sec4_25_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i179" class="anchor-spacer"></div><h3 class="article-section__title" id="_i179"> 3,5-Dichloro-2-ethyl-4a,8a-dihydroquinoxaline (<b>80</b>)</h3><div class="NLM_p last">A stirred suspension of <b>70a</b> (20.0 g, 96 mmol) in POCl<sub>3</sub> (147 g, 959 mmol) was heated at 100 °C. After 2 h, the reaction was cooled to rt and concentrated. The resulting black residue was slowly treated with ice (∼40 mL) followed by water (30 mL). The mixture was treated with NH<sub>4</sub>OH (∼35 mL) until pH 12. The resulting black precipitate was filtered and washed with water and dried under vacuum overnight to give <b>80</b>. Yield 90% (21.8 g, 86 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.99 (1 H, dd, <i>J =</i> 8.4, 1.2 Hz), 7.82 (1 H, dd, <i>J =</i> 7.5, 1.1 Hz), 7.64–7.69 (1 H, m), 3.20 (2 H, q, <i>J =</i> 7.4 Hz), 1.45 (3 H, t, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 227.0 (M + 1).</div></div><div id="sec4_25_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i180" class="anchor-spacer"></div><h3 class="article-section__title" id="_i180"> 5-Chloro-2-ethyl-3-(3-fluorophenyl)quinoxaline (<b>81</b>)</h3><div class="NLM_p last">A 5 L three-neck round-bottom flask with an overhead stirrer was charged with <b>80</b> (90.0 g, 396 mmol), 3-fluorophenylboronic acid (55.4 g, 396 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (22.9 g, 19.8 mmol), and Na<sub>2</sub>CO<sub>3</sub> (210 g, 198 mmol) in acetonitrile–water (3:1) (4000 mL) and was heated at 85 °C (internal temperature, 79.2 °C). After 8 h, the mixture was cooled to rt. The product crystallized as an orange solid overnight. The organic layer was decanted and concentrated to give a wet orange solid. The wet orange solid was suspended in water (500 mL), stirred at rt for 30 min, filtered, washed with water (1 L), and dried under vacuum to give the desired product (77.6 g). The bottom aqueous layer containing the orange crystalline solid was filtered and washed with water (1.5 L) to give (45.4 g) both samples that contained a small amount of triphenylphosphine oxide. The two samples were combined and recrystallized from hot isopropanol (1 L), providing <b>81</b>. Yield 88% (100.6 g, 351 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.08 (1 H, dd, <i>J =</i> 8.6, 1.2 Hz), 7.97–8.02 (1 H, m), 7.80–7.86 (1 H, m), 7.53–7.66 (3 H, m), 7.41 (1 H, dddd, <i>J =</i> 9.2, 8.0, 2.7, 1.2 Hz), 3.04 (2 H, q, <i>J =</i> 7.4 Hz), 1.24 (3 H, t, <i>J =</i> 7.4 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 286.9 (M + 1).</div></div><div id="sec4_25_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i181" class="anchor-spacer"></div><h3 class="article-section__title" id="_i181"> 2-(1-Bromoethyl)-5-chloro-3-(3-fluorophenyl)quinoxaline (<b>82</b>)</h3><div class="NLM_p last">To a 5 L three-neck round-bottom flask fitted with an overhead stirrer was charged <b>81</b> (80.3 g, 280 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (44.0 g, 154 mmol) in CCl<sub>4</sub> (1.50 L, 0.2 M) was added benzoyl peroxide (9.045 g, 28.01 mmol) with heating at reflux. After 17 h, the mixture was allowed to cool and saturated aqueous NaHCO<sub>3</sub> (100 mL) was added. The mixture was concentrated under reduced pressure to give a brown solid, which was suspended in saturated NaHCO<sub>3</sub> (1 L). The resulting precipitate was collected by filtration, washed with water (2 L), and dried under vacuum to give a solid (140.8 g), which was dissolved in DCM (2 L), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a brown solid (104.3 g), which was again dissolved in DCM (500 mL), filtered through a silica gel pad, and washed with 30% of EtOAc in hexane (2 L) to provide <b>82</b>. Yellow solid; yield 92% (94.3 g, 258 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.14–8.18 (1 H, m), 8.09–8.13 (1 H, m), 7.88–7.95 (1 H, m), 7.59–7.70 (3 H, m), 7.42–7.50 (1 H, m), 5.64 (1 H, q, <i>J =</i> 6.6 Hz), 2.15 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 364.8 [M + H (<sup>79</sup>Br)]<sup>+</sup> and 366.7 [M + H (<sup>81</sup>Br)]<sup>+</sup>.</div></div><div id="sec4_25_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i182" class="anchor-spacer"></div><h3 class="article-section__title" id="_i182"> 2-(1-Azidoethyl)-5-chloro-3-(3-fluorophenyl)quinoxaline (<b>83</b>)</h3><div class="NLM_p last">To a solution of <b>82</b> (94.3 g, 258 mmol) in DMSO (860 mL, 258 mmol) was added NaN<sub>3</sub> (33.6 g, 516 mmol), and the mixture was stirred at rt. After 2 h, water (1 L) was added to the mixture cooled with an ice bath. The resulting precipitate was collected by filtration, washed with water (1 L), and dried under vacuum overnight to give <b>83</b>. Dark brown solid; yield 100%. (90.2 g, 258 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.17 (1 H, dd, <i>J =</i> 8.4, 1.4 Hz), 8.11 (1 H, dd, <i>J =</i> 7.8, 1.2 Hz), 7.88–7.94 (1 H, m), 7.55–7.69 (3 H, m), 7.41–7.48 (1 H, m), 4.89 (1 H, q, <i>J =</i> 6.7 Hz), 1.65 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 327.9 (M + 1).</div></div><div id="sec4_25_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i183" class="anchor-spacer"></div><h3 class="article-section__title" id="_i183"> 1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanamine (<b>84</b>)</h3><div class="NLM_p last">To a stirred solution of <b>83</b> (84.6 g, 258. mmol) in THF–H<sub>2</sub>O (4:1, 1500 mL) at 0 °C was added PMe<sub>3</sub> (387 mL, 387 mmol, 1.0 M/THF). After 1 h 40 min, the mixture was poured into NaOH (500 mL, 2 N) with cooling. The mixture was extracted with EtOAc (3 × 500 mL). The organic layer was washed with brine (2 × 1 L), dried over MgSO<sub>4</sub>, and concentrated to give a red oil. Chromatography, 30% DCM/(89:9:1 DCM/MeOH/NH<sub>4</sub>OH), gave <b>79</b>. Red oil; yield 88% (77.9 g, 226 mmol). <sup>1</sup>H NMR (400 MHz, [D<sub>6</sub>]DMSO) δ ppm 8.10 (1 H, dd, <i>J =</i> 8.2, 1.2 Hz), 8.00–8.05 (1 H, m), 7.85 (1 H, dd, <i>J =</i> 8.4, 7.6 Hz), 7.57–7.68 (3 H, m), 7.39–7.46 (1 H, m), 4.32 (1 H, q, <i>J =</i> 6.7 Hz), 2.06 (2 H, br s), 1.31 (3 H, d, <i>J =</i> 6.7 Hz). Mass spectrum (ESI) <i>m</i>/<i>e</i> = 301.9 (M + 1).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i184"><a href="/doi/suppl/10.1021/jm501624r">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Comparison of analogs <b>1</b> and <b>2</b> and control compound D-073; additional synthesis procedures; and crystallographic data collection and refinement statistics. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501624r/suppl_file/jm501624r_si_001.pdf">jm501624r_si_001.pdf (116.64 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the cocrystal structures of PI3Kγ with compounds <b>1</b>, <b>16</b>, and <b>27</b> have been deposited in the PDB with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN">4WWN</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWO">4WWO</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWP">4WWP</a>, respectively.</p><div class="testing" data-doi="10.1021/jm501624r" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy D. Cushing</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b1c5d2c4c2d9d8dfd6f1d0dcd6d4df9fd2dedc91c5d8dcd2c4c2d9d8dfd6f1d2dedcd2d0c2c59fdfd4c5"><span class="__cf_email__" data-cfemail="17637462647f7e797057767a7072793974787a">[email protected]</span> <span class="__cf_email__" data-cfemail="780c11151b0d0b1011161f381b17151b190b0c56161d0c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaolin Hao</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youngsook Shin</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristin Andrews</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Brown</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Cardozo</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Chen</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Duquette</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ben Fisher</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Felix Gonzalez-Lopez de Turiso</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao He</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kirk R. Henne</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Ling Hu</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Randall Hungate</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael G. Johnson</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ron C. Kelly</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Lucas</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. McCarter</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence R. McGee</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julio C. Medina</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tisha San Miguel</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deanna Mohn</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vatee Pattaropong</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping H. Pettus</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Reichelt</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert M. Rzasa</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Seganish</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew S. Tasker</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert C. Wahl</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon Wannberg</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas A. Whittington</span> - <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Whoriskey</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Yu</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leeanne Zalameda</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawei Zhang</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela P. Metz</span> - <span class="hlFld-Affiliation affiliation">†Department of Therapeutic Discovery, ‡Department of Pharmacokinetics
and Drug Metabolism, and §Department of Pharmaceutics Research and Development, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Department of Inflammation
Research, and ⊥Department of Therapeutic Discovery, Amgen
Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3632e11260-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i186">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are indebted to the following people: For expert NMR elucidation we thank David Chow and Smriti Khera. For analytical or preparative scale chiral and chiral SFC separations, thanks go to Manuel Ventura and Brent Murphy. For procurement and large scale synthesis of certain advanced intermediates thanks go to Eric Wohlheiter Yong-Jae Kim, Oliver Thiel, Rob Milburn, Johann Chan, and Mike Achmatowicz. For off target cellular assay deployment and expertise not discussed in this report thanks go to Sandy Ross, David Fong, Kent Miner, and Kathy Chen. For in vitro drug metabolism and disposition experiments thanks go to Silvia Wong and Thuy Tran. For in vivo rodent pharmacokinetic study conduct thanks go to Stacy Fide and Craig Uyeda. For useful discussions in the course of this investigation thanks go to Robert J. Zamboni, and for fruitful discussion on the manuscript thanks go to Margaret Chu-Moyer. Finally, for some assistance in the preparation of this manuscript thanks go to Minna Bui.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i187" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i187"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i188" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i188"> Abbreviations Used</h2><tr><td class="NLM_term">ADDP</td><td class="NLM_def"><p class="first last">1,1′-(azodicarbonyl)dipiperidine</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">AO</td><td class="NLM_def"><p class="first last">aldehyde oxidase</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">cluster of differentiation</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">(+) DIP-Cl</td><td class="NLM_def"><p class="first last">(+)-<i>B</i>-chlorodiisopinocampheylborane</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">ETK</td><td class="NLM_def"><p class="first last">cryptic autophosphorylating protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate</p></td></tr><tr><td class="NLM_term">FOXO3a</td><td class="NLM_def"><p class="first last">forkhead box O3</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3</p></td></tr><tr><td class="NLM_term">HepG2</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomal</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">IL2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">KLH</td><td class="NLM_def"><p class="first last">keyhole limpet hemycin</p></td></tr><tr><td class="NLM_term">LLC-PK1</td><td class="NLM_def"><p class="first last">Lilly Laboratories cell porcine kidney</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NIK</td><td class="NLM_def"><p class="first last">nuclear factor κB inducing kinase</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">phosphoinositide</p></td></tr><tr><td class="NLM_term">PIP2</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4,5-bisphosphate</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">PH</td><td class="NLM_def"><p class="first last">pleckstrin homology</p></td></tr><tr><td class="NLM_term">PKB</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr><tr><td class="NLM_term">P70S6</td><td class="NLM_def"><p class="first last">serine/threonine kinase target substrate is S6 ribosomal protein</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomal</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">XO</td><td class="NLM_def"><p class="first last">xanthine oxidase</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">Xphos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i189">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Di Paolo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Camilli, P.</span><span> </span><span class="NLM_article-title">Phosphoinositides in Cell Regulation and Membrane Dynamics</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">443</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnature05185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17035995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGkurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=651-657&author=G.+Di+Paoloauthor=P.+De+Camilli&title=Phosphoinositides+in+Cell+Regulation+and+Membrane+Dynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositides in cell regulation and membrane dynamics</span></div><div class="casAuthors">Di Paolo, Gilbert; De Camilli, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">7112</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inositol phospholipids have long been known to play an important regulatory role in cell physiol.  The repertoire of cellular processes known to be directly or indirectly controlled by this class of lipids has now dramatically expanded.  Through interactions mediated by their headgroups, which can be reversibly phosphorylated to generate 7 species, phosphoinositides play a fundamental part in controlling membrane-cytosol interfaces.  These lipids mediate acute responses, but also act as constitutive signals that help define organelle identity.  Their functions, in addn. to classical signal transduction at the cell surface, include regulation of membrane traffic, the cytoskeleton, nuclear events, and the permeability and transport functions of membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmEgrRRg1UmLVg90H21EOLACvtfcHk0liZc9vC2pKmOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGkurrN&md5=9c367ca5035a56260c0fb026c1b2da72</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature05185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05185%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DG.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26atitle%3DPhosphoinositides%2520in%2520Cell%2520Regulation%2520and%2520Membrane%2520Dynamics%26jtitle%3DNature%26date%3D2006%26volume%3D443%26spage%3D651%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Schaeffer, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, P. L.</span><span> </span><span class="NLM_article-title">Tec Family Kinases in Lymphocyte Signaling and Function</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS0952-7915%2800%2900088-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=10781397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=282-288&author=E.+M.+Schaefferauthor=P.+L.+Schwartzberg&title=Tec+Family+Kinases+in+Lymphocyte+Signaling+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tec family kinases in lymphocyte signaling and function</span></div><div class="casAuthors">Schaeffer, Edward M.; Schwartzberg, Pamela L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-288</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 64 refs.  The Tec kinases are required for full Ca2+ mobilization in lymphocytes.  Recent data suggest that this process occurs via a multiprotein complex that includes LAT and SLP-76 in T cells and BLNK/SLP-65 in B cells.  Mutational analyses have revealed crit. roles for Tec kinases in lymphocyte development and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1sXHyu_Zv7Vg90H21EOLACvtfcHk0liZc9vC2pKmOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb8%253D&md5=4c4cfea706908f0e841f1f29c067d461</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900088-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900088-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DE.%2BM.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26atitle%3DTec%2520Family%2520Kinases%2520in%2520Lymphocyte%2520Signaling%2520and%2520Function%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D282%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Parker, P. J.</span><span> </span><span class="NLM_article-title">The Ubiquitous Phosphoinositides</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1042%2FBST0320893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15506918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVSltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=893-898&author=P.+J.+Parker&title=The+Ubiquitous+Phosphoinositides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitous phosphoinositides</span></div><div class="casAuthors">Parker, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">893-898</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven phosphoinositides are now known to exist, which are all derived through various metabolic routes from the parent lipid, phosphatidylinositol.  With one addnl. metabolite, diacylglycerol, these represent a rich resource of bioactive lipids responsible for recruiting protein effectors and marking membrane compartments.  The metabolic map of this pathway and the nature of the binding partner interactions are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1i5XGztZ2rVg90H21EOLACvtfcHk0liZc9vC2pKmOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVSltrg%253D&md5=4a4d16b9e15c42b0b7db67307dee70fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBST0320893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0320893%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520Ubiquitous%2520Phosphoinositides%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2004%26volume%3D32%26spage%3D893%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L. R.</span><span> </span><span class="NLM_article-title">Signaling Through Class 1 PI3Ks in Mammalian Cells</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1042%2FBST0340647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17052169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWnsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=647-662&author=P.+T.+Hawkinsauthor=K.+E.+Andersonauthor=L.+R.+Stephens&title=Signaling+Through+Class+1+PI3Ks+in+Mammalian+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling through class I PI3Ks in mammalian cells</span></div><div class="casAuthors">Hawkins, P. T.; Anderson, K. E.; Davidson, K.; Stephens, L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  It is now accepted that the activation of class I phosphoinositide 3-kinases (PI3Ks) is one of the most important signal transduction pathways used by cell-surface receptors to control intracellular events.  The receptors which access this pathway include those that recognize growth factors, hormones, antigens, and inflammatory stimuli, and the cellular events known to be regulated include cell growth, survival, proliferation, and movement.  Scientists have learned a great deal about the family of class I PI3Ks themselves and the structural adaptations which allow a variety of cell-surface receptors to regulate their activity.  Class I PI3Ks synthesize the phospholipid phosphatidylinositol 3.4,5-trisphosphate [PtdIns(3,4,5)P3] in the membranes in which they are activated, and it is now accepted that PtdIns(3,4,5)P3 and its dephosphorylation product phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P2] are messenger mols. which regulate the localization and function of multiple effectors by binding to their specific pleckstrin homol. (PH) domains.  The no. of direct PtdIns(3,4,5)P3/PtdIns(3,4)P2 effectors which exist, even within a single cell, creates an extremely complex signaling web downstream of PI3K activation.  Some key players are beginning to emerge, however, linking PI3K activity to specific cellular responses.  These include small GTPases for the Rho and Arf families which regulate the cytoskeletal and membrane rearrangements required for cell movement, and protein kinase B (PKB), which has important regulatory inputs into the regulation of cell cycle progression and survival.  The importance of the PI3K signaling pathway in regulating the balance of decisions in cell growth, proliferation, and survival is clear from the prevalence of oncogenes (e.g., PI3Kα) and tumor suppressors [e.g., PtdIns(3,4,5)P3 3-phosphatase, PTEN (phosphatase, and tension homolog deleted on chromosome 10)] found in this pathway.  The recent availability of transgenic mouse models with engineered defects in class I PI3K signaling pathways, and the development of PI3K isoform-selective inhibitors by both academic and pharmaceutical research has highlighted the importance of specific isoforms of PI3K in whole-animal physiol. and pathol., e.g., PI3Kα in growth and metabolic regulation, PI3Kβ in thrombosis, and PI3Kδ and PI3Kγ in inflammation and asthma.  Thus, the class I PI3K signaling pathway is emerging as an exciting new area for the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKzw7wttjsvrVg90H21EOLACvtfcHk0ljASrjMOaHj4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWnsLvO&md5=205c57d166593275ebe47d833888b269</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBST0340647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0340647%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DStephens%26aufirst%3DL.%2BR.%26atitle%3DSignaling%2520Through%2520Class%25201%2520PI3Ks%2520in%2520Mammalian%2520Cells%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2006%26volume%3D34%26spage%3D647%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismuth, G.</span><span> </span><span class="NLM_article-title">Fine Tuning the Immune Response with PI3K</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1111%2Fj.1600-065X.2008.00750.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=19290933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=253-272&author=D.+A.+Frumanauthor=G.+Bismuth&title=Fine+Tuning+the+Immune+Response+with+PI3K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fine tuning the immune response with PI3K</span></div><div class="casAuthors">Fruman, David A.; Bismuth, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-272</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family of lipid kinases regulates diverse aspects of lymphocyte behavior.  This review discusses how genetic and pharmacol. tools have yielded an increasingly detailed understanding of how PI3K enzymes function at different stages of lymphocyte development and activation.  Following antigen receptor engagement, activated PI3K generates 3-phosphorylated inositol lipid products that serve as membrane targeting signals for numerous proteins involved in the assembly of multiprotein complexes, termed signalosomes, and immune synapse formation.  In B cells, class IA PI3K is the dominant subgroup whose loss causes profound defects in development and antigen responsiveness.  In T cells, both class IA and IB PI3K contribute to development and immune function.  PI3K also regulates both chemokine responsiveness and antigen-driven changes in lymphocyte trafficking.  PI3K modulates the function not only of effector T cells, but also regulatory T cells; these disparate functions culminate in unexpected autoimmune phenotypes in mice with PI3K-deficient T cells.  Thus, PI3K signaling is not a simple switch to promote cellular activation, but rather an intricate web of interactions that must be properly balanced to ensure appropriate cellular responses and maintain immune homeostasis.  Defining these complexities remains a challenge for pharmaceutical development of PI3K inhibitors to combat inflammation and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjiIlGrlo-bVg90H21EOLACvtfcHk0ljASrjMOaHj4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vI&md5=83041c3a0ff535642e314761860e27ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00750.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00750.x%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DBismuth%26aufirst%3DG.%26atitle%3DFine%2520Tuning%2520the%2520Immune%2520Response%2520with%2520PI3K%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D253%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Eicholt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papakonstanti, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starkey, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilancio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Need, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamers, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">Control of Axonal Growth and Regeneration of Sensory Neurons by the P110δ PI3-Kinase</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e869</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=e869&author=B.+J.+Eicholtauthor=A.+I.+Ahmedauthor=M.+E.+Daviesauthor=E.+A.+Papakonstantiauthor=W.+Pearceauthor=M.+L.+Starkeyauthor=A.+Bilancioauthor=A.+C.+Needauthor=A.+J.+H.+Smithauthor=S.+M.+Hallauthor=F.+P.+Hamersauthor=K.+P.+Gieseauthor=E.+J.+Bradburyauthor=B.+Vanhaesebroeck&title=Control+of+Axonal+Growth+and+Regeneration+of+Sensory+Neurons+by+the+P110%CE%B4+PI3-Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEicholt%26aufirst%3DB.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%2BI.%26aulast%3DDavies%26aufirst%3DM.%2BE.%26aulast%3DPapakonstanti%26aufirst%3DE.%2BA.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DStarkey%26aufirst%3DM.%2BL.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DNeed%26aufirst%3DA.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DHall%26aufirst%3DS.%2BM.%26aulast%3DHamers%26aufirst%3DF.%2BP.%26aulast%3DGiese%26aufirst%3DK.%2BP.%26aulast%3DBradbury%26aufirst%3DE.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DControl%2520of%2520Axonal%2520Growth%2520and%2520Regeneration%2520of%2520Sensory%2520Neurons%2520by%2520the%2520P110%25CE%25B4%2520PI3-Kinase%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D9%26spage%3De869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Vallerskog, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widhe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risselada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klareskog, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollenhoven, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malmsttröm, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trollmo, C.</span><span> </span><span class="NLM_article-title">Treatment with Rituximab Affects Both the Cellular and the Humoral Arm of the Immune System in Patients with SLE</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.clim.2006.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17046329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlalt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2007&pages=62-74&author=T.+Vallerskogauthor=I.+Gunnarssonauthor=M.+Widheauthor=A.+Risseladaauthor=L.+Klareskogauthor=R.+Vollenhovenauthor=V.+Malmsttr%C3%B6mauthor=C.+Trollmo&title=Treatment+with+Rituximab+Affects+Both+the+Cellular+and+the+Humoral+Arm+of+the+Immune+System+in+Patients+with+SLE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE</span></div><div class="casAuthors">Vallerskog, Therese; Gunnarsson, Iva; Widhe, Mona; Risselada, Anke; Klareskog, Lars; van Vollenhoven, Ronald; Malmstroem, Vivianne; Trollmo, Christina</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-74</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Herein we investigated how rituximab-induced B cell depletion affected leukocyte subpopulations and antibody titers in SLE patients.  We focused our anal. on time points related to absence and return of B cells after depletion.  A correlation was found between the baseline frequency and time to repopulation; the fewer B cells initially, the longer to their return.  While the few B cells remaining after treatment were of memory, double-neg. (IgD-CD27-), and CD5+ phenotype, the returning B cells were mainly naive, indicating de novo prodn. of B cells.  Serum levels of IgG and antibodies against Ro52, Ro60, La44, measles and tetanus remained unchanged, while decreases in IgM, IgE, anti-dsDNA and anti-C1q antibodies were obsd.  Addnl., a significant increase in activated CD4+ and CD8+ T cells, as well as CD25brightFOXP3+ regulatory T cells was obsd.  In conclusion, both the humoral and the cellular immune systems were affected by treatment with rituximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr04xJLpulT-LVg90H21EOLACvtfcHk0ljASrjMOaHj4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlalt7bE&md5=157a958cc3807be90996e3be80406346</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2006.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2006.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DVallerskog%26aufirst%3DT.%26aulast%3DGunnarsson%26aufirst%3DI.%26aulast%3DWidhe%26aufirst%3DM.%26aulast%3DRisselada%26aufirst%3DA.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DVollenhoven%26aufirst%3DR.%26aulast%3DMalmsttr%25C3%25B6m%26aufirst%3DV.%26aulast%3DTrollmo%26aufirst%3DC.%26atitle%3DTreatment%2520with%2520Rituximab%2520Affects%2520Both%2520the%2520Cellular%2520and%2520the%2520Humoral%2520Arm%2520of%2520the%2520Immune%2520System%2520in%2520Patients%2520with%2520SLE%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D122%26spage%3D62%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Soond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjørgo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moltu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galleway, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twomey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskén, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunyard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span> </span><span class="NLM_article-title">PI3K p110delta Regulates T-Cell Cytokine Production during Primary and Secondary Immune Responses in Mice and Humans</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2203-3313&author=R.+Soondauthor=E.+Bj%C3%B8rgoauthor=K.+Moltuauthor=Q.+Daleauthor=T.+Pattonauthor=M.+Torgersonauthor=F.+Gallewayauthor=B.+Twomeyauthor=J.+Clarkauthor=H.+Gastonauthor=L.+Task%C3%A9nauthor=P.+Bunyardauthor=K.+Okkenhaug&title=PI3K+p110delta+Regulates+T-Cell+Cytokine+Production+during+Primary+and+Secondary+Immune+Responses+in+Mice+and+Humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoond%26aufirst%3DR.%26aulast%3DBj%25C3%25B8rgo%26aufirst%3DE.%26aulast%3DMoltu%26aufirst%3DK.%26aulast%3DDale%26aufirst%3DQ.%26aulast%3DPatton%26aufirst%3DT.%26aulast%3DTorgerson%26aufirst%3DM.%26aulast%3DGalleway%26aufirst%3DF.%26aulast%3DTwomey%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGaston%26aufirst%3DH.%26aulast%3DTask%25C3%25A9n%26aufirst%3DL.%26aulast%3DBunyard%26aufirst%3DP.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520p110delta%2520Regulates%2520T-Cell%2520Cytokine%2520Production%2520during%2520Primary%2520and%2520Secondary%2520Immune%2520Responses%2520in%2520Mice%2520and%2520Humans%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2203%26epage%3D3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilancio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkaczyk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giddings, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peskett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">Essential Role for the p110delta Phosphoinositide 3-Kinase in the Allergic Response</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnature02991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15496927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslSlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=1007-1011&author=K.+Aliauthor=A.+Bilancioauthor=M.+Thomasauthor=W.+Pearceauthor=M.+Gilfillanauthor=C.+Tkaczykauthor=N.+Kuehnauthor=A.+Grayauthor=J.+Giddingsauthor=E.+Peskettauthor=R.+Foxauthor=I.+Bruceauthor=C.+Walkerauthor=C.+Sawyerauthor=K.+Okkenhaugauthor=P.+Finanauthor=B.+Wanhaesebroeck&title=Essential+Role+for+the+p110delta+Phosphoinositide+3-Kinase+in+the+Allergic+Response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role for the p110δ phosphoinositide 3-kinase in the allergic response</span></div><div class="casAuthors">Ali, Khaled; Bilancio, Antonio; Thomas, Matthew; Pearce, Wayne; Gilfillan, Alasdair M.; Tkaczyk, Christine; Kuehn, Nicolas; Gray, Alexander; Giddings, June; Peskett, Emma; Fox, Roy; Bruce, Ian; Walker, Christoph; Sawyer, Carol; Okkenhaug, Klaus; Finan, Peter; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">7011</span>),
    <span class="NLM_cas:pages">1007-1011</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammatory substances released by mast cells induce and maintain the allergic response.  Mast cell differentiation and activation are regulated, resp., by stem cell factor (SCF; also known as Kit ligand) and by allergen in complex with allergen-specific IgE.  Activated SCF receptors and high-affinity receptors for IgE (FcεRI) engage phosphoinositide 3-kinases (PI(3)Ks) to generate intracellular lipid second messenger signals.  Here, we report that genetic or pharmacol. inactivation of the p110δ isoform of PI(3)K in mast cells leads to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE-induced degranulation and cytokine release.  Inactivation of p110δ protects mice against anaphylactic allergic responses.  These results identify p110δ as a new target for therapeutic intervention in allergy and mast-cell-related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpilIACK3bY8bVg90H21EOLACvtfcHk0lhdqOMRRgqTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslSlt7w%253D&md5=4c1295a18b969617a26d29e017ef48ce</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature02991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02991%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DK.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DGilfillan%26aufirst%3DM.%26aulast%3DTkaczyk%26aufirst%3DC.%26aulast%3DKuehn%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DGiddings%26aufirst%3DJ.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DFox%26aufirst%3DR.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DC.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DWanhaesebroeck%26aufirst%3DB.%26atitle%3DEssential%2520Role%2520for%2520the%2520p110delta%2520Phosphoinositide%25203-Kinase%2520in%2520the%2520Allergic%2520Response%26jtitle%3DNature%26date%3D2004%26volume%3D431%26spage%3D1007%26epage%3D1011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fung-Leung, W. P.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Delta (PI3Kδ) in Leukocyte Signaling and Function</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.cellsig.2010.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20940048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=603-608&author=W.+P.+Fung-Leung&title=Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+in+Leukocyte+Signaling+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function</span></div><div class="casAuthors">Fung-Leung, Wai-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-608</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  PI3Kδ is a lipid kinase of the PI3K class IA family involved in early signaling events of leukocytes responding to a wide variety of stimuli.  The leukocyte specificity of PI3Kδ is defined by its expression, whereas its signaling function is via the prodn. of phosphoinositide 3,4,5-triphosphates at the proximity of activated receptors for recruiting other signaling mols.  The importance of PI3Kδ in B cell development and function is most apparent, and its role in other leukocyte cell types can be easily demonstrated as well.  PI3Kδ participates in the development, activation and migration of T cells and NK cells.  The role of PI3Kδ in myeloid cell activities, such as inflammation driven cell infiltration, neutrophil oxidative burst, immune complex mediated macrophage activation, as well as mast cell maturation and degranulation, has been well illustrated in various studies.  As a result of the broad effects of PI3Kδ in leukocyte functions, the disruption of PI3Kδ expression or activity leads to decreased inflammatory and immune responses in vivo.  The protective role of PI3Kδ inactivation in animal models of arthritis, asthma or obstructive respiratory diseases has been demonstrated.  These findings suggest the potential efficacy achievable with PI3Kδ inhibitors in the treatment of autoimmune and respiratory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtYnBPQuNK7Vg90H21EOLACvtfcHk0lhdqOMRRgqTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yrtb8%253D&md5=3d4b3438bf9b73b3d7e9d8722f024eac</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DFung-Leung%26aufirst%3DW.%2BP.%26atitle%3DPhosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520in%2520Leukocyte%2520Signaling%2520and%2520Function%26jtitle%3DCell.%2520Signalling%26date%3D2011%26volume%3D23%26spage%3D603%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Angulo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banham-Hall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plagnol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxendale, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake-Palmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiddler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilliers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markelj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielkowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabado, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barcenas-Morales, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clatworthy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durandy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doffinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chilvers, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cant, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumararatne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condliffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nejentsev, S.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=866-871&author=I.+Anguloauthor=O.+Vadasauthor=F.+Garconauthor=E.+Banham-Hallauthor=V.+Plagnolauthor=T.+R.+Leahyauthor=H.+Baxendaleauthor=T.+Coulterauthor=J.+Curtisauthor=C.+Wuauthor=K.+Blake-Palmerauthor=O.+Perisicauthor=D.+Smythauthor=M.+Maesauthor=C.+Fiddlerauthor=J.+Jussauthor=D.+Cilliersauthor=G.+Markeljauthor=A.+Chandraauthor=G.+Farmerauthor=A.+Kielkowskaauthor=J.+Clarkauthor=S.+Krackerauthor=M.+Debreauthor=C.+Picardauthor=I.+Pellierauthor=N.+Jabadoauthor=J.+A.+Morrisauthor=G.+Barcenas-Moralesauthor=A.+Fischerauthor=L.+Stephensauthor=P.+Hawkinsauthor=J.+C.+Barrettauthor=M.+Abinunauthor=M.+Clatworthyauthor=A.+Durandyauthor=R.+Doffingerauthor=E.+R.+Chilversauthor=A.+J.+Cantauthor=D.+Kumararatneauthor=K.+Okkenhaugauthor=R.+L.+Williamsauthor=A.+Condliffeauthor=S.+Nejentsev&title=Phosphoinositide+3-Kinase+%CE%B4+Gene+Mutation+Predisposes+to+Respiratory+Infection+and+Airway+Damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo%26aufirst%3DI.%26aulast%3DVadas%26aufirst%3DO.%26aulast%3DGarcon%26aufirst%3DF.%26aulast%3DBanham-Hall%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBlake-Palmer%26aufirst%3DK.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DSmyth%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DM.%26aulast%3DFiddler%26aufirst%3DC.%26aulast%3DJuss%26aufirst%3DJ.%26aulast%3DCilliers%26aufirst%3DD.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DKielkowska%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DDebre%26aufirst%3DM.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DBarcenas-Morales%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DClatworthy%26aufirst%3DM.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DChilvers%26aufirst%3DE.%2BR.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DCondliffe%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26atitle%3DPhosphoinositide%25203-Kinase%2520%25CE%25B4%2520Gene%2520Mutation%2520Predisposes%2520to%2520Respiratory%2520Infection%2520and%2520Airway%2520Damage%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D866%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lucas, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemela, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deenick, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palendira, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannons, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biancalana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frucht, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agharahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folio, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleisher, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangye, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenardo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzel, G.</span><span> </span><span class="NLM_article-title">Dominant-Activating Germline Mutations in the Gene Encoding the PI(3)K Catalytic Subunit p110δ Result in T cell Senescence and Human Immunodeficiency</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fni.2771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=24165795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=88-97&author=C.+L.+Lucasauthor=H.+S.+Kuehnauthor=F.+Zhaoauthor=J.+E.+Niemelaauthor=E.+K.+Deenickauthor=U.+Palendiraauthor=D.+T.+Averyauthor=L.+Moensauthor=J.+L.+Cannonsauthor=M.+Biancalanaauthor=J.+Stoddardauthor=W.+Ouyangauthor=D.+M.+Fruchtauthor=V.+K.+Raoauthor=T.+P.+Atkinsonauthor=A.+Agharahimiauthor=A.+A.+Husseyauthor=L.+R.+Folioauthor=K.+N.+Olivierauthor=T.+A.+Fleisherauthor=S.+Pittalugaauthor=S.+M.+Hollandauthor=J.+I.+Cohenauthor=J.+B.+Oliveiraauthor=S.+T.+Tangyeauthor=P.+L.+Schwartzbergauthor=M.+J.+Lenardoauthor=G.+Uzel&title=Dominant-Activating+Germline+Mutations+in+the+Gene+Encoding+the+PI%283%29K+Catalytic+Subunit+p110%CE%B4+Result+in+T+cell+Senescence+and+Human+Immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</span></div><div class="casAuthors">Lucas, Carrie L.; Kuehn, Hye Sun; Zhao, Fang; Niemela, Julie E.; Deenick, Elissa K.; Palendira, Umaimainthan; Avery, Danielle T.; Moens, Leen; Cannons, Jennifer L.; Biancalana, Matthew; Stoddard, Jennifer; Ouyang, Weiming; Frucht, David M.; Rao, V. Koneti; Atkinson, T. Prescott; Agharahimi, Anahita; Hussey, Ashleigh A.; Folio, Les R.; Olivier, Kenneth N.; Fleisher, Thomas A.; Pittaluga, Stefania; Holland, Steven M.; Cohen, Jeffrey I.; Oliveira, Joao B.; Tangye, Stuart G.; Schwartzberg, Pamela L.; Lenardo, Michael J.; Uzel, Gulbu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-97</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The p110δ subunit of phosphatidylinositol-3-OH kinase (PI(3)K) is selectively expressed in leukocytes and is crit. for lymphocyte biol.  Here we report fourteen patients from seven families who were heterozygous for three different germline, gain-of-function mutations in PIK3CD (which encodes p110δ).  These patients presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremia due to cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV).  Strikingly, they had a substantial deficiency in naive T cells but an over-representation of senescent effector T cells.  In vitro, T cells from patients exhibited increased phosphorylation of the kinase Akt and hyperactivation of the metabolic checkpoint kinase mTOR, enhanced glucose uptake and terminal effector differentiation.  Notably, treatment with rapamycin to inhibit mTOR activity in vivo partially restored the abundance of naive T cells, largely 'rescued' the in vitro T cell defects and improved the clin. course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFA88fwwfZf7Vg90H21EOLACvtfcHk0lgeuIGf5wjiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L&md5=4bfccb05603009684ca01f893b29adc8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fni.2771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2771%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DDeenick%26aufirst%3DE.%2BK.%26aulast%3DPalendira%26aufirst%3DU.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DMoens%26aufirst%3DL.%26aulast%3DCannons%26aufirst%3DJ.%2BL.%26aulast%3DBiancalana%26aufirst%3DM.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DFrucht%26aufirst%3DD.%2BM.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DAtkinson%26aufirst%3DT.%2BP.%26aulast%3DAgharahimi%26aufirst%3DA.%26aulast%3DHussey%26aufirst%3DA.%2BA.%26aulast%3DFolio%26aufirst%3DL.%2BR.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DFleisher%26aufirst%3DT.%2BA.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26aulast%3DOliveira%26aufirst%3DJ.%2BB.%26aulast%3DTangye%26aufirst%3DS.%2BT.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DUzel%26aufirst%3DG.%26atitle%3DDominant-Activating%2520Germline%2520Mutations%2520in%2520the%2520Gene%2520Encoding%2520the%2520PI%25283%2529K%2520Catalytic%2520Subunit%2520p110%25CE%25B4%2520Result%2520in%2520T%2520cell%2520Senescence%2520and%2520Human%2520Immunodeficiency%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26spage%3D88%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Failla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. B.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1164%2Frccm.200906-0937OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20224070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=897-904&author=Y.+Toauthor=K.+Itoauthor=Y.+Kizawaauthor=M.+Faillaauthor=M.+Itoauthor=T.+Kusamaauthor=W.+M.+Elliottauthor=J.+C.+Hoggauthor=I.+M.+Adcockauthor=P.+B.+Barnes&title=Targeting+Phosphoinositide-3-Kinase-%CE%B4+with+Theophylline+Reverses+Corticosteroid+Insensitivity+in+Chronic+Obstructive+Pulmonary+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease</span></div><div class="casAuthors">To, Yasuo; Ito, Kazuhiro; Kizawa, Yasuo; Failla, Marco; Ito, Misako; Kusama, Tadashi; Elliott, W. Mark; Hogg, James C.; Adcock, Ian M.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">897-904</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids.  This has been linked to a redn. of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline.  Objectives: To det. the role of phosphoinositide-3-kinase-delta (PI3K-δ) on the development of corticosteroid insensitivity in COPD and under oxidative stress, and as a target for theophylline.  Methods: Corticosteroid sensitivity was detd. as the 50% inhibitory concn. of dexamethasone on tumor necrosis factor-α-induced interleukin-8 release in peripheral blood mononuclear cells from patients with COPD (n = 17) and compared with that of nonsmoking (n = 8) and smoking (n = 7) control subjects.  The effect of theophylline and a selective PI3K-δ inhibitor (IC87114) on restoration of corticosteroid sensitivity was confirmed in cigarette smoke-exposed mice.  Measurements and Main Results: Peripheral blood mononuclear cells of COPD (50% inhibitory concn. of dexamethasone: 156.8 ± 32.6 nM) were less corticosteroid sensitive than those of nonsmoking (41.2 ± 10.5 nM; P = 0.018) and smoking control subjects (47.5 ± 19.6 nM; P = 0.031).  Corticosteroid insensitivity and reduced histone deacetylase-2 activity after oxidative stress were reversed by a non-selective PI3K inhibitor (LY294002) and low concns. of theophylline.  Theophylline was a potent selective inhibitor of oxidant-activated PI3K-δ, which was up-regulated in peripheral lung tissue of patients with COPD.  Furthermore, cells with knock-down of PI3K-δ failed to develop corticosteroid insensitivity with oxidative stress.  Both theophylline and IC87114, combined with dexamethasone, inhibited corticosteroid-insensitive lung inflammation in cigarette-smoke-exposed mice in vivo.  Conclusions: Inhibition of oxidative stress dependent PI3K-δ activation by a selective inhibitor or theophylline provides a novel approach to reversing corticosteroid insensitivity in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrntINJnOqMbrVg90H21EOLACvtfcHk0lgeuIGf5wjiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO&md5=5338bbb7050e1700b0e4eda068cdb05c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0937OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0937OC%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DFailla%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BB.%26atitle%3DTargeting%2520Phosphoinositide-3-Kinase-%25CE%25B4%2520with%2520Theophylline%2520Reverses%2520Corticosteroid%2520Insensitivity%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D897%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Palanki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrasidlo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span> </span><span class="NLM_article-title">Discovery of 3,3′-(2,4-diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4279</span><span class="NLM_x">–</span> <span class="NLM_lpage">4294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051056c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4279-4294&author=M.+Palankiauthor=E.+Dneprovskaiaauthor=J.+Doukasauthor=R.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=D.+Lohseauthor=M.+Martinauthor=G.+Noronhaauthor=R.+M.+Sollauthor=W.+Wrasidloauthor=S.+Yeeauthor=H.+Zhu&title=Discovery+of+3%2C3%E2%80%B2-%282%2C4-diaminopteridine-6%2C7-diyl%29diphenol+as+an+Isozyme-Selective+Inhibitor+of+PI3K+for+the+Treatment+of+Ischemia+Reperfusion+Injury+Associated+with+Myocardial+Infarction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm051056c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051056c%26sid%3Dliteratum%253Aachs%26aulast%3DPalanki%26aufirst%3DM.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DR.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25203%252C3%25E2%2580%25B2-%25282%252C4-diaminopteridine-6%252C7-diyl%2529diphenol%2520as%2520an%2520Isozyme-Selective%2520Inhibitor%2520of%2520PI3K%2520for%2520the%2520Treatment%2520of%2520Ischemia%2520Reperfusion%2520Injury%2520Associated%2520with%2520Myocardial%2520Infarction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4279%26epage%3D4294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijapurkar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span> </span><span class="NLM_article-title">Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3003132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=103-107&author=Z.+Peiauthor=E.+Blackwoodauthor=L.+Liuauthor=S.+Malekauthor=M.+Belvinauthor=M.+Koehlerauthor=D.+Ortwineauthor=H.+Chenauthor=F.+Cohenauthor=J.+Kennyauthor=P.+Bergeronauthor=K.+Lauauthor=C.+Lyauthor=X.+Zhaoauthor=A.+Estradaauthor=T.+Truongauthor=J.+Eplerauthor=J.+Nonomiyaauthor=L.+Trinhauthor=S.+Siderisauthor=J.+Lesnickauthor=L.+Baoauthor=U.+Vijapurkarauthor=S.+Mukadamauthor=S.+Tayauthor=G.+Deshmukhauthor=Y.+Chenauthor=X.+Dingauthor=L.+Friedmanauthor=J.+Lyssikatos&title=Discovery+and+Biological+Profiling+of+Potent+and+Selective+mTOR+Inhibitor+GDC-0349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml3003132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003132%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DOrtwine%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DKenny%26aufirst%3DJ.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLy%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DEpler%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DTrinh%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DVijapurkar%26aufirst%3DU.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Biological%2520Profiling%2520of%2520Potent%2520and%2520Selective%2520mTOR%2520Inhibitor%2520GDC-0349%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+Metzauthor=D.+Whittingtonauthor=L.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DMcGee%26aufirst%3DL.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sinclair, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Means, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibeque, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assaad, A.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol-3 Kinase Delta (PI3Kδ) Inhibitor AMG 319 Is a Potent, Selective and Orally Bioavailable Small Molecule Inhibitor that Suppresses PI3K-Mediated Signaling and Viability in Neoplastic B Cells</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">4964</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4964&issue=21&author=A.+Sinclairauthor=D.+Metzauthor=T.+Cushingauthor=L.+Liuauthor=R.+Brakeauthor=C.+Starnesauthor=G.+Meansauthor=K.+Henneauthor=I.+Archibequeauthor=B.+Mattsonauthor=A.+Drewauthor=L.+Busseauthor=L.+Wangauthor=A.-S.+Al-Assaadauthor=G.+Molineux&title=Phosphatidylinositol-3+Kinase+Delta+%28PI3K%CE%B4%29+Inhibitor+AMG+319+Is+a+Potent%2C+Selective+and+Orally+Bioavailable+Small+Molecule+Inhibitor+that+Suppresses+PI3K-Mediated+Signaling+and+Viability+in+Neoplastic+B+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSinclair%26aufirst%3DA.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DCushing%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBrake%26aufirst%3DR.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DMeans%26aufirst%3DG.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DArchibeque%26aufirst%3DI.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DBusse%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAl-Assaad%26aufirst%3DA.-S.%26aulast%3DMolineux%26aufirst%3DG.%26atitle%3DPhosphatidylinositol-3%2520Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520AMG%2520319%2520Is%2520a%2520Potent%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520Small%2520Molecule%2520Inhibitor%2520that%2520Suppresses%2520PI3K-Mediated%2520Signaling%2520and%2520Viability%2520in%2520Neoplastic%2520B%2520Cells%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2011%26volume%3D118%26issue%3D21%26spage%3D4964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibeque, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, A.</span><span> </span><span class="NLM_article-title">Phosphatidylinsoitol-3 Kinase Delta (PI3Kδ) Inhibitor AMG 319 Combined with Vincristine Enhances G2/M Arrest and Apoptotic Death in Neoplastic B Cells</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">4963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4963&issue=21&author=L.+Liuauthor=B.-C.+Sunauthor=J.+Pistilloauthor=M.+Paytonauthor=L.+Wangauthor=I.+Archibequeauthor=G.+Molineuxauthor=A.+Sinclair&title=Phosphatidylinsoitol-3+Kinase+Delta+%28PI3K%CE%B4%29+Inhibitor+AMG+319+Combined+with+Vincristine+Enhances+G2%2FM+Arrest+and+Apoptotic+Death+in+Neoplastic+B+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.-C.%26aulast%3DPistillo%26aufirst%3DJ.%26aulast%3DPayton%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DArchibeque%26aufirst%3DI.%26aulast%3DMolineux%26aufirst%3DG.%26aulast%3DSinclair%26aufirst%3DA.%26atitle%3DPhosphatidylinsoitol-3%2520Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520AMG%2520319%2520Combined%2520with%2520Vincristine%2520Enhances%2520G2%252FM%2520Arrest%2520and%2520Apoptotic%2520Death%2520in%2520Neoplastic%2520B%2520Cells%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2011%26volume%3D118%26issue%3D21%26spage%3D4963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lanasa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mato, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgood, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Means, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span> </span><span class="NLM_article-title">First-in-Human Study of AMG 319, a Highly Selective, Small Molecule Inhibitor of PI3Kδ, in Adult Patients with Relapsed or Refractory Lymphoid Malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=678&issue=21&author=M.+C.+Lanasaauthor=M.+Glennauthor=A.+R.+Matoauthor=S.+D.+Allgoodauthor=S.+Wongauthor=B.+Amoreauthor=G.+Meansauthor=E.+Stevensauthor=C.+Yanauthor=G.+Fribergauthor=A.+Goy&title=First-in-Human+Study+of+AMG+319%2C+a+Highly+Selective%2C+Small+Molecule+Inhibitor+of+PI3K%CE%B4%2C+in+Adult+Patients+with+Relapsed+or+Refractory+Lymphoid+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DGlenn%26aufirst%3DM.%26aulast%3DMato%26aufirst%3DA.%2BR.%26aulast%3DAllgood%26aufirst%3DS.%2BD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DAmore%26aufirst%3DB.%26aulast%3DMeans%26aufirst%3DG.%26aulast%3DStevens%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DFriberg%26aufirst%3DG.%26aulast%3DGoy%26aufirst%3DA.%26atitle%3DFirst-in-Human%2520Study%2520of%2520AMG%2520319%252C%2520a%2520Highly%2520Selective%252C%2520Small%2520Molecule%2520Inhibitor%2520of%2520PI3K%25CE%25B4%252C%2520in%2520Adult%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Lymphoid%2520Malignancies%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D21%26spage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Herko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czuczman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, F.</span><span> </span><span class="NLM_article-title">AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">3718</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=3718&issue=21&author=A.+Herkoauthor=C.+Mavisauthor=M.+S.+Czuczmanauthor=F.+Hernandez&title=AMG+319%2C+a+Novel+Inhibitor+of+Phosphoinositide-3+Kinase+Delta+%28PI3Kd%29%2C+Demonstrates+Activity+in+Lymphoma+Pre-Clinical+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerko%26aufirst%3DA.%26aulast%3DMavis%26aufirst%3DC.%26aulast%3DCzuczman%26aufirst%3DM.%2BS.%26aulast%3DHernandez%26aufirst%3DF.%26atitle%3DAMG%2520319%252C%2520a%2520Novel%2520Inhibitor%2520of%2520Phosphoinositide-3%2520Kinase%2520Delta%2520%2528PI3Kd%2529%252C%2520Demonstrates%2520Activity%2520in%2520Lymphoma%2520Pre-Clinical%2520Models%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2012%26volume%3D120%26issue%3D21%26spage%3D3718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Knight, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for P110α in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+Knightauthor=B.+Gonzalezauthor=M.+Feldmanauthor=E.+Zunderauthor=D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+Weissauthor=R.+Williamsauthor=K.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+P110%CE%B1+in+Insulin+Signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0ljOaJMQC0I-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%26aulast%3DZunder%26aufirst%3DE.%26aulast%3DGoldenberg%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520P110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Vlahos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. F.</span><span> </span><span class="NLM_article-title">A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4<i>H</i>-1-benzopyran-4-one (LY294002)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=8106507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFGit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=5241-5248&author=C.+J.+Vlahosauthor=W.+F.+Matterauthor=K.+Y.+Huiauthor=R.+F.+Brown&title=A+Specific+Inhibitor+of+Phosphatidylinositol+3-Kinase%2C+2-%284-Morpholinyl%29-8-phenyl-4H-1-benzopyran-4-one+%28LY294002%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)</span></div><div class="casAuthors">Vlahos, Chris J.; Matter, William F.; Hui, Kwan Y.; Brown, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5241-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Phosphatidylinositol (PtIns) 3-kinase is an enzyme implicated in growth factor signal transduction by assocg. with receptor and nonreceptor tyrosine kinases, including the platelet-derived growth factor receptor.  Inhibitors of PtdIns 3-kinase could potentially give a better understanding of the function and regulatory mechanisms of the enzyme.  Quercetin, a naturally occurring bioflavonoid, was previously shown to inhibit PtdIns 3-kinase with an IC50 of 1.3 μg/mL (3.8 μM); inhibition appeared to be directed at the ATP-binding site of the kinase.  Analogs of quercetin were investigated as PtdIns 3-kinase inhibitors, with the most potent ones exhibiting IC50 values in the range of 1.7-8.4 μg/mL.  In contrast, genistein, a potent tyrosine kinase inhibitor of the isoflavone class, did not inhibit PtdIns 3-kinase significantly (IC50 > 30 μg/mL).  Since quercetin has also been shown to inhibit other PtdIns and protein kinases, other chromones were evaluated as inhibitors of PtdIns 3-kinase without affecting PtdIns 4-kinase or selected protein kinases.  One such compd., 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (also known as 2-(4-morpholinyl)-8-phenylchromone, LY294002), completely and specifically abolished PtdIns 3-kinase activity (IC50 = 0.43 μg/mL; 1.40 μM) but did not inhibit PtdIns 4-kinase or tested protein and lipid kinases.  Analogs of LY294002 demonstrated a very selective structure-activity relationship, with slight changes in structure causing marked decreases in inhibition.  LY294002 was shown to completely abolish PtdIns 3-kinase activity in fMet-Leu-Phe-stimulated human neutrophils, as well as inhibit proliferation of smooth muscle cells in cultured rabbit aortic segments.  Since PtdIns 3-kinase appears to be centrally involved with growth factor signal transduction, the development of specific inhibitors against the kinase may be beneficial in the treatment of proliferative diseases as well as in elucidating the biol. role of the kinase in cellular proliferation and growth factor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Ii0f457BC7Vg90H21EOLACvtfcHk0lis7FKIPbnI0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFGit78%253D&md5=2635c03af206ce35d55b899f92921477</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26aulast%3DMatter%26aufirst%3DW.%2BF.%26aulast%3DHui%26aufirst%3DK.%2BY.%26aulast%3DBrown%26aufirst%3DR.%2BF.%26atitle%3DA%2520Specific%2520Inhibitor%2520of%2520Phosphatidylinositol%25203-Kinase%252C%25202-%25284-Morpholinyl%2529-8-phenyl-4H-1-benzopyran-4-one%2520%2528LY294002%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D5241%26epage%3D5248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cao, G.-Q.; Chakrabarti, P. P.; Falsey, J. R.; Herberich, B.; Pettus, L. H.; Reed, A. B.; Reichelt, A.; Sham, K.; Tasker, A. S.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cao%2C+G.-Q.%3B+Chakrabarti%2C+P.+P.%3B+Falsey%2C+J.+R.%3B+Herberich%2C+B.%3B+Pettus%2C+L.+H.%3B+Reed%2C+A.+B.%3B+Reichelt%2C+A.%3B+Sham%2C+K.%3B+Tasker%2C+A.+S.%3B+Thaman%2C+M.%3B+Wurz%2C+R.+P.%3B+Xu%2C+S.%3B+Zhang%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DG.-Q." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Chen, G.; Cushing, T. D.; Fisher, B.; He, X.; Li, K.; Li, Z.; McGee, L. R.; Pattaropong, V.; Faulder, P.; Seganish, J.; Shin, Y.</span><span> </span><span class="NLM_article-title">Alkynol Alcohols as Kinase Inhibitors</span>. WO2009158011A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Chen&author=T.+D.+Cushing&author=B.+Fisher&author=X.+He&author=K.+Li&author=Z.+Li&author=L.+R.+McGee&author=V.+Pattaropong&author=P.+Faulder&author=J.+Seganish&author=Y.+Shin&title=Alkynol+Alcohols+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26atitle%3DAlkynol%2520Alcohols%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T. D.</span><span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7667</span><span class="NLM_x">–</span> <span class="NLM_lpage">7685</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez+de+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.-L.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+McBrideauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+Dual+PI3K%CE%B2%2F%CE%B4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DH.%2BJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Dual%2520PI3K%25CE%25B2%252F%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Rashidi, M.-R.; Pashaei-Asl, R.</span><span> </span><span class="NLM_article-title">Role of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of Purine-Related Drugs</span>.  <span class="citation_source-book">Readings in Advanced Pharmacokinetics—Theory, Methods and Applications</span>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group">Noreddin, A.</span>, Ed.; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Rijeka, Croatia</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.5772%2F33202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=285-314&author=M.-R.+Rashidi&author=R.+Pashaei-Aslauthor=A.+Noreddin&title=Readings+in+Advanced+Pharmacokinetics%E2%80%94Theory%2C+Methods+and+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.5772%2F33202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F33202%26sid%3Dliteratum%253Aachs%26aulast%3DRashidi%26aufirst%3DM.-R.%26atitle%3DRole%2520of%2520Aldehyde%2520Oxidase%2520and%2520Xanthine%2520Oxidase%2520in%2520the%2520Metabolism%2520of%2520Purine-Related%2520Drugs%26btitle%3DReadings%2520in%2520Advanced%2520Pharmacokinetics%25E2%2580%2594Theory%252C%2520Methods%2520and%2520Applications%26aulast%3DNoreddin%26aufirst%3DA.%26pub%3DInTech%26date%3D2012%26spage%3D285%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">White, S. L.</span><span> </span><span class="NLM_article-title">Thienopyrimidinones for Treatment of Inflammatory Disorders and Cancers</span>. WO2008064018 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+L.+White&title=Thienopyrimidinones+for+Treatment+of+Inflammatory+Disorders+and+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DS.%2BL.%26atitle%3DThienopyrimidinones%2520for%2520Treatment%2520of%2520Inflammatory%2520Disorders%2520and%2520Cancers%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sadhu, C.; Dick, K.; Treiberg, J.; Sowell, G. C.; Kesicki, E. A.; Oliver, A.</span><span> </span><span class="NLM_article-title">Inhibitors of Human Phosphatidylinositol 3-Kinase Delta</span>. US2002161014 A1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=C.+Sadhu&author=K.+Dick&author=J.+Treiberg&author=G.+C.+Sowell&author=E.+A.+Kesicki&author=A.+Oliver&title=Inhibitors+of+Human+Phosphatidylinositol+3-Kinase+Delta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26atitle%3DInhibitors%2520of%2520Human%2520Phosphatidylinositol%25203-Kinase%2520Delta%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E. C. A.</span><span> </span><span class="NLM_article-title">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8238</span><span class="NLM_x">–</span> <span class="NLM_lpage">8248</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+Use+of+Plasma+Protein+and+Tissue+Binding+Data+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0lis7FKIPbnI0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520Use%2520of%2520Plasma%2520Protein%2520and%2520Tissue%2520Binding%2520Data%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Roberts, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, J.</span><span> </span><span class="NLM_article-title">The Clinical Relevance of Plasma Protein Binding Changes</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1007%2Fs40262-012-0018-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=23150213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1-8&author=J.+A.+Robertsauthor=F.+Peaauthor=J.+Lipman&title=The+Clinical+Relevance+of+Plasma+Protein+Binding+Changes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Relevance of Plasma Protein Binding Changes</span></div><div class="casAuthors">Roberts, Jason A.; Pea, Federico; Lipman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Controversy reigns as to how protein binding changes alter the time course of unbound drug concns. in patients.  Given that the unbound concn. is responsible for drug efficacy and potential drug toxicity, this area is of significant interest to clinicians and academics worldwide.  The present uncertainty means that many questions relating to this area exist, including "How important is protein binding", "Is protein binding always const.", "Do pH and temp. changes alter binding" and "How do protein binding changes affect dosing requirements".  In this paper, we seek to address these questions and consider the data assocd. with altered pharmacokinetics in the presence of changes in protein binding and the clin. consequences that these may have on therapy, using examples from the crit. care area.  The published literature consistently indicates that a change in the protein binding and unbound concns. of some drugs are common in certain specific patient groups such as the critically ill.  Changes in pharmacokinetic parameters, including clearance and apparent vol. of distribution (Vd), may be dramatic.  Drugs with high protein binding, high intrinsic clearance (e.g. clearance by glomerular filtration) and where dosing is not titrated to effect are most likely to be affected in a clin. context.  Drugs such as highly protein bound antibacterials with multiple half-lives within a dosing interval and that have some level of renal clearance, such as ertapenem, teicoplanin, ceftriaxone and flucloxacillin, are commonly affected.  In response to these challenges, clinicians need to adapt dosing regimens rationally based on the pharmacokinetic/pharmacodynamic characteristics of the drug.  We propose that further pharmacokinetic modeling-based research is required to enable the design of robust dosing regimens for drugs affected by altered protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcv3RvMlD17Vg90H21EOLACvtfcHk0lgr722uKDPzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmsL7M&md5=447b72c3101a856fef9fc0d7aaa902a6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40262-012-0018-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-012-0018-5%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BA.%26aulast%3DPea%26aufirst%3DF.%26aulast%3DLipman%26aufirst%3DJ.%26atitle%3DThe%2520Clinical%2520Relevance%2520of%2520Plasma%2520Protein%2520Binding%2520Changes%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The Effect of Plasma Protein Binding on in Vivo Efficacy: Misconceptions in Drug Discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+Effect+of+Plasma+Protein+Binding+on+in+Vivo+Efficacy%3A+Misconceptions+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lgr722uKDPzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520Effect%2520of%2520Plasma%2520Protein%2520Binding%2520on%2520in%2520Vivo%2520Efficacy%253A%2520Misconceptions%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">CYP induction studies in fresh human hepatocytes from two donors were carried out at concentrations of 0.1, 1, and 10 μM with <b>1</b>. Induction of mRNA and CYP activity were calculated as a percent of positive control for each isoform. Positive controls included omeprazole (50 μM), phenobarbital (1 mM), and rifampicin (10 μM) for CYP1A2, 2B6, and 3A4, respectively. At concentrations of 0.1 and 1 μM, mRNA and CYP activities were less than 10% of positive controls for CYP1A2, 2B6, and 3A4. At the 10 μM concentration, mRNA was elevated to levels approximately 30% of positive control in the case of CYP3A4, 20% for CYP2B6, and <10% for CYP1A2. However, activity increases were <20% for all isoforms tested.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Boes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">Enhanced B-1 Cell Development, but Impaired IgG Antibody Responses in Mice Deficient in Secreted IgM</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">4776</span><span class="NLM_x">–</span> <span class="NLM_lpage">4787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1998&pages=4776-4787&author=M.+Boesauthor=C.+Esauauthor=M.+B.+Fischerauthor=T.+Schmidtauthor=M.+Carrollauthor=J.+Chen&title=Enhanced+B-1+Cell+Development%2C+but+Impaired+IgG+Antibody+Responses+in+Mice+Deficient+in+Secreted+IgM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoes%26aufirst%3DM.%26aulast%3DEsau%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DM.%2BB.%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEnhanced%2520B-1%2520Cell%2520Development%252C%2520but%2520Impaired%2520IgG%2520Antibody%2520Responses%2520in%2520Mice%2520Deficient%2520in%2520Secreted%2520IgM%26jtitle%3DJ.%2520Immunol.%26date%3D1998%26volume%3D160%26spage%3D4776%26epage%3D4787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="note"><p class="first last">In the case of <b>1</b>, animals were dosed at 3, 1, 0.3, and 0.1 mg/kg po/q.d. Doses started at day 1, followed by an initial KLH immunization after 2 h. The animals were treated for 10 days with drug and at day 10 with spleens and whole blood collected and analyzed by ELISA. The key compound <b>1</b> achieved exposures at the 3 mg/kg level, which was able to cover the CD-69 HWB IC<sub>90</sub> at trough concentration for a full 24 h period. The lower doses 0.1, 0.3, and 1 mg/kg were able to cover trough concentrations between the HWB IC<sub>50</sub> and IC<sub>90</sub> and evinced partial efficacy.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">For a comparison of data for D-073, <b>1</b>, and <b>2</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.<span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0020.tif.gif" alt="" /></img></span></p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrec, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hon, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">The P110δ Crystal Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+R%C3%BCckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+P110%CE%B4+Crystal+Structure%3A+Mechanisms+for+Selectivity+and+Potency+of+New+PI%283%29K+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0lgPUTbz8sFCRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520P110%25CE%25B4%2520Crystal%2520Structure%253A%2520Mechanisms%2520for%2520Selectivity%2520and%2520Potency%2520of%2520New%2520PI%25283%2529K%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">Structural Analysis of PI3-Kinase Isoforms: Identification of Residues Enabling Selective Inhibition by Small Molecule ATP-Competitive Inhibitors</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2008&pages=404-410&author=M.+J.+Zvelebilauthor=M.+D.+Waterfieldauthor=S.+J.+Shuttleworth&title=Structural+Analysis+of+PI3-Kinase+Isoforms%3A+Identification+of+Residues+Enabling+Selective+Inhibition+by+Small+Molecule+ATP-Competitive+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DStructural%2520Analysis%2520of%2520PI3-Kinase%2520Isoforms%253A%2520Identification%2520of%2520Residues%2520Enabling%2520Selective%2520Inhibition%2520by%2520Small%2520Molecule%2520ATP-Competitive%2520Inhibitors%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2008%26volume%3D477%26spage%3D404%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+Applications+of+Halogen+Bonding+in+Medicinal+Chemistry+and+Chemical+Biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lgPUTbz8sFCRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520Applications%2520of%2520Halogen%2520Bonding%2520in%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Meth-Cohn, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnowski, B.</span><span> </span><span class="NLM_article-title">Versatile New Synthesis of Quinolines and Related Fused Pyridines. Part II</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3111</span><span class="NLM_x">–</span> <span class="NLM_lpage">3113</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=3111-3113&author=O.+Meth-Cohnauthor=B.+Narineauthor=B.+Tarnowski&title=Versatile+New+Synthesis+of+Quinolines+and+Related+Fused+Pyridines.+Part+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeth-Cohn%26aufirst%3DO.%26aulast%3DNarine%26aufirst%3DB.%26aulast%3DTarnowski%26aufirst%3DB.%26atitle%3DVersatile%2520New%2520Synthesis%2520of%2520Quinolines%2520and%2520Related%2520Fused%2520Pyridines.%2520Part%2520II%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26spage%3D3111%26epage%3D3113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Danca, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigby, J. H.</span><span> </span><span class="NLM_article-title">Vinyl Isocyanates in Alkaloid Synthesis. Camptothecin Model Studies</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">4969</span><span class="NLM_x">–</span> <span class="NLM_lpage">4972</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=4969-4972&author=D.+M.+Dancaauthor=J.+H.+Rigby&title=Vinyl+Isocyanates+in+Alkaloid+Synthesis.+Camptothecin+Model+Studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanca%26aufirst%3DD.%2BM.%26aulast%3DRigby%26aufirst%3DJ.%2BH.%26atitle%3DVinyl%2520Isocyanates%2520in%2520Alkaloid%2520Synthesis.%2520Camptothecin%2520Model%2520Studies%26jtitle%3DTetrahedron%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D4969%26epage%3D4972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Michel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gennet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassat, A.</span><span> </span><span class="NLM_article-title">A One-Pot Procedure for the Synthesis of Alkynes and Bromoalkynes from Aldehydes</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">8575</span><span class="NLM_x">–</span> <span class="NLM_lpage">8578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=8575-8578&issue=49&author=P.+Michelauthor=D.+Gennetauthor=A.+Rassat&title=A+One-Pot+Procedure+for+the+Synthesis+of+Alkynes+and+Bromoalkynes+from+Aldehydes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DP.%26aulast%3DGennet%26aufirst%3DD.%26aulast%3DRassat%26aufirst%3DA.%26atitle%3DA%2520One-Pot%2520Procedure%2520for%2520the%2520Synthesis%2520of%2520Alkynes%2520and%2520Bromoalkynes%2520from%2520Aldehydes%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26issue%3D49%26spage%3D8575%26epage%3D8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Mahaney, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatucci, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffan, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadwick, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harnish, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trybulski, E. J.</span><span> </span><span class="NLM_article-title">Synthesis and Activity of a New Class of Pathway-Selective Estrogen Receptor Ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3455</span><span class="NLM_x">–</span> <span class="NLM_lpage">3466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3455-3466&author=P.+E.+Mahaneyauthor=M.+B.+Webbauthor=F.+Yeauthor=J.+P.+Sabatucciauthor=R.+J.+Steffanauthor=C.+C.+Chadwickauthor=D.+C.+Harnishauthor=E.+J.+Trybulski&title=Synthesis+and+Activity+of+a+New+Class+of+Pathway-Selective+Estrogen+Receptor+Ligands%3A+Hydroxybenzoyl-3%2C4-dihydroquinoxalin-2%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahaney%26aufirst%3DP.%2BE.%26aulast%3DWebb%26aufirst%3DM.%2BB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSabatucci%26aufirst%3DJ.%2BP.%26aulast%3DSteffan%26aufirst%3DR.%2BJ.%26aulast%3DChadwick%26aufirst%3DC.%2BC.%26aulast%3DHarnish%26aufirst%3DD.%2BC.%26aulast%3DTrybulski%26aufirst%3DE.%2BJ.%26atitle%3DSynthesis%2520and%2520Activity%2520of%2520a%2520New%2520Class%2520of%2520Pathway-Selective%2520Estrogen%2520Receptor%2520Ligands%253A%2520Hydroxybenzoyl-3%252C4-dihydroquinoxalin-2%25281H%2529-ones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3455%26epage%3D3466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="note"><p class="first last">For preparation of methyl 3-(1,3-dioxoindolin-2-yl)-2-oxobutanoate see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Yasuo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiga, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Novel 7-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic acids Bearing a Substituted Phenyl Group as Superior AMPA Receptor Antagonists with Good Physicochemical Properties</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=776-792&author=T.+Yasuoauthor=F.+Shigaauthor=J.+Asanoauthor=W.+Horiauthor=K.+Fukuchiauthor=T.+Anrakuauthor=T.+Uno&title=Design+and+Synthesis+of+Novel+7-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic+acids+Bearing+a+Substituted+Phenyl+Group+as+Superior+AMPA+Receptor+Antagonists+with+Good+Physicochemical+Properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYasuo%26aufirst%3DT.%26aulast%3DShiga%26aufirst%3DF.%26aulast%3DAsano%26aufirst%3DJ.%26aulast%3DHori%26aufirst%3DW.%26aulast%3DFukuchi%26aufirst%3DK.%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DUno%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25207-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic%2520acids%2520Bearing%2520a%2520Substituted%2520Phenyl%2520Group%2520as%2520Superior%2520AMPA%2520Receptor%2520Antagonists%2520with%2520Good%2520Physicochemical%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D776%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">D’Angelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amico, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakowec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalameda, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1789</span><span class="NLM_x">–</span> <span class="NLM_lpage">1811</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1014605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1789-1811&author=N.+D.+D%E2%80%99Angeloauthor=T.+S.+Kimauthor=K.+Andrewsauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=K.+Chenauthor=D.+D%E2%80%99Amicoauthor=D.+Freemanauthor=J.+Jiangauthor=L.+Liuauthor=J.+D.+McCarterauthor=T.+San+Miguelauthor=E.+L.+Mulladyauthor=M.+Schragauthor=R.+Subramanianauthor=J.+Tangauthor=R.+C.+Wahlauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=N.+Xiauthor=Y.+Xuauthor=P.+Yakowecauthor=K.+Yangauthor=L.+P.+Zalamedaauthor=N.+Zhangauthor=P.+Hughesauthor=M.+H.+Norman&title=Discovery+and+Optimization+of+a+Series+of+Benzothiazole+Phosphoinositide+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28mTOR%29+Dual+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm1014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014605%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%2520Benzothiazole%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528mTOR%2529%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1789%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+Determinants+of+Phosphoinositide+3-Kinase+Inhibition+by+Wortmannin%2C+LY294002%2C+Quercetin%2C+Myricetin%2C+and+Staurosporine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lgi68gmnHNGig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520Determinants%2520of%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520by%2520Wortmannin%252C%2520LY294002%252C%2520Quercetin%252C%2520Myricetin%252C%2520and%2520Staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Otwinowski, Z.; Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span>. In  <span class="citation_source-book">Macromolecular Crystallography. Part A</span>; <span class="NLM_contrib-group">Carter, C. W.,  Jr.; Sweet, R. M.</span>, Eds.; Methods in Enzymology, Vol.  <span class="NLM_volume">276</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&author=R.+M.+Sweet&title=Macromolecular+Crystallography.+Part+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26btitle%3DMacromolecular%2520Crystallography.%2520Part%2520A%26aulast%3DCarter%26aufirst%3DC.%2BW.%26volume%3D276%26pub%3DAcademic%2520Press%26date%3D1997%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0liPKk8zUCK6Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and Development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0liPKk8zUCK6Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':[],'ref35':[],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':[],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 54 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kongjun Liu, Dan Li, Wei Zheng, Mingsong Shi, Yong Chen, Minghai Tang, Tao Yang, Min Zhao, Dexin Deng, Chufeng Zhang, Jiang Liu, Xue Yuan, Zhuang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8951-8970. <a href="https://doi.org/10.1021/acs.jmedchem.1c00004" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BOptimization%25252C%252Band%252BEvaluation%252Bof%252BQuinazolinone%252BDerivatives%252Bwith%252BNovel%252BLinkers%252Bas%252BOrally%252BEfficacious%252BPhosphoinositide-3-Kinase%252BDelta%252BInhibitors%252Bfor%252BTreatment%252Bof%252BInflammatory%252BDiseases%26aulast%3DLiu%26aufirst%3DKongjun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03012021%26date%3D17062021%26volume%3D64%26issue%3D13%26spage%3D8951%26epage%3D8970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Meredeth A. McGowan, Neville John Anthony, Matthew Christopher, Yudith Garcia, Abdelghani Achab, Kathryn Lipford, Benjamin Wesley Trotter, Michael D. Altman, Xavier Fradera, Charles A. Lesburg, Chaomin Li, Stephen Alves, Craig P. Chappell, Renu Jain, Ruban Mangado, Elaine Pinheiro, Sybill M. G. Williams, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vincent Tong, Robbie L. McLeod, Hyun-Hee Lee, Hongshi Yu, Sanjiv Shah, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 5137-5156. <a href="https://doi.org/10.1021/acs.jmedchem.1c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProjected%252BDose%252BOptimization%252Bof%252BAmino-%252Band%252BHydroxypyrrolidine%252BPurine%252BPI3K%2525CE%2525B4%252BImmunomodulators%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06022021%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D5137%26epage%3D5156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Manojkumar R. Shukla, Sukanya Patra, Mahip Verma, Gayathri Sadasivam, Nirmal Jana, Sachin J. Mahangare, Prashant Vidhate, Dipak Lagad, Anand Tarage, Murthy Cheemala, Chaitanya Kulkarni, Shankar Bhagwat, Vinod D. Chaudhari, Majid Sayyed, Vipul Pachpute, Ramesh Phadtare, Gopal Gole, Samiron Phukan, Brahmam Sunkara, Charudatt Samant, Manisha Shingare, Aditya Naik, Sneha Trivedi, Ajit Kumar Marisetti, Madhusudhan Reddy, Milind Gholve, Nilesh Mahajan, Sudeep Sabde, Vinod Patil, Dipak Modi, Maneesh Mehta, Prashant Nigade, Kaustubh Tamane, Swati Tota, Hemant Goyal, Harish Volam, Shashikant Pawar, Prajakta Ahirrao, Lal Dinchhana, Sadanand Mallurwar, Atul Akarte, Anand Bokare, Rupesh Kanhere, Neetinkumar Reddy, Sarita Koul, Manoj Dandekar, Minakshi Singh, Peter R. Bernstein, Lakshmi Narasimham, Mandar Bhonde, Jayasagar Gundu, Rajan Goel, Sanjeev Kulkarni, Sharad Sharma, Rajender Kumar Kamboj, <span class="NLM_string-name hlFld-ContribAuthor">Venkata P. Palle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14700-14723. <a href="https://doi.org/10.1021/acs.jmedchem.0c01264" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01264%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitor%252B%252528S%252529-2%25252C4-Diamino-6-%252528%2525281-%2525287-fluoro-1-%2525284-fluorophenyl%252529-4-oxo-3-phenyl-4H-quinolizin-2-yl%252529ethyl%252529amino%252529pyrimidine-5-carbonitrile%252Bwith%252BImproved%252BPharmacokinetic%252BProfile%252Band%252BSuperior%252BEfficacy%252Bin%252BHematological%252BCancer%252BModels%26aulast%3DShukla%26aufirst%3DManojkumar%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20072020%26date%3D02122020%26volume%3D63%26issue%3D23%26spage%3D14700%26epage%3D14723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew W. D. Perry, Raolat Abdulai, Mickael Mogemark, Jens Petersen, Matthew J. Thomas, Barbara Valastro, <span class="NLM_string-name hlFld-ContribAuthor">Annika Westin Eriksson</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4783-4814. <a href="https://doi.org/10.1021/acs.jmedchem.8b01298" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEvolution%252Bof%252BPI3K%2525CE%2525B3%252Band%252B%2525CE%2525B4%252BInhibitors%252Bfor%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DPerry%26aufirst%3DMatthew%2BW.%2BD.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D16082018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4783%26epage%3D4814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hong Jia, Guangxiu Dai, Weiguo Su, Kun Xiao, Jianyang Weng, Zhulin Zhang, Qing Wang, Tianhai Yuan, Fuying Shi, Zheng Zhang, Wei Chen, Yang Sai, Jian Wang, Xiong Li, Yu Cai, Jun Yu, Ping Ren, Jennifer Venable, Tadimeti Rao, James P. Edwards, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Bembenek</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4936-4948. <a href="https://doi.org/10.1021/acs.jmedchem.8b02014" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b02014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b02014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b02014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BOptimization%25252C%252Band%252BEvaluation%252Bof%252BPotent%252Band%252BHighly%252BSelective%252BPI3K%2525CE%2525B3%2525E2%252580%252593PI3K%2525CE%2525B4%252BDual%252BInhibitors%26aulast%3DJia%26aufirst%3DHong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03012019%26date%3D08052019%26date%3D29042019%26volume%3D62%26issue%3D10%26spage%3D4936%26epage%3D4948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Sam D. Kattar, Meredeth A. McGowan, Kevin Wilson, Yudith Garcia, Yongi Deng, Michael Altman, Xavier Fradera, Charles Lesburg, Thierry Fischmann, Chaomin Li, Steve Alves, Sanjiv Shah, Rafael Fernandez, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vince Tong, Robbie L. McLeod, Hongshi Yu, Alan Bass, Ray Kemper, Nicholas T. Gatto, Lisa LaFranco-Scheuch, Benjamin Wesley Trotter, Timothy Guzi, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4370-4382. <a href="https://doi.org/10.1021/acs.jmedchem.8b01818" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01818%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BOverhaul%252BAffords%252Ba%252BPotent%252BPurine%252BPI3K%2525CE%2525B4%252BInhibitor%252Bwith%252BImproved%252BTolerability%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D20112018%26date%3D22042019%26date%3D15042019%26volume%3D62%26issue%3D9%26spage%3D4370%26epage%3D4382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Liu</span>, <span class="hlFld-ContribAuthor ">Qing  Shi</span>, <span class="hlFld-ContribAuthor ">David  Marcoux</span>, <span class="hlFld-ContribAuthor ">Douglas G.  Batt</span>, <span class="hlFld-ContribAuthor ">Lyndon  Cornelius</span>, <span class="hlFld-ContribAuthor ">Lan-Ying  Qin</span>, <span class="hlFld-ContribAuthor ">Zheming  Ruan</span>, <span class="hlFld-ContribAuthor ">James  Neels</span>, <span class="hlFld-ContribAuthor ">Myra  Beaudoin-Bertrand</span>, <span class="hlFld-ContribAuthor ">Anurag S.  Srivastava</span>, <span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cherney</span>, <span class="hlFld-ContribAuthor ">Hua  Gong</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Carolyn  Weigelt</span>, <span class="hlFld-ContribAuthor ">Kathleen M.  Gillooly</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Jenny H.  Xie</span>, <span class="hlFld-ContribAuthor ">Mary T.  Obermeier</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">Bogdan  Sleczka</span>, <span class="hlFld-ContribAuthor ">Kevin  Stefanski</span>, <span class="hlFld-ContribAuthor ">R. M.  Fancher</span>, <span class="hlFld-ContribAuthor ">Shweta  Padmanabhan</span>, <span class="hlFld-ContribAuthor ">Thatipamula  RP</span>, <span class="hlFld-ContribAuthor ">Ipsit  Kundu</span>, <span class="hlFld-ContribAuthor ">Kallem  Rajareddy</span>, <span class="hlFld-ContribAuthor ">Rodney  Smith</span>, <span class="hlFld-ContribAuthor ">James K.  Hennan</span>, <span class="hlFld-ContribAuthor ">Dezhi  Xing</span>, <span class="hlFld-ContribAuthor ">Jingsong  Fan</span>, <span class="hlFld-ContribAuthor ">Paul C.  Levesque</span>, <span class="hlFld-ContribAuthor ">Qian  Ruan</span>, <span class="hlFld-ContribAuthor ">Sidney  Pitt</span>, <span class="hlFld-ContribAuthor ">Rosemary  Zhang</span>, <span class="hlFld-ContribAuthor ">Donna  Pedicord</span>, <span class="hlFld-ContribAuthor ">Jie  Pan</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Hao  Lu</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Christine  Goldstine</span>, <span class="hlFld-ContribAuthor ">Stacey  Skala</span>, <span class="hlFld-ContribAuthor ">Richard A.  Rampulla</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Anuradha  Gupta</span>, <span class="hlFld-ContribAuthor ">Pirama Nayagam  Arunachalam</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Jodi K.  Muckelbauer</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Rajeev S.  Bhide</span>, <span class="hlFld-ContribAuthor ">Michael A.  Poss</span>, <span class="hlFld-ContribAuthor ">John  Hynes</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">John E.  Macor</span>, <span class="hlFld-ContribAuthor ">Stefan  Ruepp</span>, <span class="hlFld-ContribAuthor ">Gary L.  Schieven</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (12)
                                     , 5193-5208. <a href="https://doi.org/10.1021/acs.jmedchem.7b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BEfficacious%252BPhosphatidylinositol%252B3-Kinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%26aulast%3DLiu%26aufirst%3DQingjie%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D27042017%26date%3D05062017%26date%3D22062017%26date%3D25052017%26volume%3D60%26issue%3D12%26spage%3D5193%26epage%3D5208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephane  Perreault</span>, <span class="hlFld-ContribAuthor ">Jayaraman  Chandrasekhar</span>, <span class="hlFld-ContribAuthor ">Zhi-Hua  Cui</span>, <span class="hlFld-ContribAuthor ">Jerry  Evarts</span>, <span class="hlFld-ContribAuthor ">Jia  Hao</span>, <span class="hlFld-ContribAuthor ">Joshua A.  Kaplan</span>, <span class="hlFld-ContribAuthor ">Adam  Kashishian</span>, <span class="hlFld-ContribAuthor ">Kathleen S.  Keegan</span>, <span class="hlFld-ContribAuthor ">Thomas  Kenney</span>, <span class="hlFld-ContribAuthor ">David  Koditek</span>, <span class="hlFld-ContribAuthor ">Latesh  Lad</span>, <span class="hlFld-ContribAuthor ">Eve-Irene  Lepist</span>, <span class="hlFld-ContribAuthor ">Mary E.  McGrath</span>, <span class="hlFld-ContribAuthor ">Leena  Patel</span>, <span class="hlFld-ContribAuthor ">Bart  Phillips</span>, <span class="hlFld-ContribAuthor ">Joseph  Therrien</span>, <span class="hlFld-ContribAuthor ">Jennifer  Treiberg</span>, <span class="hlFld-ContribAuthor ">Anella  Yahiaoui</span>, and <span class="hlFld-ContribAuthor ">Gary  Phillips</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (4)
                                     , 1555-1567. <a href="https://doi.org/10.1021/acs.jmedchem.6b01821" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252B%2525CE%2525B2%25252F%2525CE%2525B4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BPhosphatase%252Band%252BTensin%252BHomolog%252B%252528PTEN%252529%252BDeficient%252BTumors%25253A%252BBuilding%252BPI3K%2525CE%2525B2%252BPotency%252Bin%252Ba%252BPI3K%2525CE%2525B4-Selective%252BTemplate%252Bby%252BTargeting%252BNonconserved%252BAsp856%26aulast%3DPerreault%26aufirst%3DStephane%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D14122016%26date%3D07022017%26date%3D23022017%26date%3D20012017%26volume%3D60%26issue%3D4%26spage%3D1555%26epage%3D1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix  Gonzalez-Lopez de Turiso</span>, <span class="hlFld-ContribAuthor ">Xiaolin  Hao</span>, <span class="hlFld-ContribAuthor ">Youngsook  Shin</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Iain D. G.  Campuzano</span>, <span class="hlFld-ContribAuthor ">Mario  Cardozo</span>, <span class="hlFld-ContribAuthor ">Michelle C.  Dunn</span>, <span class="hlFld-ContribAuthor ">Jason  Duquette</span>, <span class="hlFld-ContribAuthor ">Benjamin  Fisher</span>, <span class="hlFld-ContribAuthor ">Robert S.  Foti</span>, <span class="hlFld-ContribAuthor ">Kirk  Henne</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Yi-Ling  Hu</span>, <span class="hlFld-ContribAuthor ">Ron C.  Kelly</span>, <span class="hlFld-ContribAuthor ">Michael G.  Johnson</span>, <span class="hlFld-ContribAuthor ">Brian S.  Lucas</span>, <span class="hlFld-ContribAuthor ">John  McCarter</span>, <span class="hlFld-ContribAuthor ">Lawrence R.  McGee</span>, <span class="hlFld-ContribAuthor ">Julio C.  Medina</span>, <span class="hlFld-ContribAuthor ">Daniela  Metz</span>, <span class="hlFld-ContribAuthor ">Tisha  San Miguel</span>, <span class="hlFld-ContribAuthor ">Deanna  Mohn</span>, <span class="hlFld-ContribAuthor ">Thuy  Tran</span>, <span class="hlFld-ContribAuthor ">Christine  Vissinga</span>, <span class="hlFld-ContribAuthor ">Sharon  Wannberg</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">John  Whoriskey</span>, <span class="hlFld-ContribAuthor ">Gang  Yu</span>, <span class="hlFld-ContribAuthor ">Leeanne  Zalameda</span>, <span class="hlFld-ContribAuthor ">Xuxia  Zhang</span>, and <span class="hlFld-ContribAuthor ">Timothy D.  Cushing</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7252-7267. <a href="https://doi.org/10.1021/acs.jmedchem.6b00827" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00827</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00827%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252Bthe%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitors%252B2-%252528%2525281S%252529-1-%252528%2525286-Amino-5-cyano-4-pyrimidinyl%252529amino%252529ethyl%252529-6-fluoro-N-methyl-3-%2525282-pyridinyl%252529-4-quinolinecarboxamide%252B%252528AM-0687%252529%252Band%252B2-%252528%2525281S%252529-1-%252528%2525286-Amino-5-cyano-4-pyrimidinyl%252529amino%252529ethyl%252529-5-fluoro-N-methyl-3-%2525282-pyridinyl%252529-4-quinolinecarboxamide%252B%252528AM-1430%252529%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DFelix%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01062016%26date%3D25072016%26date%3D11082016%26date%3D14072016%26volume%3D59%26issue%3D15%26spage%3D7252%26epage%3D7267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Klemens  Hoegenauer</span>, <span class="hlFld-ContribAuthor ">Nicolas  Soldermann</span>, <span class="hlFld-ContribAuthor ">Frédéric  Stauffer</span>, <span class="hlFld-ContribAuthor ">Pascal  Furet</span>, <span class="hlFld-ContribAuthor ">Nadege  Graveleau</span>, <span class="hlFld-ContribAuthor ">Alexander B.  Smith</span>, <span class="hlFld-ContribAuthor ">Christina  Hebach</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Hollingworth</span>, <span class="hlFld-ContribAuthor ">Ian  Lewis</span>, <span class="hlFld-ContribAuthor ">Sascha  Gutmann</span>, <span class="hlFld-ContribAuthor ">Gabriele  Rummel</span>, <span class="hlFld-ContribAuthor ">Mark  Knapp</span>, <span class="hlFld-ContribAuthor ">Romain M.  Wolf</span>, <span class="hlFld-ContribAuthor ">Joachim  Blanz</span>, <span class="hlFld-ContribAuthor ">Roland  Feifel</span>, <span class="hlFld-ContribAuthor ">Christoph  Burkhart</span>, and <span class="hlFld-ContribAuthor ">Frédéric  Zécri</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (8)
                                     , 762-767. <a href="https://doi.org/10.1021/acsmedchemlett.6b00119" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00119%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BPharmacological%252BCharacterization%252Bof%252BNovel%252BQuinazoline-Based%252BPI3K%252BDelta-Selective%252BInhibitors%26aulast%3DHoegenauer%26aufirst%3DKlemens%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17032016%26date%3D02062016%26date%3D13062016%26date%3D11082016%26date%3D02062016%26volume%3D7%26issue%3D8%26spage%3D762%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leena  Patel</span>, <span class="hlFld-ContribAuthor ">Jayaraman  Chandrasekhar</span>, <span class="hlFld-ContribAuthor ">Jerry  Evarts</span>, <span class="hlFld-ContribAuthor ">Aaron C.  Haran</span>, <span class="hlFld-ContribAuthor ">Carmen  Ip</span>, <span class="hlFld-ContribAuthor ">Joshua A.  Kaplan</span>, <span class="hlFld-ContribAuthor ">Musong  Kim</span>, <span class="hlFld-ContribAuthor ">David  Koditek</span>, <span class="hlFld-ContribAuthor ">Latesh  Lad</span>, <span class="hlFld-ContribAuthor ">Eve-Irene  Lepist</span>, <span class="hlFld-ContribAuthor ">Mary E.  McGrath</span>, <span class="hlFld-ContribAuthor ">Nikolai  Novikov</span>, <span class="hlFld-ContribAuthor ">Stephane  Perreault</span>, <span class="hlFld-ContribAuthor ">Kamal D.  Puri</span>, <span class="hlFld-ContribAuthor ">John R.  Somoza</span>, <span class="hlFld-ContribAuthor ">Bart H.  Steiner</span>, <span class="hlFld-ContribAuthor ">Kirk L.  Stevens</span>, <span class="hlFld-ContribAuthor ">Joseph  Therrien</span>, <span class="hlFld-ContribAuthor ">Jennifer  Treiberg</span>, <span class="hlFld-ContribAuthor ">Armando G.  Villaseñor</span>, <span class="hlFld-ContribAuthor ">Arthur  Yeung</span>, and <span class="hlFld-ContribAuthor ">Gary  Phillips</span>  . </span><span class="cited-content_cbyCitation_article-title">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (7)
                                     , 3532-3548. <a href="https://doi.org/10.1021/acs.jmedchem.6b00213" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2%25252C4%25252C6-Triaminopyrimidine%252Bas%252Ba%252BNovel%252BHinge%252BBinder%252Bin%252Ba%252BSeries%252Bof%252BPI3K%2525CE%2525B4%252BSelective%252BInhibitors%26aulast%3DPatel%26aufirst%3DLeena%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09022016%26date%3D29032016%26date%3D14042016%26date%3D16032016%26volume%3D59%26issue%3D7%26spage%3D3532%26epage%3D3548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youngsook  Shin</span>, <span class="hlFld-ContribAuthor ">Julia  Suchomel</span>, <span class="hlFld-ContribAuthor ">Mario  Cardozo</span>, <span class="hlFld-ContribAuthor ">Jason  Duquette</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Kirk  Henne</span>, <span class="hlFld-ContribAuthor ">Yi-Ling  Hu</span>, <span class="hlFld-ContribAuthor ">Ron C.  Kelly</span>, <span class="hlFld-ContribAuthor ">John  McCarter</span>, <span class="hlFld-ContribAuthor ">Lawrence R.  McGee</span>, <span class="hlFld-ContribAuthor ">Julio C.  Medina</span>, <span class="hlFld-ContribAuthor ">Daniela  Metz</span>, <span class="hlFld-ContribAuthor ">Tisha  San Miguel</span>, <span class="hlFld-ContribAuthor ">Deanna  Mohn</span>, <span class="hlFld-ContribAuthor ">Thuy  Tran</span>, <span class="hlFld-ContribAuthor ">Christine  Vissinga</span>, <span class="hlFld-ContribAuthor ">Simon  Wong</span>, <span class="hlFld-ContribAuthor ">Sharon  Wannberg</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">John  Whoriskey</span>, <span class="hlFld-ContribAuthor ">Gang  Yu</span>, <span class="hlFld-ContribAuthor ">Leeanne  Zalameda</span>, <span class="hlFld-ContribAuthor ">Xuxia  Zhang</span>, and <span class="hlFld-ContribAuthor ">Timothy D.  Cushing</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 431-447. <a href="https://doi.org/10.1021/acs.jmedchem.5b01651" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01651</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01651%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BOptimization%25252C%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252BBenzimidazole%252BDerivatives%252BAM-8508%252Band%252BAM-9635%252Bas%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitors%26aulast%3DShin%26aufirst%3DYoungsook%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D21102015%26date%3D21122015%26date%3D14012016%26date%3D10122015%26volume%3D59%26issue%3D1%26spage%3D431%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuyao  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhong</span>, <span class="hlFld-ContribAuthor ">Bingbing  Li</span>, <span class="hlFld-ContribAuthor ">Shumin  Ouyang</span>, <span class="hlFld-ContribAuthor ">Lin  Deng</span>, <span class="hlFld-ContribAuthor ">Jianshan  Mo</span>, <span class="hlFld-ContribAuthor ">Shuo  Shi</span>, <span class="hlFld-ContribAuthor ">Nan  Lv</span>, <span class="hlFld-ContribAuthor ">Ruibo  Wu</span>, <span class="hlFld-ContribAuthor ">Peiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113525. <a href="https://doi.org/10.1016/j.ejmech.2021.113525" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113525%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdiscovery%252Bof%252Bpotent%252Band%252Bselective%252Bsmall-molecule%252Binhibitors%252Btargeting%252Bsignal%252Btransducer%252Band%252Bactivator%252Bof%252Btranscription%252B3%252B%252528STAT3%252529%26aulast%3DHuang%26aufirst%3DQiuyao%26date%3D2021%26volume%3D221%26spage%3D113525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katsu  Ishida</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Werner</span>, <span class="hlFld-ContribAuthor ">Marc  Lafleur</span>, <span class="hlFld-ContribAuthor ">John  Wisler</span>, <span class="hlFld-ContribAuthor ">Sharon  Wannberg</span>, <span class="hlFld-ContribAuthor ">Jackson  Kalanzi</span>, <span class="hlFld-ContribAuthor ">Jeanine L.  Bussiere</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Monticello</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-Kinase δ-Specific Inhibitor-Induced Changes in the Ovary and Testis in the Sprague Dawley Rat and Cynomolgus Monkey. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Toxicology</span><span> <strong>2021,</strong> <em>40 </em>
                                    (4)
                                     , 344-354. <a href="https://doi.org/10.1177/10915818211008175" title="DOI URL">https://doi.org/10.1177/10915818211008175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/10915818211008175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F10915818211008175%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Toxicology%26atitle%3DPhosphatidylinositol%252B3-Kinase%252B%2525CE%2525B4-Specific%252BInhibitor-Induced%252BChanges%252Bin%252Bthe%252BOvary%252Band%252BTestis%252Bin%252Bthe%252BSprague%252BDawley%252BRat%252Band%252BCynomolgus%252BMonkey%26aulast%3DIshida%26aufirst%3DKatsu%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D4%26spage%3D344%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart  Vanhaesebroeck</span>, <span class="hlFld-ContribAuthor ">Matthew W. D.  Perry</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>, <span class="hlFld-ContribAuthor ">Fabrice  André</span>, <span class="hlFld-ContribAuthor ">Klaus  Okkenhaug</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors are finally coming of age. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>170 </em><a href="https://doi.org/10.1038/s41573-021-00209-1" title="DOI URL">https://doi.org/10.1038/s41573-021-00209-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-021-00209-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-021-00209-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DPI3K%252Binhibitors%252Bare%252Bfinally%252Bcoming%252Bof%252Bage%26aulast%3DVanhaesebroeck%26aufirst%3DBart%26date%3D2021%26date%3D2021%26volume%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lihong  Yao</span>, <span class="hlFld-ContribAuthor ">Ying  Tang</span>, <span class="hlFld-ContribAuthor ">Junjie  Chen</span>, <span class="hlFld-ContribAuthor ">Jiahui  Li</span>, <span class="hlFld-ContribAuthor ">Hua  Wang</span>, <span class="hlFld-ContribAuthor ">Mei  Lu</span>, <span class="hlFld-ContribAuthor ">Lijuan  Gao</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Chang</span>, <span class="hlFld-ContribAuthor ">Xingxing  Liu</span>, <span class="hlFld-ContribAuthor ">Haixiong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Impaired airway epithelial barrier integrity was mediated by PI3Kδ in a mouse model of lipopolysaccharide-induced acute lung injury. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2021,</strong> <em>95 </em>, 107570. <a href="https://doi.org/10.1016/j.intimp.2021.107570" title="DOI URL">https://doi.org/10.1016/j.intimp.2021.107570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2021.107570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2021.107570%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DImpaired%252Bairway%252Bepithelial%252Bbarrier%252Bintegrity%252Bwas%252Bmediated%252Bby%252BPI3K%2525CE%2525B4%252Bin%252Ba%252Bmouse%252Bmodel%252Bof%252Blipopolysaccharide-induced%252Bacute%252Blung%252Binjury%26aulast%3DYao%26aufirst%3DLihong%26date%3D2021%26volume%3D95%26spage%3D107570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Le  Yu</span>, <span class="hlFld-ContribAuthor ">Jessica  Wei</span>, <span class="hlFld-ContribAuthor ">Pengda  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.semcancer.2021.06.019" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAttacking%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252Bsignaling%252Bpathway%252Bfor%252Btargeted%252Btherapeutic%252Btreatment%252Bin%252Bhuman%252Bcancer%26aulast%3DYu%26aufirst%3DLe%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dima A.  Sabbah</span>, <span class="hlFld-ContribAuthor ">Rima  Hajjo</span>, <span class="hlFld-ContribAuthor ">Sanaa K.  Bardaweel</span>, <span class="hlFld-ContribAuthor ">Haizhen A.  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>8 </em>, 1-16. <a href="https://doi.org/10.1080/13543776.2021.1924150" title="DOI URL">https://doi.org/10.1080/13543776.2021.1924150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1924150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1924150%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPhosphatidylinositol%252B3-kinase%252B%252528PI3K%252529%252Binhibitors%25253A%252Ba%252Brecent%252Bupdate%252Bon%252Binhibitor%252Bdesign%252Band%252Bclinical%252Btrials%252B%2525282016%2525E2%252580%2525932020%252529%26aulast%3DSabbah%26aufirst%3DDima%2BA.%26date%3D2021%26date%3D2021%26volume%3D8%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew W.  Buesking</span>, <span class="hlFld-ContribAuthor ">Patrick A.  Mayes</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Combs</span>. </span><span class="cited-content_cbyCitation_article-title">Immuno‐Oncology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-30. <a href="https://doi.org/10.1002/0471266949.bmc272" title="DOI URL">https://doi.org/10.1002/0471266949.bmc272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc272%26sid%3Dliteratum%253Aachs%26atitle%3DImmuno%2525E2%252580%252590Oncology%26aulast%3DBuesking%26aufirst%3DAndrew%2BW.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D30%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caiyun  Xu</span>, <span class="hlFld-ContribAuthor ">Shuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Yao  Deng</span>, <span class="hlFld-ContribAuthor ">Jiafu  Song</span>, <span class="hlFld-ContribAuthor ">Jiahui  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Ping  Chang</span>, <span class="hlFld-ContribAuthor ">Lihong  Yao</span>, <span class="hlFld-ContribAuthor ">Haixiong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Distinct roles of PI3Kδ and PI3Kγ in a toluene diisocyanate-induced murine asthma model. </span><span class="cited-content_cbyCitation_journal-name">Toxicology</span><span> <strong>2021,</strong> <em>454 </em>, 152747. <a href="https://doi.org/10.1016/j.tox.2021.152747" title="DOI URL">https://doi.org/10.1016/j.tox.2021.152747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tox.2021.152747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tox.2021.152747%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%26atitle%3DDistinct%252Broles%252Bof%252BPI3K%2525CE%2525B4%252Band%252BPI3K%2525CE%2525B3%252Bin%252Ba%252Btoluene%252Bdiisocyanate-induced%252Bmurine%252Basthma%252Bmodel%26aulast%3DXu%26aufirst%3DCaiyun%26date%3D2021%26volume%3D454%26spage%3D152747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Kan  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Xinling  Zhao</span>, <span class="hlFld-ContribAuthor ">Huazhong  Li</span>, <span class="hlFld-ContribAuthor ">Gang  Huang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Advanced Research</span><span> <strong>2021,</strong> <em>20 </em><a href="https://doi.org/10.1016/j.jare.2021.04.007" title="DOI URL">https://doi.org/10.1016/j.jare.2021.04.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jare.2021.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jare.2021.04.007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Advanced%2520Research%26atitle%3DDiscovery%252Bof%252Bnovel%252Bselective%252BPI3K%2525CE%2525B3%252Binhibitors%252Bthrough%252Bcombining%252Bmachine%252Blearning-based%252Bvirtual%252Bscreening%252Bwith%252Bmultiple%252Bprotein%252Bstructures%252Band%252Bbio-evaluation%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2021%26volume%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan A.  Werner</span>, <span class="hlFld-ContribAuthor ">Katsu  Ishida</span>, <span class="hlFld-ContribAuthor ">John  Wisler</span>, <span class="hlFld-ContribAuthor ">Christine  Karbowski</span>, <span class="hlFld-ContribAuthor ">Jackson  Kalanzi</span>, <span class="hlFld-ContribAuthor ">Jeanine  Bussiere</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Monticello</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-Kinase δ Inhibitor-Induced Immunomodulation and Secondary Opportunistic Infection in the Cynomolgus Monkey (
              Macaca fascicularis
              ). </span><span class="cited-content_cbyCitation_journal-name">Toxicologic Pathology</span><span> <strong>2020,</strong> <em>48 </em>
                                    (8)
                                     , 949-964. <a href="https://doi.org/10.1177/0192623320966238" title="DOI URL">https://doi.org/10.1177/0192623320966238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0192623320966238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0192623320966238%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicologic%2520Pathology%26atitle%3DPhosphatidylinositol%252B3-Kinase%252B%2525CE%2525B4%252BInhibitor-Induced%252BImmunomodulation%252Band%252BSecondary%252BOpportunistic%252BInfection%252Bin%252Bthe%252BCynomolgus%252BMonkey%252B%252528%252BMacaca%252Bfascicularis%252B%252529%26aulast%3DWerner%26aufirst%3DJonathan%2BA.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D8%26spage%3D949%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Sun</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Yuan  Huang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127457. <a href="https://doi.org/10.1016/j.bmcl.2020.127457" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DResearch%252Badvances%252Bon%252Bselective%252Bphosphatidylinositol%252B3%252Bkinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252Binhibitors%26aulast%3DSun%26aufirst%3DJiajia%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mayur  Narkhede</span>, <span class="hlFld-ContribAuthor ">Bruce D  Cheson</span>. </span><span class="cited-content_cbyCitation_article-title">Copanlisib in the treatment of non-Hodgkin lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (26)
                                     , 1947-1955. <a href="https://doi.org/10.2217/fon-2020-0195" title="DOI URL">https://doi.org/10.2217/fon-2020-0195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2020-0195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2020-0195%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DCopanlisib%252Bin%252Bthe%252Btreatment%252Bof%252Bnon-Hodgkin%252Blymphoma%26aulast%3DNarkhede%26aufirst%3DMayur%26date%3D2020%26volume%3D16%26issue%3D26%26spage%3D1947%26epage%3D1955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R.Y.  Bheemanaboina</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform-Selective PI3K Inhibitors for Various Diseases. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1074-1092. <a href="https://doi.org/10.2174/1568026620666200106141717" title="DOI URL">https://doi.org/10.2174/1568026620666200106141717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200106141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200106141717%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DIsoform-Selective%252BPI3K%252BInhibitors%252Bfor%252BVarious%252BDiseases%26aulast%3DBheemanaboina%26aufirst%3DRammohan%2BR.Y.%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1074%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob A.  McPhail</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 203-222. <a href="https://doi.org/10.1007/978-3-030-50621-6_9" title="DOI URL">https://doi.org/10.1007/978-3-030-50621-6_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26atitle%3DDrugging%252Bthe%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B4-Kinase%252B%252528PI4K%252529%252BFamily%252Bof%252BEnzymes%252Bfor%252BTreatment%252Bof%252BCancer%25252C%252BImmune%252BDisorders%25252C%252Band%252BViral%25252FParasitic%252BInfections%26aulast%3DMcPhail%26aufirst%3DJacob%2BA.%26date%3D2020%26date%3D2020%26spage%3D203%26epage%3D222%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDruggable%252BLipid%252BSignaling%252BPathways%26aulast%3DKihara%26aufirst%3DYasuyuki%26date%3D2020%26volume%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Cu</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 925-941. <a href="https://doi.org/10.1080/13543776.2019.1687685" title="DOI URL">https://doi.org/10.1080/13543776.2019.1687685</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1687685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1687685%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPI3K%2525CE%2525B4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282015-present%252529%26aulast%3DFeng%26aufirst%3DYifan%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D925%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Filippo  Spriano</span>, <span class="hlFld-ContribAuthor ">Chiara  Tarantelli</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gaudio</span>, <span class="hlFld-ContribAuthor ">Magdalena M.  Gerlach</span>, <span class="hlFld-ContribAuthor ">Valdemar  Priebe</span>, <span class="hlFld-ContribAuthor ">Luciano  Cascione</span>, <span class="hlFld-ContribAuthor ">Elena  Bernasconi</span>, <span class="hlFld-ContribAuthor ">Altea  Targa</span>, <span class="hlFld-ContribAuthor ">Michele  Mascia</span>, <span class="hlFld-ContribAuthor ">Stefan  Dirnhofer</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Emanuele  Zucca</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Haematology</span><span> <strong>2019,</strong> <em>187 </em>
                                    (5)
                                     , 595-601. <a href="https://doi.org/10.1111/bjh.16118" title="DOI URL">https://doi.org/10.1111/bjh.16118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bjh.16118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbjh.16118%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Haematology%26atitle%3DSingle%252Band%252Bcombined%252BBTK%252Band%252BPI3K%2525CE%2525B4%252Binhibition%252Bwith%252Bacalabrutinib%252Band%252BACP%2525E2%252580%252590319%252Bin%252Bpre%2525E2%252580%252590clinical%252Bmodels%252Bof%252Baggressive%252Blymphomas%26aulast%3DSpriano%26aufirst%3DFilippo%26date%3D2019%26date%3D2019%26volume%3D187%26issue%3D5%26spage%3D595%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karol  Molga</span>, <span class="hlFld-ContribAuthor ">Piotr  Dittwald</span>, <span class="hlFld-ContribAuthor ">Bartosz A.  Grzybowski</span>. </span><span class="cited-content_cbyCitation_article-title">Computational design of syntheses leading to compound libraries or isotopically labelled targets. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (40)
                                     , 9219-9232. <a href="https://doi.org/10.1039/C9SC02678A" title="DOI URL">https://doi.org/10.1039/C9SC02678A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC02678A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC02678A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DComputational%252Bdesign%252Bof%252Bsyntheses%252Bleading%252Bto%252Bcompound%252Blibraries%252Bor%252Bisotopically%252Blabelled%252Btargets%26aulast%3DMolga%26aufirst%3DKarol%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D40%26spage%3D9219%26epage%3D9232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Joey L.  Methot</span>, <span class="hlFld-ContribAuthor ">Abdelghani  Achab</span>, <span class="hlFld-ContribAuthor ">Matthew  Christopher</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Meredeth A.  McGowan</span>, <span class="hlFld-ContribAuthor ">Sam D.  Kattar</span>, <span class="hlFld-ContribAuthor ">Kevin  Wilson</span>, <span class="hlFld-ContribAuthor ">Yudith  Garcia</span>, <span class="hlFld-ContribAuthor ">Martin A.  Augustin</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Sanjiv  Shah</span>, <span class="hlFld-ContribAuthor ">Peter  Goldenblatt</span>, <span class="hlFld-ContribAuthor ">Jason D.  Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2575-2580. <a href="https://doi.org/10.1016/j.bmcl.2019.08.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252Bselective%252BPI3K%2525CE%2525B4%252Binhibitors%252Busing%252Ban%252Biterative%252Bscaffold-hopping%252Bworkflow%26aulast%3DFradera%26aufirst%3DXavier%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2575%26epage%3D2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Jun  Wei</span>, <span class="hlFld-ContribAuthor ">Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 112-125. <a href="https://doi.org/10.1016/j.ejmech.2019.03.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzothiadiazine%252Bderivatives%252Bas%252Bpotent%252BPI3K%2525CE%2525B4-selective%252Binhibitors%252Bfor%252Btreating%252BB-cell-mediated%252Bmalignancies%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26volume%3D170%26spage%3D112%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Jiang</span>, <span class="hlFld-ContribAuthor ">Huizhen  Guo</span>, <span class="hlFld-ContribAuthor ">Qiang  Sun</span>, <span class="hlFld-ContribAuthor ">Yumei  Wang</span>, <span class="hlFld-ContribAuthor ">Enyu  Xie</span>, <span class="hlFld-ContribAuthor ">Qingyou  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (7)
                                     , 1260. <a href="https://doi.org/10.3390/molecules24071260" title="DOI URL">https://doi.org/10.3390/molecules24071260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24071260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24071260%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DScreening%252Bof%252BPI3K-Akt-targeting%252BDrugs%252Bfor%252BSilkworm%252Bagainst%252BBombyx%252Bmori%252BNucleopolyhedrovirus%26aulast%3DWang%26aufirst%3DBingbing%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D7%26spage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Juan  Ge</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuxin  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>156 </em>, 831-846. <a href="https://doi.org/10.1016/j.ejmech.2018.07.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-2-amino-N-%2525285-%2525286-chloro-5-%2525283-methylphenylsulfonamido%252529pyridin-3-yl%252529-4-methylthiazol-2-yl%252529-3-methylbutanamide%252B%252528CHMFL-PI3KD-317%252529%252Bas%252Ba%252Bpotent%252Band%252Bselective%252Bphosphoinositide%252B3-kinase%252Bdelta%252B%252528PI3K%2525CE%2525B4%252529%252Binhibitor%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2018%26volume%3D156%26spage%3D831%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshihiro  Hamajima</span>, <span class="hlFld-ContribAuthor ">Fumie  Takahashi</span>, <span class="hlFld-ContribAuthor ">Koji  Kato</span>, <span class="hlFld-ContribAuthor ">Koichiro  Mukoyoshi</span>, <span class="hlFld-ContribAuthor ">Kousei  Yoshihara</span>, <span class="hlFld-ContribAuthor ">Susumu  Yamaki</span>, <span class="hlFld-ContribAuthor ">Yukihito  Sugano</span>, <span class="hlFld-ContribAuthor ">Ayako  Moritomo</span>, <span class="hlFld-ContribAuthor ">Kaoru  Yamagami</span>, <span class="hlFld-ContribAuthor ">Koji  Yokoo</span>, <span class="hlFld-ContribAuthor ">Hidehiko  Fukahori</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (9)
                                     , 2410-2419. <a href="https://doi.org/10.1016/j.bmc.2018.03.042" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazolopyridine%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bavailable%252BPI3K%2525CE%2525B4%252Binhibitors%26aulast%3DHamajima%26aufirst%3DToshihiro%26date%3D2018%26volume%3D26%26issue%3D9%26spage%3D2410%26epage%3D2419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heather L.  Gardner</span>, <span class="hlFld-ContribAuthor ">Sarah B.  Rippy</span>, <span class="hlFld-ContribAuthor ">Misty D.  Bear</span>, <span class="hlFld-ContribAuthor ">Kim L.  Cronin</span>, <span class="hlFld-ContribAuthor ">Heather  Heeb</span>, <span class="hlFld-ContribAuthor ">Holly  Burr</span>, <span class="hlFld-ContribAuthor ">Claire M.  Cannon</span>, <span class="hlFld-ContribAuthor ">Kumar V.  Penmetsa</span>, <span class="hlFld-ContribAuthor ">Srikant  Viswanadha</span>, <span class="hlFld-ContribAuthor ">Swaroop  Vakkalanka</span>, <span class="hlFld-ContribAuthor ">Cheryl A.  London</span>, . </span><span class="cited-content_cbyCitation_article-title">Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2018,</strong> <em>13 </em>
                                    (4)
                                     , e0195357. <a href="https://doi.org/10.1371/journal.pone.0195357" title="DOI URL">https://doi.org/10.1371/journal.pone.0195357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0195357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0195357%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DPhase%252BI%25252FII%252Bevaluation%252Bof%252BRV1001%25252C%252Ba%252Bnovel%252BPI3K%2525CE%2525B4%252Binhibitor%25252C%252Bin%252Bspontaneous%252Bcanine%252Blymphoma%26aulast%3DGardner%26aufirst%3DHeather%2BL.%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D4%26spage%3De0195357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-fu  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Shao</span>, <span class="hlFld-ContribAuthor ">Chang-peng  Wu</span>, <span class="hlFld-ContribAuthor ">Zhong-ping  Chen</span>, <span class="hlFld-ContribAuthor ">Shing-shun Tony  To</span>, <span class="hlFld-ContribAuthor ">Wei-ping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2017,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-017-0670-3" title="DOI URL">https://doi.org/10.1186/s12943-017-0670-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-017-0670-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-017-0670-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Buse%252Bof%252BPI3K%252Binhibitors%252Bfor%252Bglioblastoma%252Bmultiforme%25253A%252Bcurrent%252Bpreclinical%252Band%252Bclinical%252Bdevelopment%26aulast%3DZhao%26aufirst%3DHua-fu%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin L.  Lampson</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (11)
                                     , 1267-1279. <a href="https://doi.org/10.1080/13543784.2017.1384815" title="DOI URL">https://doi.org/10.1080/13543784.2017.1384815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1384815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1384815%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DPI3K%2525CE%2525B4-selective%252Band%252BPI3K%2525CE%2525B1%25252F%2525CE%2525B4-combinatorial%252Binhibitors%252Bin%252Bclinical%252Bdevelopment%252Bfor%252BB-cell%252Bnon-Hodgkin%252Blymphoma%26aulast%3DLampson%26aufirst%3DBenjamin%2BL.%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D11%26spage%3D1267%26epage%3D1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengying  Xie</span>, <span class="hlFld-ContribAuthor ">Ye  He</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zhen</span>, <span class="hlFld-ContribAuthor ">Yulan  Wang</span>, <span class="hlFld-ContribAuthor ">Yongping  Xu</span>, <span class="hlFld-ContribAuthor ">Liguang  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2017,</strong> <em>108 </em>
                                    (7)
                                     , 1476-1484. <a href="https://doi.org/10.1111/cas.13263" title="DOI URL">https://doi.org/10.1111/cas.13263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13263%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DPuquitinib%25252C%252Ba%252Bnovel%252Borally%252Bavailable%252BPI3K%2525CE%2525B4%252Binhibitor%25252C%252Bexhibits%252Bpotent%252Bantitumor%252Befficacy%252Bagainst%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DXie%26aufirst%3DChengying%26date%3D2017%26date%3D2017%26volume%3D108%26issue%3D7%26spage%3D1476%26epage%3D1484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honyin  Chiu</span>, <span class="hlFld-ContribAuthor ">Sharmila  Mallya</span>, <span class="hlFld-ContribAuthor ">Phuongthao  Nguyen</span>, <span class="hlFld-ContribAuthor ">Annie  Mai</span>, <span class="hlFld-ContribAuthor ">Leandra V.  Jackson</span>, <span class="hlFld-ContribAuthor ">David G.  Winkler</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  DiNitto</span>, <span class="hlFld-ContribAuthor ">Erin E.  Brophy</span>, <span class="hlFld-ContribAuthor ">Karen  McGovern</span>, <span class="hlFld-ContribAuthor ">Jeffery L.  Kutok</span>, <span class="hlFld-ContribAuthor ">David A.  Fruman</span>. </span><span class="cited-content_cbyCitation_article-title">The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fimmu.2017.00747" title="DOI URL">https://doi.org/10.3389/fimmu.2017.00747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2017.00747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2017.00747%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DThe%252BSelective%252BPhosphoinoside-3-Kinase%252Bp110%2525CE%2525B4%252BInhibitor%252BIPI-3063%252BPotently%252BSuppresses%252BB%252BCell%252BSurvival%25252C%252BProliferation%25252C%252Band%252BDifferentiation%26aulast%3DChiu%26aufirst%3DHonyin%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hima V.  Vangapandu</span>, <span class="hlFld-ContribAuthor ">Nitin  Jain</span>, <span class="hlFld-ContribAuthor ">Varsha  Gandhi</span>. </span><span class="cited-content_cbyCitation_article-title">Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (5)
                                     , 625-632. <a href="https://doi.org/10.1080/13543784.2017.1312338" title="DOI URL">https://doi.org/10.1080/13543784.2017.1312338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1312338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1312338%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DDuvelisib%25253A%252Ba%252Bphosphoinositide-3%252Bkinase%252B%2525CE%2525B4%25252F%2525CE%2525B3%252Binhibitor%252Bfor%252Bchronic%252Blymphocytic%252Bleukemia%26aulast%3DVangapandu%26aufirst%3DHima%2BV.%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D5%26spage%3D625%26epage%3D632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evan C  Lien</span>, <span class="hlFld-ContribAuthor ">Christian C  Dibble</span>, <span class="hlFld-ContribAuthor ">Alex  Toker</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K signaling in cancer: beyond AKT. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Cell Biology</span><span> <strong>2017,</strong> <em>45 </em>, 62-71. <a href="https://doi.org/10.1016/j.ceb.2017.02.007" title="DOI URL">https://doi.org/10.1016/j.ceb.2017.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ceb.2017.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ceb.2017.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Cell%2520Biology%26atitle%3DPI3K%252Bsignaling%252Bin%252Bcancer%25253A%252Bbeyond%252BAKT%26aulast%3DLien%26aufirst%3DEvan%2BC%26date%3D2017%26volume%3D45%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ina  Terstiege</span>, <span class="hlFld-ContribAuthor ">Matthew  Perry</span>, <span class="hlFld-ContribAuthor ">Jens  Petersen</span>, <span class="hlFld-ContribAuthor ">Christian  Tyrchan</span>, <span class="hlFld-ContribAuthor ">Tor  Svensson</span>, <span class="hlFld-ContribAuthor ">Helena  Lindmark</span>, <span class="hlFld-ContribAuthor ">Linda  Öster</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (3)
                                     , 679-687. <a href="https://doi.org/10.1016/j.bmcl.2016.11.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Btriazole%252Baminopyrazines%252Bas%252Ba%252Bhighly%252Bpotent%252Band%252Bselective%252Bseries%252Bof%252BPI3K%2525CE%2525B4%252Binhibitors%26aulast%3DTerstiege%26aufirst%3DIna%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D679%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lan-Ying  Qin</span>, <span class="hlFld-ContribAuthor ">Zheming  Ruan</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cherney</span>, <span class="hlFld-ContribAuthor ">T.G. Murali  Dhar</span>, <span class="hlFld-ContribAuthor ">James  Neels</span>, <span class="hlFld-ContribAuthor ">Carolyn A.  Weigelt</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Anurag S.  Srivastava</span>, <span class="hlFld-ContribAuthor ">Lyndon A.M.  Cornelius</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>, <span class="hlFld-ContribAuthor ">Kevin  Stefanski</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Gu</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Vojkan  Susulic</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  Yang</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde-Chinn</span>, <span class="hlFld-ContribAuthor ">Stacey  Skala</span>, <span class="hlFld-ContribAuthor ">Ruth  Bosnius</span>, <span class="hlFld-ContribAuthor ">Christine  Goldstein</span>, <span class="hlFld-ContribAuthor ">Paul  Davies</span>, <span class="hlFld-ContribAuthor ">Stefan  Ruepp</span>, <span class="hlFld-ContribAuthor ">Luisa  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Rajeev S.  Bhide</span>, <span class="hlFld-ContribAuthor ">Michael A.  Poss</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (4)
                                     , 855-861. <a href="https://doi.org/10.1016/j.bmcl.2017.01.016" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.01.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.01.016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B7-%2525283-%252528piperazin-1-yl%252529phenyl%252529pyrrolo%25255B2%25252C1-f%25255D%25255B1%25252C2%25252C4%25255Dtriazin-4-amine%252Bderivatives%252Bas%252Bhighly%252Bpotent%252Band%252Bselective%252BPI3K%2525CE%2525B4%252Binhibitors%26aulast%3DQin%26aufirst%3DLan-Ying%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D855%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.L.  Adams</span>, <span class="hlFld-ContribAuthor ">K.J.  Duffy</span>, <span class="hlFld-ContribAuthor ">M.L.  Moore</span>, <span class="hlFld-ContribAuthor ">J.  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 357-394. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12400-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12400-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12400-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12400-X%26sid%3Dliteratum%253Aachs%26atitle%3DCancer%252BImmunotherapy%2525E2%252580%252594An%252BEmerging%252BField%252BThat%252BBridges%252BOncology%252Band%2525C2%2525A0Immunology%252BResearch%26aulast%3DAdams%26aufirst%3DJ.L.%26date%3D2017%26spage%3D357%26epage%3D394%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Yan</span>, <span class="hlFld-ContribAuthor ">Xincheng  Li</span>, <span class="hlFld-ContribAuthor ">Chunxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Boshun  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Silver-catalyzed cyclization of nitrones with 2-azetine: a radical approach to 2,3-disubstituted quinolines. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2017,</strong> <em>4 </em>
                                    (9)
                                     , 1833-1838. <a href="https://doi.org/10.1039/C7QO00405B" title="DOI URL">https://doi.org/10.1039/C7QO00405B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7QO00405B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7QO00405B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DSilver-catalyzed%252Bcyclization%252Bof%252Bnitrones%252Bwith%252B2-azetine%25253A%252Ba%252Bradical%252Bapproach%252Bto%252B2%25252C3-disubstituted%252Bquinolines%26aulast%3DYan%26aufirst%3DHao%26date%3D2017%26date%3D2017%26volume%3D4%26issue%3D9%26spage%3D1833%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juraj  Dobiaš</span>, <span class="hlFld-ContribAuthor ">Marek  Ondruš</span>, <span class="hlFld-ContribAuthor ">Gabriela  Addová</span>, <span class="hlFld-ContribAuthor ">Andrej  Boháč</span>. </span><span class="cited-content_cbyCitation_article-title">Switchable highly regioselective synthesis of 3,4-dihydroquinoxalin-2(1
              H
              )ones from
              o
              -phenylenediamines and aroylpyruvates. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>13 </em>, 1350-1360. <a href="https://doi.org/10.3762/bjoc.13.132" title="DOI URL">https://doi.org/10.3762/bjoc.13.132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.13.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.13.132%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSwitchable%252Bhighly%252Bregioselective%252Bsynthesis%252Bof%252B3%25252C4-dihydroquinoxalin-2%2525281%252BH%252B%252529ones%252Bfrom%252Bo%252B-phenylenediamines%252Band%252Baroylpyruvates%26aulast%3DDobia%25C5%25A1%26aufirst%3DJuraj%26date%3D2017%26date%3D2017%26volume%3D13%26spage%3D1350%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Klemens  Hoegenauer</span>, <span class="hlFld-ContribAuthor ">Nicolas  Soldermann</span>, <span class="hlFld-ContribAuthor ">Christina  Hebach</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Hollingworth</span>, <span class="hlFld-ContribAuthor ">Ian  Lewis</span>, <span class="hlFld-ContribAuthor ">Anette  von Matt</span>, <span class="hlFld-ContribAuthor ">Alexander B.  Smith</span>, <span class="hlFld-ContribAuthor ">Romain M.  Wolf</span>, <span class="hlFld-ContribAuthor ">Rainer  Wilcken</span>, <span class="hlFld-ContribAuthor ">Dorothea  Haasen</span>, <span class="hlFld-ContribAuthor ">Christoph  Burkhart</span>, <span class="hlFld-ContribAuthor ">Frédéric  Zécri</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (23)
                                     , 5657-5662. <a href="https://doi.org/10.1016/j.bmcl.2016.10.069" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.10.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.10.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.10.069%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrrolidineoxy-substituted%252Bheteroaromatics%252Bas%252Bpotent%252Band%252Bselective%252BPI3K%252Bdelta%252Binhibitors%252Bwith%252Bimproved%252Bphysicochemical%252Bproperties%26aulast%3DHoegenauer%26aufirst%3DKlemens%26date%3D2016%26volume%3D26%26issue%3D23%26spage%3D5657%26epage%3D5662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Scott</span>, <span class="hlFld-ContribAuthor ">Martin F.  Hentemann</span>, <span class="hlFld-ContribAuthor ">R. Bruce  Rowley</span>, <span class="hlFld-ContribAuthor ">Cathy O.  Bull</span>, <span class="hlFld-ContribAuthor ">Susan  Jenkins</span>, <span class="hlFld-ContribAuthor ">Ann M.  Bullion</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Johnson</span>, <span class="hlFld-ContribAuthor ">Anikó  Redman</span>, <span class="hlFld-ContribAuthor ">Arthur H.  Robbins</span>, <span class="hlFld-ContribAuthor ">William  Esler</span>, <span class="hlFld-ContribAuthor ">R. Paul  Fracasso</span>, <span class="hlFld-ContribAuthor ">Timothy  Garrison</span>, <span class="hlFld-ContribAuthor ">Mark  Hamilton</span>, <span class="hlFld-ContribAuthor ">Martin  Michels</span>, <span class="hlFld-ContribAuthor ">Jill E.  Wood</span>, <span class="hlFld-ContribAuthor ">Dean P.  Wilkie</span>, <span class="hlFld-ContribAuthor ">Hong  Xiao</span>, <span class="hlFld-ContribAuthor ">Joan  Levy</span>, <span class="hlFld-ContribAuthor ">Enrico  Stasik</span>, <span class="hlFld-ContribAuthor ">Ningshu  Liu</span>, <span class="hlFld-ContribAuthor ">Martina  Schaefer</span>, <span class="hlFld-ContribAuthor ">Michael  Brands</span>, <span class="hlFld-ContribAuthor ">Julien  Lefranc</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-
              c
              ]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (14)
                                     , 1517-1530. <a href="https://doi.org/10.1002/cmdc.201600148" title="DOI URL">https://doi.org/10.1002/cmdc.201600148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600148%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Band%252BSAR%252Bof%252BNovel%252B2%25252C3-Dihydroimidazo%25255B1%25252C2-%252Bc%252B%25255Dquinazoline%252BPI3K%252BInhibitors%25253A%252BIdentification%252Bof%252BCopanlisib%252B%252528BAY%252B80-6946%252529%26aulast%3DScott%26aufirst%3DWilliam%2BJ.%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D14%26spage%3D1517%26epage%3D1530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang  Cao</span>, <span class="hlFld-ContribAuthor ">Ruiyuan  Cao</span>, <span class="hlFld-ContribAuthor ">Xialing  Liu</span>, <span class="hlFld-ContribAuthor ">Xiang  Luo</span>, <span class="hlFld-ContribAuthor ">Wu  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (7)
                                     , 876. <a href="https://doi.org/10.3390/molecules21070876" title="DOI URL">https://doi.org/10.3390/molecules21070876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21070876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21070876%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BBenzothiazole%252BDerivatives%252Bas%252BSelective%252BPI3K%2525CE%2525B2%252BInhibitors%26aulast%3DCao%26aufirst%3DShuang%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D7%26spage%3D876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya  Lin</span>, <span class="hlFld-ContribAuthor ">Yanqiong  Zhang</span>, <span class="hlFld-ContribAuthor ">Erxin  Shang</span>, <span class="hlFld-ContribAuthor ">Wenfang  Lai</span>, <span class="hlFld-ContribAuthor ">Hongwei  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuhua  Fang</span>, <span class="hlFld-ContribAuthor ">Qingxia  Qin</span>, <span class="hlFld-ContribAuthor ">Haiyu  Zhao</span>, <span class="hlFld-ContribAuthor ">Na  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of
              Glycyrrhiza
              on the Diuretic Function of
              Euphorbia kansui
              : An Ascites Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Evidence-Based Complementary and Alternative Medicine</span><span> <strong>2016,</strong> <em>2016 </em>, 1-13. <a href="https://doi.org/10.1155/2016/7620817" title="DOI URL">https://doi.org/10.1155/2016/7620817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2016/7620817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2016%2F7620817%26sid%3Dliteratum%253Aachs%26jtitle%3DEvidence-Based%2520Complementary%2520and%2520Alternative%2520Medicine%26atitle%3DEffect%252Bof%252BGlycyrrhiza%252Bon%252Bthe%252BDiuretic%252BFunction%252Bof%252BEuphorbia%252Bkansui%252B%25253A%252BAn%252BAscites%252BMouse%252BModel%26aulast%3DLin%26aufirst%3DYa%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John R.  Somoza</span>, <span class="hlFld-ContribAuthor ">David  Koditek</span>, <span class="hlFld-ContribAuthor ">Armando G.  Villaseñor</span>, <span class="hlFld-ContribAuthor ">Nikolai  Novikov</span>, <span class="hlFld-ContribAuthor ">Melanie H.  Wong</span>, <span class="hlFld-ContribAuthor ">Albert  Liclican</span>, <span class="hlFld-ContribAuthor ">Weimei  Xing</span>, <span class="hlFld-ContribAuthor ">Leanna  Lagpacan</span>, <span class="hlFld-ContribAuthor ">Ruth  Wang</span>, <span class="hlFld-ContribAuthor ">Brian E.  Schultz</span>, <span class="hlFld-ContribAuthor ">Giuseppe A.  Papalia</span>, <span class="hlFld-ContribAuthor ">Dharmaraj  Samuel</span>, <span class="hlFld-ContribAuthor ">Latesh  Lad</span>, <span class="hlFld-ContribAuthor ">Mary E.  McGrath</span>. </span><span class="cited-content_cbyCitation_article-title">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2015,</strong> <em>290 </em>
                                    (13)
                                     , 8439-8446. <a href="https://doi.org/10.1074/jbc.M114.634683" title="DOI URL">https://doi.org/10.1074/jbc.M114.634683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DStructural%25252C%252BBiochemical%25252C%252Band%252BBiophysical%252BCharacterization%252Bof%252BIdelalisib%252BBinding%252Bto%252BPhosphoinositide%252B3-Kinase%252B%2525CE%2525B4%26aulast%3DSomoza%26aufirst%3DJohn%2BR.%26date%3D2015%26volume%3D290%26issue%3D13%26spage%3D8439%26epage%3D8446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SAR development of the purinylquinoline series, which led to compound <b>1</b>. By utilization of known literature compounds and insights gained from two internal kinase programs, compounds <b>4</b> and <b>5</b> were generated, which in turn led to analog <b>6</b>. Shown are IC<sub>50</sub> values against PI3Kδ (enzyme, Alphascreen assay; for a description see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase dendogram of <b>1</b>. Red balls on the protein kinase family “tree” mark the level of binding. Binding assay results are shown as <i>K</i><sub>d</sub> values (nM) against 359 separate protein kinases, tested at 10 μM compound concentration. As can be seen from the figure, <b>1</b> was inactive under these criteria. All kinases tested at >35 POC and 80% were >70 POC. Kinase selectivity experiment and figure were supplied by DiscoveRx, formerly AMBIT Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Vehicle, benchmark compound 2-(((2-amino-9<i>H</i>-purin-6-yl)amino)methyl)-5-methyl-3-(<i>o</i>-tolyl)quinazolin-4(3<i>H</i>)-one (D-073),<a onclick="showRef(event, 'ref28 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref35">(28, 35)</a> and <b>1</b> were dosed orally to the transgenic (IgM<sub>m</sub>) mice. Fifteen minutes later they were injected (iv) with anti-IgM/FITC. Blood (a) and spleen tissue (b) were collected after 30 min, stained, and analyzed for phospho-AKT (p-AKT) levels by flow cytometry. The cells were gated on B220+ (B cells) and FITC positive cells analyzed. Mann–Whitney <i>U</i> test was used to evaluate differences between groups. The asterisk (∗) denotes statistical significance (<i>p</i> < 0.05) when compared to the control group. (c) Unbound concentrations were plotted against % remaining pAKT activity (100 – % pAKT inhibition) measured in peripheral blood B cells for each corresponding dose. Total plasma concentrations of <b>1</b> from two separate experiments (a) were converted to estimated unbound concentrations using mouse plasma protein binding data (<i>f</i><sub>u</sub> = 0.0442). The estimated in vivo unbound drug concentration pAKT IC<sub>50</sub> was 1.9 nM and was in reasonable agreement with the pAKT murine splenocyte B-cell-based in vitro unbound drug concentration IC<sub>50</sub> of 1.1 nM [calculated from 1.5 nM total drug IC<sub>50</sub> × 0.711<i>f</i><sub>u,media</sub>. Quantitation of <b>1</b> in mouse plasma was performed using a sensitive and selective LC–MS/MS method. MS analysis was carried out using electrospray ionization (ESI) in the positive mode, with detection of analyte and internal standard <i>N</i>-((1<i>R</i>)-1-(3-(4-(ethyloxy)phenyl)-4-oxo-3,4-dihydropyrido[2,3-<i>d</i>]pyrimidin-2-yl)ethyl)-<i>N</i>-(3-pyridinylmethyl)-2-(4((trifluoromethyl)oxy)phenyl)acetamide by multiple reaction monitoring (MRM). The lower limit of quantitation (LLOQ) in the assay was 0.3 ng/mL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Vehicle or <b>1</b> in 2% HPMC, 1% Pluronic F68, 10% Captisol, pH 2.0, was administered (0.1, 0.3, 1, 3 mg/kg) q.d. po for 10 days in female Lewis rats (<i>N</i> = 8/dose group). At 2 h after the first dosing, 200 μL of PBS containing 60 μg of KLH was administered to each rat intravenously. Ten days after the KLH priming, rats were euthanized and blood was taken by cardiac puncture for the measurement of KLH specific IgG (a) and IgM (b) by ELISA. The <i>y</i>-axis is represented as a mean serum dilution factor. Error bars represent the standard error of the mean (SEM) of eight rats. (c) After administration of <b>1</b>, plasma was harvested to assess exposures in each dose group. Unbound drug concentrations (mean ± SD) were measured by LC–MS/MS and plotted relative to HWB<sub>int,u</sub> CD-69 (IC<sub>50</sub> = 2.0 nM; IC<sub>90</sub> = 15 nM) and in vitro mouse anti IgM pAKT<sub>unbound</sub> (IC<sub>50</sub> = 1.1 nM; IC<sub>90</sub> = 9.2 nM) estimates, represented as dashed lines. The percent values are the attenuation of KLH-specific IgG responses from (a).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Cocrystal structure of p110γ + <b>1</b> at 2.7 Å resolution. The orientation of the pyridine ring could not be determined from the electron density and was assigned arbitrarily. Dashed lines indicate hydrogen bonds; the red sphere is an ordered water molecule. (b) Amino acid differences cluster on the P-loop (top) and at the mouth of the active site. Not all differences are shown. (c) Overlay of <b>1</b> (green) bound to PI3Kγ (blue) and <b>2</b> (yellow) bound to PI3Kδ (beige). The P-loop in PI3Kγ is colored pink. Residue labels correspond to PI3Kγ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Cocrystal structure of p110γ + <b>16</b> at 2.30 Å resolution. The 3-fluoro substituent points toward the carbonyl of Ala885 enhancing potency. (b) Crystal structure of p110γ + <b>27</b> at 2.40 Å resolution. (c) Overlay of <b>1</b> (green) onto p110γ + <b>27</b> (magenta). <b>1</b> sits lower in the pocket compared to <b>27</b>, enhancing selectivity over PI3Kγ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaBH<sub>4</sub> (1.5 equiv), THF (0.5–0.9 M), or MeOH (0.1 M), 0 °C, 0.5–4 h; (ii) boronic acid (1.1 or 1.3 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), CH<sub>3</sub>CN–H<sub>2</sub>O, 100 °C; (iii) <i>o</i>-tolylboronic acid (1.5 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (4.0 equiv), DME, EtOH, H<sub>2</sub>O, 150 °C, microwave, 60%; (iv) MeMgBr (2.0 equiv), THF (0.2 or 0.3 equiv), 0 °C; (v) NaH (4.0 equiv), DMSO (0.4 M), DABCO (4.0 equiv), chiral purification as needed; (vi) 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (2.0 equiv), DABCO (2.0 equiv), NaH (2 equiv), DMSO (2.4 mL), rt, 4 h, chiral HPLC; (vii) SOCl<sub>2</sub> (5.0 equiv), CHCl<sub>3</sub> (0.25 M); (viii) CBr<sub>4</sub> (1.5 equiv), PPh<sub>3</sub> (1.5 equiv), DCM (0.17 M), 0 °C, 0.5 h; (ix) NaN<sub>3</sub> (3.0 equiv), DMSO (0.25 M); (x) Pd–C, H<sub>2</sub>, MeOH, rt; (xi) (bromomethyl)triphenylphosphonium bromide (1.2 equiv), potassium <i>tert</i>-butoxide (6.8 equiv), −78 to 40 °C, 5 h, 41%; (xii) NaOH (0.7 mL, 4.0 equiv, 2 M), THF (0.7 mL), 6-mercaptopurine monohydrate (1.5 equiv), 4 h, reflux, 60%; (xiii) 6-chloropurine (1.2 equiv) or 6-brompurine (1.2 equiv), DIEA (2.0 equiv), EtOH (0.05 M) or <i>n</i>-BuOH, reflux; (xiv) 6-iodopurine (3.0 equiv), DMF (0.1 M), Et<sub>3</sub>N (2.90 mL), CuI (0.4 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.2 equiv), 50 °C, 3 h, 41%; (xv) EtOH/MeOH (1:1, 2 mL), 10% Pd/C (0.05 equiv), 34%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SOCl<sub>2</sub> (5 equiv), CHCl<sub>3</sub> (0.2 M); (ii) NaN<sub>3</sub> (2 equiv), DMSO (0.28 M), 4 h; (iii) 10% Pd/C, H<sub>2</sub>, MeOH (0.09 M), 70%, three steps; (iv) 6-chloropurine, DIEA, <i>n</i>-BuOH, 115 °C; (v) chiral HPLC; (vi) phthalimide (2.0 equiv), PPh<sub>3</sub> (1.7 equiv), ADDP (1.7 equiv), THF (0.2 M), rt, 35 h, 43%; (vii) NH<sub>2</sub>NH<sub>2</sub>–H<sub>2</sub>O (5.0 equiv), EtOH (0.08 M), reflux, 2 h, 97%; (viii) 6-chloropurine (2.0 equiv), Et<sub>3</sub>N (2.0 equiv), DMF (0.3 M), rt to 90 °C, 19 h, 40%.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) POCl<sub>3</sub> (7.0 equiv), DMF (2.5 equiv); (ii) MeMgBr (2.0 equiv), THF; (iii) LDA, THF; CH<sub>3</sub>CHO, −78 °C; (iv) MnO<sub>2</sub> (10.0 equiv), Tol (0.17 M), reflux, 2 h; (v) (+) DIP-Cl (2.2 equiv), THF (0.45 M), −47 °C; (vi) phthalimide (1.2 equiv), DIAD (1.2 equiv), PPh<sub>3</sub> (1.2 equiv), 0 °C to rt; (vii) boronic acid (1.1–1.8 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05–0.15 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), MeCN, water, 80–90 °C; (viii) 2-tri-<i>n</i>-butylstannylpyridine, PPh<sub>3</sub>, 1,4-dioxane, 100 °C; (ix) 2-chloro-5-fluoropyridin-3-ylboronic acid (1.2 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.5 equiv), CsF (3.0 equiv), CuI (0.2 equiv), 1,2-ethanediol, dimethyl ether (1.0 equiv), microwave, 100 °C, 1 h, 40%; (x) K<sub>2</sub>CO<sub>3</sub> (0.4 equiv (for <b>53f</b>)), or Na<sub>2</sub>CO<sub>3</sub> (5.2 equiv, (for <b>53e</b>)), Pd(dppf)Cl<sub>2</sub> (0.1 equiv), dry DMF (0.15 M), phenylboronic acid (2.0 equiv), 100 °C, 2.5 h; (xi) Pd(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub>, Xphos, tributyltin cyanide, NMP, dicyclohexylamine, 160 °C, 3.25 h, 67.5%; (xii) AlMe<sub>3</sub> (5.0 equiv), dioxane (0.02 M), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.2 equiv), reflux, 4 h, 75%; (xiii) hydrazine or hydrazine hydrate (1.5–20 equiv), EtOH (0.1 M), 50–90 °C, 0.5–4 h; (xiv) conc HCl (10–20 equiv), EtOH (0.2–0.5 M), reflux, 4 h to 6 days and (<b>54b</b>) hydrazine monohydrate (10 equiv); (xv) conc HCl, sealed flask, 24 h, 76.5% of <b>56f</b>; (xvi) 6-chloropurine (1.0–1.1 equiv) or 6-bromopurine (1.2 equiv), DIEA (1.0–3.0 equiv), <i>n</i>-BuOH (0.1–1.0 M), 100–118 °C.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span><sup><i>a</i></sup>Reagents and conditions: (i) PPh<sub>3</sub>, DIAD, DPPA, THF, 0 °C to rt; (ii) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, MeCN, water, 80–100 °C; (iii) PPh<sub>3</sub>, THF, water, 60 °C; (iv) DIEA, <i>n</i>-BuOH, 6-bromopurine or 6-chloropurine, 100–130 °C; (v) NH<sub>2</sub>NH<sub>2</sub> (10 equiv), EtOH, 90 °C, 0.5 h, then Boc<sub>2</sub>O (1.1 equiv), Et<sub>3</sub>N (1.0 equiv), reflux, 76%; (vi) OsO<sub>4</sub> (0.13 equiv), NMO (3.0 equiv), acetone (0.79 M), 100%; (vii) TFA, DCM, rt, 1 h; (viii) MeMgBr (2.0 equiv), THF, 0 °C, 98%; (ix) SOCl<sub>2</sub> (5.0 equiv), CHCl<sub>3</sub> (0. 3M), rt, 3 h; (x) potassium phthalimide (2.5 equiv), DMF (0.37 M), 1.5 h, 100 °C; (xi) NH<sub>2</sub>NH<sub>2</sub> (10 equiv), EtOH (0.1 M), reflux, 1.5 h, 60%, three steps; (xii) chiral HPLC; (xiii) NaNO<sub>2</sub> (1.1 equiv), HCl (5.0 N), 92%; (xiv) POCl<sub>3</sub>, (15.1 equiv), 90 °C, 3 h, 78%; (xv) 4-(3,3-dimethylindolin-6-yl)morpholine, 1-pentanol, 140 °C, 51%.</p></p></figure><figure data-id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ethyl 2-oxobutanoate (1.0 equiv), PPA (1.0 equiv), 100–160 °C, 2.7 h, 60%; (ii) 1,4-dioxane (0.2 M), DDQ (1.05 equiv), rt, 2.5 h, 95%; (iii) 1, 3-dibromo-5,5-dimethylimidazolidine-2,4-dione (0.7 equiv), benzoyl peroxide (0.1 equiv), CCl<sub>4</sub> (1.0 equiv), 20 h, 80 °C to reflux, 80–100%; (iv) POCl<sub>3</sub> (10–13 equiv), 1.5–2 h, 100–110 °C; (v) potassium phthalimide (1.0 equiv), DMF (0.3 M), 1–3 h, rt, 70–76%; (vi) 2-tri-<i>n</i>-butylstannylpyridine (1.3–2.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 equiv), 1,4-dioxane or toluene, 110 °C, 19–29 h; (vii) methyl, 3-(1,3-dioxoisoindolin-2-yl)-2-oxobutanoate (1.0 equiv), EtOAc (0.4 M), rt, 3 h, ∼3.5:1 mixture of regioisomers; (viii) hydrazine hydrate (5–10 equiv), EtOH, 95 °C, 1–1.5 h; (ix) chiral purification SFC or chiral HPLC; (x) DIEA (3.0 equiv), <i>n</i>-BuOH (0.1 or 0.28 M), 6-chloropurine (1.0 equiv) or 6-bromopurine (1.0 equiv), 100–110 °C, 5–24 h.</p></p></figure><figure data-id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/large/jm-2014-01624r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501624r&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 2-aminobutanic acid (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (1.0 equiv), DMSO, 80 °C, 18 h, 76%; (ii) SnCl<sub>2</sub>–2H<sub>2</sub>O (5.0 equiv), HCl, EtOH, 90 °C, 2.5 h, 94%; (iii) DDQ (1.0 equiv), 1,4-dioxane, rt, 2 h, 97%; (iv) POCl<sub>3</sub> (10 equiv), 100 °C, 2.0 h, 90%; (v) (3-fluorophenyl)boronic acid (1.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv), Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv), CH<sub>3</sub>CN–H<sub>2</sub>O (3:1, 0.1 M), 8 h, 89%; (vi) 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (0.55 equiv), benzoyl peroxide (0.1 equiv), CCl<sub>4</sub> (0.2 M), reflux, 17 h, 92% ; (vii) NaN<sub>3</sub> (2 equiv), DMSO (0.3 M), rt, 2 h, 100%; (viii) PMe<sub>3</sub> (1.0 equiv, 1 M), THF–H<sub>2</sub>O (4:1, 0.17 M), rt, 1.7 h, 87.8%; (ix) 6-chloropurine (1.0 equiv), DIEA (3.0 equiv), 1-BuOH (1.0 M), 100 °C, 22 h, 48%; (x) chiral separation using SFC, 37%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i189">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Di Paolo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Camilli, P.</span><span> </span><span class="NLM_article-title">Phosphoinositides in Cell Regulation and Membrane Dynamics</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">443</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnature05185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17035995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGkurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=651-657&author=G.+Di+Paoloauthor=P.+De+Camilli&title=Phosphoinositides+in+Cell+Regulation+and+Membrane+Dynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositides in cell regulation and membrane dynamics</span></div><div class="casAuthors">Di Paolo, Gilbert; De Camilli, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">7112</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inositol phospholipids have long been known to play an important regulatory role in cell physiol.  The repertoire of cellular processes known to be directly or indirectly controlled by this class of lipids has now dramatically expanded.  Through interactions mediated by their headgroups, which can be reversibly phosphorylated to generate 7 species, phosphoinositides play a fundamental part in controlling membrane-cytosol interfaces.  These lipids mediate acute responses, but also act as constitutive signals that help define organelle identity.  Their functions, in addn. to classical signal transduction at the cell surface, include regulation of membrane traffic, the cytoskeleton, nuclear events, and the permeability and transport functions of membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmEgrRRg1UmLVg90H21EOLACvtfcHk0li10TPNwh-ZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGkurrN&md5=9c367ca5035a56260c0fb026c1b2da72</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature05185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05185%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DG.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26atitle%3DPhosphoinositides%2520in%2520Cell%2520Regulation%2520and%2520Membrane%2520Dynamics%26jtitle%3DNature%26date%3D2006%26volume%3D443%26spage%3D651%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Schaeffer, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, P. L.</span><span> </span><span class="NLM_article-title">Tec Family Kinases in Lymphocyte Signaling and Function</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS0952-7915%2800%2900088-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=10781397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=282-288&author=E.+M.+Schaefferauthor=P.+L.+Schwartzberg&title=Tec+Family+Kinases+in+Lymphocyte+Signaling+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tec family kinases in lymphocyte signaling and function</span></div><div class="casAuthors">Schaeffer, Edward M.; Schwartzberg, Pamela L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-288</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 64 refs.  The Tec kinases are required for full Ca2+ mobilization in lymphocytes.  Recent data suggest that this process occurs via a multiprotein complex that includes LAT and SLP-76 in T cells and BLNK/SLP-65 in B cells.  Mutational analyses have revealed crit. roles for Tec kinases in lymphocyte development and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1sXHyu_Zv7Vg90H21EOLACvtfcHk0liIgx3dFraMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb8%253D&md5=4c4cfea706908f0e841f1f29c067d461</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900088-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900088-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DE.%2BM.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26atitle%3DTec%2520Family%2520Kinases%2520in%2520Lymphocyte%2520Signaling%2520and%2520Function%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D282%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Parker, P. J.</span><span> </span><span class="NLM_article-title">The Ubiquitous Phosphoinositides</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1042%2FBST0320893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15506918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVSltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=893-898&author=P.+J.+Parker&title=The+Ubiquitous+Phosphoinositides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitous phosphoinositides</span></div><div class="casAuthors">Parker, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">893-898</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven phosphoinositides are now known to exist, which are all derived through various metabolic routes from the parent lipid, phosphatidylinositol.  With one addnl. metabolite, diacylglycerol, these represent a rich resource of bioactive lipids responsible for recruiting protein effectors and marking membrane compartments.  The metabolic map of this pathway and the nature of the binding partner interactions are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1i5XGztZ2rVg90H21EOLACvtfcHk0liIgx3dFraMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVSltrg%253D&md5=4a4d16b9e15c42b0b7db67307dee70fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBST0320893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0320893%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520Ubiquitous%2520Phosphoinositides%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2004%26volume%3D32%26spage%3D893%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L. R.</span><span> </span><span class="NLM_article-title">Signaling Through Class 1 PI3Ks in Mammalian Cells</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1042%2FBST0340647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17052169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWnsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=647-662&author=P.+T.+Hawkinsauthor=K.+E.+Andersonauthor=L.+R.+Stephens&title=Signaling+Through+Class+1+PI3Ks+in+Mammalian+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling through class I PI3Ks in mammalian cells</span></div><div class="casAuthors">Hawkins, P. T.; Anderson, K. E.; Davidson, K.; Stephens, L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  It is now accepted that the activation of class I phosphoinositide 3-kinases (PI3Ks) is one of the most important signal transduction pathways used by cell-surface receptors to control intracellular events.  The receptors which access this pathway include those that recognize growth factors, hormones, antigens, and inflammatory stimuli, and the cellular events known to be regulated include cell growth, survival, proliferation, and movement.  Scientists have learned a great deal about the family of class I PI3Ks themselves and the structural adaptations which allow a variety of cell-surface receptors to regulate their activity.  Class I PI3Ks synthesize the phospholipid phosphatidylinositol 3.4,5-trisphosphate [PtdIns(3,4,5)P3] in the membranes in which they are activated, and it is now accepted that PtdIns(3,4,5)P3 and its dephosphorylation product phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P2] are messenger mols. which regulate the localization and function of multiple effectors by binding to their specific pleckstrin homol. (PH) domains.  The no. of direct PtdIns(3,4,5)P3/PtdIns(3,4)P2 effectors which exist, even within a single cell, creates an extremely complex signaling web downstream of PI3K activation.  Some key players are beginning to emerge, however, linking PI3K activity to specific cellular responses.  These include small GTPases for the Rho and Arf families which regulate the cytoskeletal and membrane rearrangements required for cell movement, and protein kinase B (PKB), which has important regulatory inputs into the regulation of cell cycle progression and survival.  The importance of the PI3K signaling pathway in regulating the balance of decisions in cell growth, proliferation, and survival is clear from the prevalence of oncogenes (e.g., PI3Kα) and tumor suppressors [e.g., PtdIns(3,4,5)P3 3-phosphatase, PTEN (phosphatase, and tension homolog deleted on chromosome 10)] found in this pathway.  The recent availability of transgenic mouse models with engineered defects in class I PI3K signaling pathways, and the development of PI3K isoform-selective inhibitors by both academic and pharmaceutical research has highlighted the importance of specific isoforms of PI3K in whole-animal physiol. and pathol., e.g., PI3Kα in growth and metabolic regulation, PI3Kβ in thrombosis, and PI3Kδ and PI3Kγ in inflammation and asthma.  Thus, the class I PI3K signaling pathway is emerging as an exciting new area for the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKzw7wttjsvrVg90H21EOLACvtfcHk0liIgx3dFraMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWnsLvO&md5=205c57d166593275ebe47d833888b269</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBST0340647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0340647%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DStephens%26aufirst%3DL.%2BR.%26atitle%3DSignaling%2520Through%2520Class%25201%2520PI3Ks%2520in%2520Mammalian%2520Cells%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2006%26volume%3D34%26spage%3D647%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismuth, G.</span><span> </span><span class="NLM_article-title">Fine Tuning the Immune Response with PI3K</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1111%2Fj.1600-065X.2008.00750.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=19290933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=253-272&author=D.+A.+Frumanauthor=G.+Bismuth&title=Fine+Tuning+the+Immune+Response+with+PI3K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fine tuning the immune response with PI3K</span></div><div class="casAuthors">Fruman, David A.; Bismuth, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-272</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family of lipid kinases regulates diverse aspects of lymphocyte behavior.  This review discusses how genetic and pharmacol. tools have yielded an increasingly detailed understanding of how PI3K enzymes function at different stages of lymphocyte development and activation.  Following antigen receptor engagement, activated PI3K generates 3-phosphorylated inositol lipid products that serve as membrane targeting signals for numerous proteins involved in the assembly of multiprotein complexes, termed signalosomes, and immune synapse formation.  In B cells, class IA PI3K is the dominant subgroup whose loss causes profound defects in development and antigen responsiveness.  In T cells, both class IA and IB PI3K contribute to development and immune function.  PI3K also regulates both chemokine responsiveness and antigen-driven changes in lymphocyte trafficking.  PI3K modulates the function not only of effector T cells, but also regulatory T cells; these disparate functions culminate in unexpected autoimmune phenotypes in mice with PI3K-deficient T cells.  Thus, PI3K signaling is not a simple switch to promote cellular activation, but rather an intricate web of interactions that must be properly balanced to ensure appropriate cellular responses and maintain immune homeostasis.  Defining these complexities remains a challenge for pharmaceutical development of PI3K inhibitors to combat inflammation and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjiIlGrlo-bVg90H21EOLACvtfcHk0lj9xKARe2WX1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vI&md5=83041c3a0ff535642e314761860e27ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00750.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00750.x%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DBismuth%26aufirst%3DG.%26atitle%3DFine%2520Tuning%2520the%2520Immune%2520Response%2520with%2520PI3K%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D253%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Eicholt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papakonstanti, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starkey, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilancio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Need, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamers, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">Control of Axonal Growth and Regeneration of Sensory Neurons by the P110δ PI3-Kinase</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e869</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=e869&author=B.+J.+Eicholtauthor=A.+I.+Ahmedauthor=M.+E.+Daviesauthor=E.+A.+Papakonstantiauthor=W.+Pearceauthor=M.+L.+Starkeyauthor=A.+Bilancioauthor=A.+C.+Needauthor=A.+J.+H.+Smithauthor=S.+M.+Hallauthor=F.+P.+Hamersauthor=K.+P.+Gieseauthor=E.+J.+Bradburyauthor=B.+Vanhaesebroeck&title=Control+of+Axonal+Growth+and+Regeneration+of+Sensory+Neurons+by+the+P110%CE%B4+PI3-Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEicholt%26aufirst%3DB.%2BJ.%26aulast%3DAhmed%26aufirst%3DA.%2BI.%26aulast%3DDavies%26aufirst%3DM.%2BE.%26aulast%3DPapakonstanti%26aufirst%3DE.%2BA.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DStarkey%26aufirst%3DM.%2BL.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DNeed%26aufirst%3DA.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DHall%26aufirst%3DS.%2BM.%26aulast%3DHamers%26aufirst%3DF.%2BP.%26aulast%3DGiese%26aufirst%3DK.%2BP.%26aulast%3DBradbury%26aufirst%3DE.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DControl%2520of%2520Axonal%2520Growth%2520and%2520Regeneration%2520of%2520Sensory%2520Neurons%2520by%2520the%2520P110%25CE%25B4%2520PI3-Kinase%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D9%26spage%3De869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Vallerskog, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widhe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risselada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klareskog, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollenhoven, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malmsttröm, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trollmo, C.</span><span> </span><span class="NLM_article-title">Treatment with Rituximab Affects Both the Cellular and the Humoral Arm of the Immune System in Patients with SLE</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.clim.2006.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=17046329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlalt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2007&pages=62-74&author=T.+Vallerskogauthor=I.+Gunnarssonauthor=M.+Widheauthor=A.+Risseladaauthor=L.+Klareskogauthor=R.+Vollenhovenauthor=V.+Malmsttr%C3%B6mauthor=C.+Trollmo&title=Treatment+with+Rituximab+Affects+Both+the+Cellular+and+the+Humoral+Arm+of+the+Immune+System+in+Patients+with+SLE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE</span></div><div class="casAuthors">Vallerskog, Therese; Gunnarsson, Iva; Widhe, Mona; Risselada, Anke; Klareskog, Lars; van Vollenhoven, Ronald; Malmstroem, Vivianne; Trollmo, Christina</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-74</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Herein we investigated how rituximab-induced B cell depletion affected leukocyte subpopulations and antibody titers in SLE patients.  We focused our anal. on time points related to absence and return of B cells after depletion.  A correlation was found between the baseline frequency and time to repopulation; the fewer B cells initially, the longer to their return.  While the few B cells remaining after treatment were of memory, double-neg. (IgD-CD27-), and CD5+ phenotype, the returning B cells were mainly naive, indicating de novo prodn. of B cells.  Serum levels of IgG and antibodies against Ro52, Ro60, La44, measles and tetanus remained unchanged, while decreases in IgM, IgE, anti-dsDNA and anti-C1q antibodies were obsd.  Addnl., a significant increase in activated CD4+ and CD8+ T cells, as well as CD25brightFOXP3+ regulatory T cells was obsd.  In conclusion, both the humoral and the cellular immune systems were affected by treatment with rituximab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr04xJLpulT-LVg90H21EOLACvtfcHk0lj9xKARe2WX1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlalt7bE&md5=157a958cc3807be90996e3be80406346</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2006.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2006.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DVallerskog%26aufirst%3DT.%26aulast%3DGunnarsson%26aufirst%3DI.%26aulast%3DWidhe%26aufirst%3DM.%26aulast%3DRisselada%26aufirst%3DA.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DVollenhoven%26aufirst%3DR.%26aulast%3DMalmsttr%25C3%25B6m%26aufirst%3DV.%26aulast%3DTrollmo%26aufirst%3DC.%26atitle%3DTreatment%2520with%2520Rituximab%2520Affects%2520Both%2520the%2520Cellular%2520and%2520the%2520Humoral%2520Arm%2520of%2520the%2520Immune%2520System%2520in%2520Patients%2520with%2520SLE%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D122%26spage%3D62%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Soond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjørgo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moltu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galleway, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twomey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskén, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunyard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span> </span><span class="NLM_article-title">PI3K p110delta Regulates T-Cell Cytokine Production during Primary and Secondary Immune Responses in Mice and Humans</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">–</span> <span class="NLM_lpage">3313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2203-3313&author=R.+Soondauthor=E.+Bj%C3%B8rgoauthor=K.+Moltuauthor=Q.+Daleauthor=T.+Pattonauthor=M.+Torgersonauthor=F.+Gallewayauthor=B.+Twomeyauthor=J.+Clarkauthor=H.+Gastonauthor=L.+Task%C3%A9nauthor=P.+Bunyardauthor=K.+Okkenhaug&title=PI3K+p110delta+Regulates+T-Cell+Cytokine+Production+during+Primary+and+Secondary+Immune+Responses+in+Mice+and+Humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoond%26aufirst%3DR.%26aulast%3DBj%25C3%25B8rgo%26aufirst%3DE.%26aulast%3DMoltu%26aufirst%3DK.%26aulast%3DDale%26aufirst%3DQ.%26aulast%3DPatton%26aufirst%3DT.%26aulast%3DTorgerson%26aufirst%3DM.%26aulast%3DGalleway%26aufirst%3DF.%26aulast%3DTwomey%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGaston%26aufirst%3DH.%26aulast%3DTask%25C3%25A9n%26aufirst%3DL.%26aulast%3DBunyard%26aufirst%3DP.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520p110delta%2520Regulates%2520T-Cell%2520Cytokine%2520Production%2520during%2520Primary%2520and%2520Secondary%2520Immune%2520Responses%2520in%2520Mice%2520and%2520Humans%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2203%26epage%3D3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilancio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkaczyk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giddings, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peskett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">Essential Role for the p110delta Phosphoinositide 3-Kinase in the Allergic Response</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnature02991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15496927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslSlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=1007-1011&author=K.+Aliauthor=A.+Bilancioauthor=M.+Thomasauthor=W.+Pearceauthor=M.+Gilfillanauthor=C.+Tkaczykauthor=N.+Kuehnauthor=A.+Grayauthor=J.+Giddingsauthor=E.+Peskettauthor=R.+Foxauthor=I.+Bruceauthor=C.+Walkerauthor=C.+Sawyerauthor=K.+Okkenhaugauthor=P.+Finanauthor=B.+Wanhaesebroeck&title=Essential+Role+for+the+p110delta+Phosphoinositide+3-Kinase+in+the+Allergic+Response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role for the p110δ phosphoinositide 3-kinase in the allergic response</span></div><div class="casAuthors">Ali, Khaled; Bilancio, Antonio; Thomas, Matthew; Pearce, Wayne; Gilfillan, Alasdair M.; Tkaczyk, Christine; Kuehn, Nicolas; Gray, Alexander; Giddings, June; Peskett, Emma; Fox, Roy; Bruce, Ian; Walker, Christoph; Sawyer, Carol; Okkenhaug, Klaus; Finan, Peter; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">7011</span>),
    <span class="NLM_cas:pages">1007-1011</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammatory substances released by mast cells induce and maintain the allergic response.  Mast cell differentiation and activation are regulated, resp., by stem cell factor (SCF; also known as Kit ligand) and by allergen in complex with allergen-specific IgE.  Activated SCF receptors and high-affinity receptors for IgE (FcεRI) engage phosphoinositide 3-kinases (PI(3)Ks) to generate intracellular lipid second messenger signals.  Here, we report that genetic or pharmacol. inactivation of the p110δ isoform of PI(3)K in mast cells leads to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE-induced degranulation and cytokine release.  Inactivation of p110δ protects mice against anaphylactic allergic responses.  These results identify p110δ as a new target for therapeutic intervention in allergy and mast-cell-related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpilIACK3bY8bVg90H21EOLACvtfcHk0liBj--cp9X4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslSlt7w%253D&md5=4c1295a18b969617a26d29e017ef48ce</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature02991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02991%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DK.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DGilfillan%26aufirst%3DM.%26aulast%3DTkaczyk%26aufirst%3DC.%26aulast%3DKuehn%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DGiddings%26aufirst%3DJ.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DFox%26aufirst%3DR.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DC.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DWanhaesebroeck%26aufirst%3DB.%26atitle%3DEssential%2520Role%2520for%2520the%2520p110delta%2520Phosphoinositide%25203-Kinase%2520in%2520the%2520Allergic%2520Response%26jtitle%3DNature%26date%3D2004%26volume%3D431%26spage%3D1007%26epage%3D1011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fung-Leung, W. P.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Delta (PI3Kδ) in Leukocyte Signaling and Function</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.cellsig.2010.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20940048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=603-608&author=W.+P.+Fung-Leung&title=Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+in+Leukocyte+Signaling+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function</span></div><div class="casAuthors">Fung-Leung, Wai-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-608</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  PI3Kδ is a lipid kinase of the PI3K class IA family involved in early signaling events of leukocytes responding to a wide variety of stimuli.  The leukocyte specificity of PI3Kδ is defined by its expression, whereas its signaling function is via the prodn. of phosphoinositide 3,4,5-triphosphates at the proximity of activated receptors for recruiting other signaling mols.  The importance of PI3Kδ in B cell development and function is most apparent, and its role in other leukocyte cell types can be easily demonstrated as well.  PI3Kδ participates in the development, activation and migration of T cells and NK cells.  The role of PI3Kδ in myeloid cell activities, such as inflammation driven cell infiltration, neutrophil oxidative burst, immune complex mediated macrophage activation, as well as mast cell maturation and degranulation, has been well illustrated in various studies.  As a result of the broad effects of PI3Kδ in leukocyte functions, the disruption of PI3Kδ expression or activity leads to decreased inflammatory and immune responses in vivo.  The protective role of PI3Kδ inactivation in animal models of arthritis, asthma or obstructive respiratory diseases has been demonstrated.  These findings suggest the potential efficacy achievable with PI3Kδ inhibitors in the treatment of autoimmune and respiratory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtYnBPQuNK7Vg90H21EOLACvtfcHk0liBj--cp9X4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yrtb8%253D&md5=3d4b3438bf9b73b3d7e9d8722f024eac</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DFung-Leung%26aufirst%3DW.%2BP.%26atitle%3DPhosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520in%2520Leukocyte%2520Signaling%2520and%2520Function%26jtitle%3DCell.%2520Signalling%26date%3D2011%26volume%3D23%26spage%3D603%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Angulo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banham-Hall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plagnol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxendale, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake-Palmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiddler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilliers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markelj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielkowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabado, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barcenas-Morales, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clatworthy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durandy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doffinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chilvers, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cant, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumararatne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condliffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nejentsev, S.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=866-871&author=I.+Anguloauthor=O.+Vadasauthor=F.+Garconauthor=E.+Banham-Hallauthor=V.+Plagnolauthor=T.+R.+Leahyauthor=H.+Baxendaleauthor=T.+Coulterauthor=J.+Curtisauthor=C.+Wuauthor=K.+Blake-Palmerauthor=O.+Perisicauthor=D.+Smythauthor=M.+Maesauthor=C.+Fiddlerauthor=J.+Jussauthor=D.+Cilliersauthor=G.+Markeljauthor=A.+Chandraauthor=G.+Farmerauthor=A.+Kielkowskaauthor=J.+Clarkauthor=S.+Krackerauthor=M.+Debreauthor=C.+Picardauthor=I.+Pellierauthor=N.+Jabadoauthor=J.+A.+Morrisauthor=G.+Barcenas-Moralesauthor=A.+Fischerauthor=L.+Stephensauthor=P.+Hawkinsauthor=J.+C.+Barrettauthor=M.+Abinunauthor=M.+Clatworthyauthor=A.+Durandyauthor=R.+Doffingerauthor=E.+R.+Chilversauthor=A.+J.+Cantauthor=D.+Kumararatneauthor=K.+Okkenhaugauthor=R.+L.+Williamsauthor=A.+Condliffeauthor=S.+Nejentsev&title=Phosphoinositide+3-Kinase+%CE%B4+Gene+Mutation+Predisposes+to+Respiratory+Infection+and+Airway+Damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo%26aufirst%3DI.%26aulast%3DVadas%26aufirst%3DO.%26aulast%3DGarcon%26aufirst%3DF.%26aulast%3DBanham-Hall%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBlake-Palmer%26aufirst%3DK.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DSmyth%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DM.%26aulast%3DFiddler%26aufirst%3DC.%26aulast%3DJuss%26aufirst%3DJ.%26aulast%3DCilliers%26aufirst%3DD.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DKielkowska%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DDebre%26aufirst%3DM.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DBarcenas-Morales%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DClatworthy%26aufirst%3DM.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DChilvers%26aufirst%3DE.%2BR.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DCondliffe%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26atitle%3DPhosphoinositide%25203-Kinase%2520%25CE%25B4%2520Gene%2520Mutation%2520Predisposes%2520to%2520Respiratory%2520Infection%2520and%2520Airway%2520Damage%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D866%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lucas, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemela, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deenick, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palendira, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannons, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biancalana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frucht, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agharahimi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folio, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleisher, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangye, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenardo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzel, G.</span><span> </span><span class="NLM_article-title">Dominant-Activating Germline Mutations in the Gene Encoding the PI(3)K Catalytic Subunit p110δ Result in T cell Senescence and Human Immunodeficiency</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fni.2771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=24165795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=88-97&author=C.+L.+Lucasauthor=H.+S.+Kuehnauthor=F.+Zhaoauthor=J.+E.+Niemelaauthor=E.+K.+Deenickauthor=U.+Palendiraauthor=D.+T.+Averyauthor=L.+Moensauthor=J.+L.+Cannonsauthor=M.+Biancalanaauthor=J.+Stoddardauthor=W.+Ouyangauthor=D.+M.+Fruchtauthor=V.+K.+Raoauthor=T.+P.+Atkinsonauthor=A.+Agharahimiauthor=A.+A.+Husseyauthor=L.+R.+Folioauthor=K.+N.+Olivierauthor=T.+A.+Fleisherauthor=S.+Pittalugaauthor=S.+M.+Hollandauthor=J.+I.+Cohenauthor=J.+B.+Oliveiraauthor=S.+T.+Tangyeauthor=P.+L.+Schwartzbergauthor=M.+J.+Lenardoauthor=G.+Uzel&title=Dominant-Activating+Germline+Mutations+in+the+Gene+Encoding+the+PI%283%29K+Catalytic+Subunit+p110%CE%B4+Result+in+T+cell+Senescence+and+Human+Immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</span></div><div class="casAuthors">Lucas, Carrie L.; Kuehn, Hye Sun; Zhao, Fang; Niemela, Julie E.; Deenick, Elissa K.; Palendira, Umaimainthan; Avery, Danielle T.; Moens, Leen; Cannons, Jennifer L.; Biancalana, Matthew; Stoddard, Jennifer; Ouyang, Weiming; Frucht, David M.; Rao, V. Koneti; Atkinson, T. Prescott; Agharahimi, Anahita; Hussey, Ashleigh A.; Folio, Les R.; Olivier, Kenneth N.; Fleisher, Thomas A.; Pittaluga, Stefania; Holland, Steven M.; Cohen, Jeffrey I.; Oliveira, Joao B.; Tangye, Stuart G.; Schwartzberg, Pamela L.; Lenardo, Michael J.; Uzel, Gulbu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-97</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The p110δ subunit of phosphatidylinositol-3-OH kinase (PI(3)K) is selectively expressed in leukocytes and is crit. for lymphocyte biol.  Here we report fourteen patients from seven families who were heterozygous for three different germline, gain-of-function mutations in PIK3CD (which encodes p110δ).  These patients presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremia due to cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV).  Strikingly, they had a substantial deficiency in naive T cells but an over-representation of senescent effector T cells.  In vitro, T cells from patients exhibited increased phosphorylation of the kinase Akt and hyperactivation of the metabolic checkpoint kinase mTOR, enhanced glucose uptake and terminal effector differentiation.  Notably, treatment with rapamycin to inhibit mTOR activity in vivo partially restored the abundance of naive T cells, largely 'rescued' the in vitro T cell defects and improved the clin. course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFA88fwwfZf7Vg90H21EOLACvtfcHk0livSE140R6mkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L&md5=4bfccb05603009684ca01f893b29adc8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fni.2771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2771%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DDeenick%26aufirst%3DE.%2BK.%26aulast%3DPalendira%26aufirst%3DU.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DMoens%26aufirst%3DL.%26aulast%3DCannons%26aufirst%3DJ.%2BL.%26aulast%3DBiancalana%26aufirst%3DM.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DFrucht%26aufirst%3DD.%2BM.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DAtkinson%26aufirst%3DT.%2BP.%26aulast%3DAgharahimi%26aufirst%3DA.%26aulast%3DHussey%26aufirst%3DA.%2BA.%26aulast%3DFolio%26aufirst%3DL.%2BR.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DFleisher%26aufirst%3DT.%2BA.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26aulast%3DOliveira%26aufirst%3DJ.%2BB.%26aulast%3DTangye%26aufirst%3DS.%2BT.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DUzel%26aufirst%3DG.%26atitle%3DDominant-Activating%2520Germline%2520Mutations%2520in%2520the%2520Gene%2520Encoding%2520the%2520PI%25283%2529K%2520Catalytic%2520Subunit%2520p110%25CE%25B4%2520Result%2520in%2520T%2520cell%2520Senescence%2520and%2520Human%2520Immunodeficiency%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26spage%3D88%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Failla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. B.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1164%2Frccm.200906-0937OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20224070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=897-904&author=Y.+Toauthor=K.+Itoauthor=Y.+Kizawaauthor=M.+Faillaauthor=M.+Itoauthor=T.+Kusamaauthor=W.+M.+Elliottauthor=J.+C.+Hoggauthor=I.+M.+Adcockauthor=P.+B.+Barnes&title=Targeting+Phosphoinositide-3-Kinase-%CE%B4+with+Theophylline+Reverses+Corticosteroid+Insensitivity+in+Chronic+Obstructive+Pulmonary+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease</span></div><div class="casAuthors">To, Yasuo; Ito, Kazuhiro; Kizawa, Yasuo; Failla, Marco; Ito, Misako; Kusama, Tadashi; Elliott, W. Mark; Hogg, James C.; Adcock, Ian M.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">897-904</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids.  This has been linked to a redn. of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline.  Objectives: To det. the role of phosphoinositide-3-kinase-delta (PI3K-δ) on the development of corticosteroid insensitivity in COPD and under oxidative stress, and as a target for theophylline.  Methods: Corticosteroid sensitivity was detd. as the 50% inhibitory concn. of dexamethasone on tumor necrosis factor-α-induced interleukin-8 release in peripheral blood mononuclear cells from patients with COPD (n = 17) and compared with that of nonsmoking (n = 8) and smoking (n = 7) control subjects.  The effect of theophylline and a selective PI3K-δ inhibitor (IC87114) on restoration of corticosteroid sensitivity was confirmed in cigarette smoke-exposed mice.  Measurements and Main Results: Peripheral blood mononuclear cells of COPD (50% inhibitory concn. of dexamethasone: 156.8 ± 32.6 nM) were less corticosteroid sensitive than those of nonsmoking (41.2 ± 10.5 nM; P = 0.018) and smoking control subjects (47.5 ± 19.6 nM; P = 0.031).  Corticosteroid insensitivity and reduced histone deacetylase-2 activity after oxidative stress were reversed by a non-selective PI3K inhibitor (LY294002) and low concns. of theophylline.  Theophylline was a potent selective inhibitor of oxidant-activated PI3K-δ, which was up-regulated in peripheral lung tissue of patients with COPD.  Furthermore, cells with knock-down of PI3K-δ failed to develop corticosteroid insensitivity with oxidative stress.  Both theophylline and IC87114, combined with dexamethasone, inhibited corticosteroid-insensitive lung inflammation in cigarette-smoke-exposed mice in vivo.  Conclusions: Inhibition of oxidative stress dependent PI3K-δ activation by a selective inhibitor or theophylline provides a novel approach to reversing corticosteroid insensitivity in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrntINJnOqMbrVg90H21EOLACvtfcHk0lilA6I_6crpsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO&md5=5338bbb7050e1700b0e4eda068cdb05c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0937OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0937OC%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DFailla%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BB.%26atitle%3DTargeting%2520Phosphoinositide-3-Kinase-%25CE%25B4%2520with%2520Theophylline%2520Reverses%2520Corticosteroid%2520Insensitivity%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D897%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Palanki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrasidlo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span> </span><span class="NLM_article-title">Discovery of 3,3′-(2,4-diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4279</span><span class="NLM_x">–</span> <span class="NLM_lpage">4294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051056c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4279-4294&author=M.+Palankiauthor=E.+Dneprovskaiaauthor=J.+Doukasauthor=R.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=D.+Lohseauthor=M.+Martinauthor=G.+Noronhaauthor=R.+M.+Sollauthor=W.+Wrasidloauthor=S.+Yeeauthor=H.+Zhu&title=Discovery+of+3%2C3%E2%80%B2-%282%2C4-diaminopteridine-6%2C7-diyl%29diphenol+as+an+Isozyme-Selective+Inhibitor+of+PI3K+for+the+Treatment+of+Ischemia+Reperfusion+Injury+Associated+with+Myocardial+Infarction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm051056c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051056c%26sid%3Dliteratum%253Aachs%26aulast%3DPalanki%26aufirst%3DM.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DR.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25203%252C3%25E2%2580%25B2-%25282%252C4-diaminopteridine-6%252C7-diyl%2529diphenol%2520as%2520an%2520Isozyme-Selective%2520Inhibitor%2520of%2520PI3K%2520for%2520the%2520Treatment%2520of%2520Ischemia%2520Reperfusion%2520Injury%2520Associated%2520with%2520Myocardial%2520Infarction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4279%26epage%3D4294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijapurkar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span> </span><span class="NLM_article-title">Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3003132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=103-107&author=Z.+Peiauthor=E.+Blackwoodauthor=L.+Liuauthor=S.+Malekauthor=M.+Belvinauthor=M.+Koehlerauthor=D.+Ortwineauthor=H.+Chenauthor=F.+Cohenauthor=J.+Kennyauthor=P.+Bergeronauthor=K.+Lauauthor=C.+Lyauthor=X.+Zhaoauthor=A.+Estradaauthor=T.+Truongauthor=J.+Eplerauthor=J.+Nonomiyaauthor=L.+Trinhauthor=S.+Siderisauthor=J.+Lesnickauthor=L.+Baoauthor=U.+Vijapurkarauthor=S.+Mukadamauthor=S.+Tayauthor=G.+Deshmukhauthor=Y.+Chenauthor=X.+Dingauthor=L.+Friedmanauthor=J.+Lyssikatos&title=Discovery+and+Biological+Profiling+of+Potent+and+Selective+mTOR+Inhibitor+GDC-0349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml3003132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003132%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DOrtwine%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DKenny%26aufirst%3DJ.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLy%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DEpler%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DTrinh%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DVijapurkar%26aufirst%3DU.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Biological%2520Profiling%2520of%2520Potent%2520and%2520Selective%2520mTOR%2520Inhibitor%2520GDC-0349%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+Metzauthor=D.+Whittingtonauthor=L.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DMcGee%26aufirst%3DL.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sinclair, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Means, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibeque, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assaad, A.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol-3 Kinase Delta (PI3Kδ) Inhibitor AMG 319 Is a Potent, Selective and Orally Bioavailable Small Molecule Inhibitor that Suppresses PI3K-Mediated Signaling and Viability in Neoplastic B Cells</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">4964</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4964&issue=21&author=A.+Sinclairauthor=D.+Metzauthor=T.+Cushingauthor=L.+Liuauthor=R.+Brakeauthor=C.+Starnesauthor=G.+Meansauthor=K.+Henneauthor=I.+Archibequeauthor=B.+Mattsonauthor=A.+Drewauthor=L.+Busseauthor=L.+Wangauthor=A.-S.+Al-Assaadauthor=G.+Molineux&title=Phosphatidylinositol-3+Kinase+Delta+%28PI3K%CE%B4%29+Inhibitor+AMG+319+Is+a+Potent%2C+Selective+and+Orally+Bioavailable+Small+Molecule+Inhibitor+that+Suppresses+PI3K-Mediated+Signaling+and+Viability+in+Neoplastic+B+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSinclair%26aufirst%3DA.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DCushing%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBrake%26aufirst%3DR.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DMeans%26aufirst%3DG.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DArchibeque%26aufirst%3DI.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DBusse%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAl-Assaad%26aufirst%3DA.-S.%26aulast%3DMolineux%26aufirst%3DG.%26atitle%3DPhosphatidylinositol-3%2520Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520AMG%2520319%2520Is%2520a%2520Potent%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520Small%2520Molecule%2520Inhibitor%2520that%2520Suppresses%2520PI3K-Mediated%2520Signaling%2520and%2520Viability%2520in%2520Neoplastic%2520B%2520Cells%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2011%26volume%3D118%26issue%3D21%26spage%3D4964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibeque, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, A.</span><span> </span><span class="NLM_article-title">Phosphatidylinsoitol-3 Kinase Delta (PI3Kδ) Inhibitor AMG 319 Combined with Vincristine Enhances G2/M Arrest and Apoptotic Death in Neoplastic B Cells</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">4963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4963&issue=21&author=L.+Liuauthor=B.-C.+Sunauthor=J.+Pistilloauthor=M.+Paytonauthor=L.+Wangauthor=I.+Archibequeauthor=G.+Molineuxauthor=A.+Sinclair&title=Phosphatidylinsoitol-3+Kinase+Delta+%28PI3K%CE%B4%29+Inhibitor+AMG+319+Combined+with+Vincristine+Enhances+G2%2FM+Arrest+and+Apoptotic+Death+in+Neoplastic+B+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.-C.%26aulast%3DPistillo%26aufirst%3DJ.%26aulast%3DPayton%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DArchibeque%26aufirst%3DI.%26aulast%3DMolineux%26aufirst%3DG.%26aulast%3DSinclair%26aufirst%3DA.%26atitle%3DPhosphatidylinsoitol-3%2520Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520AMG%2520319%2520Combined%2520with%2520Vincristine%2520Enhances%2520G2%252FM%2520Arrest%2520and%2520Apoptotic%2520Death%2520in%2520Neoplastic%2520B%2520Cells%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2011%26volume%3D118%26issue%3D21%26spage%3D4963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lanasa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mato, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgood, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Means, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span> </span><span class="NLM_article-title">First-in-Human Study of AMG 319, a Highly Selective, Small Molecule Inhibitor of PI3Kδ, in Adult Patients with Relapsed or Refractory Lymphoid Malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=678&issue=21&author=M.+C.+Lanasaauthor=M.+Glennauthor=A.+R.+Matoauthor=S.+D.+Allgoodauthor=S.+Wongauthor=B.+Amoreauthor=G.+Meansauthor=E.+Stevensauthor=C.+Yanauthor=G.+Fribergauthor=A.+Goy&title=First-in-Human+Study+of+AMG+319%2C+a+Highly+Selective%2C+Small+Molecule+Inhibitor+of+PI3K%CE%B4%2C+in+Adult+Patients+with+Relapsed+or+Refractory+Lymphoid+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DGlenn%26aufirst%3DM.%26aulast%3DMato%26aufirst%3DA.%2BR.%26aulast%3DAllgood%26aufirst%3DS.%2BD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DAmore%26aufirst%3DB.%26aulast%3DMeans%26aufirst%3DG.%26aulast%3DStevens%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DFriberg%26aufirst%3DG.%26aulast%3DGoy%26aufirst%3DA.%26atitle%3DFirst-in-Human%2520Study%2520of%2520AMG%2520319%252C%2520a%2520Highly%2520Selective%252C%2520Small%2520Molecule%2520Inhibitor%2520of%2520PI3K%25CE%25B4%252C%2520in%2520Adult%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Lymphoid%2520Malignancies%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D21%26spage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Herko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czuczman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, F.</span><span> </span><span class="NLM_article-title">AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">3718</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=3718&issue=21&author=A.+Herkoauthor=C.+Mavisauthor=M.+S.+Czuczmanauthor=F.+Hernandez&title=AMG+319%2C+a+Novel+Inhibitor+of+Phosphoinositide-3+Kinase+Delta+%28PI3Kd%29%2C+Demonstrates+Activity+in+Lymphoma+Pre-Clinical+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerko%26aufirst%3DA.%26aulast%3DMavis%26aufirst%3DC.%26aulast%3DCzuczman%26aufirst%3DM.%2BS.%26aulast%3DHernandez%26aufirst%3DF.%26atitle%3DAMG%2520319%252C%2520a%2520Novel%2520Inhibitor%2520of%2520Phosphoinositide-3%2520Kinase%2520Delta%2520%2528PI3Kd%2529%252C%2520Demonstrates%2520Activity%2520in%2520Lymphoma%2520Pre-Clinical%2520Models%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2012%26volume%3D120%26issue%3D21%26spage%3D3718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Knight, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for P110α in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+Knightauthor=B.+Gonzalezauthor=M.+Feldmanauthor=E.+Zunderauthor=D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+Weissauthor=R.+Williamsauthor=K.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+P110%CE%B1+in+Insulin+Signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0ljRPF5wInNoGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%26aulast%3DZunder%26aufirst%3DE.%26aulast%3DGoldenberg%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520P110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Vlahos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. F.</span><span> </span><span class="NLM_article-title">A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4<i>H</i>-1-benzopyran-4-one (LY294002)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=8106507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFGit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=5241-5248&author=C.+J.+Vlahosauthor=W.+F.+Matterauthor=K.+Y.+Huiauthor=R.+F.+Brown&title=A+Specific+Inhibitor+of+Phosphatidylinositol+3-Kinase%2C+2-%284-Morpholinyl%29-8-phenyl-4H-1-benzopyran-4-one+%28LY294002%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)</span></div><div class="casAuthors">Vlahos, Chris J.; Matter, William F.; Hui, Kwan Y.; Brown, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5241-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Phosphatidylinositol (PtIns) 3-kinase is an enzyme implicated in growth factor signal transduction by assocg. with receptor and nonreceptor tyrosine kinases, including the platelet-derived growth factor receptor.  Inhibitors of PtdIns 3-kinase could potentially give a better understanding of the function and regulatory mechanisms of the enzyme.  Quercetin, a naturally occurring bioflavonoid, was previously shown to inhibit PtdIns 3-kinase with an IC50 of 1.3 μg/mL (3.8 μM); inhibition appeared to be directed at the ATP-binding site of the kinase.  Analogs of quercetin were investigated as PtdIns 3-kinase inhibitors, with the most potent ones exhibiting IC50 values in the range of 1.7-8.4 μg/mL.  In contrast, genistein, a potent tyrosine kinase inhibitor of the isoflavone class, did not inhibit PtdIns 3-kinase significantly (IC50 > 30 μg/mL).  Since quercetin has also been shown to inhibit other PtdIns and protein kinases, other chromones were evaluated as inhibitors of PtdIns 3-kinase without affecting PtdIns 4-kinase or selected protein kinases.  One such compd., 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (also known as 2-(4-morpholinyl)-8-phenylchromone, LY294002), completely and specifically abolished PtdIns 3-kinase activity (IC50 = 0.43 μg/mL; 1.40 μM) but did not inhibit PtdIns 4-kinase or tested protein and lipid kinases.  Analogs of LY294002 demonstrated a very selective structure-activity relationship, with slight changes in structure causing marked decreases in inhibition.  LY294002 was shown to completely abolish PtdIns 3-kinase activity in fMet-Leu-Phe-stimulated human neutrophils, as well as inhibit proliferation of smooth muscle cells in cultured rabbit aortic segments.  Since PtdIns 3-kinase appears to be centrally involved with growth factor signal transduction, the development of specific inhibitors against the kinase may be beneficial in the treatment of proliferative diseases as well as in elucidating the biol. role of the kinase in cellular proliferation and growth factor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Ii0f457BC7Vg90H21EOLACvtfcHk0ljY1YOJQl-fEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFGit78%253D&md5=2635c03af206ce35d55b899f92921477</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26aulast%3DMatter%26aufirst%3DW.%2BF.%26aulast%3DHui%26aufirst%3DK.%2BY.%26aulast%3DBrown%26aufirst%3DR.%2BF.%26atitle%3DA%2520Specific%2520Inhibitor%2520of%2520Phosphatidylinositol%25203-Kinase%252C%25202-%25284-Morpholinyl%2529-8-phenyl-4H-1-benzopyran-4-one%2520%2528LY294002%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D5241%26epage%3D5248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cao, G.-Q.; Chakrabarti, P. P.; Falsey, J. R.; Herberich, B.; Pettus, L. H.; Reed, A. B.; Reichelt, A.; Sham, K.; Tasker, A. S.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cao%2C+G.-Q.%3B+Chakrabarti%2C+P.+P.%3B+Falsey%2C+J.+R.%3B+Herberich%2C+B.%3B+Pettus%2C+L.+H.%3B+Reed%2C+A.+B.%3B+Reichelt%2C+A.%3B+Sham%2C+K.%3B+Tasker%2C+A.+S.%3B+Thaman%2C+M.%3B+Wurz%2C+R.+P.%3B+Xu%2C+S.%3B+Zhang%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DG.-Q." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Chen, G.; Cushing, T. D.; Fisher, B.; He, X.; Li, K.; Li, Z.; McGee, L. R.; Pattaropong, V.; Faulder, P.; Seganish, J.; Shin, Y.</span><span> </span><span class="NLM_article-title">Alkynol Alcohols as Kinase Inhibitors</span>. WO2009158011A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Chen&author=T.+D.+Cushing&author=B.+Fisher&author=X.+He&author=K.+Li&author=Z.+Li&author=L.+R.+McGee&author=V.+Pattaropong&author=P.+Faulder&author=J.+Seganish&author=Y.+Shin&title=Alkynol+Alcohols+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26atitle%3DAlkynol%2520Alcohols%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T. D.</span><span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7667</span><span class="NLM_x">–</span> <span class="NLM_lpage">7685</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez+de+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.-L.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+McBrideauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+Dual+PI3K%CE%B2%2F%CE%B4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DH.%2BJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Dual%2520PI3K%25CE%25B2%252F%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Rashidi, M.-R.; Pashaei-Asl, R.</span><span> </span><span class="NLM_article-title">Role of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of Purine-Related Drugs</span>.  <span class="citation_source-book">Readings in Advanced Pharmacokinetics—Theory, Methods and Applications</span>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group">Noreddin, A.</span>, Ed.; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Rijeka, Croatia</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.5772%2F33202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=285-314&author=M.-R.+Rashidi&author=R.+Pashaei-Aslauthor=A.+Noreddin&title=Readings+in+Advanced+Pharmacokinetics%E2%80%94Theory%2C+Methods+and+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.5772%2F33202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F33202%26sid%3Dliteratum%253Aachs%26aulast%3DRashidi%26aufirst%3DM.-R.%26atitle%3DRole%2520of%2520Aldehyde%2520Oxidase%2520and%2520Xanthine%2520Oxidase%2520in%2520the%2520Metabolism%2520of%2520Purine-Related%2520Drugs%26btitle%3DReadings%2520in%2520Advanced%2520Pharmacokinetics%25E2%2580%2594Theory%252C%2520Methods%2520and%2520Applications%26aulast%3DNoreddin%26aufirst%3DA.%26pub%3DInTech%26date%3D2012%26spage%3D285%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">White, S. L.</span><span> </span><span class="NLM_article-title">Thienopyrimidinones for Treatment of Inflammatory Disorders and Cancers</span>. WO2008064018 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+L.+White&title=Thienopyrimidinones+for+Treatment+of+Inflammatory+Disorders+and+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DS.%2BL.%26atitle%3DThienopyrimidinones%2520for%2520Treatment%2520of%2520Inflammatory%2520Disorders%2520and%2520Cancers%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sadhu, C.; Dick, K.; Treiberg, J.; Sowell, G. C.; Kesicki, E. A.; Oliver, A.</span><span> </span><span class="NLM_article-title">Inhibitors of Human Phosphatidylinositol 3-Kinase Delta</span>. US2002161014 A1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=C.+Sadhu&author=K.+Dick&author=J.+Treiberg&author=G.+C.+Sowell&author=E.+A.+Kesicki&author=A.+Oliver&title=Inhibitors+of+Human+Phosphatidylinositol+3-Kinase+Delta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26atitle%3DInhibitors%2520of%2520Human%2520Phosphatidylinositol%25203-Kinase%2520Delta%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E. C. A.</span><span> </span><span class="NLM_article-title">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8238</span><span class="NLM_x">–</span> <span class="NLM_lpage">8248</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+Use+of+Plasma+Protein+and+Tissue+Binding+Data+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0ljnEVlAdEeEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520Use%2520of%2520Plasma%2520Protein%2520and%2520Tissue%2520Binding%2520Data%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Roberts, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, J.</span><span> </span><span class="NLM_article-title">The Clinical Relevance of Plasma Protein Binding Changes</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1007%2Fs40262-012-0018-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=23150213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1-8&author=J.+A.+Robertsauthor=F.+Peaauthor=J.+Lipman&title=The+Clinical+Relevance+of+Plasma+Protein+Binding+Changes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Relevance of Plasma Protein Binding Changes</span></div><div class="casAuthors">Roberts, Jason A.; Pea, Federico; Lipman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Controversy reigns as to how protein binding changes alter the time course of unbound drug concns. in patients.  Given that the unbound concn. is responsible for drug efficacy and potential drug toxicity, this area is of significant interest to clinicians and academics worldwide.  The present uncertainty means that many questions relating to this area exist, including "How important is protein binding", "Is protein binding always const.", "Do pH and temp. changes alter binding" and "How do protein binding changes affect dosing requirements".  In this paper, we seek to address these questions and consider the data assocd. with altered pharmacokinetics in the presence of changes in protein binding and the clin. consequences that these may have on therapy, using examples from the crit. care area.  The published literature consistently indicates that a change in the protein binding and unbound concns. of some drugs are common in certain specific patient groups such as the critically ill.  Changes in pharmacokinetic parameters, including clearance and apparent vol. of distribution (Vd), may be dramatic.  Drugs with high protein binding, high intrinsic clearance (e.g. clearance by glomerular filtration) and where dosing is not titrated to effect are most likely to be affected in a clin. context.  Drugs such as highly protein bound antibacterials with multiple half-lives within a dosing interval and that have some level of renal clearance, such as ertapenem, teicoplanin, ceftriaxone and flucloxacillin, are commonly affected.  In response to these challenges, clinicians need to adapt dosing regimens rationally based on the pharmacokinetic/pharmacodynamic characteristics of the drug.  We propose that further pharmacokinetic modeling-based research is required to enable the design of robust dosing regimens for drugs affected by altered protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcv3RvMlD17Vg90H21EOLACvtfcHk0ljnEVlAdEeEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmsL7M&md5=447b72c3101a856fef9fc0d7aaa902a6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40262-012-0018-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-012-0018-5%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BA.%26aulast%3DPea%26aufirst%3DF.%26aulast%3DLipman%26aufirst%3DJ.%26atitle%3DThe%2520Clinical%2520Relevance%2520of%2520Plasma%2520Protein%2520Binding%2520Changes%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The Effect of Plasma Protein Binding on in Vivo Efficacy: Misconceptions in Drug Discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+Effect+of+Plasma+Protein+Binding+on+in+Vivo+Efficacy%3A+Misconceptions+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0ljnEVlAdEeEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520Effect%2520of%2520Plasma%2520Protein%2520Binding%2520on%2520in%2520Vivo%2520Efficacy%253A%2520Misconceptions%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">CYP induction studies in fresh human hepatocytes from two donors were carried out at concentrations of 0.1, 1, and 10 μM with <b>1</b>. Induction of mRNA and CYP activity were calculated as a percent of positive control for each isoform. Positive controls included omeprazole (50 μM), phenobarbital (1 mM), and rifampicin (10 μM) for CYP1A2, 2B6, and 3A4, respectively. At concentrations of 0.1 and 1 μM, mRNA and CYP activities were less than 10% of positive controls for CYP1A2, 2B6, and 3A4. At the 10 μM concentration, mRNA was elevated to levels approximately 30% of positive control in the case of CYP3A4, 20% for CYP2B6, and <10% for CYP1A2. However, activity increases were <20% for all isoforms tested.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Boes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">Enhanced B-1 Cell Development, but Impaired IgG Antibody Responses in Mice Deficient in Secreted IgM</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">4776</span><span class="NLM_x">–</span> <span class="NLM_lpage">4787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1998&pages=4776-4787&author=M.+Boesauthor=C.+Esauauthor=M.+B.+Fischerauthor=T.+Schmidtauthor=M.+Carrollauthor=J.+Chen&title=Enhanced+B-1+Cell+Development%2C+but+Impaired+IgG+Antibody+Responses+in+Mice+Deficient+in+Secreted+IgM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoes%26aufirst%3DM.%26aulast%3DEsau%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DM.%2BB.%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEnhanced%2520B-1%2520Cell%2520Development%252C%2520but%2520Impaired%2520IgG%2520Antibody%2520Responses%2520in%2520Mice%2520Deficient%2520in%2520Secreted%2520IgM%26jtitle%3DJ.%2520Immunol.%26date%3D1998%26volume%3D160%26spage%3D4776%26epage%3D4787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="note"><p class="first last">In the case of <b>1</b>, animals were dosed at 3, 1, 0.3, and 0.1 mg/kg po/q.d. Doses started at day 1, followed by an initial KLH immunization after 2 h. The animals were treated for 10 days with drug and at day 10 with spleens and whole blood collected and analyzed by ELISA. The key compound <b>1</b> achieved exposures at the 3 mg/kg level, which was able to cover the CD-69 HWB IC<sub>90</sub> at trough concentration for a full 24 h period. The lower doses 0.1, 0.3, and 1 mg/kg were able to cover trough concentrations between the HWB IC<sub>50</sub> and IC<sub>90</sub> and evinced partial efficacy.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">For a comparison of data for D-073, <b>1</b>, and <b>2</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.<span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm501624r/20150106/images/medium/jm-2014-01624r_0020.tif.gif" alt="" /></img></span></p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrec, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hon, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">The P110δ Crystal Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+R%C3%BCckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+P110%CE%B4+Crystal+Structure%3A+Mechanisms+for+Selectivity+and+Potency+of+New+PI%283%29K+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0ljuX3bYMGUEsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520P110%25CE%25B4%2520Crystal%2520Structure%253A%2520Mechanisms%2520for%2520Selectivity%2520and%2520Potency%2520of%2520New%2520PI%25283%2529K%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">Structural Analysis of PI3-Kinase Isoforms: Identification of Residues Enabling Selective Inhibition by Small Molecule ATP-Competitive Inhibitors</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2008&pages=404-410&author=M.+J.+Zvelebilauthor=M.+D.+Waterfieldauthor=S.+J.+Shuttleworth&title=Structural+Analysis+of+PI3-Kinase+Isoforms%3A+Identification+of+Residues+Enabling+Selective+Inhibition+by+Small+Molecule+ATP-Competitive+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DStructural%2520Analysis%2520of%2520PI3-Kinase%2520Isoforms%253A%2520Identification%2520of%2520Residues%2520Enabling%2520Selective%2520Inhibition%2520by%2520Small%2520Molecule%2520ATP-Competitive%2520Inhibitors%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2008%26volume%3D477%26spage%3D404%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+Applications+of+Halogen+Bonding+in+Medicinal+Chemistry+and+Chemical+Biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0ljuX3bYMGUEsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520Applications%2520of%2520Halogen%2520Bonding%2520in%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Meth-Cohn, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnowski, B.</span><span> </span><span class="NLM_article-title">Versatile New Synthesis of Quinolines and Related Fused Pyridines. Part II</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3111</span><span class="NLM_x">–</span> <span class="NLM_lpage">3113</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=3111-3113&author=O.+Meth-Cohnauthor=B.+Narineauthor=B.+Tarnowski&title=Versatile+New+Synthesis+of+Quinolines+and+Related+Fused+Pyridines.+Part+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeth-Cohn%26aufirst%3DO.%26aulast%3DNarine%26aufirst%3DB.%26aulast%3DTarnowski%26aufirst%3DB.%26atitle%3DVersatile%2520New%2520Synthesis%2520of%2520Quinolines%2520and%2520Related%2520Fused%2520Pyridines.%2520Part%2520II%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26spage%3D3111%26epage%3D3113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Danca, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigby, J. H.</span><span> </span><span class="NLM_article-title">Vinyl Isocyanates in Alkaloid Synthesis. Camptothecin Model Studies</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">4969</span><span class="NLM_x">–</span> <span class="NLM_lpage">4972</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=4969-4972&author=D.+M.+Dancaauthor=J.+H.+Rigby&title=Vinyl+Isocyanates+in+Alkaloid+Synthesis.+Camptothecin+Model+Studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanca%26aufirst%3DD.%2BM.%26aulast%3DRigby%26aufirst%3DJ.%2BH.%26atitle%3DVinyl%2520Isocyanates%2520in%2520Alkaloid%2520Synthesis.%2520Camptothecin%2520Model%2520Studies%26jtitle%3DTetrahedron%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D4969%26epage%3D4972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Michel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gennet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassat, A.</span><span> </span><span class="NLM_article-title">A One-Pot Procedure for the Synthesis of Alkynes and Bromoalkynes from Aldehydes</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">8575</span><span class="NLM_x">–</span> <span class="NLM_lpage">8578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=8575-8578&issue=49&author=P.+Michelauthor=D.+Gennetauthor=A.+Rassat&title=A+One-Pot+Procedure+for+the+Synthesis+of+Alkynes+and+Bromoalkynes+from+Aldehydes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DP.%26aulast%3DGennet%26aufirst%3DD.%26aulast%3DRassat%26aufirst%3DA.%26atitle%3DA%2520One-Pot%2520Procedure%2520for%2520the%2520Synthesis%2520of%2520Alkynes%2520and%2520Bromoalkynes%2520from%2520Aldehydes%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26issue%3D49%26spage%3D8575%26epage%3D8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Mahaney, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatucci, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffan, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadwick, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harnish, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trybulski, E. J.</span><span> </span><span class="NLM_article-title">Synthesis and Activity of a New Class of Pathway-Selective Estrogen Receptor Ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3455</span><span class="NLM_x">–</span> <span class="NLM_lpage">3466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3455-3466&author=P.+E.+Mahaneyauthor=M.+B.+Webbauthor=F.+Yeauthor=J.+P.+Sabatucciauthor=R.+J.+Steffanauthor=C.+C.+Chadwickauthor=D.+C.+Harnishauthor=E.+J.+Trybulski&title=Synthesis+and+Activity+of+a+New+Class+of+Pathway-Selective+Estrogen+Receptor+Ligands%3A+Hydroxybenzoyl-3%2C4-dihydroquinoxalin-2%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahaney%26aufirst%3DP.%2BE.%26aulast%3DWebb%26aufirst%3DM.%2BB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSabatucci%26aufirst%3DJ.%2BP.%26aulast%3DSteffan%26aufirst%3DR.%2BJ.%26aulast%3DChadwick%26aufirst%3DC.%2BC.%26aulast%3DHarnish%26aufirst%3DD.%2BC.%26aulast%3DTrybulski%26aufirst%3DE.%2BJ.%26atitle%3DSynthesis%2520and%2520Activity%2520of%2520a%2520New%2520Class%2520of%2520Pathway-Selective%2520Estrogen%2520Receptor%2520Ligands%253A%2520Hydroxybenzoyl-3%252C4-dihydroquinoxalin-2%25281H%2529-ones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3455%26epage%3D3466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="note"><p class="first last">For preparation of methyl 3-(1,3-dioxoindolin-2-yl)-2-oxobutanoate see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Yasuo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiga, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anraku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Novel 7-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic acids Bearing a Substituted Phenyl Group as Superior AMPA Receptor Antagonists with Good Physicochemical Properties</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=776-792&author=T.+Yasuoauthor=F.+Shigaauthor=J.+Asanoauthor=W.+Horiauthor=K.+Fukuchiauthor=T.+Anrakuauthor=T.+Uno&title=Design+and+Synthesis+of+Novel+7-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic+acids+Bearing+a+Substituted+Phenyl+Group+as+Superior+AMPA+Receptor+Antagonists+with+Good+Physicochemical+Properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYasuo%26aufirst%3DT.%26aulast%3DShiga%26aufirst%3DF.%26aulast%3DAsano%26aufirst%3DJ.%26aulast%3DHori%26aufirst%3DW.%26aulast%3DFukuchi%26aufirst%3DK.%26aulast%3DAnraku%26aufirst%3DT.%26aulast%3DUno%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25207-Heterocycle-6-trifluoromethyl-3-oxoquinoxaline-2-carboxylic%2520acids%2520Bearing%2520a%2520Substituted%2520Phenyl%2520Group%2520as%2520Superior%2520AMPA%2520Receptor%2520Antagonists%2520with%2520Good%2520Physicochemical%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D776%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">D’Angelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amico, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakowec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalameda, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1789</span><span class="NLM_x">–</span> <span class="NLM_lpage">1811</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1014605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1789-1811&author=N.+D.+D%E2%80%99Angeloauthor=T.+S.+Kimauthor=K.+Andrewsauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=K.+Chenauthor=D.+D%E2%80%99Amicoauthor=D.+Freemanauthor=J.+Jiangauthor=L.+Liuauthor=J.+D.+McCarterauthor=T.+San+Miguelauthor=E.+L.+Mulladyauthor=M.+Schragauthor=R.+Subramanianauthor=J.+Tangauthor=R.+C.+Wahlauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=N.+Xiauthor=Y.+Xuauthor=P.+Yakowecauthor=K.+Yangauthor=L.+P.+Zalamedaauthor=N.+Zhangauthor=P.+Hughesauthor=M.+H.+Norman&title=Discovery+and+Optimization+of+a+Series+of+Benzothiazole+Phosphoinositide+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28mTOR%29+Dual+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm1014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014605%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%2520Benzothiazole%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528mTOR%2529%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1789%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+Determinants+of+Phosphoinositide+3-Kinase+Inhibition+by+Wortmannin%2C+LY294002%2C+Quercetin%2C+Myricetin%2C+and+Staurosporine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lj0YK3bn3e4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520Determinants%2520of%2520Phosphoinositide%25203-Kinase%2520Inhibition%2520by%2520Wortmannin%252C%2520LY294002%252C%2520Quercetin%252C%2520Myricetin%252C%2520and%2520Staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Otwinowski, Z.; Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span>. In  <span class="citation_source-book">Macromolecular Crystallography. Part A</span>; <span class="NLM_contrib-group">Carter, C. W.,  Jr.; Sweet, R. M.</span>, Eds.; Methods in Enzymology, Vol.  <span class="NLM_volume">276</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&author=R.+M.+Sweet&title=Macromolecular+Crystallography.+Part+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26btitle%3DMacromolecular%2520Crystallography.%2520Part%2520A%26aulast%3DCarter%26aufirst%3DC.%2BW.%26volume%3D276%26pub%3DAcademic%2520Press%26date%3D1997%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0linBBjOu-Ym9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and Development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501624r&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501624r&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501624r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0linBBjOu-Ym9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF','PDB','2WXF'); return false;">PDB: 2WXF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN','PDB','4WWN'); return false;">PDB: 4WWN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWO','PDB','4WWO'); return false;">PDB: 4WWO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWP','PDB','4WWP'); return false;">PDB: 4WWP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i184"><a href="/doi/suppl/10.1021/jm501624r">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33447"></div></div></div></div></div><hr /></hr><p class="last">Comparison of analogs <b>1</b> and <b>2</b> and control compound D-073; additional synthesis procedures; and crystallographic data collection and refinement statistics. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501624r/suppl_file/jm501624r_si_001.pdf">jm501624r_si_001.pdf (116.64 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the cocrystal structures of PI3Kγ with compounds <b>1</b>, <b>16</b>, and <b>27</b> have been deposited in the PDB with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN">4WWN</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWO">4WWO</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWP">4WWP</a>, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501624r&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Fjm501624r%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-1%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501624r" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d3158b30d1f3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
